{"cells":[{"cell_type":"markdown","id":"dec88c28-2af9-468d-bd6e-689509d721c3","metadata":{"id":"dec88c28-2af9-468d-bd6e-689509d721c3"},"source":["**FDA Drug Approval Feature Extaction - Language Models**\n","\n","- Harvard Capstone: Fall 2024\n","- Date: 11/29/2024"]},{"cell_type":"markdown","id":"41868fab-8fef-4656-b8fa-779e26d68bf1","metadata":{"id":"41868fab-8fef-4656-b8fa-779e26d68bf1"},"source":["## Imports"]},{"cell_type":"code","execution_count":null,"id":"226ee78c-6a30-48a9-b344-72e6a02822e9","metadata":{"id":"226ee78c-6a30-48a9-b344-72e6a02822e9"},"outputs":[],"source":["# !pip install llmware\n","# !pip install openvino\n","# !pip install openvino_genai\n","# # Install spaCy and download the English language model if not already installed\n","# !pip install spacy\n","# !python -m spacy download en_core_web_sm\n","# pip install haystack-ai \"transformers[torch,sentencepiece]\""]},{"cell_type":"code","execution_count":null,"id":"bb9c2c11-7053-4967-9842-7c9e2710a542","metadata":{"id":"bb9c2c11-7053-4967-9842-7c9e2710a542"},"outputs":[],"source":["import matplotlib.pyplot as plt\n","import seaborn as sns\n","import pandas as pd\n","import numpy as np\n","import os\n","import spacy\n","import re\n","\n","from getpass import getpass\n","\n","import torch\n","from transformers import pipeline\n","from haystack import Document\n","from haystack.components.readers import ExtractiveReader\n","import openai\n","from openai import OpenAI\n","\n","pd.set_option('display.max_colwidth', 20)\n","%config InlineBackend.figure_format = 'retina'\n","\n","# ANSI escape codes for colors and bold text\n","RED_BOLD = \"\\033[1;31m\"\n","RESET = \"\\033[0m\"\n","BOLD_BAR = \"\\033[1m\" + \"-\" * 40 + RESET\n","\n","# Instantiate the OpenAI client\n","openai_key = getpass(\"Input OpenAI Key: \")\n","client = OpenAI(api_key=openai_key)\n","\n","def print_bar(width=40):\n","    return print(\"\\033[1;36m\" + \"â€“\" * width + \"\\033[0m\")"]},{"cell_type":"code","execution_count":null,"id":"229cc3ad-3744-4533-9647-c7ce68242df3","metadata":{"id":"229cc3ad-3744-4533-9647-c7ce68242df3"},"outputs":[],"source":["# Clear PyTorch cache\n","torch.cuda.empty_cache()\n","\n","# Reset all CUDA memory allocations\n","torch.cuda.reset_peak_memory_stats()\n","torch.cuda.reset_accumulated_memory_stats()"]},{"cell_type":"code","execution_count":null,"id":"779adcb2-ee78-4b49-a432-466d378e1825","metadata":{"id":"779adcb2-ee78-4b49-a432-466d378e1825","outputId":"b4377f71-b137-484c-8ac6-303edb83dd0a"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>nct_id</th>\n","      <th>Drug Name</th>\n","      <th>conditions</th>\n","      <th>Therapy Area</th>\n","      <th>id</th>\n","      <th>description</th>\n","      <th>criteria</th>\n","      <th>healthy_volunteers</th>\n","      <th>adult</th>\n","      <th>child</th>\n","      <th>older_adult</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>NCT00000187</td>\n","      <td>ritanserin</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Toxicity/Intoxication; Neurology/Psychiatric</td>\n","      <td>24095864</td>\n","      <td>The purpose of this study is to assess ritanse...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>NCT00000200</td>\n","      <td>methadone</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Neurology/Psychiatric</td>\n","      <td>23965890</td>\n","      <td>The purpose of this study is to compare the ef...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>NCT00000395</td>\n","      <td>methotrexate</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>Immune; Dermatologic; Gastrointestinal; Ocular</td>\n","      <td>24006623</td>\n","      <td>This study looks at how the arthritis drug met...</td>\n","      <td>Inclusion Criteria:~* Individuals starting met...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>NCT00000451</td>\n","      <td>sertraline</td>\n","      <td>alcoholism</td>\n","      <td>Neurology/Psychiatric; Genitourinary/Sexual Fu...</td>\n","      <td>23799489</td>\n","      <td>This study will assess the ability of naltrexo...</td>\n","      <td>Inclusion Criteria:~* Alaska Native having bio...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>NCT00001723</td>\n","      <td>orlistat</td>\n","      <td>obesity</td>\n","      <td>Other/Miscellaneous</td>\n","      <td>24120128</td>\n","      <td>Obesity is a condition affecting one-third off...</td>\n","      <td>* INCLUSION CRITERIA:~Good general health. Ind...</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["        nct_id     Drug Name                 conditions  \\\n","0  NCT00000187    ritanserin  cocaine-related disorders   \n","1  NCT00000200     methadone  cocaine-related disorders   \n","2  NCT00000395  methotrexate       rheumatoid arthritis   \n","3  NCT00000451    sertraline                 alcoholism   \n","4  NCT00001723      orlistat                    obesity   \n","\n","                                        Therapy Area        id  \\\n","0       Toxicity/Intoxication; Neurology/Psychiatric  24095864   \n","1                              Neurology/Psychiatric  23965890   \n","2     Immune; Dermatologic; Gastrointestinal; Ocular  24006623   \n","3  Neurology/Psychiatric; Genitourinary/Sexual Fu...  23799489   \n","4                                Other/Miscellaneous  24120128   \n","\n","                                         description  \\\n","0  The purpose of this study is to assess ritanse...   \n","1  The purpose of this study is to compare the ef...   \n","2  This study looks at how the arthritis drug met...   \n","3  This study will assess the ability of naltrexo...   \n","4  Obesity is a condition affecting one-third off...   \n","\n","                                            criteria  healthy_volunteers  \\\n","0               Please contact site for information.               False   \n","1               Please contact site for information.               False   \n","2  Inclusion Criteria:~* Individuals starting met...               False   \n","3  Inclusion Criteria:~* Alaska Native having bio...               False   \n","4  * INCLUSION CRITERIA:~Good general health. Ind...               False   \n","\n","   adult  child  older_adult  \n","0   True  False        False  \n","1   True  False        False  \n","2   True  False         True  \n","3   True  False         True  \n","4  False   True        False  "]},"execution_count":16,"metadata":{},"output_type":"execute_result"}],"source":["# reading data\n","df = pd.read_csv('drug_approval_data.csv')\n","df.head()"]},{"cell_type":"markdown","id":"f50f9413-b1a1-433a-8557-7a9168ddf70e","metadata":{"id":"f50f9413-b1a1-433a-8557-7a9168ddf70e"},"source":["# First Using Spacy"]},{"cell_type":"code","execution_count":null,"id":"350be56a-088e-4d5c-a662-d5083fe2945f","metadata":{"execution":{"iopub.execute_input":"2024-11-17T17:14:24.359688Z","iopub.status.busy":"2024-11-17T17:14:24.358907Z","iopub.status.idle":"2024-11-17T17:18:39.892346Z","shell.execute_reply":"2024-11-17T17:18:39.891253Z","shell.execute_reply.started":"2024-11-17T17:14:24.359647Z"},"id":"350be56a-088e-4d5c-a662-d5083fe2945f","outputId":"0f3d7bc3-260f-43a5-b329-e50b8456ec62"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>criteria</th>\n","      <th>Spacy Gender Excluded</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>* INCLUSION CRIT...</td>\n","      <td>None</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>...</th>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","    </tr>\n","    <tr>\n","      <th>3668</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3669</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3670</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>3671</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3672</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","  </tbody>\n","</table>\n","<p>3673 rows Ã— 3 columns</p>\n","</div>"],"text/plain":["                 criteria Spacy Gender Excluded Spacy Pregnant Women Excluded\n","0     Please contact s...                 None                    No         \n","1     Please contact s...                 None                    No         \n","2     Inclusion Criter...                 None                    No         \n","3     Inclusion Criter...                 None                   Yes         \n","4     * INCLUSION CRIT...                 None                   Yes         \n","...                   ...                  ...                   ...         \n","3668  Inclusion Criter...                 None                    No         \n","3669  Inclusion Criter...                 None                    No         \n","3670  Inclusion Criter...                 None                   Yes         \n","3671  Inclusion Criter...                 None                    No         \n","3672  Inclusion Criter...                 None                    No         \n","\n","[3673 rows x 3 columns]"]},"execution_count":7,"metadata":{},"output_type":"execute_result"}],"source":["# Load spaCy English model\n","nlp = spacy.load('en_core_web_sm')\n","\n","# Define the function to extract exclusion information\n","def extract_exclusion_info(text):\n","    # Initialize default values\n","    gender_excluded = 'None'\n","    pregnant_women_excluded = 'No'\n","    text_lower = text.lower()\n","\n","    # Use spaCy to parse the text\n","    doc = nlp(text_lower)\n","\n","    # Extract Exclusion Criteria section if present\n","    exclusion_section = ''\n","    exclusion_starts = ['exclusion criteria:', 'exclusion criteria', 'exclusion:']\n","    inclusion_starts = ['inclusion criteria:', 'inclusion criteria', 'inclusion:']\n","\n","    exclusion_start_idx = None\n","    for phrase in exclusion_starts:\n","        idx = text_lower.find(phrase)\n","        if idx != -1:\n","            exclusion_start_idx = idx + len(phrase)\n","            break  # Found the start of the exclusion criteria\n","\n","    if exclusion_start_idx is not None:\n","        # Find the end of the exclusion section\n","        exclusion_end_idx = len(text_lower)\n","        for phrase in inclusion_starts:\n","            idx = text_lower.find(phrase, exclusion_start_idx)\n","            if idx != -1:\n","                exclusion_end_idx = idx\n","                break  # Found the start of the next section\n","\n","        exclusion_section = text_lower[exclusion_start_idx:exclusion_end_idx]\n","    else:\n","        # If no exclusion section found, use the entire text\n","        exclusion_section = text_lower\n","\n","    # Extract Gender Exclusion Information\n","    gender_patterns = {\n","        'Male': [\n","            r'\\bonly females\\b',\n","            r'\\bfemales only\\b',\n","            r'\\bfemale participants only\\b',\n","            r'\\bonly women\\b',\n","            r'\\bwomen only\\b',\n","            r'\\bno males\\b',\n","            r'\\bmales are excluded\\b',\n","        ],\n","        'Female': [\n","            r'\\bonly males\\b',\n","            r'\\bmales only\\b',\n","            r'\\bmale participants only\\b',\n","            r'\\bonly men\\b',\n","            r'\\bmen only\\b',\n","            r'\\bno females\\b',\n","            r'\\bfemales are excluded\\b',\n","        ],\n","    }\n","\n","    for gender, patterns in gender_patterns.items():\n","        for pattern in patterns:\n","            if re.search(pattern, exclusion_section):\n","                gender_excluded = gender\n","                break  # Exit the loop if a pattern matches\n","        if gender_excluded != 'None':\n","            break  # Exit if gender exclusion is found\n","\n","    # Extract Pregnancy Exclusion Information\n","    if re.search(r'\\bpregnant\\b', exclusion_section):\n","        pregnant_women_excluded = 'Yes'\n","    else:\n","        pregnant_women_excluded = 'No'\n","\n","    return pd.Series({\n","        'Gender Excluded': gender_excluded,\n","        'Pregnant Women Excluded': pregnant_women_excluded\n","    })\n"]},{"cell_type":"code","execution_count":null,"id":"71819381-2f53-436d-881e-b43e2a7e9494","metadata":{"execution":{"iopub.execute_input":"2024-11-17T17:24:45.225691Z","iopub.status.busy":"2024-11-17T17:24:45.224798Z","iopub.status.idle":"2024-11-17T17:24:45.246254Z","shell.execute_reply":"2024-11-17T17:24:45.244935Z","shell.execute_reply.started":"2024-11-17T17:24:45.225638Z"},"id":"71819381-2f53-436d-881e-b43e2a7e9494","outputId":"053ba045-411c-4441-923e-64c2902f2d8b"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>criteria</th>\n","      <th>Spacy Gender Excluded</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>* INCLUSION CRIT...</td>\n","      <td>None</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>...</th>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","    </tr>\n","    <tr>\n","      <th>3668</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3669</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3670</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>3671</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3672</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","  </tbody>\n","</table>\n","<p>3673 rows Ã— 3 columns</p>\n","</div>"],"text/plain":["                 criteria Spacy Gender Excluded Spacy Pregnant Women Excluded\n","0     Please contact s...                 None                    No         \n","1     Please contact s...                 None                    No         \n","2     Inclusion Criter...                 None                    No         \n","3     Inclusion Criter...                 None                   Yes         \n","4     * INCLUSION CRIT...                 None                   Yes         \n","...                   ...                  ...                   ...         \n","3668  Inclusion Criter...                 None                    No         \n","3669  Inclusion Criter...                 None                    No         \n","3670  Inclusion Criter...                 None                   Yes         \n","3671  Inclusion Criter...                 None                    No         \n","3672  Inclusion Criter...                 None                    No         \n","\n","[3673 rows x 3 columns]"]},"execution_count":30,"metadata":{},"output_type":"execute_result"}],"source":["# Apply the function to the DataFrame\n","# df[['Spacy Gender Excluded']] = df['criteria'].apply(extract_exclusion_info)['Gender Excluded']\n","df[['criteria', 'Spacy Gender Excluded', 'Spacy Pregnant Women Excluded']]"]},{"cell_type":"code","execution_count":null,"id":"8c7f0f43-1504-426d-8af7-36ffff0aed63","metadata":{"execution":{"iopub.execute_input":"2024-11-17T17:30:29.590857Z","iopub.status.busy":"2024-11-17T17:30:29.590490Z","iopub.status.idle":"2024-11-17T17:38:45.671703Z","shell.execute_reply":"2024-11-17T17:38:45.670722Z","shell.execute_reply.started":"2024-11-17T17:30:29.590825Z"},"id":"8c7f0f43-1504-426d-8af7-36ffff0aed63","outputId":"5fb85199-0344-45df-b277-7c3d182e47c8"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>criteria</th>\n","      <th>Spacy Gender Excluded</th>\n","      <th>Spacy2 Pregnant Women Excluded</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>* INCLUSION CRIT...</td>\n","      <td>Male</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>...</th>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","    </tr>\n","    <tr>\n","      <th>3668</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3669</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3670</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3671</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3672</th>\n","      <td>Inclusion Criter...</td>\n","      <td>Female</td>\n","      <td>No</td>\n","    </tr>\n","  </tbody>\n","</table>\n","<p>3673 rows Ã— 3 columns</p>\n","</div>"],"text/plain":["                 criteria Spacy Gender Excluded Spacy2 Pregnant Women Excluded\n","0     Please contact s...                 None                    No          \n","1     Please contact s...                 None                    No          \n","2     Inclusion Criter...                 None                    No          \n","3     Inclusion Criter...                 None                   Yes          \n","4     * INCLUSION CRIT...                 Male                   Yes          \n","...                   ...                  ...                   ...          \n","3668  Inclusion Criter...                 None                    No          \n","3669  Inclusion Criter...                 None                    No          \n","3670  Inclusion Criter...                 None                    No          \n","3671  Inclusion Criter...                 None                    No          \n","3672  Inclusion Criter...               Female                    No          \n","\n","[3673 rows x 3 columns]"]},"execution_count":45,"metadata":{},"output_type":"execute_result"}],"source":["# NUMBER 1\n","def extract_gender_exclusion(text):\n","    doc = nlp(text.lower())\n","    gender_excluded = 'None'\n","\n","    male_terms = {'male', 'men', 'males', 'boy', 'boys'}\n","    female_terms = {'female', 'women', 'females', 'woman', 'girl', 'girls'}\n","\n","    male_included = False\n","    female_included = False\n","\n","    # Split text into inclusion and exclusion criteria\n","    inclusion_text = ''\n","    exclusion_text = ''\n","    text_lower = text.lower()\n","    if 'inclusion criteria' in text_lower:\n","        inclusion_start = text_lower.find('inclusion criteria') + len('inclusion criteria')\n","        if 'exclusion criteria' in text_lower:\n","            exclusion_start = text_lower.find('exclusion criteria')\n","            inclusion_text = text_lower[inclusion_start:exclusion_start]\n","            exclusion_text = text_lower[exclusion_start:]\n","        else:\n","            inclusion_text = text_lower[inclusion_start:]\n","    else:\n","        inclusion_text = text_lower\n","\n","    # Check for gender terms in inclusion criteria\n","    inclusion_doc = nlp(inclusion_text)\n","    for token in inclusion_doc:\n","        if token.text in male_terms:\n","            male_included = True\n","        if token.text in female_terms:\n","            female_included = True\n","\n","    # Check for gender exclusions in exclusion criteria\n","    if exclusion_text:\n","        exclusion_doc = nlp(exclusion_text)\n","        for sent in exclusion_doc.sents:\n","            sent_text = sent.text.lower()\n","            if any(term in sent_text for term in male_terms) and ('exclude' in sent_text or 'not eligible' in sent_text or 'not allowed' in sent_text):\n","                gender_excluded = 'Male'\n","                return gender_excluded\n","            if any(term in sent_text for term in female_terms) and ('exclude' in sent_text or 'not eligible' in sent_text or 'not allowed' in sent_text):\n","                gender_excluded = 'Female'\n","                return gender_excluded\n","\n","    # Determine gender exclusion based on inclusion criteria\n","    if male_included and not female_included:\n","        gender_excluded = 'Female'\n","    elif female_included and not male_included:\n","        gender_excluded = 'Male'\n","    else:\n","        gender_excluded = 'None'\n","    return gender_excluded\n","\n","def extract_pregnancy_exclusion(text):\n","    text_lower = text.lower()\n","    # Check for phrases indicating pregnant women are excluded\n","    if re.search(r'pregnant women.*excluded|pregnant women.*not eligible|females who are pregnant|pregnant or nursing', text_lower):\n","        return 'Yes'\n","    elif re.search(r'pregnant women.*included|pregnant women.*eligible', text_lower):\n","        return 'No'\n","    else:\n","        return 'No'\n","\n","df['Spacy Gender Excluded'] = df['criteria'].apply(extract_gender_exclusion)\n","# df['Spacy2 Pregnant Women Excluded'] = df['criteria'].apply(extract_pregnancy_exclusion)\n","df[['criteria', 'Spacy Gender Excluded', 'Spacy2 Pregnant Women Excluded']]\n"]},{"cell_type":"code","execution_count":null,"id":"be17dc78-f521-4451-864b-7a40f8ab419e","metadata":{"execution":{"iopub.execute_input":"2024-11-17T17:48:36.869142Z","iopub.status.busy":"2024-11-17T17:48:36.868452Z","iopub.status.idle":"2024-11-17T17:52:43.511358Z","shell.execute_reply":"2024-11-17T17:52:43.510383Z","shell.execute_reply.started":"2024-11-17T17:48:36.869104Z"},"id":"be17dc78-f521-4451-864b-7a40f8ab419e","outputId":"9b05c0f7-4840-440e-954c-bb769884ae3c"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>criteria</th>\n","      <th>Spacy Gender Excluded</th>\n","      <th>Spacy2 Gender Excluded</th>\n","      <th>Spacy2 Pregnant Women Excluded</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>Please contact s...</td>\n","      <td>None</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>Male</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>* INCLUSION CRIT...</td>\n","      <td>Male</td>\n","      <td>Male</td>\n","      <td>Yes</td>\n","    </tr>\n","    <tr>\n","      <th>...</th>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","    </tr>\n","    <tr>\n","      <th>3668</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3669</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3670</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3671</th>\n","      <td>Inclusion Criter...</td>\n","      <td>None</td>\n","      <td>None</td>\n","      <td>No</td>\n","    </tr>\n","    <tr>\n","      <th>3672</th>\n","      <td>Inclusion Criter...</td>\n","      <td>Female</td>\n","      <td>Female</td>\n","      <td>No</td>\n","    </tr>\n","  </tbody>\n","</table>\n","<p>3673 rows Ã— 4 columns</p>\n","</div>"],"text/plain":["                 criteria Spacy Gender Excluded Spacy2 Gender Excluded  \\\n","0     Please contact s...                 None                  None     \n","1     Please contact s...                 None                  None     \n","2     Inclusion Criter...                 None                  None     \n","3     Inclusion Criter...                 None                  Male     \n","4     * INCLUSION CRIT...                 Male                  Male     \n","...                   ...                  ...                   ...     \n","3668  Inclusion Criter...                 None                  None     \n","3669  Inclusion Criter...                 None                  None     \n","3670  Inclusion Criter...                 None                  None     \n","3671  Inclusion Criter...                 None                  None     \n","3672  Inclusion Criter...               Female                Female     \n","\n","     Spacy2 Pregnant Women Excluded  \n","0                      No            \n","1                      No            \n","2                      No            \n","3                     Yes            \n","4                     Yes            \n","...                   ...            \n","3668                   No            \n","3669                   No            \n","3670                   No            \n","3671                   No            \n","3672                   No            \n","\n","[3673 rows x 4 columns]"]},"execution_count":72,"metadata":{},"output_type":"execute_result"}],"source":["# NUMBER 2\n","import spacy\n","from spacy.matcher import Matcher\n","\n","def extract_gender_exclusion(text):\n","    doc = nlp(text.lower())\n","    gender_excluded = 'None'\n","\n","    # Define terms and patterns\n","    male_terms = {'male', 'men', 'males', 'boy', 'boys'}\n","    female_terms = {'female', 'women', 'females', 'woman', 'girl', 'girls'}\n","    exclusion_terms = ['exclude', 'not eligible', 'not allowed', 'disallowed', 'prohibited', 'barred']\n","\n","    # Prepare spaCy Matcher\n","    matcher = Matcher(nlp.vocab)\n","    # Each term is a separate pattern\n","    for term in exclusion_terms:\n","        pattern = [{'LOWER': word} for word in term.split()]\n","        matcher.add(\"EXCLUSION_PATTERN\", [pattern])\n","\n","    # Check for gender terms in exclusion criteria\n","    exclusion_detected = False\n","    for sent in doc.sents:\n","        matches = matcher(sent)\n","        if matches:\n","            # If exclusion terms are found, check for gender terms in the sentence\n","            for match_id, start, end in matches:\n","                span = sent[start:end]  # The matched span\n","                if any(token.text in male_terms for token in sent) and 'exclude' in span.text:\n","                    gender_excluded = 'Male'\n","                    exclusion_detected = True\n","                if any(token.text in female_terms for token in sent) and 'exclude' in span.text:\n","                    gender_excluded = 'Female'\n","                    exclusion_detected = True\n","        if exclusion_detected:\n","            break\n","\n","    # If no explicit exclusion is found, fallback to checking the inclusion criteria\n","    if not exclusion_detected:\n","        male_included = any(token.text in male_terms for token in doc)\n","        female_included = any(token.text in female_terms for token in doc)\n","        if male_included and not female_included:\n","            gender_excluded = 'Female'\n","        elif female_included and not male_included:\n","            gender_excluded = 'Male'\n","\n","    return gender_excluded\n","\n","\n","df['Spacy2 Gender Excluded'] = df['criteria'].apply(extract_gender_exclusion)\n","df[['criteria', 'Spacy Gender Excluded', 'Spacy2 Gender Excluded', 'Spacy2 Pregnant Women Excluded']]"]},{"cell_type":"code","execution_count":null,"id":"80c9cd75-c779-434c-a322-0efa085e3488","metadata":{"execution":{"iopub.execute_input":"2024-11-17T17:44:14.717508Z","iopub.status.busy":"2024-11-17T17:44:14.717066Z","iopub.status.idle":"2024-11-17T17:44:14.724850Z","shell.execute_reply":"2024-11-17T17:44:14.723821Z","shell.execute_reply.started":"2024-11-17T17:44:14.717432Z"},"id":"80c9cd75-c779-434c-a322-0efa085e3488","outputId":"6292ca54-0667-43cc-8d41-1b0825146905"},"outputs":[{"data":{"text/plain":["2698"]},"execution_count":65,"metadata":{},"output_type":"execute_result"}],"source":["# Data mappings\n","df['Spacy Gender Excluded'] = df['Spacy Gender Excluded'].replace(['None', np.nan], None)\n","df['Spacy2 Gender Excluded'] = df['Spacy2 Gender Excluded'].replace(['None', np.nan], None)\n","df[['criteria', 'Spacy Gender Excluded', 'Spacy2 Gender Excluded']].tail(10)\n","df['Spacy Gender Excluded'].isna().sum()"]},{"cell_type":"markdown","id":"bcc2b174-ebbf-405c-a22d-bc8f3cd48e91","metadata":{"id":"bcc2b174-ebbf-405c-a22d-bc8f3cd48e91"},"source":["# Feature Extarction Using Slim-Extract\n","\n","- **DID NOT GIVE GOOD RESULTS**"]},{"cell_type":"code","execution_count":null,"id":"8131ad97-0c64-4472-9747-7dbf5f140e43","metadata":{"execution":{"iopub.execute_input":"2024-11-17T17:18:39.894288Z","iopub.status.busy":"2024-11-17T17:18:39.894015Z","iopub.status.idle":"2024-11-17T17:18:39.898320Z","shell.execute_reply":"2024-11-17T17:18:39.897465Z","shell.execute_reply.started":"2024-11-17T17:18:39.894259Z"},"id":"8131ad97-0c64-4472-9747-7dbf5f140e43"},"outputs":[],"source":["from transformers import pipeline\n","\n","# Initialize the pipeline\n","pipe = pipeline(\"text-generation\", model=\"llmware/slim-extract\", trust_remote_code=True, device=0)\n","\n","# Example criteria text\n","criteria_text = \"\"\"\n","Participants must be between 18 and 65 years of age. Both males and females are eligible. Pregnant women are excluded.\n","\"\"\"\n","\n","# Define the extraction keys\n","keys = [\"gender exclusion\", \"pregnancy exclusion\"]\n","\n","# Generate the response\n","response = pipe(\n","    f\"\"\"\n","    Extract the following information from the text:\n","    Text: {criteria_text}\n","    Extract: {keys}\n","    \"\"\"\n",")\n","\n","# Print the output\n","print(response[0][\"generated_text\"])"]},{"cell_type":"code","execution_count":null,"id":"44be4f5c-c67f-42ce-a274-a271bb5081c0","metadata":{"execution":{"iopub.execute_input":"2024-11-17T17:18:39.900047Z","iopub.status.busy":"2024-11-17T17:18:39.899741Z","iopub.status.idle":"2024-11-17T17:18:39.910385Z","shell.execute_reply":"2024-11-17T17:18:39.909492Z","shell.execute_reply.started":"2024-11-17T17:18:39.900015Z"},"id":"44be4f5c-c67f-42ce-a274-a271bb5081c0"},"outputs":[],"source":["# Define keys for extraction\n","keys = [\"gender exclusion\", \"pregnancy exclusion\"]\n","\n","# Function to process each criteria using the model\n","def extract_values(criteria, keys):\n","    extracted_values = {}\n","    for key in keys:\n","        response = model.function_call(criteria, function=\"extract\", params=[key])\n","        extracted_values[key] = response.get(key, [])\n","    return extracted_values\n","\n","# Apply the extraction to the 'criteria' column\n","extracted_results = df['criteria'].apply(lambda x: extract_values(x, keys))\n","\n","# Convert the extracted results into separate columns\n","df[\"gender_exclusion\"] = extracted_results.apply(lambda x: \", \".join(x[\"gender exclusion\"]) if x[\"gender exclusion\"] else \"Not mentioned\")\n","df[\"pregnancy_exclusion\"] = extracted_results.apply(lambda x: \", \".join(x[\"pregnancy exclusion\"]) if x[\"pregnancy exclusion\"] else \"Not mentioned\")\n","\n","# Save or display the updated DataFrame\n","df.to_csv(\"processed_results.csv\", index=False)\n","print(df[[\"criteria\", \"gender_exclusion\", \"pregnancy_exclusion\"]].head())"]},{"cell_type":"markdown","id":"21fad066-6121-4a51-99c3-e46b5bd5fd6d","metadata":{"id":"21fad066-6121-4a51-99c3-e46b5bd5fd6d"},"source":["# HackAI Text Extraction\n","\n","- **DID NOT GIVE GOOD RESULTS**"]},{"cell_type":"code","execution_count":null,"id":"de133b83-f9d6-4208-a87f-1dd027d1cd73","metadata":{"execution":{"iopub.status.busy":"2024-11-17T15:07:44.755192Z","iopub.status.idle":"2024-11-17T15:07:44.755680Z","shell.execute_reply":"2024-11-17T15:07:44.755456Z","shell.execute_reply.started":"2024-11-17T15:07:44.755431Z"},"id":"de133b83-f9d6-4208-a87f-1dd027d1cd73"},"outputs":[],"source":["# Initialize the ExtractiveReader with the specified model\n","reader = ExtractiveReader(model=\"deepset/roberta-base-squad2\")\n","reader.warm_up()\n","\n","# Create Document objects from the 'criteria' column\n","documents = [Document(content=criteria) for criteria in df['criteria'][:10]]\n","\n","# Define questions for the task\n","questions = [\n","    \"Does this exclude Males or Females? Respond with: 'Male' or 'Female'.\",\n","    \"Does this exclude pregnant women? Respond with 'Yes' or 'No'.\"\n","# ]\n","\n","# Create Document objects from the 'criteria' column\n","documents = [Document(content=criteria) for criteria in df['criteria'][:10]]\n","\n","# Define questions for the task\n","questions = [\n","    \"Does this exclude Males or Females? Respond with: 'Male' or 'Female'.\",\n","    \"Does this exclude pregnant women? Respond with 'Yes' or 'No'.\"\n","]\n","\n","# Process the documents\n","results = []\n","for doc in documents:\n","    doc_results = {}\n","    for question in questions:\n","        result = reader.run(query=question, documents=[doc])\n","        # Extract the top answer or provide a fallback\n","        answer = result[\"answers\"][0].data.strip() if result[\"answers\"] else None\n","        # Validate the answer against the expected format\n","        doc_results[question] = validate_response(question, answer)\n","    results.append(doc_results)"]},{"cell_type":"markdown","id":"962f56e6-2f03-401d-b06c-73367854ec94","metadata":{"id":"962f56e6-2f03-401d-b06c-73367854ec94"},"source":["# Drug-BERT (lloydmeta/drug-bert)\n","\n","https://huggingface.co/lloydmeta/drug-bert\n","\n","Purpose: Drug-BERT is designed to classify medical conditions based on patient drug reviews. In this, it was used to predict the condition targeted by each clinical trial.\n","\n","Architecture: Built upon Google's BERT (Bidirectional Encoder Representations from Transformers) architecture, specifically the 'bert-base-uncased' variant.\n","\n","Training Data: The model was fine-tuned on the Drug Review Dataset from Drugs.com, which includes patient reviews and associated conditions. Source\n","\n","Rationale for Use: Its proficiency in understanding medical terminologies and context makes it suitable for interpreting clinical trial descriptions.\n","\n","Derived Features:\n","\n","- Model_lloydmeta_Class: Predicted medical condition for each trial. Creates a reduced mapping space for the conditions.\n","- Model_lloydmeta_Score: Confidence score of the prediction."]},{"cell_type":"code","source":["# Use a pipeline as a high-level helper\n","from transformers import pipeline\n","\n","pipe = pipeline(\"text-classification\", model=\"lloydmeta/drug-bert\")"],"metadata":{"id":"z4SCIIyOIXWL"},"id":"z4SCIIyOIXWL","execution_count":null,"outputs":[]},{"cell_type":"code","execution_count":null,"id":"2b7831b5-9ecc-4393-8581-cba6df915b87","metadata":{"id":"2b7831b5-9ecc-4393-8581-cba6df915b87"},"outputs":[],"source":["lloydmeta_cond_class = []\n","lloydmeta_ratings = []\n","\n","# Iterate through rows in the dataframe\n","for index, row in df.iterrows():\n","    drug_name = row['Drug Name']\n","    conditions = row['conditions']\n","    description = row['description']\n","\n","    read = f\"\"\"Use the drug and the clinical trial description to rate the importance of a clinical trial with respect to human health.\n","    For the Drug Name: {drug_name},\n","    Conditions: {conditions},\n","    Description of a clinical trial: {description}\n","    \"\"\"\n","    result = pipe(description, truncation=True, max_length=512)\n","    label = result[0]['label']\n","    score = result[0]['score']\n","\n","    lloydmeta_cond_class.append(label)\n","    lloydmeta_ratings.append(score)\n","\n","df['Model_lloydmeta_Class'] = lloydmeta_cond_class\n","df['Model_lloydmeta_Score'] = lloydmeta_ratings\n","df"]},{"cell_type":"code","execution_count":null,"id":"3cac2757-5228-41ea-b242-d799f5f872f8","metadata":{"id":"3cac2757-5228-41ea-b242-d799f5f872f8"},"outputs":[],"source":["len(df['conditions'].value_counts()) # Output: 674\n","len(df['Model_lloydmeta_Class'].value_counts()) # Output: 231"]},{"cell_type":"markdown","id":"b59f5b72-18fc-4d2f-8b6d-9b089e5e7822","metadata":{"id":"b59f5b72-18fc-4d2f-8b6d-9b089e5e7822"},"source":["# ClinicalTrialBioBERT-NLI4CT (domenicrosati/ClinicalTrialBioBert-NLI4CT)\n","\n","https://huggingface.co/domenicrosati/ClinicalTrialBioBert-NLI4CT\n","\n","Purpose: Performs Natural Language Inference (NLI) to evaluate the alignment between clinical trial descriptions and specific medical statements.\n","Architecture: Based on BioBERT, pre-trained on biomedical literature and fine-tuned for NLI tasks.\n","Training Data: NLI4CT dataset with 2,400 annotated statements and clinical trial reports (Source).\n","Rationale for Use: Specializes in biomedical text and NLI tasks.\n","Derived Features: Model_domenicrosati_ratings: Inference scores for trial descriptions and medical statements alignment."]},{"cell_type":"code","execution_count":null,"id":"8ec04ee4-00ab-46bd-8bab-248bb52097a5","metadata":{"id":"8ec04ee4-00ab-46bd-8bab-248bb52097a5"},"outputs":[],"source":["# Load the pipeline with truncation enabled\n","pipe = pipeline(\n","    \"text-classification\",\n","    model=\"domenicrosati/ClinicalTrialBioBert-NLI4CT\",\n","    tokenizer=\"domenicrosati/ClinicalTrialBioBert-NLI4CT\",\n","    device=0,\n",")\n","\n","text_sentiment = \"The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.\"\n","pipe(text_sentiment)\n","# Output: [{'label': 'LABEL_0', 'score': 0.6252451539039612}]"]},{"cell_type":"code","execution_count":null,"id":"5b0c336a-7d49-4afe-ac53-1bdc5dd4d639","metadata":{"id":"5b0c336a-7d49-4afe-ac53-1bdc5dd4d639"},"outputs":[],"source":["domenicrosati_ratings = []\n","\n","# Iterate through rows in the dataframe\n","for index, row in df.iterrows():\n","    drug_name = row['Drug Name']\n","    conditions = row['conditions']\n","    description = row['description']\n","\n","    # read = f\"\"\"Use the drug and the clinical trial description to rate the importance of a clinical trial with respect to human health.\n","    # For the Drug Name: {drug_name},\n","    # Conditions: {conditions},\n","    # Description of a clinical trial: {description}\n","    # \"\"\"\n","\n","    read = f\"\"\"Determine if the following statement is entailed by or contradicts the given clinical trial description:\n","    - Statement: 'This clinical trial significantly improves human health for the drug {drug_name} targeting {conditions}.'\n","    - Clinical Trial Description: {description}\n","    \"\"\"\n","\n","    result = pipe(description, truncation=True, max_length=512)\n","    label = result[0]['label']\n","    score = result[0]['score']\n","\n","    domenicrosati_ratings.append(score)\n","\n","df['Model_domenicrosati_ratings'] = domenicrosati_ratings"]},{"cell_type":"markdown","id":"8bbf4cb9-8ce8-4f3b-8c21-abf76e7a503e","metadata":{"id":"8bbf4cb9-8ce8-4f3b-8c21-abf76e7a503e"},"source":["# Shahidu Model\n","\n","- **DID NOT GIVE GOOD RESULTS**"]},{"cell_type":"code","execution_count":null,"id":"d494bb8a-a5bd-4efd-bf3d-a3bb102e8ec8","metadata":{"id":"d494bb8a-a5bd-4efd-bf3d-a3bb102e8ec8"},"outputs":[],"source":["pipe = pipeline(\n","    \"text-classification\",\n","    model=\"shahidul034/drug_sentiment_analysis\",\n","    device=0\n",")\n","\n","# clinical trial description\n","description = \"This study evaluates a new drug for treating stage 4 advanced-stage cancer.\"\n","result = pipe(description)\n","print(result)\n","# OUTPUT: [{'label': 'bad', 'score': 0.7511181235313416}]"]},{"cell_type":"code","execution_count":null,"id":"7b0215ab-1fbe-4e5e-b91e-5f14839b1638","metadata":{"id":"7b0215ab-1fbe-4e5e-b91e-5f14839b1638"},"outputs":[],"source":["# Clinical trial description\n","description = \"This study evaluates a new drug for treating stage 1 cancer.\"\n","result = pipe(description)\n","print(result)\n","\n","# OUTPUT: [{'label': 'bad', 'score': 0.7511181235313416}]"]},{"cell_type":"code","execution_count":null,"id":"b898e8d5-95b4-4aa9-aff2-b3899561f0f1","metadata":{"id":"b898e8d5-95b4-4aa9-aff2-b3899561f0f1"},"outputs":[],"source":["ratings = []\n","\n","# Iterate through rows in the dataframe\n","for index, row in df.iterrows():\n","    description = row['description']\n","    result = pipe(description)\n","    label = result[0]['label']\n","    score = result[0]['score']\n","\n","    if index == 100:\n","        break\n","    ratings.append((index, label, score))\n","\n","ratings"]},{"cell_type":"raw","id":"7dfb82e5-eecc-4c15-aeef-260cef7e9ea4","metadata":{"id":"7dfb82e5-eecc-4c15-aeef-260cef7e9ea4"},"source":["[(0, 'bad', 0.7511181831359863),\n"," (1, 'bad', 0.7511180639266968),\n"," (2, 'bad', 0.751118540763855),\n"," (3, 'bad', 0.7511182427406311),\n"," (4, 'bad', 0.7511183619499207),\n"," (5, 'bad', 0.7511183023452759),\n"," (6, 'bad', 0.7511183023452759),\n"," (7, 'bad', 0.7511183023452759),\n"," (8, 'bad', 0.7511182427406311),\n"," (9, 'bad', 0.7511182427406311),\n"," (10, 'bad', 0.7511181831359863),\n"," (11, 'bad', 0.7511181831359863),\n"," (12, 'bad', 0.7511181831359863),\n"," (13, 'bad', 0.7511181831359863),\n"," (14, 'bad', 0.7511183023452759),\n"," (15, 'bad', 0.7511182427406311),\n"," (16, 'bad', 0.7511182427406311),\n"," (17, 'bad', 0.7511182427406311),\n"," (18, 'bad', 0.7511181831359863),\n"," (19, 'bad', 0.7511182427406311),\n"," (20, 'bad', 0.7511182427406311),\n"," (21, 'bad', 0.7511181831359863),\n"," (22, 'bad', 0.7511183023452759),\n"," (23, 'bad', 0.7511182427406311),\n"," (24, 'bad', 0.7511182427406311),\n"," (25, 'bad', 0.7511180639266968),\n"," (26, 'bad', 0.7511181831359863),\n"," (27, 'bad', 0.7511182427406311),\n"," (28, 'bad', 0.7511181235313416),\n"," (29, 'bad', 0.7511181831359863),\n"," (30, 'bad', 0.7511181831359863),\n"," (31, 'bad', 0.7511181831359863),\n"," (32, 'bad', 0.7511182427406311),\n"," (33, 'bad', 0.7511183023452759),\n"," (34, 'bad', 0.7511181235313416),\n"," (35, 'bad', 0.7511181831359863),\n"," (36, 'bad', 0.7511181235313416),\n"," (37, 'bad', 0.7511181831359863),\n"," (38, 'bad', 0.7511181831359863),\n"," (39, 'bad', 0.7511182427406311),\n"," (40, 'bad', 0.7511181831359863),\n"," (41, 'bad', 0.7511181831359863),\n"," (42, 'bad', 0.7511183023452759),\n"," (43, 'bad', 0.7511181235313416),\n"," (44, 'bad', 0.7511182427406311),\n"," (45, 'bad', 0.7511183023452759),\n"," (46, 'bad', 0.7511181831359863),\n"," (47, 'bad', 0.7511181831359863),\n"," (48, 'bad', 0.7511183023452759),\n"," (49, 'bad', 0.7511181831359863),\n"," (50, 'bad', 0.7511181831359863),\n"," (51, 'bad', 0.7511181831359863),\n"," (52, 'bad', 0.7511182427406311),\n"," (53, 'bad', 0.7511183619499207),\n"," (54, 'bad', 0.7511181831359863),\n"," (55, 'bad', 0.7511182427406311),\n"," (56, 'bad', 0.7511181831359863),\n"," (57, 'bad', 0.7511180639266968),\n"," (58, 'bad', 0.7511181831359863),\n"," (59, 'bad', 0.7511181831359863),\n"," (60, 'bad', 0.7511181831359863),\n"," (61, 'bad', 0.7511182427406311),\n"," (62, 'bad', 0.7511181235313416),\n"," (63, 'bad', 0.7511181831359863),\n"," (64, 'bad', 0.7511183023452759),\n"," (65, 'bad', 0.7511182427406311),\n"," (66, 'bad', 0.7511181831359863),\n"," (67, 'bad', 0.7511181831359863),\n"," (68, 'bad', 0.7511183619499207),\n"," (69, 'bad', 0.7511183023452759),\n"," (70, 'bad', 0.7511180639266968),\n"," (71, 'bad', 0.7511181831359863),\n"," (72, 'bad', 0.7511181831359863),\n"," (73, 'bad', 0.7511181831359863),\n"," (74, 'bad', 0.7511181831359863),\n"," (75, 'bad', 0.7511181831359863),\n"," (76, 'bad', 0.7511181831359863),\n"," (77, 'bad', 0.7511181831359863),\n"," (78, 'bad', 0.7511181831359863),\n"," (79, 'bad', 0.7511181831359863),\n"," (80, 'bad', 0.7511182427406311),\n"," (81, 'bad', 0.7511182427406311),\n"," (82, 'bad', 0.7511183023452759),\n"," (83, 'bad', 0.7511183023452759),\n"," (84, 'bad', 0.7511183023452759),\n"," (85, 'bad', 0.7511181831359863),\n"," (86, 'bad', 0.7511181831359863),\n"," (87, 'bad', 0.7511184215545654),\n"," (88, 'bad', 0.7511182427406311),\n"," (89, 'bad', 0.7511181831359863),\n"," (90, 'bad', 0.7511181831359863),\n"," (91, 'bad', 0.7511181831359863),\n"," (92, 'bad', 0.7511181235313416),\n"," (93, 'bad', 0.7511183023452759),\n"," (94, 'bad', 0.7511182427406311),\n"," (95, 'bad', 0.7511182427406311),\n"," (96, 'bad', 0.7511183023452759),\n"," (97, 'bad', 0.7511181235313416),\n"," (98, 'bad', 0.7511183023452759),\n"," (99, 'bad', 0.7511182427406311)]"]},{"cell_type":"markdown","id":"cadf66fc-254c-4707-8b65-2009b454a3f2","metadata":{"id":"cadf66fc-254c-4707-8b65-2009b454a3f2"},"source":["# HuggingFaceTB/SmolLM2-1.7B-Instruct\n","\n","- **DID NOT WORK WELL**"]},{"cell_type":"code","execution_count":null,"id":"cad763bc-8401-4820-88b7-0f422cd26c6c","metadata":{"id":"cad763bc-8401-4820-88b7-0f422cd26c6c"},"outputs":[],"source":["# Initialize the pipeline with the specified model\n","pipe = pipeline(\n","    \"text-generation\",\n","    model=\"HuggingFaceTB/SmolLM2-1.7B-Instruct\",\n","    device=0\n",")"]},{"cell_type":"code","execution_count":null,"id":"a482439b-d122-498f-968a-06999ccb3847","metadata":{"id":"a482439b-d122-498f-968a-06999ccb3847"},"outputs":[],"source":["def extract_gender_and_pregnancy_criteria(text):\n","    \"\"\"\n","    Extract gender and pregnancy-related criteria or return 'NA' if no information is mentioned.\n","    Outputs should be distinct for inclusion and exclusion criteria.\n","    \"\"\"\n","    # Simplified and focused prompt\n","    prompt_template = \"\"\"\n","    Clinical Trial Text: {text}\n","\n","    Extract the following:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","    \"\"\"\n","\n","    # Format the prompt with the input text\n","    prompt = prompt_template.format(text=text)\n","\n","    # Generate response with stricter parameters for concise output\n","    response = pipe(\n","        prompt,\n","        max_length=100,\n","        temperature=0.1,  # Lower temperature for deterministic output\n","        num_return_sequences=1,\n","        do_sample=False  # Ensure deterministic behavior\n","    )\n","    return response[0]['generated_text']\n","\n","# Test example\n","example_text = \"Inclusion Criteria: * Males and females age 21-50. Exclusion Criteria: * Pregnant women.\"\n","\n","# Generate the response\n","output = extract_gender_and_pregnancy_criteria(example_text)\n","print(output)"]},{"cell_type":"raw","id":"d6faf644-cf3f-4cdd-8123-1561d0e6452d","metadata":{"id":"d6faf644-cf3f-4cdd-8123-1561d0e6452d"},"source":["Clinical Trial Text: Inclusion Criteria: * Males and females age 21-50. Exclusion Criteria: * Pregnant women.\n","\n","    Extract the following:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","2. **Clinical Trial Text: Inclusion Criteria: Age 21-50, Exclusion Criteria: Pregnancy**\n","    Clinical Trial Text: Inclusion Criteria: Age 21-5"]},{"cell_type":"code","execution_count":null,"id":"c8203fa2-11cf-4cc7-9a4d-32a2eaee305d","metadata":{"id":"c8203fa2-11cf-4cc7-9a4d-32a2eaee305d"},"outputs":[],"source":["# Example input\n","example_text = df['criteria'][0]\n","\n","# Generate the response\n","output = extract_gender_and_pregnancy_criteria(example_text)\n","print(output)"]},{"cell_type":"raw","id":"99f4e956-da1c-48db-865d-3b46a798a53a","metadata":{"id":"99f4e956-da1c-48db-865d-3b46a798a53a"},"source":["\n","    Extract gender and pregnancy-related criteria from the following clinical trial text:\n","    Text: Please contact site for information.\n","\n","    Respond with:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","    Do not invent information. If no information is available, respond with 'NA'.\n","\n","2. Extract gender and pregnancy-related criteria from the following clinical trial text:\n","    Text: Please contact site for information.\n","\n","    Respond with:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","    Do not invent information. If no information is available, respond with 'NA'.\n","\n","3. Extract gender and pregnancy-related criteria from the following clinical trial text:\n","    Text: Please contact site for information.\n","\n","    Respond with:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","    Do not invent information. If no information is available, respond with 'NA'.\n","\n","4. Extract gender and pregnancy-related criteria from the following clinical trial text:\n","    Text: Please contact site for information.\n","\n","    Respond with:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","    Do not invent information. If no information is available, respond with 'NA'.\n","\n","5. Extract gender and pregnancy-related criteria from the following clinical trial text:\n","    Text: Please contact site for information.\n","\n","    Respond with:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","    Do not invent information. If no information is available, respond with 'NA'.\n","\n","6. Extract gender and pregnancy-related criteria from the following clinical trial text:\n","    Text: Please contact site for information.\n","\n","    Respond with:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","    Do not invent information. If no information is available, respond with 'NA'.\n","\n","7. Extract gender and pregnancy-related criteria from the following clinical trial text:\n","    Text: Please contact site for information.\n","\n","    Respond with:\n","    Inclusion: [Gender criteria and pregnancy status or 'NA']\n","    Exclusion: [Gender criteria and pregnancy status or 'NA']\n","\n","    Do not invent information. If"]},{"cell_type":"markdown","id":"51adcbcc-e499-4e9f-adbf-1e85a56cf6c4","metadata":{"id":"51adcbcc-e499-4e9f-adbf-1e85a56cf6c4"},"source":["# Text to Text Generation\n","- **DID NOT WORK WELL**"]},{"cell_type":"code","execution_count":null,"id":"faae684e-3f56-466d-a3c2-ccae4e39cdad","metadata":{"id":"faae684e-3f56-466d-a3c2-ccae4e39cdad"},"outputs":[],"source":["# Initialize the T5 text generation pipeline\n","pipe = pipeline(\n","    \"text2text-generation\",\n","    model=\"t5-large\",  # 't5-small' or 't5-large'\n","    device=0  # Set to -1 if using CPU\n",")\n","\n","def extract_criteria(text):\n","    prompt = (\n","        \"Extract the following information from the clinical trial text:\\n\"\n","        \"- Gender requirements [Male/Female/None]\"\n","        \"- Pregnancy- information [Pregnancy required/Not pregnant/NA]\\n\\n\"\n","        \"Ensure:\\n\"\n","        \"1. If no relevant information is mentioned, return 'NA'.\\n\"\n","        \"2. Do not fabricate any information.\\n\\n\"\n","        f\"Text:\\n{text}\\n\\n\"\n","        \"Respond as:\\n\"\n","        \"Inclusion: Gender: [] | Pregnancy: []\\n\"\n","        \"Exclusion: Gender: [] | Pregnancy: []\"\n","    )\n","    response = pipe(prompt, max_length=512, do_sample=False)\n","    return response[0]['generated_text']\n","\n","clinical_trial_text = \"\"\"\n","Inclusion Criteria:\n","* Female participants aged 18-45 years.\n","* Must not be pregnant at the time of enrollment.\n","Exclusion Criteria:\n","* Pregnant or breastfeeding women.\n","* Male participants.\n","\"\"\"\n","\n","result = extract_criteria(clinical_trial_text)\n","print(result)\n","# OUTPUT: Text: Inclusion: Gender: [] | Pregnancy: [] Exclusion: Gender: [] | Pregnancy: []"]},{"cell_type":"markdown","id":"569235d2-977d-47b8-be5f-b0198e2c041f","metadata":{"id":"569235d2-977d-47b8-be5f-b0198e2c041f"},"source":["# Laboratory and biomarker values\n","\n","- **DID NOT WORK WELL**"]},{"cell_type":"code","execution_count":null,"id":"071f09b9-3985-44aa-9bfb-7c37862a0d31","metadata":{"id":"071f09b9-3985-44aa-9bfb-7c37862a0d31"},"outputs":[],"source":["# Initialize the pipeline with Llama3.2 1B Instruct model\n","pipe = pipeline(\n","    \"text-generation\",\n","    model=\"/kaggle/input/llama-3.2/transformers/3b-instruct/1\",\n","    device=0,\n","    tokenizer=\"/kaggle/input/llama-3.2/transformers/3b-instruct/1\",\n",")\n","\n","# Define the chatbot's role and expertise\n","chatbot_role = \"\"\"\n","You are an expert in clinical research and data extraction.\n","Your task is to extract only measurable laboratory and biomarker values (e.g., numerical ranges, thresholds) from the provided clinical trial criteria text.\n","Avoid listing general laboratory tests without measurable values.\n","\"\"\"\n","\n","def extract_lab_values(text):\n","    # Define the focused extraction prompt\n","    prompt_template = \"\"\"\n","    Extract all measurable laboratory and biomarker values from the following text.\n","    Focus on numerical thresholds, ranges, or results, and exclude general test names unless paired with measurable values.\n","    Present the extracted data in a structured JSON format as follows:\n","    [\n","        {\n","            \"Biomarker\": \"<name>\",\n","            \"Condition\": \"<relevant condition or test context>\",\n","            \"Value\": \"<numerical value or range>\",\n","            \"Unit\": \"<measurement unit>\"\n","        },\n","        ...\n","    ]\n","\n","    Text:\n","    {text}\n","    \"\"\"\n","    # Create messages for the model\n","    messages = [\n","        {\"role\": \"system\", \"content\": chatbot_role},\n","        {\"role\": \"user\", \"content\": prompt_template.format(text=text)},\n","    ]\n","\n","    # Generate the response\n","    response = pipe(messages, max_new_tokens=128, temperature=0.5, num_return_sequences=1)\n","    return response[0]['generated_text']"]},{"cell_type":"raw","id":"f9973e83-a850-4d2c-8ebc-ebdeb70b8896","metadata":{"id":"f9973e83-a850-4d2c-8ebc-ebdeb70b8896"},"source":["{'role': 'assistant',\n"," 'content': 'Here are the extracted laboratory and biomarker values with specific thresholds or ranges:\\n\\n- Test: BMI, Value: > 95th percentile, Unit: percentile\\n- Test: Fasting glucose, Value: â‰¥ 126 mg/dL, Unit: mg/dL\\n- Test: A1C, Value: â‰¥ 6.5%, Unit: %\\n- Test: LDL cholesterol, Value: â‰¥ 130 mg/dL, Unit: mg/dL\\n- Test: Serum ALT, Value: > 2 times the upper limit of normal, Unit: (no unit specified)\\n- Test: Serum AST, Value: > 2 times the upper limit of normal, Unit: (no unit specified)\\n- Test: Creatinine clearance,'}"]},{"cell_type":"code","execution_count":null,"id":"b969ca5a-8bae-4dac-8e43-3f899e87fb28","metadata":{"id":"b969ca5a-8bae-4dac-8e43-3f899e87fb28"},"outputs":[],"source":["# Define the chatbot's role\n","chatbot_role = \"\"\"\n","You are an expert in clinical research and data extraction.\n","Your task is to extract **only measurable laboratory and biomarker values** with their specific thresholds or ranges from clinical trial text.\n","Output the results in this format for each value:\n","- Test: <test name>, Value: <value>, Unit: <unit>\n","Do not include any other text.\n","\"\"\"\n","\n","def extract_lab_values(text):\n","    # Define the extraction prompt\n","    prompt_template = f\"\"\"\n","    Extract measurable laboratory and biomarker values from the text below.\n","    Include values with specific thresholds or ranges and their units.\n","    If a value or unit is not present, state 'None'. Use this format:\n","    - Test: <test name>, Value: <value>, Unit: <unit>\n","\n","    Text:\n","    {text}\n","    \"\"\"\n","    # Generate the response\n","    messages = [\n","        {\"role\": \"system\", \"content\": chatbot_role},\n","        {\"role\": \"user\", \"content\": prompt_template},\n","    ]\n","    response = pipe(messages, max_new_tokens=150, temperature=0.3, num_return_sequences=1)\n","\n","    # Extract and clean response content\n","    return response[0]['generated_text'][-1]['content']\n","\n","# Example clinical trial text\n","example_text = \"\"\"\n","Inclusion Criteria:\n","* Obesity: BMI > 95th percentile for age and sex.\n","* Fasting glucose â‰¥ 126 mg/dL or A1C â‰¥ 6.5%.\n","* LDL cholesterol â‰¥ 130 mg/dL.\n","* Serum ALT or AST > 2 times the upper limit of normal.\n","* Creatinine clearance < 50 mL/min.\n","\"\"\"\n","\n","# Extract values\n","extracted_values = extract_lab_values(example_text)\n","print(extracted_values)"]},{"cell_type":"raw","id":"6f37c0c3-1cb1-4db5-b8dc-506a7da3e481","metadata":{"id":"6f37c0c3-1cb1-4db5-b8dc-506a7da3e481"},"source":["- Test: Fasting glucose, Value: â‰¥ 126 mg/dL, Unit: mg/dL\n","- Test: A1C, Value: â‰¥ 6.5%, Unit: %\n","- Test: LDL cholesterol, Value: â‰¥ 130 mg/dL, Unit: mg/dL\n","- Test: Serum ALT, Value: > 2 times the upper limit of normal, Unit: None\n","- Test: Serum AST, Value: > 2 times the upper limit of normal, Unit: None\n","- Test: Creatinine clearance, Value: < 50 mL/min, Unit: mL/min"]},{"cell_type":"code","execution_count":null,"id":"c0ffc4ef-1747-4bc1-8df9-ba5e05d55eb1","metadata":{"id":"c0ffc4ef-1747-4bc1-8df9-ba5e05d55eb1"},"outputs":[],"source":["laboratory_values = []\n","\n","for i, crit in df['criteria'].items():\n","    extracted_values = extract_lab_values(crit)\n","\n","    laboratory_values.append(extracted_values)\n","    print(f'{i}: {crit}')\n","    print(laboratory_values)\n","\n","    print()\n","    print('â€“â€“â€“â€“â€“â€“â€“â€“'*10)\n","\n","    if i == 10:\n","        break\n","    if i % 100 == 0:\n","        print(i)\n"]},{"cell_type":"raw","id":"97c0d53b-f756-4fb5-8f9d-015cb05bbb56","metadata":{"id":"97c0d53b-f756-4fb5-8f9d-015cb05bbb56"},"source":["0: Please contact site for information.\n","['- Test: None, Value: None, Unit: None']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","0\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","1: Please contact site for information.\n","['- Test: None, Value: None, Unit: None', '- None']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","2: Inclusion Criteria:~* Individuals starting methotrexate for rheumatoid arthritis.~* Study subjects should not currently be taking folic acid-containing vitamins.~Exclusion Criteria:~* Cancer, renal, or liver disease.~* Previous use of methotrexate within the past 6 months or current use of folic acid-containing supplements.\n","['- Test: None, Value: None, Unit: None', '- None', 'None']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","3: Inclusion Criteria:~* Alaska Native having biological Alaska Native ancestry.~* Meets criteria for alcohol dependence.~* Prior to entering the study must be abstinent between 3 and 14 days and have a withdrawal assessment.~* Stable residence to ensure that subjects can be located during the study.~Exclusion Criteria:~* Currently meets criteria for abuse or dependence on substances other than alcohol or nicotine.~* Current use of disulfiram.~* Psychotic or otherwise severely psychiatrically disabled.~* Use of other psychotropic medications including antidepressants and anxiolytics.~* Medical conditions that would not permit the use of sertraline or naltrexone, such as a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine, gastrointestinal or kidney disease.~* Hepatocellular disease or elevated bilirubin levels.~* Females who are pregnant, nursing, or not using a reliable method of birth control.~* Probation or parole requirements that might interfere with participation in the study.~* Involvement in alcohol treatment other than provided by the study or AA.~* Use of monoamine oxidase inhibitors in the past month.~* Current use of Type 1C antiarrhythmics propafenone and flecainide.\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","4: * INCLUSION CRITERIA:~Good general health. Individuals taking medications for obesity-related comorbid conditions will not be excluded.~Obesity: body mass index for age and triceps skinfold above the 95th percentile (determined by NHANES I age-, sex-, and race- specific data). All subjects will be required to be over 60 kg in body weight.~Evidence for a quantifiable obesity-related comorbidity. Examples include: systolic or diastolic hypertension (determined by age-specific charts); frank Type 2 diabetes, impaired glucose tolerance assessed by oral glucose tolerance testing; hyperinsulinemia (defined as a fasting insulin greater than 15 mIU/mL); significant hyperlipidemia (total cholesterol greater than 200 mg/dL, LDL cholesterol greater than 129 mg/dL or fasting triglycerides greater than 200 mg/dL); hepatic steatosis (SGPT or SGOT above normal range with negative hepatitis studies) or sleep apnea documented by a sleep study.~Age 12 to 17 years at the start of the study.~For girls with childbearing potential, a negative pregnancy test before taking and while taking study medication. Sexually active females must be using an effective form of birth control. These methods include total abstinence (no sex), oral contraceptives (the pill), an intrauterine device (IUD), levonogestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.~Race of all four grandparents self-identified as either all Caucasian or all African American.~EXCLUSION CRITERIA:~Volunteers will be excluded (and referred to non-experimental treatment programs) for the following reasons:~Presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal, most endocrinologic (e.g., Cushing syndrome), or pulmonary disorders (other than either asthma not requiring continuous medication or sleep apnea-related disorders);~Adolescent girls who are pregnant, who are currently nursing an infant, or who are having unprotected intercourse;~Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study;~Subjects who regularly use prescription medications unrelated to the complications of obesity. Oral contraceptive use will be permitted, provided the contraceptive has been used for at least two months before starting study medication. The use of over-the-counter and prescription medications will be reviewed on a case-by-case basis; depending on the medication, subjects who have continued to take prescription medication for at least 3 months prior to study entry may be eligible;~Recent use (within six months) of anorexiant medications for the purpose of weight reduction;~Inability to undergo MRI (e.g., volunteers with metal within their bodies including cardiac pacemakers, neural pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants, non-detachable electronic or electromechanical devices such as infusion pumps, nerve stimulators, bone growth stimulators, etc. that are contraindications).~For pilot study participants, hypersensitivity or allergy to methylene blue. Individuals with documented G6PD deficiency will be excluded.~INCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:~Volunteers will qualify for inclusion if they meet the following criteria:~1. Good general health.~2. Age 12-17 years at study entry.~3. Body mass index (BMI) for age above the 5th percentile and below 85th percentile, which is considered normal weight by CDC growth chart standards.~4. For females with childbearing potential, a negative pregnancy test at initial evaluation.~5. Race of all four grandparents self-identified as either all Caucasian or all African American.~EXCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:~Volunteers will be excluded for the following reasons:~1. Presence of past or present medical problems which would impair performance during the exercise tests;~2. Females who are pregnant, or who are currently nursing an infant;~3. Individuals who have, or whose parent or guardian has, current substance abuse or a psychiatric disorder or other condition that in the opinion of the investigators would impede competence or possibly hinder completion of the study;~4. Recent weight change of more than 3% of body weight in the past two months;~5. Recent use (within six months) of anorexiant medications for the purpose of weight reduction;~6. Physical impairments that would prevent completion of either the walk/run test or the cycle test.\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Fasting Insulin, Value: > 15 mIU/mL, Unit: mIU/mL\\n- Test: Total Cholesterol, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: LDL Cholesterol, Value: > 129 mg/dL, Unit: mg/dL\\n- Test: Fasting Triglycerides, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: above normal range, Unit: None\\n- Test: SGOT, Value: above normal range, Unit: None\\n- Test: BMI, Value: above 5th percentile']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","5: * INCLUSION CRITERIA:~PATIENTS:~Patients with metastatic solid tumors ( breast, cholangiocarcinoma, small intestine/colon/rectal, adenocarcinoma, esophageal/gastric, hepatocellular, pancreatic, prostate, bony/soft tissue sarcomas, which are histologically confirmed, progressive and incurable.~Due to low accrual, effective 12/19/2006, patients with adrenal, basal cell, transitional cell carcinoma of the bladder or uroepithelium, ovarian, small cell lung cancer, non small cell lung cancer, and adenocarcinomas of unknown primary origin are no longer eligible for the trial.~Age greater than or equal to 10 to less than or equal to 80.~No known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy.~Metastatic disease, which is bi-dimensionally evaluable radiographically.~No prior treatment for neoplasm within 30 days.~Ability to comprehend the investigational nature of the study and provide informed consent.~Availability of HLA identical or single HLA-locus mismatched family donor.~Willingness and availability to return to the NIH for scheduled follow-ups.~DONOR:~HLA identical or single HLA-locus mismatched family donor~Age greater than or equal to 10 up to 80 years old.~Ability to comprehend the investigational nature of the study and provide informed consent.~EXCLUSION CRITERIA:~PATIENT:~Pregnant or lactating.~Age less than 10 or greater than 80 years.~ECOG performance status of 3 or more.~Psychiatric disorder or mental deficiency severe as to make compliance with the BMT treatment unlikely, and making informed consent impossible.~Major anticipated illness or organ failure incompatible with survival from PBSC transplant.~DLCO: less than 40% predicted.~Left ventricular ejection fraction: less than 30%.~Serum creatinine greater than 2.5mg/dl or creatinine clearance less than 50 cc/min by 24 hr urine collection.~Serum bilirubin greater than 4 mg/dl~Transaminases greater than 5 times the upper limit of normal.~Oral intake less than 1,200 calories/day.~Recent weight loss of greater than or equal to 10% of actual body weight.~Life expectancy less than 3 months~Therapy for malignancy within 4 weeks of beginning protocol.~CNS metastatic disease associated with intracranial bleeding, uncontrolled seizure disorder or significant intracranial mass effect.~Other malignant diseases liable to relapse or progress within 5 years.~Uncontrolled infection.~DONOR:~Pregnant or lactating.~Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia).~Age less than 10 or greater than 80 years.~HIV positive. Donors who are positive for HBV, HCV or HTLV-I may be used at the discretion of the investigator following counseling and approval from the recipient.\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Fasting Insulin, Value: > 15 mIU/mL, Unit: mIU/mL\\n- Test: Total Cholesterol, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: LDL Cholesterol, Value: > 129 mg/dL, Unit: mg/dL\\n- Test: Fasting Triglycerides, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: above normal range, Unit: None\\n- Test: SGOT, Value: above normal range, Unit: None\\n- Test: BMI, Value: above 5th percentile', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: DLCO, Value: less than 40% predicted, Unit: predicted\\n- Test: Left ventricular ejection fraction, Value: less than 30%, Unit: None\\n- Test: Serum creatinine, Value: greater than 2.5mg/dl, Unit: mg/dl\\n- Test: Creatinine clearance, Value: less than 50 cc/min, Unit: cc/min\\n- Test: Serum bilirubin, Value: greater than 4 mg/dl, Unit: mg/dl\\n- Test: Transaminases, Value: greater than 5 times the upper limit of normal, Unit: None']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","6: Inclusion Criteria~Patients may be eligible for this study if they:~* Are HIV-positive.~* Have an HIV blood level between 2,000 and 200,000 copies/ml.~* Have a CD4 cell count of at least 100 cells/mm3.~* Are 18 years of age or older.~* Are available for follow-up for at least 48 weeks.~* Agree to use a barrier method of birth control (such as condoms) during the study.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Have ever received anti-HIV (antiretroviral) treatment.~* Have an HIV-related opportunistic infection or condition at the time of study entry.~* Have primary HIV infection, meaning they have recently been infected.~* Have had severe diarrhea within the 30 days before study entry.~* Have hemophilia.~* Have a history of pancreatitis, hepatitis, or a peripheral neuropathy.~* Are unable to tolerate oral medication.~* Are pregnant or breast-feeding.~* Abuse alcohol or drugs.\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Fasting Insulin, Value: > 15 mIU/mL, Unit: mIU/mL\\n- Test: Total Cholesterol, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: LDL Cholesterol, Value: > 129 mg/dL, Unit: mg/dL\\n- Test: Fasting Triglycerides, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: above normal range, Unit: None\\n- Test: SGOT, Value: above normal range, Unit: None\\n- Test: BMI, Value: above 5th percentile', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: DLCO, Value: less than 40% predicted, Unit: predicted\\n- Test: Left ventricular ejection fraction, Value: less than 30%, Unit: None\\n- Test: Serum creatinine, Value: greater than 2.5mg/dl, Unit: mg/dl\\n- Test: Creatinine clearance, Value: less than 50 cc/min, Unit: cc/min\\n- Test: Serum bilirubin, Value: greater than 4 mg/dl, Unit: mg/dl\\n- Test: Transaminases, Value: greater than 5 times the upper limit of normal, Unit: None', '- Test: HIV blood level, Value: 2,000-200,000, Unit: copies/ml\\n- Test: CD4 cell count, Value: 100, Unit: cells/mm3']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","7: DISEASE CHARACTERISTICS: Histologically proven previously untreated (except surgically) primitive neuroectodermal tumors (including medulloblastoma, anaplastic ependymoma, ependymoblastoma, or pineoblastoma) or high-grade astrocytomas Low-grade astrocytomas or optic tract tumors that are incompletely resected and have a progressive course not amenable to further surgery may also be allowed Evaluable disease by MRI, CT scan, or CT myelography~PATIENT CHARACTERISTICS: Age: Under 4 years Performance status: Not specified Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count greater than 1,500/mm3 WBC greater than 4,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGPT less than 90 IU/dL Renal: Creatinine clearance greater than 80 mL/min~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No prior mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) No prior high-dose methotrexate No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy Surgery: See Disease Characteristics Other: Recovered from acute toxic effects of any prior therapy Must be on a tyramine-free diet during procarbazine administration\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Fasting Insulin, Value: > 15 mIU/mL, Unit: mIU/mL\\n- Test: Total Cholesterol, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: LDL Cholesterol, Value: > 129 mg/dL, Unit: mg/dL\\n- Test: Fasting Triglycerides, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: above normal range, Unit: None\\n- Test: SGOT, Value: above normal range, Unit: None\\n- Test: BMI, Value: above 5th percentile', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: DLCO, Value: less than 40% predicted, Unit: predicted\\n- Test: Left ventricular ejection fraction, Value: less than 30%, Unit: None\\n- Test: Serum creatinine, Value: greater than 2.5mg/dl, Unit: mg/dl\\n- Test: Creatinine clearance, Value: less than 50 cc/min, Unit: cc/min\\n- Test: Serum bilirubin, Value: greater than 4 mg/dl, Unit: mg/dl\\n- Test: Transaminases, Value: greater than 5 times the upper limit of normal, Unit: None', '- Test: HIV blood level, Value: 2,000-200,000, Unit: copies/ml\\n- Test: CD4 cell count, Value: 100, Unit: cells/mm3', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Absolute granulocyte count, Value: 1,500/mm3, Unit: mm3\\n- Test: WBC, Value: 4,000/mm3, Unit: mm3\\n- Test: Platelet count, Value: 100,000/mm3, Unit: mm3\\n- Test: Bilirubin, Value: 1.5 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: 90 IU/dL, Unit: IU/dL\\n- Test: Creatinine clearance, Value: 80 mL/min, Unit: mL/min']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","8: DISEASE CHARACTERISTICS: Newly diagnosed undifferentiated nonlymphoblastic non-Hodgkin's lymphoma (Burkitt's or non-Burkitt's) Newly diagnosed large cell lymphoma with CNS involvement Recurrent non-Hodgkin's lymphoma L-3 and B-cell leukemia included At least 1 of the following required: LDH at least 500 IU/liter (old method) or 2,000 IU/liter (new method) Bone marrow involvement (greater than 5% lymphoblasts) CNS involvement (lymphoblasts on CSF cytospin or intracranial mass on CT or MRI scan)~PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified~PRIOR CONCURRENT THERAPY: Prior therapy allowed for non-Hodgkin's lymphoma No prior therapy for all other diseases\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Fasting Insulin, Value: > 15 mIU/mL, Unit: mIU/mL\\n- Test: Total Cholesterol, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: LDL Cholesterol, Value: > 129 mg/dL, Unit: mg/dL\\n- Test: Fasting Triglycerides, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: above normal range, Unit: None\\n- Test: SGOT, Value: above normal range, Unit: None\\n- Test: BMI, Value: above 5th percentile', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: DLCO, Value: less than 40% predicted, Unit: predicted\\n- Test: Left ventricular ejection fraction, Value: less than 30%, Unit: None\\n- Test: Serum creatinine, Value: greater than 2.5mg/dl, Unit: mg/dl\\n- Test: Creatinine clearance, Value: less than 50 cc/min, Unit: cc/min\\n- Test: Serum bilirubin, Value: greater than 4 mg/dl, Unit: mg/dl\\n- Test: Transaminases, Value: greater than 5 times the upper limit of normal, Unit: None', '- Test: HIV blood level, Value: 2,000-200,000, Unit: copies/ml\\n- Test: CD4 cell count, Value: 100, Unit: cells/mm3', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Absolute granulocyte count, Value: 1,500/mm3, Unit: mm3\\n- Test: WBC, Value: 4,000/mm3, Unit: mm3\\n- Test: Platelet count, Value: 100,000/mm3, Unit: mm3\\n- Test: Bilirubin, Value: 1.5 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: 90 IU/dL, Unit: IU/dL\\n- Test: Creatinine clearance, Value: 80 mL/min, Unit: mL/min', '- Test: LDH, Value: 500 IU/liter, Unit: IU/liter\\n- Test: LDH, Value: 2,000 IU/liter, Unit: IU/liter\\n- Test: Lymphoblasts in bone marrow, Value: greater than 5%, Unit: %']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","9: DISEASE CHARACTERISTICS: Malignant germ cell tumors of the following stages and primary sites: Stage II/III/IV ovarian tumors Grade II/III immature glial teratomas Stage II/III/IV mediastinal tumors Stage II/III/IV presacral tumors and tumors of other primary sites No intracranial or testicular primary sites~PATIENT CHARACTERISTICS: Age: Child Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified~PRIOR CONCURRENT THERAPY: Not specified\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Fasting Insulin, Value: > 15 mIU/mL, Unit: mIU/mL\\n- Test: Total Cholesterol, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: LDL Cholesterol, Value: > 129 mg/dL, Unit: mg/dL\\n- Test: Fasting Triglycerides, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: above normal range, Unit: None\\n- Test: SGOT, Value: above normal range, Unit: None\\n- Test: BMI, Value: above 5th percentile', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: DLCO, Value: less than 40% predicted, Unit: predicted\\n- Test: Left ventricular ejection fraction, Value: less than 30%, Unit: None\\n- Test: Serum creatinine, Value: greater than 2.5mg/dl, Unit: mg/dl\\n- Test: Creatinine clearance, Value: less than 50 cc/min, Unit: cc/min\\n- Test: Serum bilirubin, Value: greater than 4 mg/dl, Unit: mg/dl\\n- Test: Transaminases, Value: greater than 5 times the upper limit of normal, Unit: None', '- Test: HIV blood level, Value: 2,000-200,000, Unit: copies/ml\\n- Test: CD4 cell count, Value: 100, Unit: cells/mm3', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Absolute granulocyte count, Value: 1,500/mm3, Unit: mm3\\n- Test: WBC, Value: 4,000/mm3, Unit: mm3\\n- Test: Platelet count, Value: 100,000/mm3, Unit: mm3\\n- Test: Bilirubin, Value: 1.5 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: 90 IU/dL, Unit: IU/dL\\n- Test: Creatinine clearance, Value: 80 mL/min, Unit: mL/min', '- Test: LDH, Value: 500 IU/liter, Unit: IU/liter\\n- Test: LDH, Value: 2,000 IU/liter, Unit: IU/liter\\n- Test: Lymphoblasts in bone marrow, Value: greater than 5%, Unit: %', 'None']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","10: DISEASE CHARACTERISTICS: Histologically documented diffuse small noncleaved cell lymphoma (category J by IWF) of any stage Nodal or abdominal masses with less than 25% lymphoblasts in marrow are defined as lymphoma OR Histologically documented L3 acute lymphocytic leukemia (ALL) Greater than 25% lymphoblasts in marrow is defined as ALL, regardless of presence of bulky nodal disease Lymphoma requirements include: Documentation of lymphadenopathy, splenomegaly, or hepatomegaly, presence or absence of abdominal masses, and presence or absence of B symptoms Measurable disease other than ascites and pleural effusions, bony disease, and CNS lesions Bidimensionally measurable mass on physical exam, x-ray, or CT, or MRI OR Clearly defined hepatic mass greater than 3.5 cm on CT, MRI, or ultrasound considered to represent lymphoma OR Histologically documented hepatic lymphoma with the liver extending more than 5 cm below the costal margin on quiet respiration ALL requirements include: Documentation of monoclonal surface immunoglobulin by surface immunophenotyping Lymph node biopsy strongly recommended for patients with obvious marrow involvement Disease labeled L3 but also manifested by lymphadenopathy must be evaluated as is lymphoma (see above)~PATIENT CHARACTERISTICS: Age: 15 and over Performance status: Any status Life expectancy: At least 2 years Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times normal (unless further elevation is directly attributable to malignancy) Renal: Creatinine no greater than 1.5 times normal (unless further elevation is directly attributable to malignancy) Cardiovascular: No uncontrolled or severe cardiovascular disease, e.g.: No myocardial infarction within the past 6 months No congestive heart failure Other: HIV negative No active, uncontrolled bacterial, viral, or fungal infection No active, uncontrolled duodenal ulcer No other serious medical illness No serious psychiatric condition that would preclude informed consent or protocol compliance No second malignancy within 5 years except: Curatively treated carcinoma in situ of the cervix Curatively treated basal cell carcinoma Not pregnant Effective contraception required of fertile patients~PRIOR CONCURRENT THERAPY: Biologic: No concurrent growth factors Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No concurrent palliative radiotherapy Surgery: Not specified Other: No prior therapy\n","['- Test: None, Value: None, Unit: None', '- None', 'None', 'There are no measurable laboratory or biomarker values with specific thresholds or ranges mentioned in the provided text.', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Fasting Insulin, Value: > 15 mIU/mL, Unit: mIU/mL\\n- Test: Total Cholesterol, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: LDL Cholesterol, Value: > 129 mg/dL, Unit: mg/dL\\n- Test: Fasting Triglycerides, Value: > 200 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: above normal range, Unit: None\\n- Test: SGOT, Value: above normal range, Unit: None\\n- Test: BMI, Value: above 5th percentile', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: DLCO, Value: less than 40% predicted, Unit: predicted\\n- Test: Left ventricular ejection fraction, Value: less than 30%, Unit: None\\n- Test: Serum creatinine, Value: greater than 2.5mg/dl, Unit: mg/dl\\n- Test: Creatinine clearance, Value: less than 50 cc/min, Unit: cc/min\\n- Test: Serum bilirubin, Value: greater than 4 mg/dl, Unit: mg/dl\\n- Test: Transaminases, Value: greater than 5 times the upper limit of normal, Unit: None', '- Test: HIV blood level, Value: 2,000-200,000, Unit: copies/ml\\n- Test: CD4 cell count, Value: 100, Unit: cells/mm3', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Absolute granulocyte count, Value: 1,500/mm3, Unit: mm3\\n- Test: WBC, Value: 4,000/mm3, Unit: mm3\\n- Test: Platelet count, Value: 100,000/mm3, Unit: mm3\\n- Test: Bilirubin, Value: 1.5 mg/dL, Unit: mg/dL\\n- Test: SGPT, Value: 90 IU/dL, Unit: IU/dL\\n- Test: Creatinine clearance, Value: 80 mL/min, Unit: mL/min', '- Test: LDH, Value: 500 IU/liter, Unit: IU/liter\\n- Test: LDH, Value: 2,000 IU/liter, Unit: IU/liter\\n- Test: Lymphoblasts in bone marrow, Value: greater than 5%, Unit: %', 'None', 'Here are the measurable laboratory and biomarker values extracted from the text:\\n\\n- Test: Bilirubin, Value: 1.5 times normal, Unit: None\\n- Test: Creatinine, Value: 1.5 times normal, Unit: None']\n","\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“"]},{"cell_type":"markdown","id":"286f4371-7aa3-42d8-9271-b71ceb1cc5c0","metadata":{"id":"286f4371-7aa3-42d8-9271-b71ceb1cc5c0"},"source":["# SLM Llama3.2 3 Billion Model Parameters\n","\n","- Purpose: Evaluates the robustness of inclusion and exclusion criteria within trial descriptions.\n","- Architecture: Large language models trained on diverse datasets, focusing on clarity of trial criteria.\n","- Rationale for Use: Effective at evaluating criteria robustness.\n","- Derived Features: LLama3_2_Criteria_Robustness: Scores for inclusion/exclusion criteria robustness."]},{"cell_type":"markdown","id":"1a35a438-96b4-4db8-bc39-5469b2fd925f","metadata":{"id":"1a35a438-96b4-4db8-bc39-5469b2fd925f"},"source":["## Gender Extaction\n","\n","- **DID NOT WORK WELL**"]},{"cell_type":"code","execution_count":null,"id":"1e42c2de-187e-4bec-b229-b974eca60e11","metadata":{"id":"1e42c2de-187e-4bec-b229-b974eca60e11"},"outputs":[],"source":["# Initialize the pipeline with Llama3.2 1B Instruct model\n","pipe = pipeline(\n","    \"text-generation\",\n","    model=\"/kaggle/input/llama-3.2/transformers/3b-instruct/1\",\n","    # pad_token_id=50256,  # Explicitly set pad_token_id\n","    # eos_token_id=50256,   # Explicitly set eos_token_id\n","    device=0\n",")"]},{"cell_type":"code","execution_count":null,"id":"c0ff8eeb-068e-455e-8046-68683dd9f1aa","metadata":{"id":"c0ff8eeb-068e-455e-8046-68683dd9f1aa"},"outputs":[],"source":["chatbot_role = \"\"\"\n","You are an expert clinical trial criteria extractor.\n","You extract **gender information only** from the trial criteria text, identifying if males or females are included.\n","If no gender is mentioned, you respond with 'Both' if no actualy criteria was giving respond with NA.\n","You strictly format responses as follows:\n","- Inclusion Criteria: [Male/Female/Both/NA]\n","You do not extract or mention pregnancy.\n","\"\"\"\n","\n","def extract_gender_and_pregnancy(text):\n","    prompt_template = \"\"\"\n","    Here is the text, do your role:\n","    {text}\n","    \"\"\"\n","    # Role and message definition\n","    messages = [\n","        {\"role\": \"system\", \"content\": chatbot_role},\n","        {\"role\": \"user\", \"content\": prompt_template.format(text=text)},\n","    ]\n","\n","    # Generate the response using the pipeline\n","    response = pipe(messages, max_new_tokens=64, temperature=1e-3, num_return_sequences=1)\n","    return response[0]['generated_text']\n","\n","examples = df['criteria'][0:10]\n","for i, example in enumerate(examples):\n","\n","    print(f\"Example {i} Output:\")\n","    output0 = extract_gender_and_pregnancy(example)\n","    output = output0[-1]['content']\n","    print(output)\n","    print(output0[1]['content'])\n","    print(\"-\" * 50)"]},{"cell_type":"raw","id":"be255101-531a-4d7f-8406-87cd7b12d2ca","metadata":{"id":"be255101-531a-4d7f-8406-87cd7b12d2ca"},"source":["Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","Example 0 Output:\n","Starting from v4.46, the `logits` model output will have the same type as the model (except at train time, where it will always be FP32)\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","Inclusion Criteria: NA\n","\n","    Here is the text, do your role:\n","    Please contact site for information.\n","\n","--------------------------------------------------\n","Example 1 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","Inclusion Criteria: NA\n","\n","    Here is the text, do your role:\n","    Please contact site for information.\n","\n","--------------------------------------------------\n","Example 2 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","- Inclusion Criteria: Both\n","\n","    Here is the text, do your role:\n","    Inclusion Criteria:~* Individuals starting methotrexate for rheumatoid arthritis.~* Study subjects should not currently be taking folic acid-containing vitamins.~Exclusion Criteria:~* Cancer, renal, or liver disease.~* Previous use of methotrexate within the past 6 months or current use of folic acid-containing supplements.\n","\n","--------------------------------------------------\n","Example 3 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","- Inclusion Criteria: Both\n","- Exclusion Criteria: Female\n","\n","    Here is the text, do your role:\n","    Inclusion Criteria:~* Alaska Native having biological Alaska Native ancestry.~* Meets criteria for alcohol dependence.~* Prior to entering the study must be abstinent between 3 and 14 days and have a withdrawal assessment.~* Stable residence to ensure that subjects can be located during the study.~Exclusion Criteria:~* Currently meets criteria for abuse or dependence on substances other than alcohol or nicotine.~* Current use of disulfiram.~* Psychotic or otherwise severely psychiatrically disabled.~* Use of other psychotropic medications including antidepressants and anxiolytics.~* Medical conditions that would not permit the use of sertraline or naltrexone, such as a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine, gastrointestinal or kidney disease.~* Hepatocellular disease or elevated bilirubin levels.~* Females who are pregnant, nursing, or not using a reliable method of birth control.~* Probation or parole requirements that might interfere with participation in the study.~* Involvement in alcohol treatment other than provided by the study or AA.~* Use of monoamine oxidase inhibitors in the past month.~* Current use of Type 1C antiarrhythmics propafenone and flecainide.\n","\n","--------------------------------------------------\n","Example 4 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","- Inclusion Criteria: Both\n","- Exclusion Criteria: Female\n","\n","    Here is the text, do your role:\n","    * INCLUSION CRITERIA:~Good general health. Individuals taking medications for obesity-related comorbid conditions will not be excluded.~Obesity: body mass index for age and triceps skinfold above the 95th percentile (determined by NHANES I age-, sex-, and race- specific data). All subjects will be required to be over 60 kg in body weight.~Evidence for a quantifiable obesity-related comorbidity. Examples include: systolic or diastolic hypertension (determined by age-specific charts); frank Type 2 diabetes, impaired glucose tolerance assessed by oral glucose tolerance testing; hyperinsulinemia (defined as a fasting insulin greater than 15 mIU/mL); significant hyperlipidemia (total cholesterol greater than 200 mg/dL, LDL cholesterol greater than 129 mg/dL or fasting triglycerides greater than 200 mg/dL); hepatic steatosis (SGPT or SGOT above normal range with negative hepatitis studies) or sleep apnea documented by a sleep study.~Age 12 to 17 years at the start of the study.~For girls with childbearing potential, a negative pregnancy test before taking and while taking study medication. Sexually active females must be using an effective form of birth control. These methods include total abstinence (no sex), oral contraceptives (the pill), an intrauterine device (IUD), levonogestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.~Race of all four grandparents self-identified as either all Caucasian or all African American.~EXCLUSION CRITERIA:~Volunteers will be excluded (and referred to non-experimental treatment programs) for the following reasons:~Presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal, most endocrinologic (e.g., Cushing syndrome), or pulmonary disorders (other than either asthma not requiring continuous medication or sleep apnea-related disorders);~Adolescent girls who are pregnant, who are currently nursing an infant, or who are having unprotected intercourse;~Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study;~Subjects who regularly use prescription medications unrelated to the complications of obesity. Oral contraceptive use will be permitted, provided the contraceptive has been used for at least two months before starting study medication. The use of over-the-counter and prescription medications will be reviewed on a case-by-case basis; depending on the medication, subjects who have continued to take prescription medication for at least 3 months prior to study entry may be eligible;~Recent use (within six months) of anorexiant medications for the purpose of weight reduction;~Inability to undergo MRI (e.g., volunteers with metal within their bodies including cardiac pacemakers, neural pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants, non-detachable electronic or electromechanical devices such as infusion pumps, nerve stimulators, bone growth stimulators, etc. that are contraindications).~For pilot study participants, hypersensitivity or allergy to methylene blue. Individuals with documented G6PD deficiency will be excluded.~INCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:~Volunteers will qualify for inclusion if they meet the following criteria:~1. Good general health.~2. Age 12-17 years at study entry.~3. Body mass index (BMI) for age above the 5th percentile and below 85th percentile, which is considered normal weight by CDC growth chart standards.~4. For females with childbearing potential, a negative pregnancy test at initial evaluation.~5. Race of all four grandparents self-identified as either all Caucasian or all African American.~EXCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:~Volunteers will be excluded for the following reasons:~1. Presence of past or present medical problems which would impair performance during the exercise tests;~2. Females who are pregnant, or who are currently nursing an infant;~3. Individuals who have, or whose parent or guardian has, current substance abuse or a psychiatric disorder or other condition that in the opinion of the investigators would impede competence or possibly hinder completion of the study;~4. Recent weight change of more than 3% of body weight in the past two months;~5. Recent use (within six months) of anorexiant medications for the purpose of weight reduction;~6. Physical impairments that would prevent completion of either the walk/run test or the cycle test.\n","\n","--------------------------------------------------\n","Example 5 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","- Inclusion Criteria: Both\n","- Exclusion Criteria: Female\n","\n","    Here is the text, do your role:\n","    * INCLUSION CRITERIA:~PATIENTS:~Patients with metastatic solid tumors ( breast, cholangiocarcinoma, small intestine/colon/rectal, adenocarcinoma, esophageal/gastric, hepatocellular, pancreatic, prostate, bony/soft tissue sarcomas, which are histologically confirmed, progressive and incurable.~Due to low accrual, effective 12/19/2006, patients with adrenal, basal cell, transitional cell carcinoma of the bladder or uroepithelium, ovarian, small cell lung cancer, non small cell lung cancer, and adenocarcinomas of unknown primary origin are no longer eligible for the trial.~Age greater than or equal to 10 to less than or equal to 80.~No known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy.~Metastatic disease, which is bi-dimensionally evaluable radiographically.~No prior treatment for neoplasm within 30 days.~Ability to comprehend the investigational nature of the study and provide informed consent.~Availability of HLA identical or single HLA-locus mismatched family donor.~Willingness and availability to return to the NIH for scheduled follow-ups.~DONOR:~HLA identical or single HLA-locus mismatched family donor~Age greater than or equal to 10 up to 80 years old.~Ability to comprehend the investigational nature of the study and provide informed consent.~EXCLUSION CRITERIA:~PATIENT:~Pregnant or lactating.~Age less than 10 or greater than 80 years.~ECOG performance status of 3 or more.~Psychiatric disorder or mental deficiency severe as to make compliance with the BMT treatment unlikely, and making informed consent impossible.~Major anticipated illness or organ failure incompatible with survival from PBSC transplant.~DLCO: less than 40% predicted.~Left ventricular ejection fraction: less than 30%.~Serum creatinine greater than 2.5mg/dl or creatinine clearance less than 50 cc/min by 24 hr urine collection.~Serum bilirubin greater than 4 mg/dl~Transaminases greater than 5 times the upper limit of normal.~Oral intake less than 1,200 calories/day.~Recent weight loss of greater than or equal to 10% of actual body weight.~Life expectancy less than 3 months~Therapy for malignancy within 4 weeks of beginning protocol.~CNS metastatic disease associated with intracranial bleeding, uncontrolled seizure disorder or significant intracranial mass effect.~Other malignant diseases liable to relapse or progress within 5 years.~Uncontrolled infection.~DONOR:~Pregnant or lactating.~Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia).~Age less than 10 or greater than 80 years.~HIV positive. Donors who are positive for HBV, HCV or HTLV-I may be used at the discretion of the investigator following counseling and approval from the recipient.\n","\n","--------------------------------------------------\n","Example 6 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","- Inclusion Criteria: Both\n","- Exclusion Criteria: Female\n","\n","    Here is the text, do your role:\n","    Inclusion Criteria~Patients may be eligible for this study if they:~* Are HIV-positive.~* Have an HIV blood level between 2,000 and 200,000 copies/ml.~* Have a CD4 cell count of at least 100 cells/mm3.~* Are 18 years of age or older.~* Are available for follow-up for at least 48 weeks.~* Agree to use a barrier method of birth control (such as condoms) during the study.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Have ever received anti-HIV (antiretroviral) treatment.~* Have an HIV-related opportunistic infection or condition at the time of study entry.~* Have primary HIV infection, meaning they have recently been infected.~* Have had severe diarrhea within the 30 days before study entry.~* Have hemophilia.~* Have a history of pancreatitis, hepatitis, or a peripheral neuropathy.~* Are unable to tolerate oral medication.~* Are pregnant or breast-feeding.~* Abuse alcohol or drugs.\n","\n","--------------------------------------------------\n","Example 7 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","- Inclusion Criteria: Both\n","\n","    Here is the text, do your role:\n","    DISEASE CHARACTERISTICS: Histologically proven previously untreated (except surgically) primitive neuroectodermal tumors (including medulloblastoma, anaplastic ependymoma, ependymoblastoma, or pineoblastoma) or high-grade astrocytomas Low-grade astrocytomas or optic tract tumors that are incompletely resected and have a progressive course not amenable to further surgery may also be allowed Evaluable disease by MRI, CT scan, or CT myelography~PATIENT CHARACTERISTICS: Age: Under 4 years Performance status: Not specified Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count greater than 1,500/mm3 WBC greater than 4,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGPT less than 90 IU/dL Renal: Creatinine clearance greater than 80 mL/min~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No prior mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) No prior high-dose methotrexate No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy Surgery: See Disease Characteristics Other: Recovered from acute toxic effects of any prior therapy Must be on a tyramine-free diet during procarbazine administration\n","\n","--------------------------------------------------\n","Example 8 Output:\n","Setting `pad_token_id` to `eos_token_id`:None for open-end generation.\n","- Inclusion Criteria: Both\n","\n","    Here is the text, do your role:\n","    DISEASE CHARACTERISTICS: Newly diagnosed undifferentiated nonlymphoblastic non-Hodgkin's lymphoma (Burkitt's or non-Burkitt's) Newly diagnosed large cell lymphoma with CNS involvement Recurrent non-Hodgkin's lymphoma L-3 and B-cell leukemia included At least 1 of the following required: LDH at least 500 IU/liter (old method) or 2,000 IU/liter (new method) Bone marrow involvement (greater than 5% lymphoblasts) CNS involvement (lymphoblasts on CSF cytospin or intracranial mass on CT or MRI scan)~PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified~PRIOR CONCURRENT THERAPY: Prior therapy allowed for non-Hodgkin's lymphoma No prior therapy for all other diseases\n","\n","--------------------------------------------------\n","Example 9 Output:\n","- Inclusion Criteria: Both\n","\n","    Here is the text, do your role:\n","    DISEASE CHARACTERISTICS: Malignant germ cell tumors of the following stages and primary sites: Stage II/III/IV ovarian tumors Grade II/III immature glial teratomas Stage II/III/IV mediastinal tumors Stage II/III/IV presacral tumors and tumors of other primary sites No intracranial or testicular primary sites~PATIENT CHARACTERISTICS: Age: Child Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified~PRIOR CONCURRENT THERAPY: Not specified\n","\n","--------------------------------------------------"]},{"cell_type":"code","execution_count":null,"id":"b0ec8e34-9761-4b3f-9ff0-de0ca2e3d531","metadata":{"id":"b0ec8e34-9761-4b3f-9ff0-de0ca2e3d531"},"outputs":[],"source":["# llama3_gender_in\n","\n"," # Function to clean the list\n","def clean_inclusion_criteria(data):\n","    # Extract the text after '- Inclusion Criteria:' or 'Inclusion Criteria:'\n","    cleaned_data = []\n","    for entry in data:\n","        if '- Inclusion Criteria:' in entry:\n","            value = entry.split('- Inclusion Criteria:')[1].split('\\n')[0].strip()\n","        elif 'Inclusion Criteria:' in entry:\n","            value = entry.split('Inclusion Criteria:')[1].strip()\n","        else:\n","            value = None\n","\n","        # Keep only valid choices\n","        if value in ['NA', 'Both', 'Male', 'Female']:\n","            cleaned_data.append(value)\n","        else:\n","            cleaned_data.append(None)\n","    return cleaned_data\n","\n","def clean_inclusion_criteria(data):\n","    valid_options = ['NA', 'Both', 'Male', 'Female']\n","    cleaned_data = []\n","\n","    for entry in data:\n","        # Normalize the text by splitting on \"Inclusion Criteria:\" and cleaning up\n","        if 'Inclusion Criteria:' in entry:\n","            value = entry.split('Inclusion Criteria:')[-1].split('\\n')[0].strip()\n","        else:\n","            value = 'NA'  # Default to 'NA' if no match\n","\n","        # Normalize combinations like \"Male/Female\" or \"Male/Female/Both/NA\" to \"Both\"\n","        value = value.replace('Male/Female', 'Both').replace('Male or Female', 'Both').strip()\n","\n","        # Ensure we only capture valid options\n","        if value in valid_options:\n","            cleaned_data.append(value)\n","        else:\n","            cleaned_data.append('NA')\n","\n","    return cleaned_data\n","\n","cleaned_list = clean_inclusion_criteria(llama3_gender_in)\n","cleaned_list[0:20]"]},{"cell_type":"code","execution_count":null,"id":"ef242974-0d31-406e-b1d4-047315a1d6e0","metadata":{"id":"ef242974-0d31-406e-b1d4-047315a1d6e0"},"outputs":[],"source":["['NA',\n"," 'NA',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Female',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both',\n"," 'Both']"]},{"cell_type":"code","execution_count":null,"id":"d7987493-5007-4f4f-b998-d90fc06a29c2","metadata":{"id":"d7987493-5007-4f4f-b998-d90fc06a29c2"},"outputs":[],"source":["# Adding to list\n","df['llama3_gender_Inclusion'] = cleaned_list\n","df['llama3_gender_Inclusion'].value_counts()\n"]},{"cell_type":"markdown","id":"13f898c3-fb57-4376-aacd-b34bd0c083ae","metadata":{"id":"13f898c3-fb57-4376-aacd-b34bd0c083ae"},"source":["# Llama3.2 Robustness of Criteria Rating"]},{"cell_type":"code","execution_count":null,"id":"d2503aca-5566-437e-899e-3ed41523f64f","metadata":{"id":"d2503aca-5566-437e-899e-3ed41523f64f"},"outputs":[],"source":["# Initialize the pipeline with Llama3.2 1B Instruct model\n","pipe = pipeline(\n","    \"text-generation\",\n","    model=\"/kaggle/input/llama-3.2/transformers/3b-instruct/1\",\n","    device=0,\n","    tokenizer=\"/kaggle/input/llama-3.2/transformers/3b-instruct/1\",\n",")"]},{"cell_type":"code","execution_count":null,"id":"4127a993-96d6-445e-b5a7-08253027456e","metadata":{"id":"4127a993-96d6-445e-b5a7-08253027456e"},"outputs":[],"source":["for i, crit in df['criteria'].items():\n","    print(f'{i}: {crit}')\n","    print('â€“â€“â€“â€“â€“â€“â€“â€“'*10)\n","\n","    if i == 10:\n","         break"]},{"cell_type":"raw","id":"932bf621-acdc-4fab-9200-11b9dbb5f94b","metadata":{"id":"932bf621-acdc-4fab-9200-11b9dbb5f94b"},"source":["0: Please contact site for information.\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","1: Please contact site for information.\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","2: Inclusion Criteria:~* Individuals starting methotrexate for rheumatoid arthritis.~* Study subjects should not currently be taking folic acid-containing vitamins.~Exclusion Criteria:~* Cancer, renal, or liver disease.~* Previous use of methotrexate within the past 6 months or current use of folic acid-containing supplements.\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","3: Inclusion Criteria:~* Alaska Native having biological Alaska Native ancestry.~* Meets criteria for alcohol dependence.~* Prior to entering the study must be abstinent between 3 and 14 days and have a withdrawal assessment.~* Stable residence to ensure that subjects can be located during the study.~Exclusion Criteria:~* Currently meets criteria for abuse or dependence on substances other than alcohol or nicotine.~* Current use of disulfiram.~* Psychotic or otherwise severely psychiatrically disabled.~* Use of other psychotropic medications including antidepressants and anxiolytics.~* Medical conditions that would not permit the use of sertraline or naltrexone, such as a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine, gastrointestinal or kidney disease.~* Hepatocellular disease or elevated bilirubin levels.~* Females who are pregnant, nursing, or not using a reliable method of birth control.~* Probation or parole requirements that might interfere with participation in the study.~* Involvement in alcohol treatment other than provided by the study or AA.~* Use of monoamine oxidase inhibitors in the past month.~* Current use of Type 1C antiarrhythmics propafenone and flecainide.\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","4: * INCLUSION CRITERIA:~Good general health. Individuals taking medications for obesity-related comorbid conditions will not be excluded.~Obesity: body mass index for age and triceps skinfold above the 95th percentile (determined by NHANES I age-, sex-, and race- specific data). All subjects will be required to be over 60 kg in body weight.~Evidence for a quantifiable obesity-related comorbidity. Examples include: systolic or diastolic hypertension (determined by age-specific charts); frank Type 2 diabetes, impaired glucose tolerance assessed by oral glucose tolerance testing; hyperinsulinemia (defined as a fasting insulin greater than 15 mIU/mL); significant hyperlipidemia (total cholesterol greater than 200 mg/dL, LDL cholesterol greater than 129 mg/dL or fasting triglycerides greater than 200 mg/dL); hepatic steatosis (SGPT or SGOT above normal range with negative hepatitis studies) or sleep apnea documented by a sleep study.~Age 12 to 17 years at the start of the study.~For girls with childbearing potential, a negative pregnancy test before taking and while taking study medication. Sexually active females must be using an effective form of birth control. These methods include total abstinence (no sex), oral contraceptives (the pill), an intrauterine device (IUD), levonogestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.~Race of all four grandparents self-identified as either all Caucasian or all African American.~EXCLUSION CRITERIA:~Volunteers will be excluded (and referred to non-experimental treatment programs) for the following reasons:~Presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal, most endocrinologic (e.g., Cushing syndrome), or pulmonary disorders (other than either asthma not requiring continuous medication or sleep apnea-related disorders);~Adolescent girls who are pregnant, who are currently nursing an infant, or who are having unprotected intercourse;~Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study;~Subjects who regularly use prescription medications unrelated to the complications of obesity. Oral contraceptive use will be permitted, provided the contraceptive has been used for at least two months before starting study medication. The use of over-the-counter and prescription medications will be reviewed on a case-by-case basis; depending on the medication, subjects who have continued to take prescription medication for at least 3 months prior to study entry may be eligible;~Recent use (within six months) of anorexiant medications for the purpose of weight reduction;~Inability to undergo MRI (e.g., volunteers with metal within their bodies including cardiac pacemakers, neural pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants, non-detachable electronic or electromechanical devices such as infusion pumps, nerve stimulators, bone growth stimulators, etc. that are contraindications).~For pilot study participants, hypersensitivity or allergy to methylene blue. Individuals with documented G6PD deficiency will be excluded.~INCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:~Volunteers will qualify for inclusion if they meet the following criteria:~1. Good general health.~2. Age 12-17 years at study entry.~3. Body mass index (BMI) for age above the 5th percentile and below 85th percentile, which is considered normal weight by CDC growth chart standards.~4. For females with childbearing potential, a negative pregnancy test at initial evaluation.~5. Race of all four grandparents self-identified as either all Caucasian or all African American.~EXCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS:~Volunteers will be excluded for the following reasons:~1. Presence of past or present medical problems which would impair performance during the exercise tests;~2. Females who are pregnant, or who are currently nursing an infant;~3. Individuals who have, or whose parent or guardian has, current substance abuse or a psychiatric disorder or other condition that in the opinion of the investigators would impede competence or possibly hinder completion of the study;~4. Recent weight change of more than 3% of body weight in the past two months;~5. Recent use (within six months) of anorexiant medications for the purpose of weight reduction;~6. Physical impairments that would prevent completion of either the walk/run test or the cycle test.\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","5: * INCLUSION CRITERIA:~PATIENTS:~Patients with metastatic solid tumors ( breast, cholangiocarcinoma, small intestine/colon/rectal, adenocarcinoma, esophageal/gastric, hepatocellular, pancreatic, prostate, bony/soft tissue sarcomas, which are histologically confirmed, progressive and incurable.~Due to low accrual, effective 12/19/2006, patients with adrenal, basal cell, transitional cell carcinoma of the bladder or uroepithelium, ovarian, small cell lung cancer, non small cell lung cancer, and adenocarcinomas of unknown primary origin are no longer eligible for the trial.~Age greater than or equal to 10 to less than or equal to 80.~No known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy.~Metastatic disease, which is bi-dimensionally evaluable radiographically.~No prior treatment for neoplasm within 30 days.~Ability to comprehend the investigational nature of the study and provide informed consent.~Availability of HLA identical or single HLA-locus mismatched family donor.~Willingness and availability to return to the NIH for scheduled follow-ups.~DONOR:~HLA identical or single HLA-locus mismatched family donor~Age greater than or equal to 10 up to 80 years old.~Ability to comprehend the investigational nature of the study and provide informed consent.~EXCLUSION CRITERIA:~PATIENT:~Pregnant or lactating.~Age less than 10 or greater than 80 years.~ECOG performance status of 3 or more.~Psychiatric disorder or mental deficiency severe as to make compliance with the BMT treatment unlikely, and making informed consent impossible.~Major anticipated illness or organ failure incompatible with survival from PBSC transplant.~DLCO: less than 40% predicted.~Left ventricular ejection fraction: less than 30%.~Serum creatinine greater than 2.5mg/dl or creatinine clearance less than 50 cc/min by 24 hr urine collection.~Serum bilirubin greater than 4 mg/dl~Transaminases greater than 5 times the upper limit of normal.~Oral intake less than 1,200 calories/day.~Recent weight loss of greater than or equal to 10% of actual body weight.~Life expectancy less than 3 months~Therapy for malignancy within 4 weeks of beginning protocol.~CNS metastatic disease associated with intracranial bleeding, uncontrolled seizure disorder or significant intracranial mass effect.~Other malignant diseases liable to relapse or progress within 5 years.~Uncontrolled infection.~DONOR:~Pregnant or lactating.~Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia).~Age less than 10 or greater than 80 years.~HIV positive. Donors who are positive for HBV, HCV or HTLV-I may be used at the discretion of the investigator following counseling and approval from the recipient.\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","6: Inclusion Criteria~Patients may be eligible for this study if they:~* Are HIV-positive.~* Have an HIV blood level between 2,000 and 200,000 copies/ml.~* Have a CD4 cell count of at least 100 cells/mm3.~* Are 18 years of age or older.~* Are available for follow-up for at least 48 weeks.~* Agree to use a barrier method of birth control (such as condoms) during the study.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Have ever received anti-HIV (antiretroviral) treatment.~* Have an HIV-related opportunistic infection or condition at the time of study entry.~* Have primary HIV infection, meaning they have recently been infected.~* Have had severe diarrhea within the 30 days before study entry.~* Have hemophilia.~* Have a history of pancreatitis, hepatitis, or a peripheral neuropathy.~* Are unable to tolerate oral medication.~* Are pregnant or breast-feeding.~* Abuse alcohol or drugs.\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","7: DISEASE CHARACTERISTICS: Histologically proven previously untreated (except surgically) primitive neuroectodermal tumors (including medulloblastoma, anaplastic ependymoma, ependymoblastoma, or pineoblastoma) or high-grade astrocytomas Low-grade astrocytomas or optic tract tumors that are incompletely resected and have a progressive course not amenable to further surgery may also be allowed Evaluable disease by MRI, CT scan, or CT myelography~PATIENT CHARACTERISTICS: Age: Under 4 years Performance status: Not specified Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count greater than 1,500/mm3 WBC greater than 4,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGPT less than 90 IU/dL Renal: Creatinine clearance greater than 80 mL/min~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No prior mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) No prior high-dose methotrexate No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy Surgery: See Disease Characteristics Other: Recovered from acute toxic effects of any prior therapy Must be on a tyramine-free diet during procarbazine administration\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","8: DISEASE CHARACTERISTICS: Newly diagnosed undifferentiated nonlymphoblastic non-Hodgkin's lymphoma (Burkitt's or non-Burkitt's) Newly diagnosed large cell lymphoma with CNS involvement Recurrent non-Hodgkin's lymphoma L-3 and B-cell leukemia included At least 1 of the following required: LDH at least 500 IU/liter (old method) or 2,000 IU/liter (new method) Bone marrow involvement (greater than 5% lymphoblasts) CNS involvement (lymphoblasts on CSF cytospin or intracranial mass on CT or MRI scan)~PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified~PRIOR CONCURRENT THERAPY: Prior therapy allowed for non-Hodgkin's lymphoma No prior therapy for all other diseases\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","9: DISEASE CHARACTERISTICS: Malignant germ cell tumors of the following stages and primary sites: Stage II/III/IV ovarian tumors Grade II/III immature glial teratomas Stage II/III/IV mediastinal tumors Stage II/III/IV presacral tumors and tumors of other primary sites No intracranial or testicular primary sites~PATIENT CHARACTERISTICS: Age: Child Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified~PRIOR CONCURRENT THERAPY: Not specified\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\n","10: DISEASE CHARACTERISTICS: Histologically documented diffuse small noncleaved cell lymphoma (category J by IWF) of any stage Nodal or abdominal masses with less than 25% lymphoblasts in marrow are defined as lymphoma OR Histologically documented L3 acute lymphocytic leukemia (ALL) Greater than 25% lymphoblasts in marrow is defined as ALL, regardless of presence of bulky nodal disease Lymphoma requirements include: Documentation of lymphadenopathy, splenomegaly, or hepatomegaly, presence or absence of abdominal masses, and presence or absence of B symptoms Measurable disease other than ascites and pleural effusions, bony disease, and CNS lesions Bidimensionally measurable mass on physical exam, x-ray, or CT, or MRI OR Clearly defined hepatic mass greater than 3.5 cm on CT, MRI, or ultrasound considered to represent lymphoma OR Histologically documented hepatic lymphoma with the liver extending more than 5 cm below the costal margin on quiet respiration ALL requirements include: Documentation of monoclonal surface immunoglobulin by surface immunophenotyping Lymph node biopsy strongly recommended for patients with obvious marrow involvement Disease labeled L3 but also manifested by lymphadenopathy must be evaluated as is lymphoma (see above)~PATIENT CHARACTERISTICS: Age: 15 and over Performance status: Any status Life expectancy: At least 2 years Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times normal (unless further elevation is directly attributable to malignancy) Renal: Creatinine no greater than 1.5 times normal (unless further elevation is directly attributable to malignancy) Cardiovascular: No uncontrolled or severe cardiovascular disease, e.g.: No myocardial infarction within the past 6 months No congestive heart failure Other: HIV negative No active, uncontrolled bacterial, viral, or fungal infection No active, uncontrolled duodenal ulcer No other serious medical illness No serious psychiatric condition that would preclude informed consent or protocol compliance No second malignancy within 5 years except: Curatively treated carcinoma in situ of the cervix Curatively treated basal cell carcinoma Not pregnant Effective contraception required of fertile patients~PRIOR CONCURRENT THERAPY: Biologic: No concurrent growth factors Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No concurrent palliative radiotherapy Surgery: Not specified Other: No prior therapy\n","â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“"]},{"cell_type":"code","execution_count":null,"id":"abd0ea06-68be-4e10-8048-7f3df46c158b","metadata":{"id":"abd0ea06-68be-4e10-8048-7f3df46c158b"},"outputs":[],"source":["def clinical_trial_robustness(text):\n","    # chatbot role\n","    chatbot_role = \"You are a clinical trial expert specializing in evaluating the robustness of trial criteria.\"\n","\n","    # Criteria Prompt Robustness\n","    prompt_template = f\"\"\"\n","    Evaluate the following clinical trial criteria text for robustness.\n","    Rate it as one of the following:\n","    - Strong: Clear, detailed, and minimizes bias.\n","    - Normal: Moderately clear but with some potential gaps.\n","    - Weak: Vague, incomplete, or prone to significant bias.\n","    - NA: Please contact site for information.\n","\n","    Criteria Text:\n","    {text}\n","\n","    \"\"\"\n","    # Create the message for the model\n","    messages = [\n","        {\"role\": \"system\", \"content\": chatbot_role},\n","        {\"role\": \"user\", \"content\": prompt_template},\n","    ]\n","\n","    # Generate the response\n","    response = pipe(messages, max_new_tokens=20, temperature=0.7, num_return_sequences=1)\n","    return response[0]['generated_text'][-1]['content']\n","\n","# Provide only the rating (Strong, Normal, Weak, NA)."]},{"cell_type":"code","execution_count":null,"id":"32fd2ba9-c200-4b80-b2b5-8433a6c6814b","metadata":{"id":"32fd2ba9-c200-4b80-b2b5-8433a6c6814b"},"outputs":[],"source":["critical = df['criteria'][2]\n","print(critical)\n","print()\n","clinical_trial_robustness(critical)"]},{"cell_type":"raw","id":"fd4991e6-803a-4a11-bd38-43efdf56a852","metadata":{"id":"fd4991e6-803a-4a11-bd38-43efdf56a852"},"source":["Starting from v4.46, the `logits` model output will have the same type as the model (except at train time, where it will always be FP32)\n","'I would rate the clinical trial criteria text as \"Normal\".\\n\\nHere\\'s why:\\n\\n* The inclusion criteria"]},{"cell_type":"code","execution_count":null,"id":"22d39f64-3799-413c-a7ab-6f83ee506a13","metadata":{"id":"22d39f64-3799-413c-a7ab-6f83ee506a13"},"outputs":[],"source":["robustness = []\n","\n","for i, crit in df['criteria'].items():\n","    extracted_values = clinical_trial_robustness(crit)\n","\n","    robustness.append(extracted_values)\n","    # print(f'{i}: {crit}')\n","    # print(robustness[i])\n","    print('â€“â€“â€“â€“â€“â€“â€“â€“'*10)\n","\n","    if i % 500 == 0:\n","        print(i)"]},{"cell_type":"code","execution_count":null,"id":"247b2bc3-6e2a-428d-8e40-8d77fddedf5f","metadata":{"id":"247b2bc3-6e2a-428d-8e40-8d77fddedf5f"},"outputs":[],"source":["import re\n","\n","def extract_ratings_from_responses(responses):\n","    # ratings\n","    possible_ratings = [\"Strong\", \"Normal\", \"Weak\", \"NA\"]\n","    extracted_ratings = []\n","\n","    for response in responses:\n","        match = re.search(r'\\b(Strong|Normal|Weak|NA)\\b', response, re.IGNORECASE)\n","        if match:\n","            extracted_ratings.append(match.group(1))\n","        else:\n","            extracted_ratings.append(\"Unknown\")\n","\n","    return extracted_ratings\n","\n","extract_ratings_from_responses(robustness[0:10])"]},{"cell_type":"raw","id":"08740804-4972-4dbd-b421-ee417e2e1377","metadata":{"id":"08740804-4972-4dbd-b421-ee417e2e1377"},"source":["['NA',\n"," 'NA',\n"," 'Weak',\n"," 'Strong',\n"," 'Strong',\n"," 'Normal',\n"," 'Strong',\n"," 'Strong',\n"," 'Weak',\n"," 'Weak']"]},{"cell_type":"code","execution_count":null,"id":"fb8d2145-acc3-4ad3-8a76-da3adf9073f5","metadata":{"id":"fb8d2145-acc3-4ad3-8a76-da3adf9073f5"},"outputs":[],"source":["robustness_cleaned = extract_ratings_from_responses(robustness)\n","df['LLama3_2_Criteria_Robustness'] = robustness_cleaned\n","df['LLama3_2_Criteria_Robustness'] = df['LLama3_2_Criteria_Robustness'].replace('NA', 'Unknown')"]},{"cell_type":"markdown","id":"08a4a010-1e12-47ee-9431-7ffde30bb6aa","metadata":{"id":"08a4a010-1e12-47ee-9431-7ffde30bb6aa"},"source":["# OpenAI - LLM\n","\n","- Purpose: Rates clinical trial descriptions on human interpretability and helpfulness.\n","- Derived Features: GBT4o_Human_Interpretability: Scores for clarity and usefulness of trial descriptions."]},{"cell_type":"code","execution_count":null,"id":"7cf15592-932e-4e54-b0ca-e87b608c6d41","metadata":{"id":"7cf15592-932e-4e54-b0ca-e87b608c6d41","outputId":"fa5f92e2-d968-4370-b208-ac101cbe9f1f"},"outputs":[{"name":"stdout","output_type":"stream","text":["\u001b[1;31m3500:\u001b[0m Description: This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3501:\u001b[0m Description: The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo or Non-steroidal anti-inflammatory drugs (NSAIDs).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3502:\u001b[0m Description: This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared. This is done to find the best way to change the dose of insulin 287. Participants will either get insulin 287 that they will have to inject once a week or insulin glargine that participants will have to inject once a day. Which treatment participants get is decided by chance. The study will last for about 5 months (23 weeks). Participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the study doctor will ask participants to:~* measure blood sugar every day with a blood sugar meter using a finger prick.~* write down different information in a diary daily and return this to the study doctor.~* wear a medical device (sensor) that measure blood sugar all the time for 18 weeks (about 4 months) during the study.~Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3503:\u001b[0m Description: Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3504:\u001b[0m Description: The primary objective of the study is to evaluate the efficacy of REGN5069 compared to placebo in patients with pain due to radiographically-confirmed OA of the knee who have a history of inadequate joint pain relief or intolerance to current analgesic therapy.~The secondary objectives of the study are:~* To characterize the concentrations of functional REGN5069 in serum over time when patients are treated for up to 12 weeks~* To assess the safety and tolerability of REGN5069 compared with placebo when patients are treated for up to 12 weeks~* To measure levels of anti-drug antibodies (ADAs) against REGN5069 following multiple IV administrations\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3505:\u001b[0m Description: Patients with multiple myeloma (a type of blood cancer affecting the white blood cells) or amyloidosis (abnormal buildup of a protein called amyloid in the body) are often given treatment with the drugs lenalidomide or pomalidomide. Some patients may experience an allergic reaction to these drugs which would mean stopping the treatment.~The purpose of this research study is to see how safe and useful desensitization is in allowing patients to receive further treatment with lenalidomide or pomalidomide.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3506:\u001b[0m Description: FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT (PBSCT), as final postremission consolidation in AML/MDS elderly patients.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3507:\u001b[0m Description: This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab (FHTR2163) injections.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3508:\u001b[0m Description: Keyriched-1 is a multicenter, interventional, prospective, single arm, open label, neoadjuvant phase II trial evaluating the pathological complete response (pCR) rate induced by pembrolizumab in combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3509:\u001b[0m Description: The Investigators would like to study the incidence of complete remission (CR) at day +30 after Clofarabine followed by haploidentical transplant. The conditioning regimen used is Fludarabine, Busulfan (2 doses) or cyclophosphamide (2 doses) and Total Body Irradiation (TBI) with post transplant cyclophosphamide for patients with Acute Myeloid Leukemia (AML) who are not in remission prior to considering allogeneic transplant with haploidentical donors.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3510:\u001b[0m Description: The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3511:\u001b[0m Description: An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3512:\u001b[0m Description: In this study, the investigators are testing a new formulation of lidocaine for its suitability in managing chronic scrotal pain (CSCP). The new formulation ST-CP is a lidocaine sustained-release formulation and is expected to provide pain relief over 4 weeks. Currently, the drug lidocaine is not available as an injectable slow-release formulation and chronic scrotal pain patients are often left untreated.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3513:\u001b[0m Description: This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetoclax, in pediatric and young adult participants with acute leukemias or solid tumors.~This study is divided into three parts: Part 1 will begin with dose escalation of idasanutlin as a single agent in pediatric participants with relapsed or refractory solid tumors to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and to characterize dose-limiting toxicities (DLTs). Following MTD/MAD identification, three separate safety run-in cohorts in neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) will be conducted to identify the recommended Phase 2 dose (RP2D) of idasanutlin in each combination, with chemotherapy or venetoclax. Part 2 will evaluate the safety and early efficacy of idasanutlin in combination with chemotherapy or venetoclax in newly enrolled pediatric and young adult participants in neuroblastoma, AML,and ALL cohorts at idasanutlin RP2D. Part 3 will potentially be conducted as an additional expansion phase of the idasanutlin combination cohorts in neuroblastoma, AML, or ALL for further response and safety assessment.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3514:\u001b[0m Description: Effective post-surgical pain management is a crucial component of a patient's postoperative course following posterior colporrhaphy. Narcotics are the cornerstone for postoperative analgesia with a frequent re-dosing requirement, a lengthy list of side effects and adverse reaction risks. The colorectal, orthopedic and general surgery literatures have reported on an extended-release bupivacaine liposomal injection, ExparelÂ®, which remarkably reduces acute post-operative pain; however, literature regarding this medication specific to Urogynecology and Gynecology is limited.~The investigators propose a prospective, randomized, double blind, trial with 120 subjects recruited from the Walter Reed National Military Medical Center (WRNMMC) Urogynecology Clinic to study postsurgical pain control after posterior repair. There will be two arms in the study; one arm with bupivacaine alone and a second arm with bupivacaine mixed with ExparelÂ®(extended-release, liposomal bupivacaine) injected vaginally in patients undergoing posterior colporrhaphy. Subjects will be randomized to receive either 20 milliliter (mL) of plain bupivacaine or 20mL (10ml+10ml) mixture of bupivacaine plus ExparelÂ®.~The primary objective of the trial will be to evaluate the postsurgical vaginal pain using a visual analog pain scale at days 1, 2, 3 post-procedure. All subjects will have acetaminophen, a non-steroidal anti-inflammatory drug and narcotic pain medication available for pain control regardless of assignment, which is the usual postoperative pain control regimen. The investigators hypothesize a 30% difference in post-operative pain measurements between the two groups.~Additional objectives of this study are to evaluate total medication usage on days 1, 2 and 3 and any post-operative voiding and defecatory dysfunction, comparing the two groups\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3515:\u001b[0m Description: To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3516:\u001b[0m Description: The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3517:\u001b[0m Description: The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living related donor.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3518:\u001b[0m Description: This study is a 3-arm pilot, randomized, double-blinded, placebo-controlled study of low-dose naltrexone and gabapentin versus placebo among HIV-positive persons with heavy alcohol use and chronic pain to provide estimates of their effects on 1) pain; 2) inflammation; and 3) measures of HIV control. Participants will be followed for 12 weeks. Assessments of study outcomes will be compared at week 8 (end of treatment phase).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3519:\u001b[0m Description: Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant prostate cancer (mCRPC).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3520:\u001b[0m Description: This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3521:\u001b[0m Description: Pilot study. The primary end point is the evaluation the efficacy of treatment with atorvastatin compared to colchicine for the decrease of high sensitivity troponin I levels in patients with rheumatoid arthritis with severe activity according of the Disease Activity Score 28 (DAS 28\\> 5.1), through a randomized controlled clinical trial blinded to the rheumatologist and the cardiologist who will carry out the evaluation of the patient.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3522:\u001b[0m Description: The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care therapies.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3523:\u001b[0m Description: An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3524:\u001b[0m Description: This study aims to evaluate the efficacy and safety of pyrotinib in combination with nab-paclitaxel or trastuzumab with nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced HER2-positive breast cancer.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3525:\u001b[0m Description: A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3526:\u001b[0m Description: This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while to recover, putting the patient at increased risk of infection. Dilanubicel consists of blood stem cells that help to produce mature blood cells, including immune cells. Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Total body irradiation is a type of whole-body radiation. Giving chemotherapy and total-body irradiation before a cord blood transplant with dilanubicel may help to kill any cancer cells that are in the body and make room in the patient's bone marrow for new stem cells to grow and reduce the risk of infection.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3527:\u001b[0m Description: This is a prospective randomized double-blind controlled trial assessing the benefits of intramuscular ketorolac before or immediately after office ureteral stent removal.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3528:\u001b[0m Description: The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity, cardiovascular function and patient reported outcomes.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3529:\u001b[0m Description: This phase II trial studies how well itacitinib works in preventing graft versus host disease in patients with blood disorders undergoing donor stem cell transplantation. A donor transplantation uses blood-making cells from a family member or unrelated donor to remove and replace abnormal blood cells. Graft versus host disease is a reaction of the donor's immune cells against the patient's body. Itacitinib plus standard treatment may help prevent graft versus host disease in patients who have received a donor stem cell transplantation.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3530:\u001b[0m Description: The investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3531:\u001b[0m Description: A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3532:\u001b[0m Description: This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3533:\u001b[0m Description: This clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combination treatments in adult patients with non-alcoholic fatty liver disease (NAFLD) who manifest a non-alcoholic steatohepatitis (NASH)-like biomarker phenotype.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3534:\u001b[0m Description: This study will evaluate combining stem cells from the patient's matched sibling donor (a standard CD34-selected transplant) with a second infusion of white blood cells called CD8 memory T-cells from their sibling donor.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3535:\u001b[0m Description: The purpose of this study is to investigate adalimumab, a drug that is currently licensed for treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and inflammatory bowel disease (Crohn's disease). It is a protein (human monoclonal antibody) that is designed to block the effects of an inflammatory cytokine, tumour necrosis factor alpha (TNF alpha) which is a causative factor in joint inflammation. It is given as a subcutaneous injection.~Management of established rheumatoid arthritis has been transformed with the use of TNFantagonists, the first in the class of biological agents. The benefits in early RA are also continuing to emerge. Oligoarthritis represents a subgroup of early inflammatory arthritis that warrants more effective treatment strategy including the potential to modulate the disease course and halt further progression. The TNFantagonists offer the potential of achieving this, justifying this initial investigation.~Hence, this study is designed to establish the benefit of adalimumab in preventing progression of oligoarthritis. The primary aim of the study is to assess how many patients achieve remission i.e. no further evidence of joint inflammation or damage. The investigators will do this by including patients who present with inflammation of four or less joints who do not fulfil criteria for a definite arthritis condition such as rheumatoid arthritis. The investigators will perform clinical, laboratory (blood tests) and imaging assessments at regular intervals on these patients to check on safety of the study drug adalimumab and evaluate any changes in disease activity that may have resulted from use of adalimumab. All patients will receive treatment with a standard therapy (methotrexate) with randomisation of half of the patients to receive the active study drug, adalimumab as additional treatment for six months.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3536:\u001b[0m Description: This study has 2 phases.~The main aims of Phase 1b are:~* to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors.~* to learn how much modakafusp alfa adults can receive without getting any major side effects from it.~The main aims of Phase 2 are:~* to check for side effects from modakafusp alfa when given together with pembrolizumab in adults with metastatic cutaneous melanoma which cannot be completely removed by surgery.~* to learn how these medicines improve their symptoms.~Participants will receive modakafusp alfa for up to 1 year (Phase 1b) or modakafusp alfa given together with pembrolizumab for up to 2 years (Phase 2). Those whose symptoms improve might continue treatment for longer.~In both phases of the study, participants will revisit the study clinic within 30 days after their last dose or before they start other cancer treatment, whichever happens first.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3537:\u001b[0m Description: The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3538:\u001b[0m Description: This is a randomized, double-blind, double-dummy study of single dose HDIT101 versus Standard of Care Valaciclovir.~HSV-2-positive patients with at least 4 anogenital herpes lesions in the last 12 months (or at least 2 herpes lesions with previous valaciclovir long-term therapy) can be included.~If a patients develops a anogenital Herpes lesion within 4 months after the screening visit, the patients will be randomized in a 2:1 ratio to HDIT i.v. infusion + episodic treatment with 500 mg Valaciclovir-placebo OR to a single HDIT placebo infusion + episodic treatment with 500 mg Valaciclovir orally bid for 3 days.~Study duration per patient will be 180 days starting with the randomization visit. In addition to the randomization visit, 4 visits at the site and 2 phone calls are scheduled.~At every occurence of a herpetic lesion during the study, patients are treated with Valaciclovir/ Valaciclovir-placebo and need to present at the site twice to document start and end date of the lesion (unscheduled visits).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3539:\u001b[0m Description: The purpose of this study is to assess the safety, early bactericidal activity (EBA) and pharmacokinetics of TBA-7371 in adult participants with rifampicin-sensitive tuberculosis and select dose regimen(s) for future studies.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3540:\u001b[0m Description: The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary SjÃ¶gren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3541:\u001b[0m Description: Primary Objective:~To determine whether amcenestrant given at 2 different doses improved the antiproliferative activity when compared to letrozole.~Secondary Objectives:~* To assess the proportion of participants with a relative decrease from Baseline in percentage of positive tumor cells tested by immunohistochemistry greater than or equal to (\\>=) 50 percent (%) (Ki67 \\>=50%) in the three treatment arms.~* To assess estrogen receptor (ER) degradation in biopsies in participants in the three treatment arms.~* To assess safety in the three treatment arms.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3542:\u001b[0m Description: This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination with EyleaÂ® dosed at every other month, compared to EyleaÂ® monotherapy dosed at every other month in approximately eighty-one subjects with exudative age-related macular degeneration (AMD).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3543:\u001b[0m Description: The choice of the sedation protocol has a massive impact on the duration of mechanical ventilation and the timing of extubation. Many sedation protocols are described in the literature. The investigators aim to assess if a transdermal fentanyl-based sedation protocol can have an impact on the global Work of Breathing (WOB)\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3544:\u001b[0m Description: This phase II trial studies how well a reduced intensity conditioning regimen after donor stem cell transplant works in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as cyclophosphamide, tacrolimus, and mycophenolate mofetil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a reduce intensity conditioning regimen consisting of cyclophosphamide, tacrolimus, mycophenolate mofetil, and daratumumab after donor stem cell transplant may improve survival and reduce the risk of multiple myeloma coming back.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3545:\u001b[0m Description: Background:~Metformin is a pill youth with type 2 diabetes take. It can cause side effects like diarrhea and upset stomach. Researchers want to see if a fiber supplement can help decrease these side effects.~Objective:~To see if a prebiotic fiber supplement helps improve the gastrointestinal side effects of people taking metformin and helps with their blood sugars.~Eligibility:~People ages 10-25 with type 2 diabetes who are taking or will take metformin~Design:~Participants will be screened with:~Physical exam~Medical history~Blood and urine tests~Meeting with a nutritionist~Participants will stop taking all diabetes medication for 1 week. They will then take metformin by mouth for 1 week. They will be randomly assigned to take either a fiber supplement or a placebo by mouth during the same week. They will then stop all study treatments for 2-3 weeks. Then they will restart metformin for 1 week. The groups that received the fiber versus the placebo will be reversed. All participants will then continue taking metformin and take the fiber for 1 month.~Participants will have 6 visits over about 2 months. These will include:~Blood and urine tests~Meal tests: A plastic tube will be inserted in the participant s arm vein for blood draws. They will drink a special meal.~Dual-energy x-ray absorptiometry (DXA) scan: Participants will lie on their back while the scan measures their body fat and muscle.~While they are home, participants will:~Fill out daily surveys online~Wear daily activity and blood sugar monitors~Collect their stool~Eat only certain foods for two 1-week periods...\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3546:\u001b[0m Description: This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3547:\u001b[0m Description: This phase II trial studies how well vorinostat and combination chemotherapy before donor stem cell transplantation work in treating patients with aggressive B-cell or T-cell non-Hodgkin lymphoma that has come back (relapsed). Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as busulfan, gemcitabine, and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vorinostat together with combination chemotherapy before donor stem cell transplantation may help to control lymphoma.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3548:\u001b[0m Description: This is a prospective Belgian, multi-center, open-label, single-arm phase II study of weekly paclitaxel at a dose of 80mg/mÂ² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/mÂ² and cyclophosphamide at a dose of 600 mg/mÂ² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer to evaluate tumor response in the breast and the axilla.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3549:\u001b[0m Description: To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response \\[CR\\] or partial response \\[PR\\]) or stable disease (SD) from further platinum based chemotherapy.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3550:\u001b[0m Description: Urinary tract infection (UTI) is a common problem after surgery for pelvic organ prolapse and stress urinary incontinence. This prospective, randomized, single-masked (subject), two-parallel armed study aims to determine the effect of a single postoperative intravesical instillation of 80 mg of gentamicin sulfate in 50 mL of saline versus usual care on the proportion of women treated for UTI within 6 weeks following surgery for pelvic organ prolapse (POP) or stress urinary incontinence (SUI).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3551:\u001b[0m Description: This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3552:\u001b[0m Description: The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3553:\u001b[0m Description: This study aims to evaluate the effects of niraparib in those who have received neoadjuvant chemotherapy and subsequent interval debulking surgery, with or without hyperthermic intraperitoneal chemotherapy, and would also explore if there are any biomarkers, other than BRCA / HRD status and platinum sensitivity, that may help to identify those who may benefit from PARPi especially those who are HRD negative.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3554:\u001b[0m Description: This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop the growth of tumor cells by decreasing the amount of estrogen made by the body. Giving anastrozole and letrozole after surgery may prevent breast cancer from coming back (recurrence).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3555:\u001b[0m Description: This is a phase 2 single-arm, open-label determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in subjects with Hormone receptor positive patients with localized non-metastatic breast cancer who develop local recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3556:\u001b[0m Description: This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3557:\u001b[0m Description: This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3558:\u001b[0m Description: This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3559:\u001b[0m Description: This is a 3-part Phase 1 dose-ranging study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single (Part 1) and multiple (Part 2) ascending doses of BCX9930 in healthy subjects and in subjects with paroxysmal nocturnal hemoglobinuria (PNH; Part 3). Pharmacokinetics is an analysis of how the body handles the study drug BCX9930 and pharmacodynamics is an analysis of the activity that the study drug BCX9930 may have in the body.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3560:\u001b[0m Description: This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3561:\u001b[0m Description: It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071. Another aim is to see if it improves how participants think and remember.~At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 groups by chance.~Both groups will have 2 treatments but in a different order. The treatments are TAK-071 tablets or placebo. In this study, a placebo will look like the TAK-071 but will not have any medicine in it.~One group will take TAK-071 for 6 weeks, have at least a 3-week break, then take a placebo for 6 weeks. The other group will take a placebo for 6 weeks, have at least a 3-week break, then take TAK-071 for 6 weeks. The participants will not know the order of their 2 treatments, nor will their study doctors. This is to help make sure the results are more reliable.~The participants will visit the clinic at the beginning and end of each treatment for a check-up. 14 days after the 2nd treatment, clinic staff will telephone the participants for a final check-up.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3562:\u001b[0m Description: This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3563:\u001b[0m Description: This is a Phase 2 randomized, double-blind, parallel group, vehicle-controlled study to evaluate the safety and efficacy of topical ATx201 OINTMENT in adolescents and adults with mild to moderate Atopic Dermatitis\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3564:\u001b[0m Description: The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3565:\u001b[0m Description: This is a Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with small cell lung cancer or squamous non-small cell lung cancer who have progressed after 1 or 2 lines of therapies.~The primary objectives of the study are to evaluate the overall response rate of subjects treated with CC-90011 in combination with nivolumab in three cohorts:~* Cohort A: SCLC in ICI naÃ¯ve subjects~* Cohort B: SCLC in ICI progressor subjects~* Cohort C: sqNSCLC in ICI progressor subjects Overall response rate is defined as the proportion of subjects in the treated population who had complete response (CR) or partial response (PR) as assessed by Investigator review per RECIST v1.1.~In Cohort A, expected ORR for nivolumab monotherapy is 14% while target ORR is 30%. To achieve at least 80% power with one-sided type 1 error 0.1, 39 subjects will be enrolled according to a 2-stage group sequential design based on a binomial test. In stage 1, 12 subjects will be enrolled and treated with CC-90011 in combination with nivolumab. If there are 2 or more subjects responding, Cohort A will continue to enroll an additional 27 subjects. If 1 or less subjects respond in stage 1, Cohort A will stop for futility.~In Cohort B and C, expected ORR for nivolumab monotherapy is 5% while target ORR is 15%. To achieve at least 80% power with one-sided type 1 error 0.1, 48 subjects will be enrolled according to a 2-stage group sequential design based on a binomial test. In stage 1, 14 subjects will be enrolled and treated with CC-90011 in combination with nivolumab. If there are 1 or more subjects responding, Cohort B and C will continue to enroll an additional 34 subjects each. If 0 subjects respond in stage 1, Cohort B and C will stop for futility.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3566:\u001b[0m Description: This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3567:\u001b[0m Description: The purpose of this study is to test if delaying the start of the olaparib until there is a rise in a tumor marker called CA-125 will result in a longer time until the next or different treatment for the patient's cancer. The study will also evaluate how delaying the start of maintenance therapy will affect symptoms; physical functioning; quality of life; and impact on finances.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3568:\u001b[0m Description: This study aims to investigate the effect of metformin as host-directed therapy in obese/overweight patients with dengue~Primary Objective~To evaluate the safety and tolerability of metformin in obese/overweight young adults and children with dengue~Secondary Objectives~* To assess the effect of metformin therapy in obese/overweight patients with dengue on physiological, clinical and virological parameters~* To assess the immunomodulation effects of metformin therapy in obese/overweight patients with dengue~* To assess difference in gene expression between treatment group compared to non-treatment population\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3569:\u001b[0m Description: The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3570:\u001b[0m Description: Hydroxychloroquine is widely used to treat autoimmune diseases. Clinical investigation has found that a high concentration of cytokines were detected in the plasma of critically ill patients infected with SARS-CoV-2, therefore, hydroxychloroquine as anti-inflammatory agents may reduce this response in accord with their use in autoimmune disease where the cytokine response can be reduced.~Favipiravir is an antiviral drug developed in Japan that the data sheet notes that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses, arenaviruses, bunyaviruses and alphaviruses. In February the drug was used for COVID-19 disease in China and was declared effective in treatment, and a report published (in press) comparing Favipiravir with Lopinavir /ritonavir suggested that Favipiravir was superior for prevention of disease progression and viral clearance.~The objective of this pilot study is to compare three arms: hydroxychloroquine; favipiravir; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an open label randomized clinical trial. The difference between groups will allow an effect size to be determined for a definitive clinical trial.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3571:\u001b[0m Description: The study was planned to be conducted in 2 parts: Part 1 to determine the efficacy and safety of ECF843 vs vehicle, followed by Part 2 with additional exploratory assessments of ECF843 vs Vehicle. Both parts of the study included a double-masked study design, with randomization stratified for subjects with Sjogren's Syndrome.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3572:\u001b[0m Description: This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3573:\u001b[0m Description: Resveratrol is a plant polyphenol (that is sold commercially as a supplement) that might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept pilot study we will compare the effects of resveratrol to placebo to assess the safety of the resveratrol and explore effectiveness.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3574:\u001b[0m Description: With an appropriate oral dose of Varenicline (VCN) identified from experiments 1 \\& 2 of the study (see NCT02933372), the investigators will administer VCN to Parkinson Disease (PD) participants to determine if VCN improves walking speed and measures of balance. PD participants will receive VCN or a placebo (fake drug) for 3 weeks to assess the effects of VCN administration on gait speed and balance. Participants will undergo examinations to assess the intensity of their Parkinsonism and asked questions to assess their mood and thinking.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3575:\u001b[0m Description: This phase II trial studies how well daratumumab, azacitidine, and dexamethasone work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and was previously treated with daratumumab. Daratumumab is an antibody made up of immune cells that attaches to a protein on myeloma cells, called cluster of differentiation 38 (CD38). CD38 is found in higher levels on tumor cells than on normal cells. Daratumumab prevents the growth of tumors who have high levels of CD38 by causing those cells to die. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is a steroid that helps decrease inflammation and lowers the body's normal immune response to help reduce the effect of any infusion-related reactions. Giving azacitidine may help increase the levels of CD38 on the tumor cells to increase the function of daratumumab to attach to those tumor cells to help destroy them.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3576:\u001b[0m Description: The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3577:\u001b[0m Description: The purpose of this research is to find out if a drug (sargramostim) also known as LeukineÂ® could help patient recover faster from COVID-19. Sargramostim may help the lungs recover from the effects of COVID-19, and this research study will help to find this out.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3578:\u001b[0m Description: Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3579:\u001b[0m Description: This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA-N2 non-small cell lung cancer.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3580:\u001b[0m Description: This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3581:\u001b[0m Description: This is a randomized, multicenter, open-label, two-arm, Phase II study to evaluate the efficacy, safety, and pharmacokinetics of giredestrant versus anastrozole (in the window-of-opportunity phase) and giredestrant plus palbociclib compared with anastrozole plus palbociclib (in the neoadjuvant phase) in postmenopausal women with untreated, estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, early breast cancer.~The study consists of a screening period of up to 28 days, a window-of-opportunity phase for 14 days, followed by a neoadjuvant treatment phase for 16 weeks (four 28-day cycles), surgery, and an end of study visit (28 days after the final dose of study treatment).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3582:\u001b[0m Description: Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of ivermectin for the treatment of initial infection with SARS-CoV2 infection.~Study arms: A) placebo B) ivermectin 600 Î¼g/kg daily for 5 consecutive days (I_600) + placebo. C) ivermectin 1200 Î¼g/kg daily at empty stomach with water for 5 consecutive days (I_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres.~In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3583:\u001b[0m Description: To address the need to intervene to prevent the spread of COVID-19 in long-term care homes, we propose a randomized clinical trial of chemoprophylaxis in long-term care homes experiencing COVID-19 outbreaks. LTCH units experiencing an outbreak of COVID-19 will be randomized to chemoprophylaxis with favipiravir or placebo in a 1:1 ratio.~Chemoprophylaxis in this setting refers to the use of favipiravir for pre-exposure prophylaxis, post-exposure prophylaxis, pre-emptive therapy, or treatment for established COVID-19. This design mimics the approach to influenza outbreaks, which has proven efficacy for outbreak control. The primary outcome will be control of the outbreak, defined as no new microbiologically confirmed case of COVID-19 for 24 consecutive days up to day 40.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3584:\u001b[0m Description: The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3585:\u001b[0m Description: This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3586:\u001b[0m Description: This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model which can predict neoadjuvant endocrine therapeutic results.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3587:\u001b[0m Description: This is a two arm, randomized, phase II study of patients with advanced KRAS mutation positive and PD-L1 high NSCLC who have not received therapy for advanced stage disease. Patients will be randomized between Arm A and Arm B treatment. Arm A treatment will consist of durvalumab every 4 weeks for 13 cycles. Arm B treatment will consist of durvalumab with chemotherapy every 3 weeks for 4 cycles followed by durvalumab with pemetrexed every 3 weeks for 13 cycles.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3588:\u001b[0m Description: This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil tablets 20mg, 40mg group, each group 10 cases.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3589:\u001b[0m Description: This phase II trial investigates how well azacitidine, venetoclax, and trametinib work in treating patients with acute myeloid leukemia or higher-risk myelodysplastic syndrome that has come back (relapsed) or has not responded to treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax and trametinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. The goal of this study is learn if the combination of azacitidine, venetoclax, and trametinib can help to control acute myeloid leukemia or myelodysplastic syndrome.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3590:\u001b[0m Description: Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3591:\u001b[0m Description: The current pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms, followed by a later 'inflammatory' phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with better outcome. Antiviral medications are most likely to be effective when administered soon after infection. There is therefore an urgent need to study subjects who have recently developed symptoms, or have recently been tested positive with or without symptoms, and who can be sampled frequently to understand changes in viral load. This cohort will allow us to collect detailed trajectory data on early disease and understand how pharmacological interventions may affect this. The objective of the FLARE trial is to assess whether early antiviral therapy with either favipiravir + Lopinavir/ritonavir (LPV/r), LPV/r or favipiravir is associated with a decrease in viral load compared with placebo. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3592:\u001b[0m Description: This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3593:\u001b[0m Description: The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3594:\u001b[0m Description: A study looking at the feasibility of doing a full-scale RCT that investigates the use of tranexamic acid intravesically prior to continuous bladder irrigation treatment in the emergency department for urinary retention due to clots.~We want to know:~* patient experience and acceptability of the intervention~* study procedures (recruitment, site appropriateness, staff engagement)~* safety data~* identify resource use\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3595:\u001b[0m Description: The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3596:\u001b[0m Description: The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3597:\u001b[0m Description: Population studies estimate that patients who have episodic migraine transition to chronic migraine at a rate of about 2.5% per year.~CM is a devastating disorder associated to severe disability. Patients with CM frequently overuse symptomatic medications in the attempt to control their disease, which adds up to the high costs associated to the disorder In this frame, it seems of the outmost importance to strive at preventing the transition from EM to CM.~At the moment Onabotulinum toxin A (BoNT-A) represents the only drug specifically approved for CM prophylaxis.~The aim of the present study was to evaluate the efficacy of BoNT-A in reducing the number of migraine days in a population of migraineurs with a high frequency of migraine attacks over a 12-month period.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3598:\u001b[0m Description: The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional therapeutic efficacy.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","\u001b[1;31m3599:\u001b[0m Description: In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n"]}],"source":["# Print results with colored bar and red bold numbers\n","start = 3_500\n","finish = start + 100\n","description = df['description'][start:finish]\n","\n","for idx, desc in enumerate(description):\n","    print(f\"{RED_BOLD}{idx + start}:{RESET} \", end='')\n","    print(f\"Description: {desc}\")\n","    # print(f\"{RED_BOLD}{RESET}{BOLD_BAR}{RESET}\")\n","    print_bar(100)"]},{"cell_type":"code","execution_count":null,"id":"40981f8f-6e55-4529-b4f6-083485b85d81","metadata":{"id":"40981f8f-6e55-4529-b4f6-083485b85d81"},"outputs":[],"source":["# PROMPT Setup\n","prompt_template = \"\"\"\n","You are a critical trial evaluator tasked with rating the importance of clinical trial descriptions and their relevance to humans.\n","Please use the following scale:\n","- 1: Slightly important (e.g., moderately useful but limited in applicability).\n","- 2: Moderately important (e.g., provides useful information but limited in applicability).\n","- 3: Very important (e.g., substantial public health relevance or innovative).\n","\n","Description:\n","{description}\n","\n","Please provide a rating (1, 2, or 3).\n","\"\"\"\n","\n","# PROMPT Setup 2\n","prompt_template = \"\"\"\n","You are a critical trial evaluator tasked with rating the importance of clinical trial descriptions and their relevance to humans.\n","Please use the following scale:\n","- 1: Not important (e.g., limited scope, no broader relevance, lacks detail).\n","- 2: Slightly important (e.g., moderately useful but limited in applicability).\n","- 3: Moderately important (e.g., provides useful information but not groundbreaking).\n","- 4: Very important (e.g., substantial public health relevance or innovative).\n","- 5: Extremely important (e.g., transformative, wide-ranging implications).\n","\n","Each description should be rated with clear justification.\n","\n","Description:\n","{description}\n","\n","Please provide a rating (1 to 5) and a succinct explanation of your reasoning.\n","\"\"\"\n","\n","\n","# Final PROMPT Setup\n","prompt_template = f\"\"\"\n","You are an expert in clinical trial evaluation tasked with assessing and categorizing trial descriptions based on their importance and relevance to public health and medical innovation. Use the following scale to rate each trial:\n","\n","\n","- \"Not important\": Limited scope, low relevance, or lacking broader implications.\n","- \"Slightly important\": Moderately relevant but limited in scope or potential impact.\n","- \"Moderately important\": Provides useful information with practical implications but not groundbreaking.\n","- \"Very important\": Significant potential for public health improvement or medical innovation.\n","- \"Extremely important\": Transformative potential with wide-ranging public health or scientific implications.\n","\n","\n","Respond in the following format only:\n","(index, Rating)\n","\n","\n","Description:\n","{description}\n","\"\"\"\n","\n","description = \"The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.\"\n","prompt = prompt_template.format(description=description)\n","print(prompt)"]},{"cell_type":"markdown","id":"1626bf40-3bfb-4ee6-9650-6066fb8a08cd","metadata":{"id":"1626bf40-3bfb-4ee6-9650-6066fb8a08cd"},"source":["## One by One test"]},{"cell_type":"code","execution_count":null,"id":"5b87d64c-91ef-4c4c-8f02-176db306b4e4","metadata":{"id":"5b87d64c-91ef-4c4c-8f02-176db306b4e4"},"outputs":[],"source":["# Function to process each description\n","def rate_descriptions(client, descriptions):\n","    ratings = []\n","    for description in descriptions:\n","        # Format the prompt\n","        prompt = prompt_template.format(description=description)\n","\n","        # Call OpenAI API using the new client API\n","        response = client.chat.completions.create(\n","            model=\"gpt-4o\",\n","            messages=[\n","                {\"role\": \"system\", \"content\": \"You are an assistant tasked with rating clinical trial descriptions.\"},\n","                {\"role\": \"user\", \"content\": prompt}\n","            ],\n","            max_tokens=25,\n","            temperature=0.0\n","        )\n","\n","        # Extract response and convert to a dictionary if needed\n","        rating = response.choices[0].message.content.strip()\n","        ratings.append((description, rating))\n","\n","    return ratings\n","\n","descriptions = df['description'][10:25]\n","\n","# Process descriptions\n","results = rate_descriptions(client, descriptions)\n","\n","# Print results with colored bar and red bold numbers\n","for idx, (desc, rating) in enumerate(results, start=1):\n","    print(f\"{RED_BOLD}{idx}{RESET} {BOLD_BAR}\")\n","    print(f\"Description: {desc}\")\n","    print(f\"Rating: {rating}\\n\")"]},{"cell_type":"markdown","id":"c69a5190-6a17-4eda-b314-115b3f681ff3","metadata":{"id":"c69a5190-6a17-4eda-b314-115b3f681ff3"},"source":["## Batches Method Results"]},{"cell_type":"code","execution_count":null,"id":"cd738824-2dd2-484b-b3f7-4afbae4af280","metadata":{"id":"cd738824-2dd2-484b-b3f7-4afbae4af280"},"outputs":[],"source":["# Function to process N descriptions at a time\n","def rate_descriptions_in_batches(client, descriptions, batch_size=20):\n","    ratings = []\n","    for i in range(0, len(descriptions), batch_size):\n","        # Batch descriptions\n","        batch = descriptions[i:i + batch_size]\n","\n","        # Format all descriptions into a single prompt\n","        descriptions_prompt = \"\\n\\n\".join(\n","            [f\"{idx + 1}. {desc}\" for idx, desc in enumerate(batch, start=i)]\n","        )\n","\n","        # Full prompt for the batch\n","        prompt = f\"\"\"\n","        You are a critical trial evaluator tasked with rating the importance of clinical trial descriptions and their relevance to humans.\n","        Please use the following scale and rate the following {len(batch)} descriptions based on the scale below::\n","        - 1: Slightly important (e.g., moderately useful but limited in applicability).\n","        - 2: Moderately important (e.g., provides useful information but limited in applicability).\n","        - 3: Very important (e.g., substantial public health relevance or innovative).\n","\n","        Description:\n","        {descriptions_prompt}\n","\n","        Please provide your ratings in the format:\n","        1. Rating: [1-5]\n","        2. Rating: [1-5]\n","        ...\n","        \"\"\"\n","\n","        # Call OpenAI API\n","        response = client.chat.completions.create(\n","            model=\"gpt-4o\",\n","            messages=[\n","                {\"role\": \"system\", \"content\": \"You are an assistant tasked with rating clinical trial descriptions.\"},\n","                {\"role\": \"user\", \"content\": prompt}\n","            ],\n","            max_tokens=100,\n","            temperature=0.3\n","        )\n","\n","        # Extract response\n","        batch_ratings = response.choices[0].message.content.strip()\n","\n","        # Append results\n","        ratings.append(batch_ratings)\n","\n","    return ratings\n","\n","\n","# Example: Processing a range of descriptions\n","descriptions = df['description'][100:120].tolist()\n","\n","# Process descriptions in batches\n","results = rate_descriptions_in_batches(client, descriptions, batch_size=10)\n","\n","# Print results\n","for idx, batch_result in enumerate(results, start=1):\n","    print(f\"{RED_BOLD}{idx}{RESET} {BOLD_BAR}\")\n","    print(batch_result)\n","    print(\"\\n\" + \"=\" * 80 + \"\\n\")"]},{"cell_type":"code","source":["# PROMPT Setup\n","prompt_template = \"\"\"\n","You are an expert in clinical trial evaluation tasked with assessing and categorizing trial descriptions based on their importance and relevance to public health and medical innovation. Use the following scale to rate each trial:\n","\n","- \"Not important\": Limited scope, low relevance, or lacking broader implications.\n","- \"Slightly important\": Moderately relevant but limited in scope or potential impact.\n","- \"Moderately important\": Provides useful information with practical implications but not groundbreaking.\n","- \"Very important\": Significant potential for public health improvement or medical innovation.\n","- \"Extremely important\": Transformative potential with wide-ranging public health or scientific implications.\n","\n","For each description, provide:\n","1. A succinct importance rating from the scale above.\n","2. A brief explanation for the rating.\n","\n","Description:\n","{description}\n","\n","Please rate the importance of the clinical trial and justify your assessment.\n","\"\"\"\n","\n","description = \"The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.\"\n","prompt = prompt_template.format(description=description)\n","print(prompt)\n"],"metadata":{"id":"jjYevr0eCg0Y"},"id":"jjYevr0eCg0Y","execution_count":null,"outputs":[]},{"cell_type":"markdown","source":["   Cleaned up output from batches:\n","   \n","    (0, \"Slightly important\"),\n","    (1, \"Moderately important\"),\n","    (2, \"Very important\"),\n","    (3, \"Moderately important\"),\n","    (4, \"Very important\"),\n","    (5, \"Extremely important\"),\n","    (6, \"Very important\"),\n","    (7, \"Moderately important\"),\n","    (8, \"Moderately important\"),\n","    (9, \"Moderately important\"),\n","    (10, \"Moderately important\"),\n","    (11, \"Very important\"),\n","    (12, \"Moderately important\"),\n","    (13, \"Moderately important\"),\n","    (14, \"Moderately important\"),\n","    (15, \"Very important\"),\n","    (16, \"Moderately important\"),\n","    (17, \"Moderately important\"),\n","    (18, \"Moderately important\"),\n","    (19, \"Moderately important\"),\n","    (20, \"Moderately important\"),\n","    (21, \"Moderately important\"),\n","    (22, \"Moderately important\"),\n","    (23, \"Moderately important\"),\n","    (24, \"Moderately important\"),\n","    (25, \"Moderately important\"),\n","    (26, \"Slightly important\"),\n","    (27, \"Moderately important\"),\n","    (28, \"Very important\"),\n","    (29, \"Very important\"),\n","    (30, \"Moderately important\"),\n","    (31, \"Moderately important\"),\n","    (32, \"Moderately important\"),\n","    (33, \"Slightly important\"),\n","    (34, \"Moderately important\"),\n","    (35, \"Slightly important\"),\n","    (36, \"Moderately important\"),\n","    (37, \"Moderately important\"),\n","    (38, \"Slightly important\"),\n","    (39, \"Moderately important\"),\n","    (40, \"Slightly important\"),\n","    (41, \"Moderately important\"),\n","    (42, \"Moderately important\"),\n","    (43, \"Slightly important\"),\n","    (44, \"Slightly important\"),\n","    (45, \"Moderately important\"),\n","    (46, \"Moderately important\"),\n","    (47, \"Moderately important\"),\n","    (48, \"Moderately important\"),\n","    (49, \"Very important\"),\n","    (50, \"Very important\"),\n","    (51, \"Slightly important\"),\n","    (52, \"Slightly important\"),\n","    (53, \"Moderately important\"),\n","    (54, \"Slightly important\"),\n","    (55, \"Slightly important\"),\n","    (56, \"Moderately important\"),\n","    (57, \"Slightly important\"),\n","    (58, \"Moderately important\"),\n","    (59, \"Moderately important\"),\n","    (60, \"Moderately important\"),\n","    (61, \"Moderately important\"),\n","    (62, \"Moderately important\"),\n","    (63, \"Slightly important\"),\n","    (64, \"Very important\"),\n","    (65, \"Moderately important\"),\n","    (66, \"Slightly important\"),\n","    (67, \"Slightly important\"),\n","    (68, \"Moderately important\"),\n","    (69, \"Moderately important\"),\n","    (70, \"Slightly important\"),\n","    (71, \"Slightly important\"),\n","    (72, \"Moderately important\"),\n","    (73, \"Moderately important\"),\n","    (74, \"Moderately important\"),\n","    (75, \"Slightly important\"),\n","    (76, \"Moderately important\"),\n","    (77, \"Moderately important\"),\n","    (78, \"Moderately important\"),\n","    (79, \"Slightly important\"),\n","    (80, \"Moderately important\"),\n","    (81, \"Moderately important\"),\n","    (82, \"Very important\"),\n","    (83, \"Very important\"),\n","    (84, \"Very important\"),\n","    (85, \"Very important\"),\n","    (86, \"Slightly important\"),\n","    (87, \"Moderately important\"),\n","    (88, \"Moderately important\"),\n","    (89, \"Slightly important\"),\n","    (90, \"Slightly important\"),\n","    (91, \"Moderately important\"),\n","    (92, \"Slightly important\"),\n","    (93, \"Very important\"),\n","    (94, \"Very important\"),\n","    (95, \"Very important\"),\n","    (96, \"Very important\"),\n","    (97, \"Moderately important\"),\n","    (98, \"Moderately important\"),\n","    (99, \"Moderately important\"),\n","    (100, \"Moderately important\"),\n","    (101, \"Moderately important\"),\n","    (102, \"Very important\"),\n","    (103, \"Moderately important\"),\n","    (104, \"Moderately important\"),\n","    (105, \"Moderately important\"),\n","    (106, \"Slightly important\"),\n","    (107, \"Slightly important\"),\n","    (108, \"Moderately important\"),\n","    (109, \"Slightly important\"),\n","    (110, \"Slightly important\"),\n","    (111, \"Slightly important\"),\n","    (112, \"Slightly important\"),\n","    (113, \"Slightly important\"),\n","    (114, \"Slightly important\"),\n","    (115, \"Moderately important\"),\n","    (116, \"Slightly important\"),\n","    (117, \"Moderately important\"),\n","    (118, \"Slightly important\"),\n","    (119, \"Slightly important\"),\n","    (120, \"Moderately important\"),\n","    (121, \"Very important\"),\n","    (122, \"Moderately important\"),\n","    (123, \"Very important\"),\n","    (124, \"Moderately important\"),\n","    (125, \"Very important\"),\n","    (126, \"Moderately important\"),\n","    (127, \"Moderately important\"),\n","    (128, \"Moderately important\"),\n","    (129, \"Slightly important\"),\n","    (130, \"Moderately important\"),\n","    (131, \"Slightly important\"),\n","    (132, \"Moderately important\"),\n","    (133, \"Very important\"),\n","    (134, \"Very important\"),\n","    (135, \"Very important\"),\n","    (136, \"Very important\"),\n","    (137, \"Moderately important\"),\n","    (138, \"Moderately important\"),\n","    (139, \"Moderately important\"),\n","    (140, \"Moderately important\"),\n","    (141, \"Moderately important\"),\n","    (142, \"Slightly important\"),\n","    (143, \"Slightly important\"),\n","    (144, \"Slightly important\"),\n","    (145, \"Slightly important\"),\n","    (146, \"Slightly important\"),\n","    (147, \"Very important\"),\n","    (148, \"Moderately important\"),\n","    (149, \"Moderately important\"),\n","    (150, \"Moderately important\"),\n","    (151, \"Moderately important\"),\n","    (152, \"Moderately important\"),\n","    (153, \"Moderately important\"),\n","    (154, \"Moderately important\"),\n","    (155, \"Slightly important\"),\n","    (156, \"Moderately important\"),\n","    (157, \"Moderately important\"),\n","    (158, \"Very important\"),\n","    (159, \"Very important\"),\n","    (160, \"Very important\"),\n","    (161, \"Very important\"),\n","    (162, \"Moderately important\"),\n","    (163, \"Moderately important\"),\n","    (164, \"Moderately important\"),\n","    (165, \"Very important\"),\n","    (166, \"Moderately important\"),\n","    (167, \"Moderately important\"),\n","    (168, \"Moderately important\"),\n","    (169, \"Moderately important\"),\n","    (170, \"Moderately important\"),\n","    (171, \"Moderately important\"),\n","    (172, \"Moderately important\"),\n","    (173, \"Very important\"),\n","    (174, \"Very important\"),\n","    (175, \"Very important\"),\n","    (176, \"Very important\"),\n","    (177, \"Very important\"),\n","    (178, \"Very important\"),\n","    (179, \"Moderately important\"),\n","    (180, \"Moderately important\"),\n","    (181, \"Moderately important\"),\n","    (182, \"Moderately important\"),\n","    (183, \"Moderately important\"),\n","    (184, \"Moderately important\"),\n","    (185, \"Very important\"),\n","    (186, \"Moderately important\"),\n","    (187, \"Moderately important\"),\n","    (188, \"Moderately important\"),\n","    (189, \"Moderately important\"),\n","    (190, \"Moderately important\"),\n","    (191, \"Moderately important\"),\n","    (192, \"Moderately important\"),\n","    (193, \"Moderately important\"),\n","    (194, \"Moderately important\"),\n","    (195, \"Moderately important\"),\n","    (196, \"Moderately important\"),\n","    (197, \"Moderately important\"),\n","    (198, \"Moderately important\"),"],"metadata":{"id":"jzHT5smnCIAJ"},"id":"jzHT5smnCIAJ"},{"cell_type":"markdown","id":"c8aa2507-8771-451e-9cdc-7f47bbdcfae4","metadata":{"id":"c8aa2507-8771-451e-9cdc-7f47bbdcfae4"},"source":["# Fed Chunks Below to GPT 4o"]},{"cell_type":"raw","id":"04d9b50e-3e15-4196-bd44-9833d6cfbc53","metadata":{"jupyter":{"source_hidden":true},"id":"04d9b50e-3e15-4196-bd44-9833d6cfbc53"},"source":["[\n","    (0, \"Slightly important\"),\n","    (1, \"Moderately important\"),\n","    (2, \"Very important\"),\n","    (3, \"Moderately important\"),\n","    (4, \"Very important\"),\n","    (5, \"Extremely important\"),\n","    (6, \"Very important\"),\n","    (7, \"Moderately important\"),\n","    (8, \"Moderately important\"),\n","    (9, \"Moderately important\"),\n","    (10, \"Moderately important\"),\n","    (11, \"Very important\"),\n","    (12, \"Moderately important\"),\n","    (13, \"Moderately important\"),\n","    (14, \"Moderately important\"),\n","    (15, \"Very important\"),\n","    (16, \"Moderately important\"),\n","    (17, \"Moderately important\"),\n","    (18, \"Moderately important\"),\n","    (19, \"Moderately important\"),\n","    (20, \"Moderately important\"),\n","    (21, \"Moderately important\"),\n","    (22, \"Moderately important\"),\n","    (23, \"Moderately important\"),\n","    (24, \"Moderately important\"),\n","    (25, \"Moderately important\"),\n","    (26, \"Slightly important\"),\n","    (27, \"Moderately important\"),\n","    (28, \"Very important\"),\n","    (29, \"Very important\"),\n","    (30, \"Moderately important\"),\n","    (31, \"Moderately important\"),\n","    (32, \"Moderately important\"),\n","    (33, \"Slightly important\"),\n","    (34, \"Moderately important\"),\n","    (35, \"Slightly important\"),\n","    (36, \"Moderately important\"),\n","    (37, \"Moderately important\"),\n","    (38, \"Slightly important\"),\n","    (39, \"Moderately important\"),\n","    (40, \"Slightly important\"),\n","    (41, \"Moderately important\"),\n","    (42, \"Moderately important\"),\n","    (43, \"Slightly important\"),\n","    (44, \"Slightly important\"),\n","    (45, \"Moderately important\"),\n","    (46, \"Moderately important\"),\n","    (47, \"Moderately important\"),\n","    (48, \"Moderately important\"),\n","    (49, \"Very important\"),\n","    (50, \"Very important\"),\n","    (51, \"Slightly important\"),\n","    (52, \"Slightly important\"),\n","    (53, \"Moderately important\"),\n","    (54, \"Slightly important\"),\n","    (55, \"Slightly important\"),\n","    (56, \"Moderately important\"),\n","    (57, \"Slightly important\"),\n","    (58, \"Moderately important\"),\n","    (59, \"Moderately important\"),\n","    (60, \"Moderately important\"),\n","    (61, \"Moderately important\"),\n","    (62, \"Moderately important\"),\n","    (63, \"Slightly important\"),\n","    (64, \"Very important\"),\n","    (65, \"Moderately important\"),\n","    (66, \"Slightly important\"),\n","    (67, \"Slightly important\"),\n","    (68, \"Moderately important\"),\n","    (69, \"Moderately important\"),\n","    (70, \"Slightly important\"),\n","    (71, \"Slightly important\"),\n","    (72, \"Moderately important\"),\n","    (73, \"Moderately important\"),\n","    (74, \"Moderately important\"),\n","    (75, \"Slightly important\"),\n","    (76, \"Moderately important\"),\n","    (77, \"Moderately important\"),\n","    (78, \"Moderately important\"),\n","    (79, \"Slightly important\"),\n","    (80, \"Moderately important\"),\n","    (81, \"Moderately important\"),\n","    (82, \"Very important\"),\n","    (83, \"Very important\"),\n","    (84, \"Very important\"),\n","    (85, \"Very important\"),\n","    (86, \"Slightly important\"),\n","    (87, \"Moderately important\"),\n","    (88, \"Moderately important\"),\n","    (89, \"Slightly important\"),\n","    (90, \"Slightly important\"),\n","    (91, \"Moderately important\"),\n","    (92, \"Slightly important\"),\n","    (93, \"Very important\"),\n","    (94, \"Very important\"),\n","    (95, \"Very important\"),\n","    (96, \"Very important\"),\n","    (97, \"Moderately important\"),\n","    (98, \"Moderately important\"),\n","    (99, \"Moderately important\"),\n","    (100, \"Moderately important\"),\n","    (101, \"Moderately important\"),\n","    (102, \"Very important\"),\n","    (103, \"Moderately important\"),\n","    (104, \"Moderately important\"),\n","    (105, \"Moderately important\"),\n","    (106, \"Slightly important\"),\n","    (107, \"Slightly important\"),\n","    (108, \"Moderately important\"),\n","    (109, \"Slightly important\"),\n","    (110, \"Slightly important\"),\n","    (111, \"Slightly important\"),\n","    (112, \"Slightly important\"),\n","    (113, \"Slightly important\"),\n","    (114, \"Slightly important\"),\n","    (115, \"Moderately important\"),\n","    (116, \"Slightly important\"),\n","    (117, \"Moderately important\"),\n","    (118, \"Slightly important\"),\n","    (119, \"Slightly important\"),\n","    (120, \"Moderately important\"),\n","    (121, \"Very important\"),\n","    (122, \"Moderately important\"),\n","    (123, \"Very important\"),\n","    (124, \"Moderately important\"),\n","    (125, \"Very important\"),\n","    (126, \"Moderately important\"),\n","    (127, \"Moderately important\"),\n","    (128, \"Moderately important\"),\n","    (129, \"Slightly important\"),\n","    (130, \"Moderately important\"),\n","    (131, \"Slightly important\"),\n","    (132, \"Moderately important\"),\n","    (133, \"Very important\"),\n","    (134, \"Very important\"),\n","    (135, \"Very important\"),\n","    (136, \"Very important\"),\n","    (137, \"Moderately important\"),\n","    (138, \"Moderately important\"),\n","    (139, \"Moderately important\"),\n","    (140, \"Moderately important\"),\n","    (141, \"Moderately important\"),\n","    (142, \"Slightly important\"),\n","    (143, \"Slightly important\"),\n","    (144, \"Slightly important\"),\n","    (145, \"Slightly important\"),\n","    (146, \"Slightly important\"),\n","    (147, \"Very important\"),\n","    (148, \"Moderately important\"),\n","    (149, \"Moderately important\"),\n","    (150, \"Moderately important\"),\n","    (151, \"Moderately important\"),\n","    (152, \"Moderately important\"),\n","    (153, \"Moderately important\"),\n","    (154, \"Moderately important\"),\n","    (155, \"Slightly important\"),\n","    (156, \"Moderately important\"),\n","    (157, \"Moderately important\"),\n","    (158, \"Very important\"),\n","    (159, \"Very important\"),\n","    (160, \"Very important\"),\n","    (161, \"Very important\"),\n","    (162, \"Moderately important\"),\n","    (163, \"Moderately important\"),\n","    (164, \"Moderately important\"),\n","    (165, \"Very important\"),\n","    (166, \"Moderately important\"),\n","    (167, \"Moderately important\"),\n","    (168, \"Moderately important\"),\n","    (169, \"Moderately important\"),\n","    (170, \"Moderately important\"),\n","    (171, \"Moderately important\"),\n","    (172, \"Moderately important\"),\n","    (173, \"Very important\"),\n","    (174, \"Very important\"),\n","    (175, \"Very important\"),\n","    (176, \"Very important\"),\n","    (177, \"Very important\"),\n","    (178, \"Very important\"),\n","    (179, \"Moderately important\"),\n","    (180, \"Moderately important\"),\n","    (181, \"Moderately important\"),\n","    (182, \"Moderately important\"),\n","    (183, \"Moderately important\"),\n","    (184, \"Moderately important\"),\n","    (185, \"Very important\"),\n","    (186, \"Moderately important\"),\n","    (187, \"Moderately important\"),\n","    (188, \"Moderately important\"),\n","    (189, \"Moderately important\"),\n","    (190, \"Moderately important\"),\n","    (191, \"Moderately important\"),\n","    (192, \"Moderately important\"),\n","    (193, \"Moderately important\"),\n","    (194, \"Moderately important\"),\n","    (195, \"Moderately important\"),\n","    (196, \"Moderately important\"),\n","    (197, \"Moderately important\"),\n","    (198, \"Moderately important\"),\n","    (199, \"Moderately important\"),\n","    (200, \"Moderately important\"),\n","    (201, \"Very important\"),\n","    (202, \"Moderately important\"),\n","    (203, \"Very important\"),\n","    (204, \"Moderately important\"),\n","    (205, \"Very important\"),\n","    (206, \"Moderately important\"),\n","    (207, \"Very important\"),\n","    (208, \"Slightly important\"),\n","    (209, \"Moderately important\"),\n","    (210, \"Moderately important\"),\n","    (211, \"Moderately important\"),\n","    (212, \"Moderately important\"),\n","    (213, \"Moderately important\"),\n","    (214, \"Moderately important\"),\n","    (215, \"Moderately important\"),\n","    (216, \"Moderately important\"),\n","    (217, \"Very important\"),\n","    (218, \"Moderately important\"),\n","    (219, \"Very important\"),\n","    (220, \"Moderately important\"),\n","    (221, \"Moderately important\"),\n","    (222, \"Moderately important\"),\n","    (223, \"Moderately important\"),\n","    (224, \"Slightly important\"),\n","    (225, \"Moderately important\"),\n","    (226, \"Moderately important\"),\n","    (227, \"Moderately important\"),\n","    (228, \"Moderately important\"),\n","    (229, \"Slightly important\"),\n","    (230, \"Very important\"),\n","    (231, \"Slightly important\"),\n","    (232, \"Moderately important\"),\n","    (233, \"Moderately important\"),\n","    (234, \"Moderately important\"),\n","    (235, \"Moderately important\"),\n","    (236, \"Very important\"),\n","    (237, \"Moderately important\"),\n","    (238, \"Very important\"),\n","    (239, \"Very important\"),\n","    (240, \"Moderately important\"),\n","    (241, \"Moderately important\"),\n","    (242, \"Moderately important\"),\n","    (243, \"Very important\"),\n","    (244, \"Moderately important\"),\n","    (245, \"Moderately important\"),\n","    (246, \"Moderately important\"),\n","    (247, \"Slightly important\"),\n","    (248, \"Moderately important\"),\n","    (249, \"Very important\"),\n","    (250, \"Very important\"),\n","    (251, \"Moderately important\"),\n","    (252, \"Moderately important\"),\n","    (253, \"Moderately important\"),\n","    (254, \"Very important\"),\n","    (255, \"Moderately important\"),\n","    (256, \"Slightly important\"),\n","    (257, \"Moderately important\"),\n","    (258, \"Moderately important\"),\n","    (259, \"Very important\"),\n","    (260, \"Moderately important\"),\n","    (261, \"Very important\"),\n","    (262, \"Slightly important\"),\n","    (263, \"Moderately important\"),\n","    (264, \"Moderately important\"),\n","    (265, \"Slightly important\"),\n","    (266, \"Moderately important\"),\n","    (267, \"Moderately important\"),\n","    (268, \"Moderately important\"),\n","    (269, \"Very important\"),\n","    (270, \"Moderately important\"),\n","    (271, \"Slightly important\"),\n","    (272, \"Moderately important\"),\n","    (273, \"Very important\"),\n","    (274, \"Moderately important\"),\n","    (275, \"Not important\"),\n","    (276, \"Very important\"),\n","    (277, \"Very important\"),\n","    (278, \"Moderately important\"),\n","    (279, \"Very important\"),\n","    (280, \"Moderately important\"),\n","    (281, \"Moderately important\"),\n","    (282, \"Moderately important\"),\n","    (283, \"Moderately important\"),\n","    (284, \"Moderately important\"),\n","    (285, \"Very important\"),\n","    (286, \"Moderately important\"),\n","    (287, \"Moderately important\"),\n","    (288, \"Moderately important\"),\n","    (289, \"Moderately important\"),\n","    (290, \"Slightly important\"),\n","    (291, \"Not important\"),\n","    (292, \"Not important\"),\n","    (293, \"Not important\"),\n","    (294, \"Very important\"),\n","    (295, \"Moderately important\"),\n","    (296, \"Moderately important\"),\n","    (297, \"Moderately important\"),\n","    (298, \"Very important\"),\n","    (299, \"Slightly important\"),\n","    (300, \"Moderately important\"),\n","    (301, \"Moderately important\"),\n","    (302, \"Moderately important\"),\n","    (303, \"Moderately important\"),\n","    (304, \"Very important\"),\n","    (305, \"Moderately important\"),\n","    (306, \"Moderately important\"),\n","    (307, \"Very important\"),\n","    (308, \"Moderately important\"),\n","    (309, \"Moderately important\"),\n","    (310, \"Moderately important\"),\n","    (311, \"Moderately important\"),\n","    (312, \"Slightly important\"),\n","    (313, \"Moderately important\"),\n","    (314, \"Moderately important\"),\n","    (315, \"Moderately important\"),\n","    (316, \"Moderately important\"),\n","    (317, \"Moderately important\"),\n","    (318, \"Moderately important\"),\n","    (319, \"Slightly important\"),\n","    (320, \"Very important\"),\n","    (321, \"Very important\"),\n","    (322, \"Moderately important\"),\n","    (323, \"Very important\"),\n","    (324, \"Moderately important\"),\n","    (325, \"Very important\"),\n","    (326, \"Very important\"),\n","    (327, \"Moderately important\"),\n","    (328, \"Moderately important\"),\n","    (329, \"Slightly important\"),\n","    (330, \"Moderately important\"),\n","    (331, \"Moderately important\"),\n","    (332, \"Moderately important\"),\n","    (333, \"Not important\"),\n","    (334, \"Very important\"),\n","    (335, \"Moderately important\"),\n","    (336, \"Moderately important\"),\n","    (337, \"Very important\"),\n","    (338, \"Slightly important\"),\n","    (339, \"Very important\"),\n","    (340, \"Moderately important\"),\n","    (341, \"Moderately important\"),\n","    (342, \"Moderately important\"),\n","    (343, \"Moderately important\"),\n","    (344, \"Slightly important\"),\n","    (345, \"Very important\"),\n","    (346, \"Moderately important\"),\n","    (347, \"Moderately important\"),\n","    (348, \"Very important\"),\n","    (349, \"Moderately important\"),\n","    (350, \"Slightly important\"),\n","    (351, \"Moderately important\"),\n","    (352, \"Moderately important\"),\n","    (353, \"Very important\"),\n","    (354, \"Moderately important\"),\n","    (355, \"Moderately important\"),\n","    (356, \"Moderately important\"),\n","    (357, \"Slightly important\"),\n","    (358, \"Moderately important\"),\n","    (359, \"Moderately important\"),\n","    (360, \"Moderately important\"),\n","    (361, \"Moderately important\"),\n","    (362, \"Moderately important\"),\n","    (363, \"Moderately important\"),\n","    (364, \"Slightly important\"),\n","    (365, \"Moderately important\"),\n","    (366, \"Moderately important\"),\n","    (367, \"Moderately important\"),\n","    (368, \"Moderately important\"),\n","    (369, \"Moderately important\"),\n","    (370, \"Slightly important\"),\n","    (371, \"Moderately important\"),\n","    (372, \"Moderately important\"),\n","    (373, \"Moderately important\"),\n","    (374, \"Moderately important\"),\n","    (375, \"Moderately important\"),\n","    (376, \"Moderately important\"),\n","    (377, \"Moderately important\"),\n","    (378, \"Not important\"),\n","    (379, \"Moderately important\"),\n","    (380, \"Moderately important\"),\n","    (381, \"Moderately important\"),\n","    (382, \"Moderately important\"),\n","    (383, \"Very important\"),\n","    (384, \"Very important\"),\n","    (385, \"Moderately important\"),\n","    (386, \"Moderately important\"),\n","    (387, \"Moderately important\"),\n","    (388, \"Slightly important\"),\n","    (389, \"Moderately important\"),\n","    (390, \"Moderately important\"),\n","    (391, \"Moderately important\"),\n","    (392, \"Moderately important\"),\n","    (393, \"Moderately important\"),\n","    (394, \"Moderately important\"),\n","    (395, \"Moderately important\"),\n","    (396, \"Moderately important\"),\n","    (397, \"Moderately important\"),\n","    (398, \"Moderately important\"),\n","    (399, \"Moderately important\"),\n","    (400, \"Very important\"),\n","    (401, \"Moderately important\"),\n","    (402, \"Very important\"),\n","    (403, \"Moderately important\"),\n","    (404, \"Extremely important\"),\n","    (405, \"Moderately important\"),\n","    (406, \"Moderately important\"),\n","    (407, \"Moderately important\"),\n","    (408, \"Moderately important\"),\n","    (409, \"Moderately important\"),\n","    (410, \"Very important\"),\n","    (411, \"Very important\"),\n","    (412, \"Very important\"),\n","    (413, \"Moderately important\"),\n","    (414, \"Slightly important\"),\n","    (415, \"Extremely important\"),\n","    (416, \"Slightly important\"),\n","    (417, \"Moderately important\"),\n","    (418, \"Very important\"),\n","    (419, \"Moderately important\"),\n","    (420, \"Moderately important\"),\n","    (421, \"Moderately important\"),\n","    (422, \"Moderately important\"),\n","    (423, \"Moderately important\"),\n","    (424, \"Moderately important\"),\n","    (425, \"Moderately important\"),\n","    (426, \"Moderately important\"),\n","    (427, \"Moderately important\"),\n","    (428, \"Moderately important\"),\n","    (429, \"Very important\"),\n","    (430, \"Moderately important\"),\n","    (431, \"Very important\"),\n","    (432, \"Moderately important\"),\n","    (433, \"Moderately important\"),\n","    (434, \"Moderately important\"),\n","    (435, \"Moderately important\"),\n","    (436, \"Very important\"),\n","    (437, \"Moderately important\"),\n","    (438, \"Moderately important\"),\n","    (439, \"Moderately important\"),\n","    (440, \"Slightly important\"),\n","    (441, \"Slightly important\"),\n","    (442, \"Extremely important\"),\n","    (443, \"Very important\"),\n","    (444, \"Very important\"),\n","    (445, \"Moderately important\"),\n","    (446, \"Moderately important\"),\n","    (447, \"Moderately important\"),\n","    (448, \"Moderately important\"),\n","    (449, \"Moderately important\"),\n","    (450, \"Moderately important\"),\n","    (451, \"Moderately important\"),\n","    (452, \"Moderately important\"),\n","    (453, \"Moderately important\"),\n","    (454, \"Moderately important\"),\n","    (455, \"Moderately important\"),\n","    (456, \"Moderately important\"),\n","    (457, \"Slightly important\"),\n","    (458, \"Slightly important\"),\n","    (459, \"Slightly important\"),\n","    (460, \"Moderately important\"),\n","    (461, \"Moderately important\"),\n","    (462, \"Slightly important\"),\n","    (463, \"Moderately important\"),\n","    (464, \"Very important\"),\n","    (465, \"Moderately important\"),\n","    (466, \"Very important\"),\n","    (467, \"Very important\"),\n","    (468, \"Moderately important\"),\n","    (469, \"Moderately important\"),\n","    (470, \"Moderately important\"),\n","    (471, \"Moderately important\"),\n","    (472, \"Slightly important\"),\n","    (473, \"Very important\"),\n","    (474, \"Very important\"),\n","    (475, \"Moderately important\"),\n","    (476, \"Slightly important\"),\n","    (477, \"Slightly important\"),\n","    (478, \"Moderately important\"),\n","    (479, \"Moderately important\"),\n","    (480, \"Very important\"),\n","    (481, \"Moderately important\"),\n","    (482, \"Moderately important\"),\n","    (483, \"Moderately important\"),\n","    (484, \"Moderately important\"),\n","    (485, \"Moderately important\"),\n","    (486, \"Moderately important\"),\n","    (487, \"Moderately important\"),\n","    (488, \"Moderately important\"),\n","    (489, \"Moderately important\"),\n","    (490, \"Moderately important\"),\n","    (491, \"Slightly important\"),\n","    (492, \"Moderately important\"),\n","    (493, \"Moderately important\"),\n","    (494, \"Moderately important\"),\n","    (495, \"Moderately important\"),\n","    (496, \"Very important\"),\n","    (497, \"Very important\"),\n","    (498, \"Very important\"),\n","    (499, \"Moderately important\"),\n","    (500, \"Moderately important\"),\n","    (501, \"Moderately important\"),\n","    (502, \"Very important\"),\n","    (503, \"Moderately important\"),\n","    (504, \"Moderately important\"),\n","    (505, \"Slightly important\"),\n","    (506, \"Slightly important\"),\n","    (507, \"Very important\"),\n","    (508, \"Slightly important\"),\n","    (509, \"Slightly important\"),\n","    (510, \"Moderately important\"),\n","    (511, \"Moderately important\"),\n","    (512, \"Moderately important\"),\n","    (513, \"Very important\"),\n","    (514, \"Very important\"),\n","    (515, \"Very important\"),\n","    (516, \"Moderately important\"),\n","    (517, \"Very important\"),\n","    (518, \"Moderately important\"),\n","    (519, \"Moderately important\"),\n","    (520, \"Moderately important\"),\n","    (521, \"Moderately important\"),\n","    (522, \"Moderately important\"),\n","    (523, \"Moderately important\"),\n","    (524, \"Slightly important\"),\n","    (525, \"Moderately important\"),\n","    (526, \"Moderately important\"),\n","    (527, \"Slightly important\"),\n","    (528, \"Slightly important\"),\n","    (529, \"Moderately important\"),\n","    (530, \"Slightly important\"),\n","    (531, \"Moderately important\"),\n","    (532, \"Slightly important\"),\n","    (533, \"Moderately important\"),\n","    (534, \"Moderately important\"),\n","    (535, \"Moderately important\"),\n","    (536, \"Moderately important\"),\n","    (537, \"Moderately important\"),\n","    (538, \"Slightly important\"),\n","    (539, \"Slightly important\"),\n","    (540, \"Slightly important\"),\n","    (541, \"Slightly important\"),\n","    (542, \"Moderately important\"),\n","    (543, \"Moderately important\"),\n","    (544, \"Moderately important\"),\n","    (545, \"Moderately important\"),\n","    (546, \"Slightly important\"),\n","    (547, \"Moderately important\"),\n","    (548, \"Very important\"),\n","    (549, \"Moderately important\"),\n","    (550, \"Moderately important\"),\n","    (551, \"Moderately important\"),\n","    (552, \"Moderately important\"),\n","    (553, \"Slightly important\"),\n","    (554, \"Very important\"),\n","    (555, \"Very important\"),\n","    (556, \"Slightly important\"),\n","    (557, \"Slightly important\"),\n","    (558, \"Moderately important\"),\n","    (559, \"Moderately important\"),\n","    (560, \"Very important\"),\n","    (561, \"Moderately important\"),\n","    (562, \"Moderately important\"),\n","    (563, \"Moderately important\"),\n","    (564, \"Moderately important\"),\n","    (565, \"Moderately important\"),\n","    (566, \"Moderately important\"),\n","    (567, \"Moderately important\"),\n","    (568, \"Moderately important\"),\n","    (569, \"Moderately important\"),\n","    (570, \"Very important\"),\n","    (571, \"Very important\"),\n","    (572, \"Moderately important\"),\n","    (573, \"Moderately important\"),\n","    (574, \"Very important\"),\n","    (575, \"Slightly important\"),\n","    (576, \"Very important\"),\n","    (577, \"Moderately important\"),\n","    (578, \"Moderately important\"),\n","    (579, \"Moderately important\"),\n","    (580, \"Moderately important\"),\n","    (581, \"Moderately important\"),\n","    (582, \"Moderately important\"),\n","    (583, \"Moderately important\"),\n","    (584, \"Slightly important\"),\n","    (585, \"Moderately important\"),\n","    (586, \"Moderately important\"),\n","    (587, \"Moderately important\"),\n","    (588, \"Moderately important\"),\n","    (589, \"Slightly important\"),\n","    (590, \"Slightly important\"),\n","    (591, \"Slightly important\"),\n","    (592, \"Moderately important\"),\n","    (593, \"Moderately important\"),\n","    (594, \"Moderately important\"),\n","    (595, \"Moderately important\"),\n","    (596, \"Moderately important\"),\n","    (597, \"Moderately important\"),\n","    (598, \"Moderately important\"),\n","    (599, \"Moderately important\")\n","    (600, \"Moderately important\"),\n","    (601, \"Slightly important\"),\n","    (602, \"Very important\"),\n","    (603, \"Slightly important\"),\n","    (604, \"Moderately important\"),\n","    (605, \"Very important\"),\n","    (606, \"Very important\"),\n","    (607, \"Very important\"),\n","    (608, \"Moderately important\"),\n","    (609, \"Moderately important\"),\n","    (610, \"Slightly important\"),\n","    (611, \"Slightly important\"),\n","    (612, \"Slightly important\"),\n","    (613, \"Very important\"),\n","    (614, \"Moderately important\"),\n","    (615, \"Very important\"),\n","    (616, \"Moderately important\"),\n","    (617, \"Moderately important\"),\n","    (618, \"Moderately important\"),\n","    (619, \"Extremely important\"),\n","    (620, \"Very important\"),\n","    (621, \"Moderately important\"),\n","    (622, \"Very important\"),\n","    (623, \"Moderately important\"),\n","    (624, \"Slightly important\"),\n","    (625, \"Slightly important\"),\n","    (626, \"Moderately important\"),\n","    (627, \"Moderately important\"),\n","    (628, \"Slightly important\"),\n","    (629, \"Moderately important\"),\n","    (630, \"Moderately important\"),\n","    (631, \"Very important\"),\n","    (632, \"Very important\"),\n","    (633, \"Moderately important\"),\n","    (634, \"Moderately important\"),\n","    (635, \"Moderately important\"),\n","    (636, \"Moderately important\"),\n","    (637, \"Moderately important\"),\n","    (638, \"Slightly important\"),\n","    (639, \"Moderately important\"),\n","    (640, \"Moderately important\"),\n","    (641, \"Slightly important\"),\n","    (642, \"Slightly important\"),\n","    (643, \"Moderately important\"),\n","    (644, \"Very important\"),\n","    (645, \"Slightly important\"),\n","    (646, \"Moderately important\"),\n","    (647, \"Moderately important\"),\n","    (648, \"Moderately important\"),\n","    (649, \"Very important\"),\n","    (650, \"Very important\"),\n","    (651, \"Very important\"),\n","    (652, \"Very important\"),\n","    (653, \"Moderately important\"),\n","    (654, \"Slightly important\"),\n","    (655, \"Slightly important\"),\n","    (656, \"Moderately important\"),\n","    (657, \"Very important\"),\n","    (658, \"Very important\"),\n","    (659, \"Moderately important\"),\n","    (660, \"Very important\"),\n","    (661, \"Moderately important\"),\n","    (662, \"Moderately important\"),\n","    (663, \"Moderately important\"),\n","    (664, \"Slightly important\"),\n","    (665, \"Slightly important\"),\n","    (666, \"Moderately important\"),\n","    (667, \"Slightly important\"),\n","    (668, \"Moderately important\"),\n","    (669, \"Moderately important\"),\n","    (670, \"Moderately important\"),\n","    (671, \"Moderately important\"),\n","    (672, \"Moderately important\"),\n","    (673, \"Very important\"),\n","    (674, \"Slightly important\"),\n","    (675, \"Moderately important\"),\n","    (676, \"Moderately important\"),\n","    (677, \"Moderately important\"),\n","    (678, \"Moderately important\"),\n","    (679, \"Slightly important\"),\n","    (680, \"Slightly important\"),\n","    (681, \"Moderately important\"),\n","    (682, \"Slightly important\"),\n","    (683, \"Slightly important\"),\n","    (684, \"Slightly important\"),\n","    (685, \"Moderately important\"),\n","    (686, \"Very important\"),\n","    (687, \"Very important\"),\n","    (688, \"Very important\"),\n","    (689, \"Moderately important\"),\n","    (690, \"Moderately important\"),\n","    (691, \"Moderately important\"),\n","    (692, \"Moderately important\"),\n","    (693, \"Moderately important\"),\n","    (694, \"Moderately important\"),\n","    (695, \"Very important\"),\n","    (696, \"Moderately important\"),\n","    (697, \"Moderately important\"),\n","    (698, \"Slightly important\"),\n","    (699, \"Slightly important\"),\n","    (700, \"Moderately important\"),\n","    (701, \"Moderately important\"),\n","    (702, \"Moderately important\"),\n","    (703, \"Moderately important\"),\n","    (704, \"Moderately important\"),\n","    (705, \"Moderately important\"),\n","    (706, \"Very important\"),\n","    (707, \"Very important\"),\n","    (708, \"Very important\"),\n","    (709, \"Moderately important\"),\n","    (710, \"Moderately important\"),\n","    (711, \"Moderately important\"),\n","    (712, \"Moderately important\"),\n","    (713, \"Moderately important\"),\n","    (714, \"Moderately important\"),\n","    (715, \"Very important\"),\n","    (716, \"Moderately important\"),\n","    (717, \"Very important\"),\n","    (718, \"Moderately important\"),\n","    (719, \"Moderately important\"),\n","    (720, \"Slightly important\"),\n","    (721, \"Slightly important\"),\n","    (722, \"Very important\"),\n","    (723, \"Moderately important\"),\n","    (724, \"Moderately important\"),\n","    (725, \"Moderately important\"),\n","    (726, \"Moderately important\"),\n","    (727, \"Moderately important\"),\n","    (728, \"Moderately important\"),\n","    (729, \"Slightly important\"),\n","    (730, \"Moderately important\"),\n","    (731, \"Moderately important\"),\n","    (732, \"Moderately important\"),\n","    (733, \"Moderately important\"),\n","    (734, \"Moderately important\"),\n","    (735, \"Moderately important\"),\n","    (736, \"Moderately important\"),\n","    (737, \"Moderately important\"),\n","    (738, \"Moderately important\"),\n","    (739, \"Moderately important\"),\n","    (740, \"Moderately important\"),\n","    (741, \"Moderately important\"),\n","    (742, \"Moderately important\"),\n","    (743, \"Moderately important\"),\n","    (744, \"Moderately important\"),\n","    (745, \"Moderately important\"),\n","    (746, \"Moderately important\"),\n","    (747, \"Moderately important\"),\n","    (748, \"Moderately important\"),\n","    (749, \"Moderately important\"),\n","    (750, \"Moderately important\"),\n","    (751, \"Moderately important\"),\n","    (752, \"Moderately important\"),\n","    (753, \"Moderately important\"),\n","    (754, \"Moderately important\"),\n","    (755, \"Moderately important\"),\n","    (756, \"Moderately important\"),\n","    (757, \"Moderately important\"),\n","    (758, \"Moderately important\"),\n","    (759, \"Moderately important\"),\n","    (760, \"Moderately important\"),\n","    (761, \"Moderately important\"),\n","    (762, \"Moderately important\"),\n","    (763, \"Moderately important\"),\n","    (764, \"Moderately important\"),\n","    (765, \"Moderately important\"),\n","    (766, \"Moderately important\"),\n","    (767, \"Moderately important\"),\n","    (768, \"Moderately important\"),\n","    (769, \"Moderately important\"),\n","    (770, \"Moderately important\"),\n","    (771, \"Moderately important\"),\n","    (772, \"Moderately important\"),\n","    (773, \"Moderately important\"),\n","    (774, \"Moderately important\"),\n","    (775, \"Moderately important\"),\n","    (776, \"Moderately important\"),\n","    (777, \"Moderately important\"),\n","    (778, \"Moderately important\"),\n","    (779, \"Moderately important\"),\n","    (780, \"Moderately important\"),\n","    (781, \"Moderately important\"),\n","    (782, \"Moderately important\"),\n","    (783, \"Moderately important\"),\n","    (784, \"Moderately important\"),\n","    (785, \"Moderately important\"),\n","    (786, \"Moderately important\"),\n","    (787, \"Moderately important\"),\n","    (788, \"Moderately important\"),\n","    (789, \"Moderately important\"),\n","    (790, \"Moderately important\"),\n","    (791, \"Moderately important\"),\n","    (792, \"Moderately important\"),\n","    (793, \"Moderately important\"),\n","    (794, \"Moderately important\"),\n","    (795, \"Moderately important\"),\n","    (796, \"Moderately important\"),\n","    (797, \"Moderately important\"),\n","    (798, \"Moderately important\"),\n","    (799, \"Moderately important\"),\n","....\n","....\n","    (3663, 'Moderately important'),\n","     (3664, 'Moderately important'),\n","     (3665, 'Moderately important'),\n","     (3666, 'Moderately important'),\n","     (3667, 'Moderately important'),\n","     (3668, 'Moderately important'),\n","     (3669, 'Moderately important'),\n","     (3670, 'Moderately important'),\n","     (3671, 'Moderately important'),\n","     (3672, 'Moderately important')\n","]"]},{"cell_type":"code","execution_count":null,"id":"31ab6211-8aa3-43d6-a9bc-8b940528f768","metadata":{"id":"31ab6211-8aa3-43d6-a9bc-8b940528f768","outputId":"ffa8b113-9ba0-4a19-ba43-cdb92d932fc9"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>nct_id</th>\n","      <th>Drug Name</th>\n","      <th>conditions</th>\n","      <th>Therapy Area</th>\n","      <th>id</th>\n","      <th>description</th>\n","      <th>criteria</th>\n","      <th>healthy_volunteers</th>\n","      <th>adult</th>\n","      <th>child</th>\n","      <th>older_adult</th>\n","      <th>Model_lloydmeta_Class</th>\n","      <th>Model_lloydmeta_Score</th>\n","      <th>Model_domenicrosati_ratings</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","      <th>Spacy2 Pregnant Women Excluded</th>\n","      <th>llama3_gender_Inclusion</th>\n","      <th>LLama3_2_Criteria_Robustness</th>\n","      <th>LLM_GBT_4o_Human_Importance_Ratings</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>NCT00000187</td>\n","      <td>ritanserin</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Toxicity/Intoxication; Neurology/Psychiatric</td>\n","      <td>24095864</td>\n","      <td>The purpose of this study is to assess ritanse...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.831781</td>\n","      <td>0.625245</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>NaN</td>\n","      <td>Unknown</td>\n","      <td>Slightly important</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>NCT00000200</td>\n","      <td>methadone</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Neurology/Psychiatric</td>\n","      <td>23965890</td>\n","      <td>The purpose of this study is to compare the ef...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.537430</td>\n","      <td>0.662990</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>NaN</td>\n","      <td>Unknown</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>NCT00000395</td>\n","      <td>methotrexate</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>Immune; Dermatologic; Gastrointestinal; Ocular</td>\n","      <td>24006623</td>\n","      <td>This study looks at how the arthritis drug met...</td>\n","      <td>Inclusion Criteria:~* Individuals starting met...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>0.999085</td>\n","      <td>0.564219</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Both</td>\n","      <td>Weak</td>\n","      <td>Very important</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>NCT00000451</td>\n","      <td>sertraline</td>\n","      <td>alcoholism</td>\n","      <td>Neurology/Psychiatric; Genitourinary/Sexual Fu...</td>\n","      <td>23799489</td>\n","      <td>This study will assess the ability of naltrexo...</td>\n","      <td>Inclusion Criteria:~* Alaska Native having bio...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>alcohol dependence</td>\n","      <td>0.996837</td>\n","      <td>0.575893</td>\n","      <td>Yes</td>\n","      <td>Yes</td>\n","      <td>Both</td>\n","      <td>Strong</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>NCT00001723</td>\n","      <td>orlistat</td>\n","      <td>obesity</td>\n","      <td>Other/Miscellaneous</td>\n","      <td>24120128</td>\n","      <td>Obesity is a condition affecting one-third off...</td>\n","      <td>* INCLUSION CRITERIA:~Good general health. Ind...</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>obesity</td>\n","      <td>0.999277</td>\n","      <td>0.663715</td>\n","      <td>Yes</td>\n","      <td>Yes</td>\n","      <td>Both</td>\n","      <td>Strong</td>\n","      <td>Very important</td>\n","    </tr>\n","    <tr>\n","      <th>...</th>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","    </tr>\n","    <tr>\n","      <th>3668</th>\n","      <td>NCT06076681</td>\n","      <td>amoxicillin</td>\n","      <td>helicobacter pylori infection</td>\n","      <td>Infection</td>\n","      <td>23868759</td>\n","      <td>This phase â… b/â…¡a, single-center, randomized, o...</td>\n","      <td>Inclusion Criteria:~* Signing the informed con...</td>\n","      <td>True</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>helicobacter pylori infection</td>\n","      <td>0.901176</td>\n","      <td>0.679332</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Both</td>\n","      <td>Strong</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>3669</th>\n","      <td>NCT06076694</td>\n","      <td>amoxicillin</td>\n","      <td>helicobacter pylori infection</td>\n","      <td>Infection</td>\n","      <td>24138415</td>\n","      <td>This is a single-center, randomized, open-labe...</td>\n","      <td>Inclusion Criteria:~* Signing the informed con...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>helicobacter pylori infection</td>\n","      <td>0.148174</td>\n","      <td>0.676120</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Both</td>\n","      <td>Weak</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>3670</th>\n","      <td>NCT06085638</td>\n","      <td>azacitidine</td>\n","      <td>chronic myelomonocytic leukemia</td>\n","      <td>Cancer</td>\n","      <td>23994955</td>\n","      <td>To learn if adding venetoclax to the chemother...</td>\n","      <td>Inclusion Criteria:~1. Patients must be at lea...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>nausea/vomiting, chemotherapy induced</td>\n","      <td>0.623298</td>\n","      <td>0.643846</td>\n","      <td>Yes</td>\n","      <td>No</td>\n","      <td>Both</td>\n","      <td>Strong</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>3671</th>\n","      <td>NCT06160609</td>\n","      <td>GSK-3174998</td>\n","      <td>relapsed/refractory multiple myeloma</td>\n","      <td>Cancer</td>\n","      <td>23930468</td>\n","      <td>The primary purpose is to determine the safety...</td>\n","      <td>Inclusion Criteria:~* Participant must be 18 y...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>high cholesterol, familial heterozygous</td>\n","      <td>0.019065</td>\n","      <td>0.754822</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Both</td>\n","      <td>Strong</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>3672</th>\n","      <td>NCT06309732</td>\n","      <td>methotrexate</td>\n","      <td>testicular neoplasms</td>\n","      <td>Immune</td>\n","      <td>24116236</td>\n","      <td>St Bartholomew's hospital completed a study us...</td>\n","      <td>Inclusion Criteria:~* Germ Cell Tumour (GCT), ...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>melanoma, metastatic</td>\n","      <td>0.019100</td>\n","      <td>0.572456</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Male</td>\n","      <td>Strong</td>\n","      <td>Moderately important</td>\n","    </tr>\n","  </tbody>\n","</table>\n","<p>3673 rows Ã— 19 columns</p>\n","</div>"],"text/plain":["           nct_id     Drug Name                            conditions  \\\n","0     NCT00000187    ritanserin             cocaine-related disorders   \n","1     NCT00000200     methadone             cocaine-related disorders   \n","2     NCT00000395  methotrexate                  rheumatoid arthritis   \n","3     NCT00000451    sertraline                            alcoholism   \n","4     NCT00001723      orlistat                               obesity   \n","...           ...           ...                                   ...   \n","3668  NCT06076681   amoxicillin         helicobacter pylori infection   \n","3669  NCT06076694   amoxicillin         helicobacter pylori infection   \n","3670  NCT06085638   azacitidine       chronic myelomonocytic leukemia   \n","3671  NCT06160609   GSK-3174998  relapsed/refractory multiple myeloma   \n","3672  NCT06309732  methotrexate                  testicular neoplasms   \n","\n","                                           Therapy Area        id  \\\n","0          Toxicity/Intoxication; Neurology/Psychiatric  24095864   \n","1                                 Neurology/Psychiatric  23965890   \n","2        Immune; Dermatologic; Gastrointestinal; Ocular  24006623   \n","3     Neurology/Psychiatric; Genitourinary/Sexual Fu...  23799489   \n","4                                   Other/Miscellaneous  24120128   \n","...                                                 ...       ...   \n","3668                                          Infection  23868759   \n","3669                                          Infection  24138415   \n","3670                                             Cancer  23994955   \n","3671                                             Cancer  23930468   \n","3672                                             Immune  24116236   \n","\n","                                            description  \\\n","0     The purpose of this study is to assess ritanse...   \n","1     The purpose of this study is to compare the ef...   \n","2     This study looks at how the arthritis drug met...   \n","3     This study will assess the ability of naltrexo...   \n","4     Obesity is a condition affecting one-third off...   \n","...                                                 ...   \n","3668  This phase â… b/â…¡a, single-center, randomized, o...   \n","3669  This is a single-center, randomized, open-labe...   \n","3670  To learn if adding venetoclax to the chemother...   \n","3671  The primary purpose is to determine the safety...   \n","3672  St Bartholomew's hospital completed a study us...   \n","\n","                                               criteria  healthy_volunteers  \\\n","0                  Please contact site for information.               False   \n","1                  Please contact site for information.               False   \n","2     Inclusion Criteria:~* Individuals starting met...               False   \n","3     Inclusion Criteria:~* Alaska Native having bio...               False   \n","4     * INCLUSION CRITERIA:~Good general health. Ind...               False   \n","...                                                 ...                 ...   \n","3668  Inclusion Criteria:~* Signing the informed con...                True   \n","3669  Inclusion Criteria:~* Signing the informed con...               False   \n","3670  Inclusion Criteria:~1. Patients must be at lea...               False   \n","3671  Inclusion Criteria:~* Participant must be 18 y...               False   \n","3672  Inclusion Criteria:~* Germ Cell Tumour (GCT), ...               False   \n","\n","      adult  child  older_adult                    Model_lloydmeta_Class  \\\n","0      True  False        False                        opiate withdrawal   \n","1      True  False        False                        opiate withdrawal   \n","2      True  False         True                     rheumatoid arthritis   \n","3      True  False         True                       alcohol dependence   \n","4     False   True        False                                  obesity   \n","...     ...    ...          ...                                      ...   \n","3668   True  False         True            helicobacter pylori infection   \n","3669   True  False         True            helicobacter pylori infection   \n","3670   True  False         True    nausea/vomiting, chemotherapy induced   \n","3671   True  False         True  high cholesterol, familial heterozygous   \n","3672   True   True        False                     melanoma, metastatic   \n","\n","      Model_lloydmeta_Score  Model_domenicrosati_ratings  \\\n","0                  0.831781                     0.625245   \n","1                  0.537430                     0.662990   \n","2                  0.999085                     0.564219   \n","3                  0.996837                     0.575893   \n","4                  0.999277                     0.663715   \n","...                     ...                          ...   \n","3668               0.901176                     0.679332   \n","3669               0.148174                     0.676120   \n","3670               0.623298                     0.643846   \n","3671               0.019065                     0.754822   \n","3672               0.019100                     0.572456   \n","\n","     Spacy Pregnant Women Excluded Spacy2 Pregnant Women Excluded  \\\n","0                               No                             No   \n","1                               No                             No   \n","2                               No                             No   \n","3                              Yes                            Yes   \n","4                              Yes                            Yes   \n","...                            ...                            ...   \n","3668                            No                             No   \n","3669                            No                             No   \n","3670                           Yes                             No   \n","3671                            No                             No   \n","3672                            No                             No   \n","\n","     llama3_gender_Inclusion LLama3_2_Criteria_Robustness  \\\n","0                        NaN                      Unknown   \n","1                        NaN                      Unknown   \n","2                       Both                         Weak   \n","3                       Both                       Strong   \n","4                       Both                       Strong   \n","...                      ...                          ...   \n","3668                    Both                       Strong   \n","3669                    Both                         Weak   \n","3670                    Both                       Strong   \n","3671                    Both                       Strong   \n","3672                    Male                       Strong   \n","\n","     LLM_GBT_4o_Human_Importance_Ratings  \n","0                     Slightly important  \n","1                   Moderately important  \n","2                         Very important  \n","3                   Moderately important  \n","4                         Very important  \n","...                                  ...  \n","3668                Moderately important  \n","3669                Moderately important  \n","3670                Moderately important  \n","3671                Moderately important  \n","3672                Moderately important  \n","\n","[3673 rows x 19 columns]"]},"execution_count":22,"metadata":{},"output_type":"execute_result"}],"source":["df['4o_Description_Ratings'] = four_ratings\n","df['LLM_GBT_4o_Human_Importance_Ratings'].value_counts()"]},{"cell_type":"code","execution_count":null,"id":"7802be4e-a8c0-4c55-aa43-2b3c91d0dd4d","metadata":{"id":"7802be4e-a8c0-4c55-aa43-2b3c91d0dd4d","outputId":"8ce3f370-5c9f-499a-a0e1-0b7fc131625e"},"outputs":[{"data":{"text/plain":["LLM_GBT_4o_Human_Importance_Ratings\n","Moderately important    2245\n","Slightly important       807\n","Very important           582\n","Not important             33\n","Extremely important        6\n","Name: count, dtype: int64"]},"execution_count":23,"metadata":{},"output_type":"execute_result"}],"source":["df['LLM_GBT_4o_Human_Importance_Ratings'].value_counts()"]},{"cell_type":"markdown","id":"42d7bb61-cdb0-432b-b8a0-035c2586ad95","metadata":{"id":"42d7bb61-cdb0-432b-b8a0-035c2586ad95"},"source":["# Data Cleaning"]},{"cell_type":"code","execution_count":null,"id":"fb3b0bf6-4399-423b-97e3-2eda07715384","metadata":{"id":"fb3b0bf6-4399-423b-97e3-2eda07715384","outputId":"4dfaa1b7-05e7-4370-d46d-433294e7e02b"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>nct_id</th>\n","      <th>Drug Name</th>\n","      <th>conditions</th>\n","      <th>Therapy Area</th>\n","      <th>id</th>\n","      <th>description</th>\n","      <th>criteria</th>\n","      <th>healthy_volunteers</th>\n","      <th>adult</th>\n","      <th>child</th>\n","      <th>older_adult</th>\n","      <th>Model_lloydmeta_Class</th>\n","      <th>Model_lloydmeta_Score</th>\n","      <th>Model_domenicrosati_ratings</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","      <th>Spacy2 Pregnant Women Excluded</th>\n","      <th>LLama3_2_Criteria_Robustness</th>\n","      <th>LLM_GBT_4o_Human_Importance_Ratings</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>NCT00000187</td>\n","      <td>ritanserin</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Toxicity/Intoxication; Neurology/Psychiatric</td>\n","      <td>24095864</td>\n","      <td>The purpose of this study is to assess ritanse...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.831781</td>\n","      <td>0.625245</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Unknown</td>\n","      <td>Slightly important</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>NCT00000200</td>\n","      <td>methadone</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Neurology/Psychiatric</td>\n","      <td>23965890</td>\n","      <td>The purpose of this study is to compare the ef...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.537430</td>\n","      <td>0.662990</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Unknown</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>NCT00000395</td>\n","      <td>methotrexate</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>Immune; Dermatologic; Gastrointestinal; Ocular</td>\n","      <td>24006623</td>\n","      <td>This study looks at how the arthritis drug met...</td>\n","      <td>Inclusion Criteria:~* Individuals starting met...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>0.999085</td>\n","      <td>0.564219</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>Weak</td>\n","      <td>Very important</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>NCT00000451</td>\n","      <td>sertraline</td>\n","      <td>alcoholism</td>\n","      <td>Neurology/Psychiatric; Genitourinary/Sexual Fu...</td>\n","      <td>23799489</td>\n","      <td>This study will assess the ability of naltrexo...</td>\n","      <td>Inclusion Criteria:~* Alaska Native having bio...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>alcohol dependence</td>\n","      <td>0.996837</td>\n","      <td>0.575893</td>\n","      <td>Yes</td>\n","      <td>Yes</td>\n","      <td>Strong</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>NCT00001723</td>\n","      <td>orlistat</td>\n","      <td>obesity</td>\n","      <td>Other/Miscellaneous</td>\n","      <td>24120128</td>\n","      <td>Obesity is a condition affecting one-third off...</td>\n","      <td>* INCLUSION CRITERIA:~Good general health. Ind...</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>obesity</td>\n","      <td>0.999277</td>\n","      <td>0.663715</td>\n","      <td>Yes</td>\n","      <td>Yes</td>\n","      <td>Strong</td>\n","      <td>Very important</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["        nct_id     Drug Name                 conditions  \\\n","0  NCT00000187    ritanserin  cocaine-related disorders   \n","1  NCT00000200     methadone  cocaine-related disorders   \n","2  NCT00000395  methotrexate       rheumatoid arthritis   \n","3  NCT00000451    sertraline                 alcoholism   \n","4  NCT00001723      orlistat                    obesity   \n","\n","                                        Therapy Area        id  \\\n","0       Toxicity/Intoxication; Neurology/Psychiatric  24095864   \n","1                              Neurology/Psychiatric  23965890   \n","2     Immune; Dermatologic; Gastrointestinal; Ocular  24006623   \n","3  Neurology/Psychiatric; Genitourinary/Sexual Fu...  23799489   \n","4                                Other/Miscellaneous  24120128   \n","\n","                                         description  \\\n","0  The purpose of this study is to assess ritanse...   \n","1  The purpose of this study is to compare the ef...   \n","2  This study looks at how the arthritis drug met...   \n","3  This study will assess the ability of naltrexo...   \n","4  Obesity is a condition affecting one-third off...   \n","\n","                                            criteria  healthy_volunteers  \\\n","0               Please contact site for information.               False   \n","1               Please contact site for information.               False   \n","2  Inclusion Criteria:~* Individuals starting met...               False   \n","3  Inclusion Criteria:~* Alaska Native having bio...               False   \n","4  * INCLUSION CRITERIA:~Good general health. Ind...               False   \n","\n","   adult  child  older_adult Model_lloydmeta_Class  Model_lloydmeta_Score  \\\n","0   True  False        False     opiate withdrawal               0.831781   \n","1   True  False        False     opiate withdrawal               0.537430   \n","2   True  False         True  rheumatoid arthritis               0.999085   \n","3   True  False         True    alcohol dependence               0.996837   \n","4  False   True        False               obesity               0.999277   \n","\n","   Model_domenicrosati_ratings Spacy Pregnant Women Excluded  \\\n","0                     0.625245                            No   \n","1                     0.662990                            No   \n","2                     0.564219                            No   \n","3                     0.575893                           Yes   \n","4                     0.663715                           Yes   \n","\n","  Spacy2 Pregnant Women Excluded LLama3_2_Criteria_Robustness  \\\n","0                             No                      Unknown   \n","1                             No                      Unknown   \n","2                             No                         Weak   \n","3                            Yes                       Strong   \n","4                            Yes                       Strong   \n","\n","  LLM_GBT_4o_Human_Importance_Ratings  \n","0                  Slightly important  \n","1                Moderately important  \n","2                      Very important  \n","3                Moderately important  \n","4                      Very important  "]},"execution_count":26,"metadata":{},"output_type":"execute_result"}],"source":["df.drop(columns=['llama3_gender_Inclusion'], inplace=True)\n","df.head()"]},{"cell_type":"code","execution_count":null,"id":"c51452ad-bb4d-4757-aff1-ce49eb224587","metadata":{"id":"c51452ad-bb4d-4757-aff1-ce49eb224587","outputId":"bc58b212-c2d2-4565-ef09-96fcbaef8896"},"outputs":[{"name":"stdout","output_type":"stream","text":["LLama3_2_Criteria_Robustness\n","Strong     3258\n","Normal      213\n","Weak        185\n","Unknown      17\n","Name: count, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","Model_lloydmeta_Class\n","non-small cell lung cance            435\n","colorectal cance                     192\n","multiple myeloma                     174\n","melanoma, metastatic                 165\n","opiate withdrawal                    149\n","                                    ... \n","head lice                              1\n","influenza                              1\n","emergency contraception                1\n","hepatitis b                            1\n","upper respiratory tract infection      1\n","Name: count, Length: 231, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","Spacy Pregnant Women Excluded\n","No     2002\n","Yes    1671\n","Name: count, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","Spacy2 Pregnant Women Excluded\n","No     3100\n","Yes     573\n","Name: count, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","LLama3_2_Criteria_Robustness\n","Strong     3258\n","Normal      213\n","Weak        185\n","Unknown      17\n","Name: count, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","LLM_GBT_4o_Human_Importance_Ratings\n","Moderately important    2245\n","Slightly important       807\n","Very important           582\n","Not important             33\n","Extremely important        6\n","Name: count, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n"]}],"source":["print(df['LLama3_2_Criteria_Robustness'].value_counts())\n","print_bar()\n","\n","print(df['Model_lloydmeta_Class'].value_counts())\n","print_bar()\n","\n","print(df['Spacy Pregnant Women Excluded'].value_counts())\n","print_bar()\n","\n","print(df['Spacy2 Pregnant Women Excluded'].value_counts())\n","print_bar()\n","\n","print(df['LLama3_2_Criteria_Robustness'].value_counts())\n","print_bar()\n","\n","print(df['LLM_GBT_4o_Human_Importance_Ratings'].value_counts())\n","print_bar()"]},{"cell_type":"code","execution_count":null,"id":"95f49d63-7c74-4df7-84b8-f062e9d665ff","metadata":{"id":"95f49d63-7c74-4df7-84b8-f062e9d665ff","outputId":"9fa1a091-582f-4614-cbd6-aa6c9fa6f3a2"},"outputs":[{"name":"stdout","output_type":"stream","text":["LLama3_2_Criteria_Robustness\n","2    3258\n","1     213\n","0     202\n","Name: count, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n","LLM_GBT_4o_Human_Importance_Ratings\n","Moderately important    2245\n","Slightly important       840\n","Very important           588\n","Name: count, dtype: int64\n","\u001b[1;36mâ€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“\u001b[0m\n"]}],"source":["# Mapping values to numeric\n","df['LLama3_2_Criteria_Robustness'] = df['LLama3_2_Criteria_Robustness'].replace({\"Unknown\": \"Weak\"})\n","df['LLama3_2_Criteria_Robustness'] = df['LLama3_2_Criteria_Robustness'].replace({\"Weak\": 0, \"Normal\": 1, \"Strong\": 2})\n","\n","print(df['LLama3_2_Criteria_Robustness'].value_counts())\n","print_bar()\n","\n","# GPT 4o Mapping\n","df['LLM_GBT_4o_Human_Importance_Ratings'] = df['LLM_GBT_4o_Human_Importance_Ratings'].replace(\n","    {\"Extremely important\": \"Very important\", \"Not important\": \"Slightly important\"})\n","\n","print(df['LLM_GBT_4o_Human_Importance_Ratings'].value_counts())\n","print_bar()"]},{"cell_type":"markdown","id":"138ebd5a-6790-49b7-90ac-10e5b7639522","metadata":{"id":"138ebd5a-6790-49b7-90ac-10e5b7639522"},"source":["## Saving Final Data"]},{"cell_type":"code","execution_count":null,"id":"38ad4f2a-3eb1-42d7-8f0c-2623161b557a","metadata":{"id":"38ad4f2a-3eb1-42d7-8f0c-2623161b557a"},"outputs":[],"source":["columns = [\n","    'nct_id',\n","    'id',\n","    'Drug Name',\n","    'conditions',\n","    'Therapy Area',\n","    # 'healthy_volunteers',\n","    # 'adult',\n","    # 'child',\n","    # 'older_adult',\n","    # 'Model_lloydmeta_Class',\n","    # 'Model_lloydmeta_Score',\n","    'Model_domenicrosati_ratings',\n","    'Spacy Pregnant Women Excluded',\n","    # 'Spacy2 Pregnant Women Excluded',\n","    'LLama3_2_Criteria_Robustness',\n","    'LLM_GBT_4o_Human_Importance_Ratings',\n","    'description',\n","    'criteria',\n","]\n","\n","df[columns].to_csv(\"Clincal_data_Language_Model_MAPPINGS.csv\", index=False)"]},{"cell_type":"code","execution_count":null,"id":"9bf51971-cff4-4a94-ae92-f38b9bc7ce03","metadata":{"id":"9bf51971-cff4-4a94-ae92-f38b9bc7ce03","outputId":"ff40195b-662a-4ffb-9cb7-514651f1e433"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>nct_id</th>\n","      <th>id</th>\n","      <th>Drug Name</th>\n","      <th>conditions</th>\n","      <th>Therapy Area</th>\n","      <th>Model_domenicrosati_ratings</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","      <th>LLama3_2_Criteria_Robustness</th>\n","      <th>LLM_GBT_4o_Human_Importance_Ratings</th>\n","      <th>description</th>\n","      <th>criteria</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>NCT00000187</td>\n","      <td>24095864</td>\n","      <td>ritanserin</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Toxicity/Intoxication; Neurology/Psychiatric</td>\n","      <td>0.625245</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>0</td>\n","      <td>The purpose of this study is to assess ritanse...</td>\n","      <td>Please contact site for information.</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>NCT00000200</td>\n","      <td>23965890</td>\n","      <td>methadone</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Neurology/Psychiatric</td>\n","      <td>0.662990</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>1</td>\n","      <td>The purpose of this study is to compare the ef...</td>\n","      <td>Please contact site for information.</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>NCT00000395</td>\n","      <td>24006623</td>\n","      <td>methotrexate</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>Immune; Dermatologic; Gastrointestinal; Ocular</td>\n","      <td>0.564219</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>2</td>\n","      <td>This study looks at how the arthritis drug met...</td>\n","      <td>Inclusion Criteria:~* Individuals starting met...</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>NCT00000451</td>\n","      <td>23799489</td>\n","      <td>sertraline</td>\n","      <td>alcoholism</td>\n","      <td>Neurology/Psychiatric; Genitourinary/Sexual Fu...</td>\n","      <td>0.575893</td>\n","      <td>Yes</td>\n","      <td>2</td>\n","      <td>1</td>\n","      <td>This study will assess the ability of naltrexo...</td>\n","      <td>Inclusion Criteria:~* Alaska Native having bio...</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>NCT00001723</td>\n","      <td>24120128</td>\n","      <td>orlistat</td>\n","      <td>obesity</td>\n","      <td>Other/Miscellaneous</td>\n","      <td>0.663715</td>\n","      <td>Yes</td>\n","      <td>2</td>\n","      <td>2</td>\n","      <td>Obesity is a condition affecting one-third off...</td>\n","      <td>* INCLUSION CRITERIA:~Good general health. Ind...</td>\n","    </tr>\n","    <tr>\n","      <th>...</th>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","      <td>...</td>\n","    </tr>\n","    <tr>\n","      <th>3668</th>\n","      <td>NCT06076681</td>\n","      <td>23868759</td>\n","      <td>amoxicillin</td>\n","      <td>helicobacter pylori infection</td>\n","      <td>Infection</td>\n","      <td>0.679332</td>\n","      <td>No</td>\n","      <td>2</td>\n","      <td>1</td>\n","      <td>This phase â… b/â…¡a, single-center, randomized, o...</td>\n","      <td>Inclusion Criteria:~* Signing the informed con...</td>\n","    </tr>\n","    <tr>\n","      <th>3669</th>\n","      <td>NCT06076694</td>\n","      <td>24138415</td>\n","      <td>amoxicillin</td>\n","      <td>helicobacter pylori infection</td>\n","      <td>Infection</td>\n","      <td>0.676120</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>1</td>\n","      <td>This is a single-center, randomized, open-labe...</td>\n","      <td>Inclusion Criteria:~* Signing the informed con...</td>\n","    </tr>\n","    <tr>\n","      <th>3670</th>\n","      <td>NCT06085638</td>\n","      <td>23994955</td>\n","      <td>azacitidine</td>\n","      <td>chronic myelomonocytic leukemia</td>\n","      <td>Cancer</td>\n","      <td>0.643846</td>\n","      <td>Yes</td>\n","      <td>2</td>\n","      <td>1</td>\n","      <td>To learn if adding venetoclax to the chemother...</td>\n","      <td>Inclusion Criteria:~1. Patients must be at lea...</td>\n","    </tr>\n","    <tr>\n","      <th>3671</th>\n","      <td>NCT06160609</td>\n","      <td>23930468</td>\n","      <td>GSK-3174998</td>\n","      <td>relapsed/refractory multiple myeloma</td>\n","      <td>Cancer</td>\n","      <td>0.754822</td>\n","      <td>No</td>\n","      <td>2</td>\n","      <td>1</td>\n","      <td>The primary purpose is to determine the safety...</td>\n","      <td>Inclusion Criteria:~* Participant must be 18 y...</td>\n","    </tr>\n","    <tr>\n","      <th>3672</th>\n","      <td>NCT06309732</td>\n","      <td>24116236</td>\n","      <td>methotrexate</td>\n","      <td>testicular neoplasms</td>\n","      <td>Immune</td>\n","      <td>0.572456</td>\n","      <td>No</td>\n","      <td>2</td>\n","      <td>1</td>\n","      <td>St Bartholomew's hospital completed a study us...</td>\n","      <td>Inclusion Criteria:~* Germ Cell Tumour (GCT), ...</td>\n","    </tr>\n","  </tbody>\n","</table>\n","<p>3673 rows Ã— 11 columns</p>\n","</div>"],"text/plain":["           nct_id        id     Drug Name  \\\n","0     NCT00000187  24095864    ritanserin   \n","1     NCT00000200  23965890     methadone   \n","2     NCT00000395  24006623  methotrexate   \n","3     NCT00000451  23799489    sertraline   \n","4     NCT00001723  24120128      orlistat   \n","...           ...       ...           ...   \n","3668  NCT06076681  23868759   amoxicillin   \n","3669  NCT06076694  24138415   amoxicillin   \n","3670  NCT06085638  23994955   azacitidine   \n","3671  NCT06160609  23930468   GSK-3174998   \n","3672  NCT06309732  24116236  methotrexate   \n","\n","                                conditions  \\\n","0                cocaine-related disorders   \n","1                cocaine-related disorders   \n","2                     rheumatoid arthritis   \n","3                               alcoholism   \n","4                                  obesity   \n","...                                    ...   \n","3668         helicobacter pylori infection   \n","3669         helicobacter pylori infection   \n","3670       chronic myelomonocytic leukemia   \n","3671  relapsed/refractory multiple myeloma   \n","3672                  testicular neoplasms   \n","\n","                                           Therapy Area  \\\n","0          Toxicity/Intoxication; Neurology/Psychiatric   \n","1                                 Neurology/Psychiatric   \n","2        Immune; Dermatologic; Gastrointestinal; Ocular   \n","3     Neurology/Psychiatric; Genitourinary/Sexual Fu...   \n","4                                   Other/Miscellaneous   \n","...                                                 ...   \n","3668                                          Infection   \n","3669                                          Infection   \n","3670                                             Cancer   \n","3671                                             Cancer   \n","3672                                             Immune   \n","\n","      Model_domenicrosati_ratings Spacy Pregnant Women Excluded  \\\n","0                        0.625245                            No   \n","1                        0.662990                            No   \n","2                        0.564219                            No   \n","3                        0.575893                           Yes   \n","4                        0.663715                           Yes   \n","...                           ...                           ...   \n","3668                     0.679332                            No   \n","3669                     0.676120                            No   \n","3670                     0.643846                           Yes   \n","3671                     0.754822                            No   \n","3672                     0.572456                            No   \n","\n","      LLama3_2_Criteria_Robustness  LLM_GBT_4o_Human_Importance_Ratings  \\\n","0                                0                                    0   \n","1                                0                                    1   \n","2                                0                                    2   \n","3                                2                                    1   \n","4                                2                                    2   \n","...                            ...                                  ...   \n","3668                             2                                    1   \n","3669                             0                                    1   \n","3670                             2                                    1   \n","3671                             2                                    1   \n","3672                             2                                    1   \n","\n","                                            description  \\\n","0     The purpose of this study is to assess ritanse...   \n","1     The purpose of this study is to compare the ef...   \n","2     This study looks at how the arthritis drug met...   \n","3     This study will assess the ability of naltrexo...   \n","4     Obesity is a condition affecting one-third off...   \n","...                                                 ...   \n","3668  This phase â… b/â…¡a, single-center, randomized, o...   \n","3669  This is a single-center, randomized, open-labe...   \n","3670  To learn if adding venetoclax to the chemother...   \n","3671  The primary purpose is to determine the safety...   \n","3672  St Bartholomew's hospital completed a study us...   \n","\n","                                               criteria  \n","0                  Please contact site for information.  \n","1                  Please contact site for information.  \n","2     Inclusion Criteria:~* Individuals starting met...  \n","3     Inclusion Criteria:~* Alaska Native having bio...  \n","4     * INCLUSION CRITERIA:~Good general health. Ind...  \n","...                                                 ...  \n","3668  Inclusion Criteria:~* Signing the informed con...  \n","3669  Inclusion Criteria:~* Signing the informed con...  \n","3670  Inclusion Criteria:~1. Patients must be at lea...  \n","3671  Inclusion Criteria:~* Participant must be 18 y...  \n","3672  Inclusion Criteria:~* Germ Cell Tumour (GCT), ...  \n","\n","[3673 rows x 11 columns]"]},"execution_count":35,"metadata":{},"output_type":"execute_result"}],"source":["df_cleaned = pd.read_csv(\"Clincal_data_Language_Model_MAPPINGS.csv\")\n","df_cleaned"]},{"cell_type":"markdown","id":"dd4fd8d8-140f-4647-9f67-29e8878dd582","metadata":{"id":"dd4fd8d8-140f-4647-9f67-29e8878dd582"},"source":["# LM EDA"]},{"cell_type":"code","execution_count":null,"id":"a51ecf60-44e0-42c0-b741-e142efab449d","metadata":{"id":"a51ecf60-44e0-42c0-b741-e142efab449d","outputId":"e5c8ec65-eaf7-4ec9-9555-66ed7e9dfa45"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>nct_id</th>\n","      <th>Drug Name</th>\n","      <th>conditions</th>\n","      <th>Therapy Area</th>\n","      <th>id</th>\n","      <th>description</th>\n","      <th>criteria</th>\n","      <th>healthy_volunteers</th>\n","      <th>adult</th>\n","      <th>child</th>\n","      <th>older_adult</th>\n","      <th>Model_lloydmeta_Class</th>\n","      <th>Model_lloydmeta_Score</th>\n","      <th>Model_domenicrosati_ratings</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","      <th>Spacy2 Pregnant Women Excluded</th>\n","      <th>LLama3_2_Criteria_Robustness</th>\n","      <th>LLM_GBT_4o_Human_Importance_Ratings</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>NCT00000187</td>\n","      <td>ritanserin</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Toxicity/Intoxication; Neurology/Psychiatric</td>\n","      <td>24095864</td>\n","      <td>The purpose of this study is to assess ritanse...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.831781</td>\n","      <td>0.625245</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>Slightly important</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>NCT00000200</td>\n","      <td>methadone</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Neurology/Psychiatric</td>\n","      <td>23965890</td>\n","      <td>The purpose of this study is to compare the ef...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.537430</td>\n","      <td>0.662990</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>NCT00000395</td>\n","      <td>methotrexate</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>Immune; Dermatologic; Gastrointestinal; Ocular</td>\n","      <td>24006623</td>\n","      <td>This study looks at how the arthritis drug met...</td>\n","      <td>Inclusion Criteria:~* Individuals starting met...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>0.999085</td>\n","      <td>0.564219</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>Very important</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["        nct_id     Drug Name                 conditions  \\\n","0  NCT00000187    ritanserin  cocaine-related disorders   \n","1  NCT00000200     methadone  cocaine-related disorders   \n","2  NCT00000395  methotrexate       rheumatoid arthritis   \n","\n","                                     Therapy Area        id  \\\n","0    Toxicity/Intoxication; Neurology/Psychiatric  24095864   \n","1                           Neurology/Psychiatric  23965890   \n","2  Immune; Dermatologic; Gastrointestinal; Ocular  24006623   \n","\n","                                         description  \\\n","0  The purpose of this study is to assess ritanse...   \n","1  The purpose of this study is to compare the ef...   \n","2  This study looks at how the arthritis drug met...   \n","\n","                                            criteria  healthy_volunteers  \\\n","0               Please contact site for information.               False   \n","1               Please contact site for information.               False   \n","2  Inclusion Criteria:~* Individuals starting met...               False   \n","\n","   adult  child  older_adult Model_lloydmeta_Class  Model_lloydmeta_Score  \\\n","0   True  False        False     opiate withdrawal               0.831781   \n","1   True  False        False     opiate withdrawal               0.537430   \n","2   True  False         True  rheumatoid arthritis               0.999085   \n","\n","   Model_domenicrosati_ratings Spacy Pregnant Women Excluded  \\\n","0                     0.625245                            No   \n","1                     0.662990                            No   \n","2                     0.564219                            No   \n","\n","  Spacy2 Pregnant Women Excluded  LLama3_2_Criteria_Robustness  \\\n","0                             No                             0   \n","1                             No                             0   \n","2                             No                             0   \n","\n","  LLM_GBT_4o_Human_Importance_Ratings  \n","0                  Slightly important  \n","1                Moderately important  \n","2                      Very important  "]},"execution_count":49,"metadata":{},"output_type":"execute_result"}],"source":["# Pre-Cleaned Data\n","df.head(3)"]},{"cell_type":"code","execution_count":null,"id":"65f9fcfb-29d4-47b4-a0d6-2408edb95815","metadata":{"id":"65f9fcfb-29d4-47b4-a0d6-2408edb95815","outputId":"4ae76e84-b5eb-4fd7-9af8-cd4a11c10638"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>nct_id</th>\n","      <th>id</th>\n","      <th>Drug Name</th>\n","      <th>conditions</th>\n","      <th>Therapy Area</th>\n","      <th>Model_domenicrosati_ratings</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","      <th>LLama3_2_Criteria_Robustness</th>\n","      <th>LLM_GBT_4o_Human_Importance_Ratings</th>\n","      <th>description</th>\n","      <th>criteria</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>NCT00000187</td>\n","      <td>24095864</td>\n","      <td>ritanserin</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Toxicity/Intoxication; Neurology/Psychiatric</td>\n","      <td>0.625245</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>0</td>\n","      <td>The purpose of this study is to assess ritanse...</td>\n","      <td>Please contact site for information.</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>NCT00000200</td>\n","      <td>23965890</td>\n","      <td>methadone</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Neurology/Psychiatric</td>\n","      <td>0.662990</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>1</td>\n","      <td>The purpose of this study is to compare the ef...</td>\n","      <td>Please contact site for information.</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>NCT00000395</td>\n","      <td>24006623</td>\n","      <td>methotrexate</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>Immune; Dermatologic; Gastrointestinal; Ocular</td>\n","      <td>0.564219</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>2</td>\n","      <td>This study looks at how the arthritis drug met...</td>\n","      <td>Inclusion Criteria:~* Individuals starting met...</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["        nct_id        id     Drug Name                 conditions  \\\n","0  NCT00000187  24095864    ritanserin  cocaine-related disorders   \n","1  NCT00000200  23965890     methadone  cocaine-related disorders   \n","2  NCT00000395  24006623  methotrexate       rheumatoid arthritis   \n","\n","                                     Therapy Area  \\\n","0    Toxicity/Intoxication; Neurology/Psychiatric   \n","1                           Neurology/Psychiatric   \n","2  Immune; Dermatologic; Gastrointestinal; Ocular   \n","\n","   Model_domenicrosati_ratings Spacy Pregnant Women Excluded  \\\n","0                     0.625245                            No   \n","1                     0.662990                            No   \n","2                     0.564219                            No   \n","\n","   LLama3_2_Criteria_Robustness  LLM_GBT_4o_Human_Importance_Ratings  \\\n","0                             0                                    0   \n","1                             0                                    1   \n","2                             0                                    2   \n","\n","                                         description  \\\n","0  The purpose of this study is to assess ritanse...   \n","1  The purpose of this study is to compare the ef...   \n","2  This study looks at how the arthritis drug met...   \n","\n","                                            criteria  \n","0               Please contact site for information.  \n","1               Please contact site for information.  \n","2  Inclusion Criteria:~* Individuals starting met...  "]},"execution_count":50,"metadata":{},"output_type":"execute_result"}],"source":["# Cleaned Data\n","df_cleaned.head(3)"]},{"cell_type":"code","execution_count":null,"id":"aad93d24-9627-453a-9590-111aa8c3b043","metadata":{"id":"aad93d24-9627-453a-9590-111aa8c3b043","outputId":"0cf75c91-4c03-4330-fb89-ac5174e1fbfc"},"outputs":[{"data":{"text/plain":["Index(['nct_id', 'id', 'Drug Name', 'conditions', 'Therapy Area',\n","       'Model_domenicrosati_ratings', 'Spacy Pregnant Women Excluded',\n","       'LLama3_2_Criteria_Robustness', 'LLM_GBT_4o_Human_Importance_Ratings',\n","       'description', 'criteria'],\n","      dtype='object')"]},"execution_count":52,"metadata":{},"output_type":"execute_result"}],"source":["df_cleaned.columns"]},{"cell_type":"code","execution_count":null,"id":"ac9d99a2-3295-42c1-b6ea-c7b55017407d","metadata":{"id":"ac9d99a2-3295-42c1-b6ea-c7b55017407d","outputId":"4eec5891-c073-41c3-a43e-7eb447092a34"},"outputs":[{"data":{"text/plain":["LLM_GBT_4o_Human_Importance_Ratings\n","Moderately important    2245\n","Slightly important       840\n","Very important           588\n","Name: count, dtype: int64"]},"execution_count":53,"metadata":{},"output_type":"execute_result"}],"source":["df['LLM_GBT_4o_Human_Importance_Ratings'].value_counts()"]},{"cell_type":"code","execution_count":null,"id":"f848e3ed-482d-4566-90ce-2bb24a4a9003","metadata":{"id":"f848e3ed-482d-4566-90ce-2bb24a4a9003","outputId":"fa71bb7b-4898-4e52-cdfe-6987c92644ae"},"outputs":[{"data":{"text/plain":["LLM_GBT_4o_Human_Importance_Ratings\n","1    2245\n","0     840\n","2     588\n","Name: count, dtype: int64"]},"execution_count":55,"metadata":{},"output_type":"execute_result"}],"source":["df_cleaned"]},{"cell_type":"code","execution_count":null,"id":"abcdb353-fe19-47b6-966d-4c953ed9cf7b","metadata":{"id":"abcdb353-fe19-47b6-966d-4c953ed9cf7b","outputId":"e1bc9c56-7fd3-49e7-d074-41f0230eb8ba"},"outputs":[{"data":{"image/png":"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","text/plain":["<Figure size 1000x600 with 1 Axes>"]},"metadata":{"image/png":{"height":589,"width":988}},"output_type":"display_data"}],"source":["import matplotlib.pyplot as plt\n","\n","# Data for importance levels and their counts\n","importance_levels = [\"Moderately important\", \"Slightly important\", \"Very important\", \"Not important\", \"Extremely important\"]\n","counts = [2245, 807, 582, 33, 6]\n","\n","# Create the bar chart\n","plt.figure(figsize=(10, 6))\n","plt.bar(importance_levels, counts, color='skyblue', edgecolor='black')\n","\n","# Add titles and labels\n","plt.title('Distribution of Importance Levels', fontsize=16)\n","plt.xlabel('Importance Level', fontsize=12)\n","plt.ylabel('Count', fontsize=12)\n","plt.xticks(rotation=45, fontsize=10)\n","plt.grid(axis='y', linestyle='--', alpha=0.7)\n","# Show the plot\n","plt.tight_layout()\n","plt.show()"]},{"cell_type":"code","execution_count":null,"id":"ab205c88-34a3-4dc9-90cf-e9d87d5c035f","metadata":{"id":"ab205c88-34a3-4dc9-90cf-e9d87d5c035f","outputId":"87c5aa8c-6549-48f6-d98b-6762496ba796"},"outputs":[{"data":{"image/png":"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","text/plain":["<Figure size 1000x600 with 1 Axes>"]},"metadata":{"image/png":{"height":590,"width":989}},"output_type":"display_data"},{"name":"stderr","output_type":"stream","text":["/var/folders/c1/0khxp9497hn1qlgvwr740t9m0000gn/T/ipykernel_13985/2368468952.py:33: FutureWarning: \n","\n","Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `x` variable to `hue` and set `legend=False` for the same effect.\n","\n","  sns.boxplot(x=importance_levels, y=alignment_scores, palette=\"Set2\")\n"]},{"data":{"image/png":"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","text/plain":["<Figure size 1200x800 with 1 Axes>"]},"metadata":{"image/png":{"height":789,"width":1189}},"output_type":"display_data"}],"source":["# Simulating alignment scores (Model_domenicrosati_ratings)\n","alignment_scores = df_cleaned['Model_domenicrosati_ratings']\n","\n","# Simulating corresponding importance levels\n","importance_categories = [\"Moderately important\", \"Slightly important\", \"Very important\"]\n","importance_levels = df_cleaned['LLM_GBT_4o_Human_Importance_Ratings']\n","\n","# --- Visualization 1: Distribution of Alignment Scores with Mean, STD, and KDE --- #\n","plt.figure(figsize=(10, 6))\n","\n","# Histogram\n","sns.histplot(alignment_scores, bins=30, kde=True, color='C3', edgecolor='black', alpha=0.8, label=\"Histogram with KDE\")\n","\n","# Mean and STD lines\n","mean_score = np.mean(alignment_scores)\n","std_score = np.std(alignment_scores)\n","\n","plt.axvline(mean_score, color='red', linestyle='--', linewidth=2, label=f'Mean: {mean_score:.2f}')\n","plt.axvline(mean_score + std_score, color='green', linestyle='--', linewidth=2, label=f'Mean + 1 STD: {mean_score + std_score:.2f}')\n","plt.axvline(mean_score - std_score, color='green', linestyle='--', linewidth=2, label=f'Mean - 1 STD: {mean_score - std_score:.2f}')\n","\n","# Formatting\n","plt.title('Distribution of Alignment Scores', fontsize=16)\n","plt.xlabel('Alignment Score (Model_domenicrosati_ratings)', fontsize=13)\n","plt.ylabel('Frequency', fontsize=13)\n","plt.legend(fontsize=13)\n","plt.grid(axis='y', linestyle='--', alpha=0.7)\n","plt.tight_layout()\n","plt.show()\n","\n","# --- Visualization 2: Alignment Scores vs Importance Levels (Boxplot) --- #\n","plt.figure(figsize=(12, 8))\n","sns.boxplot(x=importance_levels, y=alignment_scores, palette=\"Set2\")\n","plt.title('Alignment Scores by Importance Levels', fontsize=16)\n","plt.xlabel('Importance Level', fontsize=12)\n","plt.ylabel('Alignment Score (Model_domenicrosati_ratings)', fontsize=12)\n","plt.xticks(rotation=45, fontsize=10)\n","plt.grid(axis='y', linestyle='--', alpha=0.7)\n","plt.tight_layout()\n","plt.show()\n","\n"]},{"cell_type":"code","execution_count":null,"id":"b6ab99de-93b2-420e-9b62-b9258ac7a64f","metadata":{"id":"b6ab99de-93b2-420e-9b62-b9258ac7a64f","outputId":"7288742f-b62f-4275-d222-d6ece6ea5a86"},"outputs":[{"data":{"text/html":["<div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>nct_id</th>\n","      <th>Drug Name</th>\n","      <th>conditions</th>\n","      <th>Therapy Area</th>\n","      <th>id</th>\n","      <th>description</th>\n","      <th>criteria</th>\n","      <th>healthy_volunteers</th>\n","      <th>adult</th>\n","      <th>child</th>\n","      <th>older_adult</th>\n","      <th>Model_lloydmeta_Class</th>\n","      <th>Model_lloydmeta_Score</th>\n","      <th>Model_domenicrosati_ratings</th>\n","      <th>Spacy Pregnant Women Excluded</th>\n","      <th>Spacy2 Pregnant Women Excluded</th>\n","      <th>LLama3_2_Criteria_Robustness</th>\n","      <th>LLM_GBT_4o_Human_Importance_Ratings</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>NCT00000187</td>\n","      <td>ritanserin</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Toxicity/Intoxication; Neurology/Psychiatric</td>\n","      <td>24095864</td>\n","      <td>The purpose of this study is to assess ritanse...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.831781</td>\n","      <td>0.625245</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>Slightly important</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>NCT00000200</td>\n","      <td>methadone</td>\n","      <td>cocaine-related disorders</td>\n","      <td>Neurology/Psychiatric</td>\n","      <td>23965890</td>\n","      <td>The purpose of this study is to compare the ef...</td>\n","      <td>Please contact site for information.</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>opiate withdrawal</td>\n","      <td>0.537430</td>\n","      <td>0.662990</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>NCT00000395</td>\n","      <td>methotrexate</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>Immune; Dermatologic; Gastrointestinal; Ocular</td>\n","      <td>24006623</td>\n","      <td>This study looks at how the arthritis drug met...</td>\n","      <td>Inclusion Criteria:~* Individuals starting met...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>rheumatoid arthritis</td>\n","      <td>0.999085</td>\n","      <td>0.564219</td>\n","      <td>No</td>\n","      <td>No</td>\n","      <td>0</td>\n","      <td>Very important</td>\n","    </tr>\n","    <tr>\n","      <th>3</th>\n","      <td>NCT00000451</td>\n","      <td>sertraline</td>\n","      <td>alcoholism</td>\n","      <td>Neurology/Psychiatric; Genitourinary/Sexual Fu...</td>\n","      <td>23799489</td>\n","      <td>This study will assess the ability of naltrexo...</td>\n","      <td>Inclusion Criteria:~* Alaska Native having bio...</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>alcohol dependence</td>\n","      <td>0.996837</td>\n","      <td>0.575893</td>\n","      <td>Yes</td>\n","      <td>Yes</td>\n","      <td>2</td>\n","      <td>Moderately important</td>\n","    </tr>\n","    <tr>\n","      <th>4</th>\n","      <td>NCT00001723</td>\n","      <td>orlistat</td>\n","      <td>obesity</td>\n","      <td>Other/Miscellaneous</td>\n","      <td>24120128</td>\n","      <td>Obesity is a condition affecting one-third off...</td>\n","      <td>* INCLUSION CRITERIA:~Good general health. Ind...</td>\n","      <td>False</td>\n","      <td>False</td>\n","      <td>True</td>\n","      <td>False</td>\n","      <td>obesity</td>\n","      <td>0.999277</td>\n","      <td>0.663715</td>\n","      <td>Yes</td>\n","      <td>Yes</td>\n","      <td>2</td>\n","      <td>Very important</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>"],"text/plain":["        nct_id     Drug Name                 conditions  \\\n","0  NCT00000187    ritanserin  cocaine-related disorders   \n","1  NCT00000200     methadone  cocaine-related disorders   \n","2  NCT00000395  methotrexate       rheumatoid arthritis   \n","3  NCT00000451    sertraline                 alcoholism   \n","4  NCT00001723      orlistat                    obesity   \n","\n","                                        Therapy Area        id  \\\n","0       Toxicity/Intoxication; Neurology/Psychiatric  24095864   \n","1                              Neurology/Psychiatric  23965890   \n","2     Immune; Dermatologic; Gastrointestinal; Ocular  24006623   \n","3  Neurology/Psychiatric; Genitourinary/Sexual Fu...  23799489   \n","4                                Other/Miscellaneous  24120128   \n","\n","                                         description  \\\n","0  The purpose of this study is to assess ritanse...   \n","1  The purpose of this study is to compare the ef...   \n","2  This study looks at how the arthritis drug met...   \n","3  This study will assess the ability of naltrexo...   \n","4  Obesity is a condition affecting one-third off...   \n","\n","                                            criteria  healthy_volunteers  \\\n","0               Please contact site for information.               False   \n","1               Please contact site for information.               False   \n","2  Inclusion Criteria:~* Individuals starting met...               False   \n","3  Inclusion Criteria:~* Alaska Native having bio...               False   \n","4  * INCLUSION CRITERIA:~Good general health. Ind...               False   \n","\n","   adult  child  older_adult Model_lloydmeta_Class  Model_lloydmeta_Score  \\\n","0   True  False        False     opiate withdrawal               0.831781   \n","1   True  False        False     opiate withdrawal               0.537430   \n","2   True  False         True  rheumatoid arthritis               0.999085   \n","3   True  False         True    alcohol dependence               0.996837   \n","4  False   True        False               obesity               0.999277   \n","\n","   Model_domenicrosati_ratings Spacy Pregnant Women Excluded  \\\n","0                     0.625245                            No   \n","1                     0.662990                            No   \n","2                     0.564219                            No   \n","3                     0.575893                           Yes   \n","4                     0.663715                           Yes   \n","\n","  Spacy2 Pregnant Women Excluded  LLama3_2_Criteria_Robustness  \\\n","0                             No                             0   \n","1                             No                             0   \n","2                             No                             0   \n","3                            Yes                             2   \n","4                            Yes                             2   \n","\n","  LLM_GBT_4o_Human_Importance_Ratings  \n","0                  Slightly important  \n","1                Moderately important  \n","2                      Very important  \n","3                Moderately important  \n","4                      Very important  "]},"execution_count":81,"metadata":{},"output_type":"execute_result"}],"source":["df.head()"]},{"cell_type":"code","execution_count":null,"id":"75463f42-8f8d-4ba5-9106-6aa6568d0d83","metadata":{"id":"75463f42-8f8d-4ba5-9106-6aa6568d0d83","outputId":"efaef4ca-44a4-44df-a999-99871ca54420"},"outputs":[{"data":{"image/png":"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","text/plain":["<Figure size 640x480 with 1 Axes>"]},"metadata":{"image/png":{"height":454,"width":580}},"output_type":"display_data"}],"source":["\n","# Map LLama3_2_Criteria_Robustness to \"Weak\", \"Normal\", \"Strong\" (including handling \"Unknown\" and \"See website\")\n","criteria_mapping_labels = {\n","    2: \"Strong\",\n","    1: \"Normal\",\n","    0: \"Weak\",\n","    0: \"Weak\",\n","}\n","df['Criteria_Robustness_Labeled'] = df['LLama3_2_Criteria_Robustness'].replace(criteria_mapping_labels)\n","\n","# Barplot for Criteria Robustness with labels\n","plt.figure()\n","robustness_counts_labels = df['Criteria_Robustness_Labeled'].value_counts()\n","robustness_counts_labels.plot(kind='bar', color='blue')\n","plt.title(\"LLama3 Inclusion/Exclusion Criteria Robustness Ratings\")\n","plt.xlabel(\"Criteria Robustness Rating\")\n","plt.ylabel(\"Frequency\")\n","plt.grid(alpha=0.1)\n","plt.xticks(rotation=0)\n","plt.show()\n","\n","caption_llama3 = \"\"\"\n","Figure: Distribution of criteria robustness ratings from the LLama3 model.\n","'Unknown' values are mapped to 'Weak' based on the justification that a lack of specific clarity in criteria\n","can be interpreted as weak robustness. This categorization ensures a more interpretable dataset for evaluation purposes.\n","\"\"\""]},{"cell_type":"code","execution_count":null,"id":"32f5b17b-ad78-4e7b-a3cc-85d4b0120395","metadata":{"id":"32f5b17b-ad78-4e7b-a3cc-85d4b0120395","outputId":"98160c26-cc06-4a67-af73-78075babe6a5"},"outputs":[{"name":"stderr","output_type":"stream","text":["/var/folders/c1/0khxp9497hn1qlgvwr740t9m0000gn/T/ipykernel_13985/3042981459.py:10: FutureWarning: Series.__getitem__ treating keys as positions is deprecated. In a future version, integer keys will always be treated as labels (consistent with DataFrame behavior). To access a value by position, use `ser.iloc[pos]`\n","  plt.text(index, value + 5, f\"{pregnancy_exclusion_percentages[index]:.1f}%\", ha='center')\n"]},{"data":{"image/png":"iVBORw0KGgoAAAANSUhEUgAABIkAAAOMCAYAAADJ2ONlAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjkuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8hTgPZAAAACXBIWXMAAB7CAAAewgFu0HU+AADnJ0lEQVR4nOzdd3gUVf/38c+mkYQkEHoPTToiJRTpiDTpIghIk6aUG/0pxRvEAgp2UFCkCKg0QUAFEVBD7wgK0nsNEGoggZSd5w+ezL1L2ibsJsC+X9eVK7M7Z86c2dkp+51TLIZhGAIAAAAAAIBb88jsAgAAAAAAACDzESQCAAAAAAAAQSIAAAAAAAAQJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQASJAAAAAAAAIIJEAAAAAAAAEEEiAAAAAAAAiCARAAAAAAAARJAIAAAAAAAAIkgEAAAAAAAAESQCALdnsVjMv4dJz549zXLPmjUrs4sDwM0VLVrUPCedOHEis4uTJidOnDDLXrRo0cwuToZx9+vIrFmzzO3v2bNnkmky87vRoEEDc91r1qzJ0HU7w8NefinzjpGH9d70UUGQCLgPa9as0YABA1StWjXlzp1bPj4+8vPzU548eVStWjV16dJFn332mXbs2CHDMDK7uC5x8eJFzZo1S127dlXFihWVL18++fj4KFu2bCpWrJieeeYZvfPOO9qzZ09mFzVNjhw5YneBCg4O1p07dzK7WHjE2H7H7v3z9PRUcHCwypYtq27dumnRokWKi4vL7CIDaWL7IzQ9fwASi4+P16pVqzR06FDVrFlTRYsWVdasWeXn56f8+fOrRo0aGjRokJYuXarY2NjMLi7SyTZA56y/t99+O7M3Cw8Br8wuAPAw2r9/v1588UVt2bIl0bzY2Fjdvn1bly5d0s6dOzVv3jxJUvny5bV3796MLqrLXLlyRePHj9ekSZMUHR2daH5sbKxu3LihEydO6Ndff9Xbb7+tqlWr6r333lPTpk0zocRpM3v2bLvX165d008//aSOHTtmUongbqxWq65du6Zr167pwIED+v777/XYY49pzpw5Cg0NzeziAQAywbx58/T222/r0KFDSc4PDw9XeHi4tm3bpsmTJytnzpwaMmSIXnvtNfn7+2dwaQE8jAgSAWm0a9cuNWrUSNeuXTPfy5s3r6pVq6Z8+fLJYrHo8uXL2rt3r44cOWLWILJN/7D7559/1KpVK506dcru/dKlS6tMmTLKnTu3oqOjFR4erp07d5rbvnPnTjVr1kwLFix4oIMthmHou+++S/T+7NmzH+hy4+HWtm1bFSxY0HwdHx+vCxcuaMOGDbp06ZIk6fDhw2rYsKHWrVunKlWqZFZRgXQJDAxU9+7dM7sYwEPp9u3b6tWrl+bPn2/3fvbs2VW9enXlyZNHvr6+Cg8P1+HDh3Xw4EFJ0uXLlzV69Ght3rxZv/76a2YUHekUFBSkgQMHpphm27Zt2r59uySpQIECateuXYrpq1ev7rTy4RFmAHBYTEyMUaZMGUOSIckoUKCAsWTJEiM+Pj7J9BcvXjSmTZtm1KtXzyhUqFAGl9Y1tm3bZgQEBJifgbe3tzFw4EDj+PHjSaaPjY01wsLCjJYtW5rLzJw5M0PLnFZ//vmnWVY/Pz9z2tPT0zh//nxmF8/pEraPS0LGs/3sw8LCkkxz584dY8yYMYbFYjHTVqxY0bBarRlbWCAdZs6caX5vQ0JCMrs4LhUSEmJua3LXRCA97ty5Y9StW9fumlGzZk1j9erVRlxcXJLLHD161Bg9erQRGBhoSDLq16+fKI3t8dmjRw/XboQbql+/fqrX+Pv11ltvmetIah8/rLg3zVz0SQSkwdKlS3XgwAFJkp+fn8LCwtS2bVt5eCR9KOXOnVt9+vTR2rVrH9oO62xduXJFzz33nG7evClJCg4O1po1azRp0qRkOzP08vJSgwYN9Msvv2j9+vUqXLhwBpY4fWybmnXp0kVVq1aVdLdmx5w5czKrWHBTPj4+GjVqlF577TXzvT179mj16tWZWCoAQEZ5/fXXtX79evP1iBEjtHnzZjVu3Fienp5JLlO8eHG98847OnbsmDp06JBRRQXwCCBIBKTBqlWrzOk2bdqoVKlSDi9bokQJVxQpQw0bNkwnT56UJHl6emr58uV68sknHV6+Tp062rlzp5544gkXlfD+3bp1Sz/++KP5ulu3burWrZv5+t6+ioCMMmLECLuA9O+//56JpQEAZIQNGzboiy++MF+//PLLGjdunMPL58qVSwsXLtTIkSNdUTwAjyCCREAanD171pwOCQlxWr5JDZF5+vRpjRo1SpUqVVKOHDmUNWtWlSlTRq+++qqOHDniUL6xsbFauXKlhg0bpoYNG6pAgQLy9fWVn5+fChUqpObNm2vChAlmzaCUnDt3zq6fniFDhqhWrVpp3tbcuXPbBYnatGljbntabnreeustc7n27dunuRzJ+fHHH83PIyQkRPXq1VPnzp3l5XW3C7c9e/Zo165dDuWV1LChUVFR+vLLL1WnTh3lzZtXWbJkUeHChdW5c2dt3LjRoXyduV9T48r9c+DAAQ0bNkw1a9ZUrly55OPjI19fX+XJk0dVq1ZVr169NHv2bF29ejXJ5R0dltUwDC1dulRdunRR6dKlFRQUJE9PT2XNmlVFixZVo0aNNHz4cIWFhclqtTq8jRktZ86cKl26tPn62LFjdvOTOo+cP39e77//vqpXr658+fLJ09NT2bNnTzL/2NhYfffdd+rYsaOKFy+uwMBAZc2aVcWKFVPnzp21ZMmSNI3SePXqVY0dO1bVqlVTcHCwAgICVLp0afXp08fsP0FybJjbpNIcPHhQr7zyisqWLauAgAAFBQWpUqVKeuONNxQREeFQGS9evKiZM2eqR48eqly5snLkyCFvb29lz55dZcqUUa9evbRy5UqH8nr77bcTjR4TFxenb7/9Vo0bN1bBggWVJUsW5c+fX23bttWyZcscytfWP//8oxEjRqhGjRrmSJIJn2unTp00Y8YMXb9+3W6ZSpUqmeVKGEjBET169DCX+7//+780l9VVBg0aZJarUKFCunLlSorpjx8/rmzZspnLfPzxxymmT89nnBZFixY1y3LixIlU0zt6nouNjdX333+v9u3bq3jx4goICJCXl5cCAwNVsmRJNW3aVKNHj9a2bduSXD49w5xv2bJFgwYNUvny5RUcHCxfX18VKlRIzZo106RJk3Tr1q1U88iI4yYljny+mV3G8ePHm9OFCxfWRx99lK58nn766XQt5+h3wxXn6fQMIb9ixQr1799fFSpUUM6cOc1zepUqVdS/f3/9/PPPKY4UunPnTo0bN04tW7Y0jyUfHx/lzZtXTz75pEaOHJmoT86HQVLf4+joaM2YMUNNmjRRkSJF5OPjI4vFot27d5vLpeUclFH3prYiIiL08ccfq3HjxuY6E/Z5+fLl1aFDB3366ac6fvy4U9f7yMvs9m7Aw+SZZ54x28d27NjRafne22b5p59+MrJly2bXHtf2z8/Pz/j6669TzPPUqVNGzpw5k83D9i9nzpzGqlWrUszv3XffNdN7eHgYJ0+edMq2//LLL2a+jz32mEPLxMfHG0WKFDGXW758uVPKYhiG0ahRIzPf//73v+b7LVq0MN8fMmSIQ3n16NHDrh+mf//91yhbtmyK+2L06NEp5uns/WoYKbf7dtX+eeuttwxPT0+HtqNr165Jrufezzcp4eHhRq1atRxajyRj9erVDm2js9iu25H+Cp588kkz/dNPP203797zyNKlS43g4OBE25gtW7ZE+YaFhRklSpRI9fOpWbOmcebMmVTL+eeffxp58+ZNNh8PDw/j7bffTvQZOPI5GYZhfPXVV0aWLFlS/O5v3749xTJOnDjR4e9go0aNjIiIiBTzs+0X4q233jLOnDljt7+S+uvVq1eyfdrZunr1qtGpUye7fqmS+8ubN6/dsl988YU5r3HjxqmuyzAM4/r164a/v7+53L///uvQcklxdp9E0dHRRvny5c0827dvn2za2NhYo2bNmmbap556Ktm+vO7nM07gSJ9Eae23yJHz3MGDB1O9ttj+HT58OFEex48fd3g/3bx50+jUqVOq68mfP7/x66+/ppiXK48bRzjy+WZmGU+ePGn3nRw7dux952nLkT6JHP1uuOI8nZY+ffbu3WtUq1bNoWOgU6dOSeYRGhrq0PLe3t7GBx98kGJ50lr+9HK0T6J7v8f79u2zO5fa/u3atctczpFjJKPvTRMkd5+T1F/BggVTXSf+h9HNgDSwbTL2yy+/aN++fSpXrpxT17Fjxw6NHDlSMTExypkzpxo0aKDg4GCdOHFCa9euVWxsrKKjo9W/f395enqqd+/eSeZz69YtXb58WdLdvoPKly+vkJAQBQQEKCYmRsePH9eWLVt0+/ZtXb58WS1atNDatWuTbT72559/mtN16tRRkSJFnLK9zZs3V+HChXX69GkdPnxY69atU7169VJcZvXq1eZTnISnls5w6tQphYWFma9tm5l1797dHBVk7ty5+uijj+Tt7e1w3ufOnVPjxo11/vx5Zc+eXXXr1lW+fPkUERGhP//803wy/e6776pcuXLq1KlTkvk4e7+mxhX7Z+LEiXrnnXfM17ly5VLNmjWVP39+WSwWXblyRQcOHND+/fsVHx+frnJLd/uQeuaZZ7Rz507zvQoVKqhChQrKnj27bt++rfDwcP399986f/58inmtWbNGDRs2NF+HhYWpQYMG6S5betnWqsqWLVuy6TZt2qS3335bsbGxypkzp+rVq6dcuXLp4sWLiWrCLVy4UF27dlVsbKyku/2t1axZU0WLFpWHh4cOHTqkzZs3Ky4uTlu2bFGtWrW0fft25c2bN8l1b9myRS1btlRUVJSku0+XQ0NDVb58ecXExGjbtm06fPiw3n77beXKlSvNn8GsWbP08ssvS7o7omK1atXk5+enAwcOaOPGjTIMQ5cvX1br1q21f//+ZD+nc+fOmd+v4sWLq2zZssqdO7d8fX117do17dmzR//++6+ku+e/xo0ba8uWLcqSJUuqZbx586aaNWumvXv3yt/fX3Xr1lXhwoUVGRmpsLAwXbx4UZI0c+ZMlS5dWsOHD082r3PnzqlRo0bmSEXS3dGMateurfz58ys2NlanTp3Szp07dePGDd2+fdtu+RdeeEHDhg1TdHS0/vjjD504cSLVmiLz5s0z91+tWrWcfp27H76+vpo7d66qV6+uO3fuaPHixZo+fbr69OmTKO27776rLVu2SLpbE+/bb79Nssba/X7GmSkyMlKNGzfW6dOnJUkeHh6qXLmyWXMjKipKZ8+e1d9//+1wDbuUREVFqVGjRnY1kgoUKKC6desqICBAR44c0YYNGxQfH6/z58+rdevWmjdvnkN94jjzuHGVjC5jWFiYXQ3OLl263Fd+GcVZ52lHrVmzRq1bt1ZkZKT5XpEiRVS9enXlyJFDt27d0sGDB/X3338rNjY22WM44d4lS5YsKl++vEqWLKls2bLJMAydP39eW7duVUREhGJjY819O2zYsPsqe2a4fPmymjVrplOnTsnX11d16tRRSEiIbt68aZ4z0yKj702lu7+XOnToYNYKs713yZIli27cuKGjR49qz5495vUMaZC5MSrg4WI76pX+fzT8ww8/dOjJekpsnzT4+PgYkozXX3/duH37tl2606dP241u4e/vbxw5ciTJPE+cOGEMHjzY2Lp1a7JPs65fv2689tprZn6lSpVKMm1MTIzh6+trphs6dOh9be+9bJ9udO/ePdX0zz33nJn+zTffdFo5xo4da+ZbrVo1u3lRUVFGUFCQOf+nn35KNT/bpy8JT9OGDx9u3Lp1yy7d5cuX7WowFS9ePNmn3c7crwlsv9NJceb+iY2NNXLlymXOHzdunBETE5NkPpcvXza++eabZJ/WpfZ0a+nSpeb8/PnzG1u2bEm2zHv37jWGDx9ubN26Ncn5YWFhdp+Ts54IpiXPiIgIw8PDI9nj0PY84uXlZVgsFmPMmDGJPl/b88revXvNEfwsFovx+uuvG1evXk207qNHjxp16tQx82/evHmSZYyOjjYee+wxM12xYsWMbdu2JUq3YMECw9/fP9FT5uTYpsmSJYuRO3duY8WKFYnSrV271u44feedd5LNc8aMGcYXX3yR4vn777//tnsyPWbMmGTT2h4nCdvVo0cP4/Lly3bpbt26ZXTu3NlMGxAQYNy8eTPJPGNjY43atWubaf38/IxJkyYleczcuXPH+Pnnn422bdsmmmd7rKRWW9Ew7J+mz5gxI9X0KXHV6GYTJkww882aNatx8OBBu/nr16+3qym2ePHiJPNx1mdsGJlTk8j2cyhXrpxx4MCBJPOxWq3Gtm3bjJdfftk4depUovmO1hZ5+eWXzXSenp7GhAkTEl1fDh06ZFStWtVMFxQUlOy2uuK4SYu01iTK6DL27t3bzC9Pnjz3lVdSXFWTyFnnaUdq4pw6dcruvqJYsWJJrtcwDOPKlSvGlClTjNdffz3J+S+//LKxfPlyIyoqKsn5cXFxxsyZM42sWbMa0t0aRceOHbuv8t+v9NQk8vLyMiQZHTp0MC5evGiXLj4+3u7858gxkhn3pm3btjXnP/vss8aVK1eSTBcdHW0sX77c6N+/f7LrQmIEiYA0atWqld2JK+HHVenSpY1u3boZEydONLZu3WrExsY6nKftRUSS8dJLLyWbNjIy0ihTpoyZtlu3bve9TS+99JKZX1JVw0+fPm1XvlmzZt33Om2dOnXK/PHr7+9vXL9+Pdm0ERERZiDNYrE4dZjhUqVKmds4ceLERPNffPFFc35KTRwS2F5YJRlvvPFGsmnDw8PNmw5JKQY0HJXafk2Q2oXYmftnz5495rpq166dru1KkNqNi+3NyLRp0+5rXQ9CkOj111+3S//bb7/Zzb/3POJIswTb4OSnn36aYtqbN28a5cqVS/E7+tVXX5nzUwpiG4ZhLF68ONG5NDn3/vj4+++/k007adIkM22ZMmVS3CZHXLt2zciXL58h3Q02JjfctO0NuCSjc+fOyeYZHR1tFC5c2Ew7f/78JNNNmzbNTOPt7W2sW7cuXduwceNGM58iRYqkeGP+zz//mGkDAwPv+0eu7Y/QwMBAY+DAgQ7/pdSU2Gq1Gs2aNTPzrlatmvnD5urVq3ZNXvv27ZtsPs76jA0jc4JEzz77rDn/fprLOhIIOHLkiF2getKkScnmd+XKFaNo0aJm2l69eiWZzhXHTVqkNUiU0WV86qmnzLwaNGhwX3klxZVBImecpx0JsnTt2tWufOHh4cnm5yzz58831zls2LBk0z2oQSJJRpMmTRxqEunIMZIWzro3TWjeliVLFiMyMvK+ywV7dFwNpNHcuXPVrl07u/cMw9DBgwf13XffaciQIapRo4ayZ8+u559/3q75kiMCAwPtOim8V0BAgD788EPz9cKFC++rE01J6tWrlzmd1IhJ93YMmlzHt+lVuHBhs0lSVFRUip2rfvfdd4qJiZEkNW7c2OEONlOzefNmHTp0SJLk5eWl559/PlEa2+Zny5YtS7XDVFu5c+fW6NGjk52fN29ePfPMM+br5DoXTYvU9qujnLl/bty4YU7nzp073WVyREauy5ViYmL03nvv6ZNPPjHfK1++fIqdkBYoUCDVZg5///232Yy0cuXKeuWVV1JMnzVrVr355pvm6zlz5iRKM2PGDHP6lVdeSXFUx3bt2tk14XNUv3799Pjjjyc7v3v37mZH8wcPHrT7HqRHtmzZzHP++fPntW/fvlSX8fHx0aeffprsfF9fX3Xu3Nl8ndzxbrvP/+///k9169Z1tNh2nnzySZUvX17S3eYUq1evTjat7T58/vnnlTVr1nStMymRkZGaPHmyw38pnQcTOlHNkyePpLtNDxK+ny+99JLZbKRUqVKaMGFCsvk46zPOLBl5nps2bZrZuf8TTzyhAQMGJJs2ODhYH3zwgfl67ty5qd6rOOu4caWMLqPtfYaz771cKaPO02fPntWCBQvM11OmTEm2KbQzdejQQQEBAZIe3pFGJ0yYYDdiakZx1r1pwnfG39/f3BdwHvokAtIoICBAixcv1q+//qoJEybojz/+SHJEpFu3bmnBggVasGCBWrdurVmzZik4ODjV/Fu3bp1q2+wWLVood+7cunTpkm7fvq3Nmzen2C9PbGystm7dqr///lvh4eGKjIy0G9nBtg237YgGSc2X5JKTcb9+/cw+f2bMmKH+/fsnmc72B0xSfVCkl+3Q9k2bNjV/eNiqX7++QkJCdPLkScXExGjevHkaOHCgQ/m3atVKvr6+KaapXLmyfvjhB0lyaNSb+92vaeGs/VO4cGFzOiwsTIcOHVKpUqXuq2zJsV3XtGnT1LJlS3l6eqYrrwYNGqRpZK/0mDhxohYtWmS+tlqtunDhgtavX69Lly6Z7/v7+2vmzJkp3tx16NDBvAFPTsL+lKTOnTunOLpYgkaNGpnTGzZssJsXGRmpv/76y3z9wgsvpJrfCy+8kOZA+nPPPZfi/MDAQJUoUUIHDx6UYRg6efKkKlasmOIyFy9e1JYtW7R//35dvXpVt27dstvfO3bsMKd3796dan516tRRvnz5UkxTuXJlczqp4/3kyZM6cOCA+XrQoEEp5peavn37moHAGTNmqGnTponSxMTE6PvvvzdfO/Mc6wp58+bVzJkzzQD7Rx99pBs3bpg/Gr29vTV37lz5+/snubyzP+PMYHuemzJlir766iuXrcu2b8KEEY9S0q5dO+XIkUNXrlzRnTt3Ur1XccZx42oZXUbb6/jD9EPYFefppPz+++/mfc9jjz3mtD4qpbsjHe7atUsnTpzQjRs3dOfOHbv5Cd//PXv2yGq1ZkrAJb0ef/xxlS1b1iV5Z9S9aeHChXXs2DFdvXpVCxYsSLYvT6QPQSIgnVq0aKEWLVro0qVLWrNmjTZt2qSdO3dq165diYZ3/Pnnn1W3bl1t3rxZgYGBKebryLDynp6eCg0NNX/k7dq1K8kLY3R0tN5//31NmTLF4Q4rk0p3b5mdPXylJLVs2VIFChTQuXPntH37du3ZsyfRDcO2bdu0d+9eSXc7O27btq1T1n3nzh27J1G2NYZsWSwWde3aVe+//76ku4ElR4NEjtz85MyZ05xO6amas/ZrWjhr/xQuXFg1a9bUli1bdP36dVWtWlXdunVTu3btVLt27WR/zKVHhw4d9Pbbb8tqtWr58uWqUKGCXnzxRTVv3lzly5d3KCiSkZYuXZpqmhIlSuj7779XaGhoiumqVq2aal6bN282p8PCwnTy5MlUl7ENnCR0lJvgn3/+MQPmQUFBKlOmTKr51ahRI9U093LmsbRv3z4NHz5cK1ascLiTdEeOJWeU0bbz0Mcee0yFChVyqHzJ6d69u0aMGKHbt2/rp59+0uXLl+3KIN39DiZ0PlqxYkVVr179vtZ5r5CQEKf/sG/RooUGDx6sL774Qlar1S5IMmbMmBSPBWd/xpmhY8eO+uabbyTdDRLt3LlTPXr0UNOmTVWyZEmnrccwDLsfdI50OOvt7a3q1avrt99+kyT99ddfKf6Id+ax7SoZXUbb+y9X3Hu5SkZ9TrbHsLMGk5g9e7bef/99s3Z5amJjY3X9+nWHHgQ/KBy5R0irjL437dixo9nyonPnzmagqGHDhkk+6EXaECQC7lPu3Ln13HPPmU9NEkYAmjlzpr799lszev7vv/9q5MiR+vzzz1PMz9FRw2zT2dYySHD16lU1atQozVH6e2sNSVKOHDnsXl+7di1NeTrC09NTL774osaOHSvp7pPue5sI2NZS6datm3x8fJyy7p9++sncpqCgILVu3TrZtN26dTODRNu3b9f+/fsdehrjyMgdtqOlJYw0dS9n7te0cOb+mTFjhho1aqQLFy7o5s2b+uqrr/TVV1/Jy8tLTzzxhOrVq6emTZvqqaeeSnfNH0kqW7asPvzwQw0dOlSGYejAgQMaNmyYhg0bpuDgYD355JOqX7++2rRp47LaTPfDw8NDgYGByp8/v6pWrao2bdqobdu2Do2q50izk3PnzpnTK1asSHP5bEdak+zPQ4UKFXIoCJeeH+XOOpZWrlypNm3aJHo6nBpHjiVnlPHChQvmdPHixR0sXfKCg4PVoUMHff/994qJidF3332XqImhq2pqutqHH36osLAwM0gtSQ0bNtTQoUNTXM7Zn3FmaNq0qRkkk+5el7Zv3y7pbk2rOnXqqEGDBmrbtu19BcGuX79u9z0NCQlxaDnbJsep/SB01rHtShldRtv7L1fce7lKRn1OzjyGDcNQ7969NXPmzDQvGxkZ+VAFiZzdNDUz7k1HjRqlNWvWaMuWLTIMQ0uWLNGSJUsk3Q36161bV0899ZRatWqV6gN6JPbw1IsDHhJeXl6qU6eOZsyYobVr19pVD542bZqio6NTXN7RmhS2/UQkdZIdOHCgebL28fFRnz599NNPP+nQoUNm1U/jbuf1On78uLlcUk3n8ubNa9dUypE+OdKjT58+ZnXdhB8yCaKiojR//ny7tM5i29Ts2WeflZ+fX7Jpy5Qpo2rVqiW5bEqcVWvFmfs1rZy1f8qVK6e///5bgwcPtruRjIuL044dO/Tpp5+qadOmCgkJ0fTp0++rzK+99prCwsL01FNP2e2Dq1evavny5Ro2bJhKly6txo0ba8+ePfe1rvuVMNRxwl98fLyuXbum/fv36/vvv9dzzz3nUIBIUorf4QT325fZvTVvbJ9yO3oeS0/zCWccS5cuXVKnTp3MAFFISIjGjRunDRs26Ny5c4qKipLVajX3xVtvvWUu68ix5IwyuqKZSb9+/cxp24CQdLevooT+IbJkyeJQc8EHhY+PT6KHGa1bt061+cfD2pTnXp9//rkWL16cqObXhQsX9OOPP2rw4MEqUqSIOnToYPbVlFb31mJxtK+q1O5VbD1otTuTktFltA2yuereyxUy6nNy5jE8bdo0uwBRs2bNNHv2bO3Zs0dXr17VnTt37K7RtoFSZ9xjZSRH7hHSIjPuTbNmzaq1a9fqo48+StT/5eHDh/XNN9+oa9euypcvn4YNG5bq7y/YI0gEuNCTTz6p//73v+br27dvm0/4khMVFeVQ3rdu3TKn742Qnz171vzB7uHhod9++03Tpk1T69at9dhjjykgIMCuhkZqN27e3t52zUK2bt3qUBnTKiQkxOyM9/Lly3bNbxYuXGhWR65Vq5bKlSvnlHWGh4dr5cqV5uuZM2fKYrGk+GfbP8n333+fYTcHzt6vaeXM/ZM3b159/vnnunDhgtasWaMxY8aoefPmCgoKMtOcPXtWffv21X/+85/7Knf9+vX1+++/6/z581qwYIH+85//qEqVKnY/IP/44w/VqFFDGzduvK91PUxsf7wtXrzY7ubX0T9btjfo6TmPZaRp06aZQbJKlSrpn3/+0YgRI1S7dm3lz59ffn5+dj9ynH0sOcIVzUzq1q1rNgPcu3evXae6M2fONM9l7du3TxR0eZCNHz9e69ats3tv1KhRqTYXeRia8jh6fWnXrp22bt2qkydPavbs2erfv7/dedgwDP3444+qUqWKw81obN37A9zRYzelexWkrk6dOub0xYsXM6UfpgeZM4/hjz/+2Jx+5513tGLFCnXv3l0VKlRQ9uzZE9WOzozrwoMoM+9NfXx89Prrr+vYsWPavXu3Pv/8cz3//PMqWLCgmSYqKkofffSRGjZsSKAoDQgSAS52b/v78+fPp5je0ad8tv2B5MqVy27en3/+af6Aa968eaojCDnSF8m9Hdbe2x+JsyT3pNtVzSDmzJnjcF8kSTl79myGjWzhiv2aVs7eP1myZFH9+vU1atQo/frrr4qIiNCKFSvsboy/+OKLVIOrjsibN686duyoiRMnaufOnQoPD9eECRPMfhGio6OT7ZD7UWQ7Akx4ePh952d7Hjp79qxDy5w5c+a+15sef/zxhzk9atQou+BkUlxxLKXGdv/YPnm9X3379jWnE45bwzDsnqA/TE3Ntm/fblfTq3Tp0pLuBie6du2aYjMWV33GKbGtDWjbmWty0lrjr0iRIurevbumTJmif//9V6dOndI777xj1u67fPmy/u///i9thdbd5kO2ZXf0XsU2qHHvvQpS17BhQ7uA9dy5czOxNA8eZx3Dp0+f1uHDhyXdHUXujTfeSDH9jRs3EjW5dlcPwr2pxWJRpUqVNHjwYM2bN09nzpzRX3/9ZTeS2tatWzV58mSnr/tRRZAIcLF7R7TKkiVLiultO+FLTnx8vN2P5ipVqtjNt+1rxJHOA+99ApuU3r17m09R4uPjNXHixFSXSY/WrVubI4f8/vvvOnXqlA4dOqT169dLuvs0s2PHjk5bn21zsaJFi6pGjRoO/eXPnz/JPFzJFfs1rVy9f7y9vdWsWTP9/vvvqlChgvn+L7/8cn8FT0Lu3Lk1ZMgQ/fTTT+Z7//77r44dO+b0dT2IbGsHOqMG1eOPP27Wzrp+/brdqFHJyYwhrKW0HUvx8fGZUsOsZs2a5vShQ4ecFlDr0aOHeR2aP3++oqKi9Pvvv5s37sWLF0/1Jv9BkRAISgi29OzZU+vWrTM7Ld2xY4dGjx6d7PKu+oxTYhuQTOgkPCX32wy2cOHCGj16tKZOnWq+t2rVqjT3xWWxWPTEE0+Yrzdt2pTqMnFxcSneqyB1ISEhat68ufn666+/drimpjuwPYbTOlKmLdtrQpkyZVJt2r1hwwaXj3j6sHgQ7k2TUrlyZX3zzTd2Dz1+/vnnDFn3o4AgEeBif//9t93r1Dqm/vnnn1Md5eG3337TxYsXJd0NQt07IpptM5rUbiaioqL07bffpphGkgoWLGjXR8WECRPS1ezs0qVLKXZs5+XlZUb+rVarZs6caY7cIknPP/+80/qO2LVrl90N+I8//qgtW7Y49JfQSagkLVmyJENGWXHFfk2rjNo/WbJkUZMmTczXtp1TOlvt2rXtmta4cl0PkpYtW5rTixcvvu/tDgoKshv6ec6cOakuYzvcekZKy7G0dOlSp9S0SquQkBC7TvGd9QQ0Z86cat++vaS7T8MXLlxoVxPwxRdffCj6hpGk//znP+bT/xIlSuiLL75Qnjx57M5JH374odasWZPk8q76jFNi23dGap287tixw2k1nGwHZIiNjdWVK1fSnIdtjeLZs2en+iPZdrS8pO5V4JgRI0aY06dOndLw4cPTlc/q1audVaQHxtNPPy0vr7vjMB0+fNiu+4C0SMs1QZLdKIru7kG4N02J7bnPXe7vnIEgEZAGn376aZqaFkVFRZkjYUl3q8XaPolLyo0bN+z6MbrXrVu3NGzYMPN1hw4dEo0iYTvCw6+//ppic6rXXnvN4ZPmhx9+qMKFC0u6+3T9mWeeSVOgaMOGDapatWqqN8Z9+vQxf6TMnDnTrqaOqzqsLlu2bJqecrZs2dL83KOjo7Vw4UKnlSs5rtqvaXU/++fq1asO97Fh26QxPcOZOjq06rVr1+z6MnCXoVOrV69uDhkcHR2tbt262XVGnpKYmJgkq9q/+OKL5vSECRNS/IH7888/2zX7yki2x1JKTxYvXbqkV199NSOKlCTbZkGffPKJWWPvftk2G50wYYLZv5inp6dd9fwH2aJFi8xgkJeXl+bMmWMGqJ955hkNHDhQ0t1gdvfu3ZNtGuKqzzg5tjX4UqqFGhcXpyFDhqSan6PnOdvzqYeHh93w447q27ev+YPwr7/+squddK9r167Z3at07tzZoRGvkFjdunU1YMAA8/WkSZP05ptvOrz85cuX9dxzz+m9995zRfEyVYECBdSpUyfzdf/+/dN171OsWDHzvmbv3r0p1ihesGCBli1blvbCPqIy4970zp07DvdBdb/3ku6KIBGQBtu2bdPTTz+t0NBQffnllyme6LZu3ar69evb1VQZPnx4qqOt+Pj4aPLkyRoxYkSiH2xnz57VM888Y45w4efnZ9cXQ4JGjRqZ/Q8cOXJEPXr0SDR06o0bN9SvXz9NmTLF4VFKcubMqYULF5rpL1++rHr16mnIkCHJtjGOi4vT2rVr1bp1a9WtW9ehvoyKFy+up556StLdtssJT/ErVqxod4N9P2JjY+3a9nft2jVNy2fJkkUdOnQwX2dEkzNX7de0up/989NPP6lUqVL6+OOPk+2A886dO5o0aZIWLVpkvmdb3d5RHTt2VMuWLbVo0aJkn26dPXtWXbp0MY+1UqVKqUSJEonSrVmzxq7z8uRqJjxsvvjiC/OH9erVq1WvXr0UA7+HDh3SmDFjVLRo0SSbYPXq1UslS5aUdLcT0caNG2vnzp2J0i1atEhdunRJtfmtq7Rq1cqcHjduXJI1mv766y/Vr19fp0+fdtmxlJqePXvqySeflHT3nNWsWTN9+eWXSfazExMTo19++UXt2rVLNd8GDRrosccek3S3NktC06PmzZurQIECTtwC1zhz5oxd/2GjR49OdO756KOPzI6bT58+rZdeeinJvFz1GSenU6dO5n3A5s2bNWLEiEQ/qs6cOaOWLVtq06ZNqR4jtWrVUpcuXbRixYpkg7yHDh1Sjx49zNdPPfVUok54HVGiRAm7z33QoEGaPHlyosD/kSNH1KRJEzNIHBQUlGKzP6Tu008/Nb+nkjR27FjVqVNHf/75Z7I/yo8dO6a33npLxYoVs7uePmrGjRtn1gY+efKkatWqlWyNomvXrmnq1Kl2AUzpbn9ZCU3XrFarOnTooIMHD9qlsVqtmjx5srp16yZPT89E3Um4q8y4Nz1//rwKFy6s119/3W4wmXutXr3a7ndSeu4l3ZVXZhcAeBjt2LFDO3bs0MCBA1WiRAmVL19euXLlkpeXl9mc6t4n6O3atdPgwYNTzXvs2LEaOXKkPvjgA82YMUMNGjRQcHCwTp48qTVr1tjdBE6YMMH8QWYrODhYr7/+ut59911Jd5t9rFixQjVq1FDBggV1/vx5rVmzRrdu3ZKXl5e+/PJLuxvIlNSoUUMbNmxQq1atdObMGcXExOjzzz/X559/rjJlyqhMmTLKlSuXbt++rfDwcO3cuTPRE1xHRjjp169folpbvXv3dqiMjlixYoUuXbok6W5fC126dElzHl27djWbaWzYsEHHjh2ze6LibK7cr2l1P/vn6NGjGjp0qIYOHaoiRYro8ccfN5/uhIeHa8uWLXZNIbp27Wp3c+woq9Wq5cuXa/ny5fLx8VH58uVVqlQpZcuWTZGRkTp16pQ2b95s/sDx9PR0WV9bD6oKFSpo3rx56tSpk6KiorR161bVrFlTJUqUUJUqVZQjRw7dvn1bFy9e1D///JNqh9R+fn6aNWuWnn76aUVHR+vYsWMKDQ1VjRo1VK5cOcXExGjbtm3m6EqTJk3SoEGDJGXs0NI9evTQJ598okOHDunOnTvq1q2b3n//fVWqVEm+vr7au3eveeNZqVIlNW3aVB9++GGGlS+Bl5eXFixYoEaNGunw4cOKiorSwIEDNXLkSHMktri4OJ08eVI7d+7UjRs3HK6t0bdv30Q/lFzdYfWVK1fM/e2ofv366fHHHzdfJ9QMSjhH1KlTJ8nat35+fpo7d65q1KihO3fu6IcfflDz5s3Vs2dPu3Su/IyTEhISopdeeklffvmlJOmDDz7QvHnzVK9ePfn6+uro0aPauHGjYmJi1LhxY+XLly/FZpmxsbGaN2+e5s2bJz8/Pz3++OMqXry4goKCdPXqVR07dszuR5Sfn5/dKE5p9fHHH2vHjh3avn274uLiNGjQII0fP1516tRRQECAjh49qnXr1pmBCy8vL82YMSPRENVImyxZsuj3339Xjx49zJrLGzdu1FNPPaXg4GBVr15defLkUZYsWXThwgUdOnQoUZDjUR1drnDhwvrhhx/Utm1b3bx5U8ePH1ezZs0UEhKi6tWrK0eOHLp586YOHTqk3bt3KzY2Vm3atEmUz5gxY9SkSRNZrVbt2rVLFStWVO3atVW8eHHdvHlT69evNwefee+99zR16tRMGdTgQZNZ96bXrl3TJ598ok8++UQ5cuRQ5cqVVbBgQfn6+pr3LLY1wkqVKuVQ7Uz8fwYAh02dOtUoVqyYIcnhPz8/P+Pdd981YmNjk823fv36ZvqwsDBj6dKlRlBQULJ5+vr6Gl9++WWKZY2LizO6d++eYtmyZ89uLFmyxDh+/Lj5XkhIiEOfxaVLl4z/+7//M/z8/Bz+LOrUqWOsXbvWofxjYmKMPHnymMtmyZLFuHz5skPLOqJ9+/Zm3rVr105XHvHx8UahQoXMfN566y27+T169DDnzZw5M9X8Zs6caabv0aNHkmlcsV9tl3VUevfPwoULDYvF4tD3xcPDwxgwYIARExOTZF6pfb4tW7Z0+LuZJ08eY+nSpcmWOywszC59WFiYox9VipyZ573nkbTYvXu3UbVqVYc/r6JFixq7du1KNr/Vq1cbuXPnTnHfvv3220ZMTIz5XrZs2ZLNL63fUUc+i4MHDxrFixdPcTtr165tnDlzxnjrrbeSPc4TOJLGlu13qn79+immvXz5stGuXTuH9k3BggVTXbdhGMbFixcNHx8fc7n8+fOneJ1KL9vzWnr+lixZYpff+PHj7b4zx48fT3H9n3zyiZk+MDDQOHr0aJLpnPEZh4SEmGlSKld0dLTRokWLFNfRsmVL4+rVq6me5ypUqODwZ1msWDFj48aNSZYpLfcBkZGRRseOHVNdX/78+Y1ff/01xbxcedw4wpHrdGaX0ZbVajW+++47o2TJkg7v9/z58xsfffSRcfv27UT5OXLf4ap7CUfO02m5ru3evduoVKmSQ59J165dk8zjq6++Mry8vJJdzsPDwxg9erRhtVodOt7v57rsKNvvZ0rft7R+jxM4coxk9L3pmTNnjCxZsjh8DDRo0MA4f/68w9sMw6AmEZAGffv2Vd++fbV3716tXbtWW7Zs0YEDB3Ty5Eldv35dhmEoMDBQ+fLl0+OPP66GDRvqueeeU3BwcJrW06ZNG/3zzz+aMmWKli9frlOnTikmJkaFCxdWs2bNNGjQILOpQHI8PT01e/ZsPffcc5o6daq2bt2qq1evKjg4WEWKFFGbNm304osvqkCBAsk2+0lJrly59Mknn2j48OFatmyZVq9erT179ujSpUu6cuWK/P39lTNnTpUvX161atVShw4dVKpUKYfz9/b2VsuWLc0+J9q1a2fXufD9uHLlil178rQ2NUvg4eGhzp0766OPPpIkffvtt3rrrbdcWiPC1fvVUendPx06dND58+e1atUqbdy4UX///beOHTtmVk3Oli2bSpUqpTp16qh79+5mc5H0+Pnnn7Vr1y798ccf2rp1q/bv368zZ87o1q1bypIli3Lnzq3HH39cLVq0UJcuXVIdBv1RVqlSJe3YsUOrVq3S0qVLtXHjRp07d07Xrl0zP6vSpUurRo0aatq0qWrVqpXi97xx48Y6cOCAJk2apKVLl+rYsWOKjY1VwYIFVa9ePfXv31+hoaF2TXazZ8+eAVv6P6VKldKuXbs0efJkLV68WAcPHlRMTIzy5cunihUrqkuXLurYsaM8PT0ztFxJyZEjhxYvXqzt27dr7ty5WrNmjc6cOaOrV6/Kz89PhQoV0hNPPKFmzZrZNYNNSe7cuc3mKtLd2lUJHcA+qP766y+7vlgmT56cag2VV199Vb/99ptWr16tyMhIde3aVevXr0+0ra74jJPj6+urZcuWad68eZo9e7b++usvXb9+XXny5FGlSpXUs2dPdejQwaFrye7du7VlyxaFhYVp27ZtOnjwoM6dO6eoqCj5+/srX758euKJJ9S6dWt17NjRKU08AwICtGDBAr3yyiv67rvvtGbNGp07d07R0dHKlSuXKlSooJYtW+rFF1/MtKaajyqLxaIXXnhBzz//vP744w+tWrVKGzZs0Pnz5xURESGr1arg4GAVK1ZMoaGhatasmZo0afJAnMdcrVKlStq1a5eWLl2qpUuXavPmzbpw4YJu3bqloKAgFS9eXNWrV1erVq3UtGnTJPN46aWXVLt2bX322WcKCwvTuXPn5Ofnp4IFC6pRo0Z68cUX7QZowF0ZfW9asGBBXb58WX/++afWr1+vnTt36siRI7p06ZJiYmIUGBiokJAQhYaGqlOnTmrcuPH9b6SbsRgG4/cBma1BgwZau3atpLtDeCZ0JuvODMNQiRIlzGZ7v//+u9kPDjIf+wfOsHr1anMUu2bNmmnFihWZXCL3cevWLeXLl083b96UxWLRoUOHkmy+DAAA3AsdVwN4IIWFhZkBiOLFi9sNvYvMx/6BMyxYsMCcDg0NzcSSuJ8FCxaYo8M0aNCAABEAAJBEkAjAA+rzzz83p/v375+hndoidewf3K+tW7fq22+/NV+np/N4pI9hGPriiy/M18mN/AUAANwPQSIAD5yff/5ZP/30k6S7o3G4esQdpA37Byk5deqUnnvuOW3YsEFJtWiPj4/X999/r6ZNm5rDjLdu3VplypTJ6KK6rUmTJmn37t2SpKJFi97XkO4AAODR8mD3UAjALRw5ckSTJk1SfHy8Dh06pNWrV5vzhg4d6rQOq5E+7B+khdVq1aJFi7Ro0SLlyZNHVatWVf78+eXp6akLFy5o8+bNunTpkpk+f/78mjJlSiaW+NG3bds2zZ07VzExMfrnn3+0ceNGc967774rb2/vTCwdAAB4kBAkApDpzpw5o4kTJyZ6v3bt2ho+fHgmlAi22D9Ir4sXL6bYGXW1atW0aNEi5c+fPwNL5X727duX5DH83HPPqVu3bplQIgAA8KAiSATggeLj46NixYqpU6dOGjFihHx8fDK7SLDB/kFqihYtqq1bt+qXX37Rli1bdObMGUVEROjatWsKCAhQ3rx5VatWLbVv316tWrXK7OK6HV9fX5UqVUq9evXS4MGDM7s4AADgAWMxkuowAAAAAAAAAG6FjqsBAAAAAABAkAgAAAAAAAAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAACR5ZXYB8Oi4ffu29uzZI0nKnTu3vLz4egEAAAAA4GxxcXG6dOmSJKlixYry9fV1Sr78iofT7NmzR9WrV8/sYgAAAAAA4Da2bdum0NBQp+RFczMAAAAAAABQkwjOkzt3bnN627Ztyp8/fyaWBoAzWa1WRUZGSpICAwPl4cEzBgAAHnRcv4FH1/nz582WPLa/xe8XQSI4jW0fRPnz51ehQoUysTQAnMlqterGjRuSpKCgIG4yAQB4CHD9BtyDM/sD5iwBAAAAAAAAgkQAAAAAAAAgSAQAAAAAAAARJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAACJIBAAPFIvF4tBfgwYN0pRvVFSUihcvbi5ftGjR+y5r0aJFHSprautatGiRatWqpaxZsyooKEhPP/201q1bl+r69+zZI29vb+XIkUMRERH3vT0AAACAuyNIBABuYPTo0Tp+/HhmFyORTz75RM8995y2bNmiqKgoRUZG6vfff1ejRo20ePHiFJcdOHCg4uLi9N577ylXrlwZVGIAAADg0eWV2QUAACT28ssva8CAAcnOz5o1q8N57dq1SxMmTJCvr6+8vb0VGRnpjCKa2rRpo7FjxyY738fHJ8n3jx07phEjRkiSWrZsqSFDhigmJkZjxozRli1b1KdPHzVp0kQBAQGJlv3222+1fv16Va1aVf3793fOhgAAAABujiARADyA8uTJowoVKtx3PvHx8erbt6/i4+P11ltvacaMGU4PEmXPnj1dZZ0zZ47i4uJUtmxZ/fTTT/LwuFu5tV69eipatKguX76spUuX6oUXXrBb7vr16xo2bJgsFosmT55sLgcAAADg/nBnDQCPsIkTJ2rnzp0qXbq0hg8fntnFsbN7925JUseOHe0CPQEBAWrZsqVdGltvvvmmLly4oBdffFE1atTIiKICAAAAboEgEQA8ok6ePKnRo0dLkqZMmZJss6/Mcv36dUlS/vz5E83Lly+fXZoEf//9t7788ksFBwdr/Pjxri8kAAAA4EYIEgHAI2rAgAG6deuWunXrlubR0DJCtmzZJEnh4eGJ5iW8l5BGkgzD0MCBAxUfH09n1QAAAIALECQCgAfQwoULVa5cOfn7+yswMFCPPfaYevToobCwMIeWnz9/vn799VcFBwfrk08+cWlZ161bpyeeeEKBgYHy9/dXsWLF1KlTJy1dulSGYSS7XKVKlSRJixYtskt369YtLVu2TJL0xBNPmO/Pnj1bGzduVJUqVeisGgAAAHABi5HSHTyQBmfOnFHhwoUlSadPn1ahQoUyuUTAw8disaSapm3btpo1a5ZdLRtbV69eVdmyZXXhwgV9/fXX6tevnzmvaNGiOnnypEJCQnTixAmHy2W1WnXjxg1JUlBQkDw8PMy8UlK7dm0tWLBABQsWTDTvyJEjKlOmjOLj49WuXTsNGjRId+7c0XvvvaeNGzcqe/bsOnXqlAIDA3Xt2jWVLl1aly5d0qZNm1SzZk2Hyw4AgLtK6voN4NHgqt/fjG4GAA8Qf39/tW7dWk899ZTKlCmjgIAAXbp0SWvXrtWUKVPMEb/atGmj1atXy9vbO1EeQ4cO1YULF1SrVi317dvXZWX18fFR69at1aRJE1WoUEHZsmXTtWvXtHnzZn311Vc6ffq0Nm7cqKefflqbN29OFNQqWbKk3n33XY0cOVJLlizRkiVLzHmenp6aOnWqAgMDJUmjRo3SxYsX9eKLLxIgAgAAAFyEmkRwGmoSAffv2rVryp49e5LzLly4oObNm2vXrl2S7o5c9p///Mcuzbp169SgQQN5enpq586devzxx+3mO7MmUUpljYyMVIcOHbRq1SpJ0quvvqpPP/00ybTz5s3ThAkTtGfPHnl6eqp69ep68803zX6Udu3apdDQUAUFBenQoUNmX0Tz58/XZ599pj179sjHx0e1a9fWmDFjVKVKFYe3CwCARxk1iYBHl6t+fxMkgtMQJAJc79ixYypTpoxiY2NVsmRJHT582Jx3584dVapUSQcPHtRrr72mjz/+ONHyzgwSpeb69esqXry4rly5oqxZs+rKlStpHmHNMAw9+eST2rJliyZPnqwBAwZIkj744AONGDHC3KabN28qIiJCfn5+WrlyperWrZum9QAA8CgiSAQ8ulz1+5uzBAA8RIoXL66nn35a0t0+fc6dO2fOe++993Tw4EEVLlxY77zzTmYV0ZQtWzY9//zzku52Rr1jx4405/HNN99oy5YtqlKlil566SVJ0tGjRzVq1ChZLBYtXLhQx48f18WLF/XKK68oOjpavXv3ltVqdeq2AAAAAO6APokA4CFTrlw5/frrr5Kks2fPqkCBApLu1q6RpMaNG+uXX35Jctlbt26Z/+fPny9JypMnjxo1auSysiY4e/Zsmpa9evWqRowYIYvFosmTJ5tPP+fOnau4uDi1atVKHTp0kHS3w+9x48Zpzpw5Onz4sDZt2qQ6deo4b0MAAAAAN+C2QaIdO3bo119/1YYNG7Rv3z5dunRJ3t7eKlCggGrXrq3evXun6QfGihUrNHXqVG3fvl2XLl1S7ty5FRoaqn79+ql58+YO5REXF6fp06drzpw5OnDggG7evKkCBQqocePG+s9//qPy5cs7lE9ERIQ+//xzLV261GxOUrRoUbVt21ZDhgxRzpw5Hd4uAA+e5EZAi4mJkSTNnDlTM2fOTDGPiIgIde7cWZJUv359lwWJHBmtLTn//e9/FRERkaiz6t27d0u6O3KaLV9fX1WpUkUrV67U7t27CRIBAAAAaeSWQaJ69epp/fr1id6PiYnR4cOHdfjwYc2aNUvdu3fXtGnTUuxDw2q1ql+/fpoxY4bd+2fPntXZs2e1dOlS9enTR19//XWKbYAjIiLUokULbd++3e79Y8eOaerUqZo9e7YmTZqkPn36pLhtW7duVdu2bRUeHm73/p49e7Rnzx5Nnz5dS5cuVfXq1VPMB8CDa9++feZ0Qi2iB1V6y7pz505NnTpVwcHBGj9+vN2869evS1Ki0dIkmR1pJ6QBAAAA4Di37JMooQ+PAgUKaMiQIVq0aJG2bdumzZs369NPP1XBggUlSd9++6169uyZYl4jR440A0SVK1fWvHnztG3bNs2bN0+VK1eWJE2fPl2jRo1KNo/4+Hi1a9fODBC1b99eK1as0NatW/X5558rT548unPnjvr3768VK1Ykm8/p06fVqlUrhYeHy8vLS8OGDdO6deu0bt06DRs2TF5eXjp//rxatWqlM2fOOPx5AXhwHD9+XKtXr5YklShRwjxfSXc7eU7tLyQkRJIUEhJivrdmzRqXlPX69etmkzZ/f39Vq1bNoeUMw9DAgQNltVo1duxY5c6d225+QnAoqfPY6dOnJd3tnBMAAABAGhlu6JlnnjEWLFhgxMXFJTn/0qVLRqlSpQxJhiRj7dq1SaY7ePCg4eXlZUgyqlWrZkRFRdnNv3XrllGtWjVDkuHl5WUcPnw4yXxmzJhhrmvAgAGJ5h8+fNgICgoyJBklS5Y0YmNjk8ynW7duZj4//PBDovkLFiww5/fo0SPJPO7H6dOnzfxPnz7t9PyBR93PP/+c7PFtGIYRHh5uVK5c2TzOPvnkkzSvIyQkxJBkhISEpJiufv365nqOHz9uxMfHG1evXjWuXr1qxMfHGytWrEh0zrMVGRlpNGnSxMxj8ODBDpdx6tSphiSjcuXKRnx8fKL577zzjnk+tD2PHzlyxPD09DQkGevWrXN4fQAAPKruvX4DeHS46ve3xTAMI8MiUg+RZcuWqVWrVpKkwYMH6/PPP0+UZsCAAfrqq68kSZs3b7brMyPBli1bVKtWLTP95MmTE6UpV66c9u/frxw5cuj06dPy9/dPlGb8+PF64403JEk//PCDnnvuObv54eHhKliwoKxWq5o2barffvstye1q1qyZVq5cKQ8PD509e1b58uVL6WNIE1cNwQe4i6JFiyo2NlbPPvusatWqpaJFi8rPz08RERFas2aNvv76a0VEREiS6tSpo99//11ZsmRJ8zpOnjypkJAQs8+ypDRo0EBr166VdLf2UpEiReyG0G3UqJH27Nmj9u3bq06dOipRooQCAgJ0/fp1bdq0SVOmTNGpU6ckSaVLl9amTZuUI0eOVMt35coVlSpVSleuXNGmTZuSPK8ePXpUZcqUUVxcnJ555hm9+uqrunnzpoYNG6ZDhw6pRIkSOnToEMP8AgDcntVqtbt+c20EHh2u+v3tln0SOaJhw4bm9NGjRxPNNwxDP/30kySpTJkySf6QkaSaNWuqdOnSOnjwoH766SdNmjTJriPXQ4cOaf/+/ZKkjh07JhkgkqSePXuaQaIlS5YkChL9/PPP5pDPvXr1Sna7evbsqZUrV8pqternn39Wv379kk0LIOOdO3dOX3zxhb744otk0zz77LOaPn16mgNEznblyhVNnz5d06dPTzZN/fr1NWfOHIcCRJL0xhtv6PLly+rVq1ey59USJUpozJgxeuONN7R8+XItX77cnJclSxbNmDGDm2AAAAAgHbiLTsadO3fMaU9Pz0Tzjx8/bvZtVL9+/RTzSph/9uzZRE/uN2zYkChdUvLly6dSpUpJkjZu3JhovqP52M5LKh8AmWf27Nl655131KxZM5UqVUo5cuSQl5eXsmfProoVK6p///7atGmTFi1aZHbQnFk+/vhjjR8/Xm3atFGZMmWUK1cueXl5KSgoSGXKlFGPHj3022+/KSwszK7fpJRs375d06dPV/bs2fXBBx+kmHbEiBGaO3euqlWrJj8/PwUFBal58+basGFDqudkAAAAAEmjJlEyEppZSFLZsmUTzbcdsadMmTIp5mU7f//+/SpWrFi68zl06JBOnz6tW7duKWvWrInyyZYtW4pNyPLnz6+goCDduHHDrMHkqNQ6uz5//rw5bbVazZpNABxTt25d1a1bN9V093NsHTt2zKF8/vzzz0TrTEhvtVpVpUoVValSJdX1Gf+/c2xHVK1aVbGxsQ6VT5I6deqkTp06JXqfcw8AAHfde/0G8Ohw1TFNkCgJVqvVbsjljh07JkpjGzBJre1fQjtB6X8j79xPPoZh6MyZMypdunSifBxph1i4cGH9+++/icriyHKOioyMNNs/49E26+C1zC4CMoJhlU/cbUlSjNc1yUJFVHfQs3T2zC4CAOA+WK1W3bp1y3xNc2zg0REZGemSfDlLJOGzzz7Ttm3bJN0djr5q1aqJ0tjukICAgBTzs63xc/PmTZfmk1oetvncmwcAAAAAAHBf1CS6x9q1azVixAhJUp48eczRy+51+/Ztc9rHxyfFPG07l42OjnZpPqnlYZvPvXmkJrWaR+fPn1f16tUlSYGBgQoKCkpT/ng43faOyewiICMY/6vOetvbn5pEboLzOAA83GybozC6GfBocVXLHYJENv7991+1a9dOcXFx8vX11cKFC5UnT54k0/r6+prTMTEp/0i27QTbz88vxXxsX6c1n6ioqFTLYpvPvXmkJi1D6nl4eHARchcEC9xHwr62eLDf3QTncQB4+CWcy7k/Bx4trjqeOUv8f8ePH1eTJk109epVeXp6av78+apXr16y6QMDA83p1Jpt2bYDvrc5mLPzcaQJWUI+jjRNAwAAAAAA7oEgkaRz586pcePGOnfunCwWi7755hu1adMmxWVsa9WkNuqXbTOtezt/Tk8+FoslUa2ehNep5WGbT1o6ogYAAAAAAI82tw8SRURE6OmnnzaHhf7iiy/UvXv3VJcrV66cOX3gwIEU09rOL1u27H3nU7hwYbtOrG3zuX79usLDw5PN4/z582bbxXvLAgAAAAAA3JdbB4muX7+upk2bat++fZKk8ePHa+DAgQ4tW6xYMRUoUEDS3c6uU7Ju3TpJUsGCBVW0aFG7eXXq1DGnU8onPDxchw4dkiTVrl070XxH87Gdl1Q+AAAAAADAPbltkCgqKkrPPPOM/vrrL0nSyJEjNXz4cIeXt1gsZpO0AwcOaMuWLUmm27Jli1kDqE2bNrJYLHbzS5UqZdbo+eGHHxQVFZVkPrNmzTKn27Vrl2h+69atzY6rZs6cmWy5E/Lx8PBQ69atk00HAAAAAADci1sGiWJiYtSuXTtt3LhRkjRkyBCNHTs2zfm88sor8vT0lCQNHjw40ZDy0dHRGjx4sCTJy8tLr7zySpL5vP7665KkK1euaNiwYYnmHz16VOPGjZMklSxZMskgUb58+dS1a1dJ0sqVK7Vo0aJEaRYuXKiVK1dKkrp166Z8+fI5spkAAAAAAMANeGV2ATJD586dtWrVKklSo0aN1Lt3b+3duzfZ9D4+PipVqlSi90uVKqWhQ4dq/Pjx2rFjh2rXrq3hw4erRIkSOnr0qD744APt2rVLkjR06FA99thjSebfo0cPffPNN9q4caMmT56s8PBw9e3bV8HBwdq2bZvGjBmjGzduyMPDQ59//rm8vJLebe+9955+++03Xbp0SZ07d9aOHTvUsmVLSdKyZcv0ySefSJJy586drqAYAAAAAAB4dFkMwzAyuxAZ7d4mX6kJCQnRiRMnkpxntVrVt29fffPNN8ku37t3b02dOtVsDpaUiIgItWjRQtu3b09yfpYsWTRp0iT16dMnxbJu3bpVbdu2Tbbz6nz58mnp0qWqUaNGivmkx5kzZ8wR006fPp1oBDY8msbvisjsIiAjGFb5xt5tDnvb21+yuGVFVLczonKuzC4CAOA+WK1Wc9CaoKCgFH+PAHi4uOr3N2eJ++Th4aEZM2Zo+fLlatOmjQoUKCAfHx8VKFBAbdq00a+//qrp06enekLOlSuXNm3apC+//FJ16tRRzpw55evrq+LFi6tv377auXNnqgEiSapRo4b27NmjUaNGqUKFCgoICFBAQIAqVqyoUaNGae/evS4JEAEAAAAAgIebW9YkgmtQk8g9UZPITVCTyC1RkwgAHm7UJAIeXdQkAgAAAAAAgMsQJAIAAAAAAABBIgAAAAAAABAkAgAAAAAAgAgSAQAAAAAAQASJAAAAAAAAIIJEAAAAAAAAEEEiAAAAAAAAiCARAAAAAAAARJAIAAAAAAAAIkgEAAAAAAAAESQCAAAAAACACBIBAAAAAABABIkAAAAAAAAggkQAAAAAAAAQQSIAAAAAAACIIBEAAAAAAABEkAgAAAAAAAAiSAQAAAAAAAARJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQASJAAAAAAAAIIJEAAAAAAAAEEEiAAAAAAAAiCARAAAAAAAARJAIAAAAAAAAIkgEAAAAAAAAESQCAAAAAACACBIBAAAAAABABIkAAAAAAAAggkQAAAAAAAAQQSIAAAAAAACIIBEAAAAAAABEkAgAAAAAAAAiSAQAAAAAAAARJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQASJAAAAAAAAIIJEAAAAAAAAEEEiAAAAAAAAiCARAAAAAAAARJAIAAAAAAAAIkgEAAAAAAAAESQCAAAAAACACBIBAAAAAABABIkAAAAAAAAggkQAAAAAAAAQQSIAAAAAAACIIBEAAAAAAADkxkGiixcvatmyZRo9erSaN2+uXLlyyWKxyGKxqGfPnqkuf+LECTO9o39FixZNMq8GDRo4nIcj9u7dq/79+6tEiRLy8/NT7ty5VbduXU2ZMkVxcXFp+JQAAAAAAIC78MrsAmSWvHnzZvg6S5cu7fJ1TJs2TYMGDVJMTIz53u3bt7VhwwZt2LBBM2fO1PLly5UrVy6XlwUAAAAAADw83DZIZKtIkSIqU6aMVq1a5fAyBQsW1J49e1JNN27cOM2dO1eS1KNHjxTTVqtWTTNnznS4DPf69ddf9dJLL8lqtSpv3rwaOXKkatSooStXrmjatGlavHixtm3bpnbt2mnNmjXy9PRM97oAAAAAAMCjxW2DRKNHj1ZoaKhCQ0OVN29enThxQsWKFXN4eW9vb1WoUCHFNPHx8VqzZo0kKTAwUO3atUsxfdasWVPNMzmxsbEaPHiwrFargoKCtHHjRpUoUcKc36xZMw0cOFBffvmlNmzYoO+++86hZnUAAAAAAMA9uG2fRO+8845atmzp0mZnv//+u86dOydJ6tChg/z8/Fy2riVLlujYsWOSpDfeeMMuQJTgo48+UnBwsDkNAAAAAACQwG2DRBnh22+/NadTa2p2v5YuXWpOJ1dDyN/fXx07dpQk7du3T4cOHXJpmQAAAAAAwMODIJGLREZGmoGbokWLql69ei5d34YNGyTd7Rw7X758yaarX7++Ob1x40aXlgkAAAAAADw8CBK5yKJFixQVFSVJ6tatm0PD1x84cEA1atRQ9uzZ5evrq0KFCqlNmzb69ttvFRsbm+xyN2/e1OnTpyVJZcqUSXEdtvP379/vyKYAAAAAAAA34LYdV7uabVOz7t27O7TMhQsXdOHCBfP12bNndfbsWf3888/64IMPtGjRIpUtWzbRcmfOnDGnCxUqlOI6ChcubE4nBJYcZbuepJw/f96ctlqtslqtacofDymD/ewWDOv/9jX73G1wHgeAh5vtPTnndODR4qpjmiCRC5w6dUpr166VJD355JMqWbJkiuk9PDz01FNPqUWLFqpUqZJy5sypyMhI/fXXX/r666+1f/9+7du3Tw0bNtS2bdtUpEgRu+UjIyPN6YCAgBTXlTVrVnP65s2badou2wBTaiIjI3Xjxo005Y+Hk29sVGYXARnBsMon7vb/XluoiOoOOI8DwMPNarXq1q1b5msPD67fwKPCNg7gTASJXOD777+XYRiSHKtFtHjxYmXPnj3R+3Xr1tWAAQPUt29fzZ49WxcuXNArr7yixYsX26W7fft/P9x8fHxSXFeWLFnM6ejo6FTLBgAAAAAA3ANBIhf47rvvJN0NyHTq1CnV9EkFiBJ4e3tr+vTp2rJliw4ePKglS5bo7NmzKliwoJnG19fXnI6JiUlxXXfu3DGn/fz8Ui2brdSap50/f17Vq1eXJAUGBiooKChN+ePhdNs75e8cHhE2Tcxue/tTk8hNcB4HgIebbXOUoKAgahIBjxBX1fgmSORk27Zt04EDByRJrVu3TjEA5CgvLy/17t1bw4YNkyStXbtWXbp0MecHBgaa06k1IbOtbppa07R7pdbfkS0PDw8uQu6CYIH7SNjXFg/2u5vgPA4AD7+Eczn358CjxVXHM2cJJ0tPh9WOKFeunDl99uxZu3m2tYpS61zatjZQWvoYAgAAAAAAjzaCRE4UGxur+fPnS5Ly5MmjZs2aOS1vi8WS7LzAwEAz4JNQiyk5tvOTGikNAAAAAAC4J4JETrR8+XJdvnxZktSlSxd5eTmvNd++ffvM6QIFCiSaX6dOHUnSwYMHFR4enmw+CaOuSVLt2rWdVj4AAAAAAPBwI0jkRLZNzXr06OG0fOPi4vTNN9+Yr+vVq5coTdu2bc3pWbNmJZlPVFSUfvjhB0l3m6+VKlXKaWUEAAAAYG/48OGyWCzm35o1a5JMN2vWLLt0Kf0ld6/vqKJFizq0nqJFi6aYz6JFi1SrVi1lzZpVQUFBevrpp7Vu3bpU179nzx55e3srR44cioiIuK9tAeB8BImc5MqVK1q+fLkkqWLFinriiSccWi4sLEzXrl1Ldn5sbKz69Omj/fv3S5JatWqVZF9C7dq1U/HixSVJ48aN09GjRxOlGTp0qK5evWpOAwAAAHCN3bt369NPP83sYrjEJ598oueee05btmxRVFSUIiMj9fvvv6tRo0ZavHhxissOHDhQcXFxeu+995QrV64MKjEAR7nt6GYbNmzQkSNHzNe2UewjR44kitD37Nkzxfzmz59vDj+fllpEs2fPVuvWrdW6dWs1aNBApUuXVlBQkG7evKmdO3dq6tSpZlOzPHnyaOLEiUnm4+3trS+++EKtWrXSjRs3VLt2bY0aNUrVq1fX1atXNW3aNP3444+S7jZN69atm8NlBAAAAOA4q9Wqfv36KS4uTnny5NHFixcdXnblypVJdi+RIC0jDqekTZs2Gjt2bLLzfXx8knz/2LFjGjFihCSpZcuWGjJkiGJiYjRmzBht2bJFffr0UZMmTZIcSfnbb7/V+vXrVbVqVfXv398p2wHAudw2SDR9+nTNnj07yXkbN27Uxo0b7d5LLUiU0NTM09NTXbt2TVNZbt68qblz52ru3LnJpqlYsaLmz5+vYsWKJZumRYsWmjJligYNGqQLFy5o8ODBidJUr15dS5YskaenZ5rKCAAAAMAxn3/+ubZv364yZcqoXbt2GjdunMPLlipVKtWmXs6QPXt2VahQIc3LzZkzR3FxcSpbtqx++ukncxjuevXqqWjRorp8+bKWLl2qF154wW6569eva9iwYbJYLJo8ebLLhu8GcH84Mp3g8OHD2rp1qyTp6aefVr58+Rxedvjw4frss8/UsWNHVahQQXnz5pW3t7cCAgJUokQJderUSQsXLtSuXbtUrly5VPPr27evdu7cqb59+6p48eLy9fVVzpw5VadOHX311VfauHEj1ToBAAAAFzl16pTefPNNSdKUKVOSrZHzsNq9e7ckqWPHjnaBnoCAALVs2dIuja0333xTFy5c0IsvvqgaNWpkRFEBpIPb1iSaNWvWfXf6luCxxx6TYRjpWrZs2bIqW7asXnnlFaeURZIqVKigqVOnOi0/AAAAAI4ZOHCgbt68qR49eqh+/foKCwvL7CI51fXr1yVJ+fPnTzQv4WF5QpoEf//9t7788ksFBwdr/Pjxri8kgHSjJhEAAAAAOMEPP/ygZcuWKUeOHPr4448zuzgukS1bNklSeHh4onkJ7yWkkSTDMDRw4EDFx8fTWTXwECBIBAAAAAD36dq1axoyZIgk6YMPPkh3MKRXr14qUKCAfHx8lCtXLtWsWVOjRo3S2bNnnVlcrVu3Tk888YQCAwPl7++vYsWKqVOnTlq6dGmKrSQqVaokSVq0aJFdulu3bmnZsmWSZDfS8+zZs7Vx40ZVqVKFzqqBhwBBIgAAAAC4T8OGDVN4eLhq166t3r17pzufNWvW6Pz584qNjdXly5e1detWvffeeypZsqS+/vprp5X3+PHj+vvvv3Xz5k1FR0frxIkT+uGHH9SuXTvVrVs32aBUly5d5Onpqb179+rZZ5/Vn3/+qRUrVqhp06a6fPmysmfPrjZt2ki6GzgbPnw4nVUDDxG37ZMIAAAAAJxh/fr1mj59ury8vDRlyhRZLJY051G8eHG1b99etWrVUuHChSXdHW7+xx9/1KJFi3T79m299NJLslgs6tevX7rL6uPjo9atW6tJkyaqUKGCsmXLpmvXrmnz5s366quvdPr0aW3cuFFPP/20Nm/ebNd0TJJKliypd999VyNHjtSSJUu0ZMkSc56np6emTp2qwMBASdKoUaN08eJFvfjii6pZs2a6ywwg41iM9Pa4DNzjzJkz5gXt9OnTKlSoUCaXCBlh/K6IzC4CMoJhlW9slCTptre/ZOFJoDsYUZl+IwAgNTExMapUqZIOHDigoUOH6sMPP7Sb//bbb+udd96RJIWFhalBgwaJ8rh+/bqCgoKSDS4tW7ZM7du3V2xsrPz9/XX06FGHRlS2Wq26ceOGJCkoKEgeHh66du2asmfPnmT6yMhIdejQQatWrZIkvfrqq/r000+TTDtv3jxNmDBBe/bskaenp6pXr64333zT3L5du3YpNDRUQUFBOnTokNn8bv78+frss8+0Z88e+fj4qHbt2hozZoyqVKmS6vYA+B9X/f7mLh8AAAAA0un999/XgQMHVKRIEb311lvpyiNbtmwp1j5q2bKlRo8eLUmKiorSjBkz0rUeSckGiCQpMDBQP/zwg3LkyCFJmjp1qmJiYpJM27lzZ23dulVRUVGKjIzUH3/8YQaIDMPQgAEDFB8fr7Fjx5oBog8++ECdO3fWtm3blDdvXnl7e+vXX39VnTp1tH79+nRvEwDnIUgEAAAAAOlw4MABjRs3TpL0xRdfKGvWrC5bV79+/cxA0tq1a122nmzZsun555+XdLcz6h07dqQ5j2+++UZbtmxRlSpV9NJLL0mSjh49qlGjRslisWjhwoU6fvy4Ll68qFdeeUXR0dHq3bu3rFarU7cFQNrRJxEAAAAApMNnn32mmJgYFS9eXFFRUZo/f36iNHv37jWn//zzT3OY+FatWqUpqJQnTx7lzJlTERERTh/p7F7lypUzp9O6rqtXr2rEiBGJOqueO3eu4uLi1KpVK3Xo0EGSZLFYNG7cOM2ZM0eHDx/Wpk2bVKdOHedtCIA0I0gEAAAAAOlw584dSXc7mO7cuXOq6ceMGWNOHz9+PM01j9LTIXZ63M96/vvf/yoiIiJRZ9W7d++WJNWuXdsuva+vr6pUqaKVK1dq9+7dBImATEZzMwAAAAB4wF26dEkREXcHDClQoIBL17Vv3z5zOi3r2rlzp6ZOnarg4GCNHz/ebt7169clKdFoadL/+klKSAMg8xAkAgAAAIB0mDVrlgzDSPHPtjPrsLAw8/2iRYumaV1Tp05VwsDU9evXd+Zm2Ll+/brZbM7f31/VqlVzaDnDMDRw4EBZrVaNHTtWuXPntpufEBw6c+ZMomVPnz4t6e4IbAAyF0EiAAAAAMgkJ06c0K5du1JMs2zZMr377ruSJD8/P/Xq1SvJdA0aNJDFYpHFYtGJEycSzf/tt98UHR2d7Hpu3rypjh076vLly5Kk3r17K0uWLA5tx/Tp07V161ZVrlzZ7KzaVqVKlSRJCxYsUHx8vPn+0aNHtXXrVknSE0884dC6ALgOfRIBAAAAQCY5ceKEGjZsqFq1aqlVq1aqVKmS8uTJI+luX0eLFi3SokWLzFpEH3/8sQoWLJiudY0fP15du3ZV+/btVadOHZUoUUIBAQG6fv26Nm3apClTpujUqVOSpNKlS+vtt992KN8rV67ojTfekMVi0Zdffml2Vm2ra9euGjNmjI4cOaI2bdro1Vdf1c2bNzVs2DDFx8erRIkSiforApDxCBIBAAAAQCbbvHmzNm/enOx8f39/ffbZZ+rXr999refKlSuaPn26pk+fnmya+vXra86cOcqRI4dDeb7xxhu6fPmyevXqZddZta0SJUpozJgxeuONN7R8+XItX77cnJclSxbNmDEjyeASgIxFkAgAAAAAMknVqlX1/fffa/PmzdqxY4fOnz+viIgIxcXFKTg4WOXLl9dTTz2lPn36mDWM0uvjjz/WH3/8oc2bN+vgwYOKiIjQtWvX5O/vrwIFCqhGjRrq3LmzmjRp4vAIZ9u3b9f06dOVPXt2ffDBBymmHTFihEJCQvTpp5/q33//lbe3t2rXrq13333X4b6PALiWxUiotwjcpzNnzqhw4cKS7nY+V6hQoUwuETLC+F0RmV0EZATDKt/YKEnSbW9/ycKTPncwonKuzC4CAOA+WK1W3bhxQ9LdTqGpqQM8Olz1+5uaRAAAAICb4SGPm7B7yBPDQx43wUMe3A/OEgAAAAAAACBIBAAAAAAAAIJEAAAAAAAAEEEiAAAAAAAAiCARAAAAAAAARJAIAAAAAAAAIkgEAAAAAAAAESQCAAAAAACACBIBAAAAAABABIkAAAAAAAAggkQAAAAAAAAQQSIAAAAAAACIIBEAAAAAAABEkAgAAAAAAAAiSAQAAAAAAAARJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQASJAAAAAAAAIIJEAAAAAAAAEEEiAAAAAAAAiCARAAAAAAAARJAIAAAAAAAAIkgEAAAAAAAAESQCAAAAAACACBIBAAAAAABABIkAAAAAAAAggkQAAAAAAAAQQSIAAAAAAACIIBEAAAAAAABEkAgAAAAAAAAiSAQAAAAAAAARJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQG4cJLp48aKWLVum0aNHq3nz5sqVK5csFossFot69uzpUB6zZs0yl0ntb9asWanmFxUVpQ8//FChoaHKkSOHsmbNqjJlyui1117TyZMnHd62kydP6rXXXlOZMmWUNWtW5ciRQ6Ghofroo48UFRXlcD4AAAAAAMB9eGV2ATJL3rx5M7sIdo4cOaIWLVro8OHDdu8fPHhQBw8e1PTp0zVnzhy1bNkyxXx++eUXvfDCC7px44b5XlRUlHbs2KEdO3Zo+vTpWr58uUqWLOmS7QAAAAAAAA8ntw0S2SpSpIjKlCmjVatWpTuPlStXqkCBAsnOL1SoULLzIiMj9cwzz5gBor59++r555+Xn5+fwsLCNG7cON24cUOdOnXSxo0b9cQTTySZz65du9SpUydFR0crICBAb7zxhho2bKjo6GjNnz9f06ZN06FDh/TMM89ox44dCgwMTPf2AgAAAACAR4vbBolGjx6t0NBQhYaGKm/evDpx4oSKFSuW7vxKlSqlokWLpmvZjz76SIcOHZIkffjhhxo6dKg5r1atWmrQoIHq16+vqKgovfLKK1qzZk2S+QwZMkTR0dHy8vLSqlWrVKtWLXNeo0aN9Nhjj2nYsGE6dOiQPvnkE7399tvpKi8AAAAAAHj0uG2fRO+8845atmyZ6c3OYmNj9fnnn0uSypYtq9deey1RmieffFK9e/eWJK1du1bbt29PlGbbtm1av369JKl37952AaIEr732msqWLStJmjhxomJjY522HQAAAAAA4OHmtkGiB0VYWJiuX78uSerRo4c8PJLeJbadaS9ZsiTR/KVLl5rTvXr1SjIPDw8Pde/eXZJ07do1hYWFpbPUAAAAAADgUUOQKJNt2LDBnK5fv36y6apVqyZ/f39J0saNG5PNJ2vWrKpatWqy+diuI6l8AAAAAACAeyJI5CS9evVSgQIF5OPjo1y5cqlmzZoaNWqUzp49m+Jy+/btM6fLlCmTbDovLy9zRLL9+/cnmp/wXsmSJeXllXxXU7brSCofAAAAAADgnty242pns+1M+vLly7p8+bK2bt2qTz75RBMmTFD//v2TXO7MmTOS7tYAyp49e4rrKFy4sP755x9dunRJd+7cUZYsWSRJt2/fVkREhKSUR1GTpODgYGXNmlW3bt3S6dOnHdw6+7Im5/z58+a01WqV1WpNU/54SBnsZ7dgWP+3r9nnboPzOPAI41zuHrh+uyWu3+7BVfuZINF9Kl68uNq3b69atWqpcOHCkqRjx47pxx9/1KJFi3T79m299NJLslgs6tevX6LlIyMjJUkBAQGpritr1qzm9M2bN80gUUIeacnn1q1bunnzZqppbSVsnyMiIyN148aNNOWPh5NvbFRmFwEZwbDKJ+72/15bqIjqDjiPA48urt9uguu3W+L67R5s4wDORJDoPrRr1049evSQxWKxez80NFSdOnXSsmXL1L59e8XGxurVV19V69atlS9fPru0t2/fPWn7+Pikur6EoJAkRUdHJ8ojrfnY5gEAAAAAANwbQaL7kC1bthTnt2zZUqNHj9abb76pqKgozZgxQyNHjrRL4+vrK0mKiYlJdX137twxp/38/BLlkdZ8bPNwRGrN086fP6/q1atLkgIDAxUUFJSm/PFwuu2d+ncOjwCbKuq3vf15EukmOI8Djy6u326C67db4vrtHlxVY4wgkYv169dPo0ePlmEYWrt2baIgUWBgoCQ51PTr1q1b5rRts7KEPNKajyNN02yl1t+RLQ8PD3l4cBFyC9xsuI+EfW3xYL+7Cc7jwCOM87j74Prtdrh+uwdX7We+PS6WJ08e5cyZU5KSHOksIfBy69YtXbt2LcW8Emry5M6d267pma+vr7mO1DqXvnr1qhkkSksfQwAAAAAA4NFGkCgD3Ntnka1y5cqZ0wcOHEg2XVxcnI4ePSpJKlu2bLL5HDlyRHFxccnmY7uOpPIBAAAAAADuiSCRi126dMkcnr5AgQKJ5tepU8ecXrt2bbL57Nixw6wBVLt27WTzuXXrlnbu3JlsPrbrSCofAAAAAADgnggSudjUqVNlGIYkqX79+onmN2jQwOwAe/bs2Wbae82aNcucbteuXaL5bdu2NadnzpyZZB5Wq1XffvutJCl79uxq2LChQ9sAAAAAAAAefQSJ0unEiRPatWtXimmWLVumd999V9LdkcR69eqVKI2Pj4/+85//SJL279+vjz/+OFGazZs3a8aMGZLuBppCQ0MTpalevbrq1q0rSZoxY4Y2b96cKM0nn3yi/fv3S5KGDBkib2/vFMsPAAAAAADch9uObrZhwwYdOXLEfJ3QJEy626+Pbc0dSerZs6fd6xMnTqhhw4aqVauWWrVqpUqVKilPnjySpGPHjmnRokVatGiRWTPo448/VsGCBZMsy9ChQ7VgwQIdOnRIw4YN05EjR/T888/Lz89PYWFhev/99xUXFyc/Pz9NmDAh2W2aOHGiateurejoaDVp0kT//e9/1bBhQ0VHR2v+/PmaOnWqJKlUqVJ67bXXHP2oAAAAAACAG7AYybVvesT17NlTs2fPdjj9vR/TmjVrHGqu5e/vr88++0z9+vVLMd2RI0fUokULHT58OMn5QUFBmjNnjlq2bJliPr/88oteeOEF3bhxI8n5pUqV0vLly1WyZMlUy55WZ86cMUdMO336tDlyGx5t43dFpJ4IDz/DKt/YKEnSbW9/htB1EyMq58rsIgBwEa7fboLrt1vi+u0eXPX7221rEt2vqlWr6vvvv9fmzZu1Y8cOnT9/XhEREYqLi1NwcLDKly+vp556Sn369DFrGKWkZMmS2rVrlyZPnqyFCxfqyJEjiomJUeHChdWiRQsNGTJEISEhqebTqlUr/fPPP5o4caKWL1+uM2fOyMfHRyVLltRzzz2nQYMGyd/f3xkfAQAAAAAAeIS4bU0iOB81idwTTyLdBE8i3RJPIoFHF9dvN8H12y1x/XYPrvr9zVkCAAAAAAAABIkAAAAAAABAkAgAAAAAAAAiSAQAAAAAAAARJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQASJAAAAAAAAIIJEAAAAAAAAEEEiAAAAAAAAiCARAAAAAAAARJAIAAAAAAAAIkgEAAAAAAAAESQCAAAAAACACBIBAAAAAABABIkAAAAAAAAggkQAAAAAAAAQQSIAAAAAAACIIBEAAAAAAABEkAgAAAAAAAAiSAQAAAAAAAARJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAAESQCAAAAAAAAMrAIFFUVJSioqKSnf/FF1+obt26Klu2rFq0aKFffvklo4oGAAAAAADg9jIkSPTLL78oMDBQ+fPnV2RkZKL5L774ol555RVt2rRJBw8e1MqVK9W2bVuNGzcuI4oHAAAAAADg9jIkSLRy5UoZhqHWrVsrMDDQbt6GDRs0a9YsSZK/v78qV64sX19fGYah0aNHa+/evRlRRAAAAAAAALeWIUGiLVu2yGKxqGHDhonmTZ06VZJUoEAB7d+/Xzt37tSBAwdUuHBhWa1Wff311xlRRAAAAAAAALeWIUGiixcvSpJKly6daN5vv/0mi8WiwYMHq1ChQpKkwoULa/DgwTIMQ2vXrs2IIgIAAAAAALi1DAkSXbp0SZISNTX7999/FRERIUlq06aN3bxq1apJkk6ePJkBJQQAAAAAAHBvGRIk8vT0lCRduXLF7v0NGzZIknLnzp2ollFwcLAk6fbt2xlQQgAAAAAAAPeWIUGiggULSpJ2795t9/7y5ctlsVhUt27dRMtcv35dkpQrVy6Xlw8AAAAAAMDdZUiQqG7dujIMQ5MmTTKbl23fvl2//fabJKlp06aJltm/f78kKV++fBlRRAAAAAAAALeWIUGiAQMGyMPDQ8ePH1fx4sVVrVo11a9fX3FxcQoODlanTp0SLfPnn3/KYrGoXLlyGVFEAAAAAAAAt5YhQaIqVaroo48+ksVi0c2bN/XXX3/p9u3b8vb21rRp0xJ1aH39+nUtX75cktSgQYOMKCIAAAAAAIBb88qoFb366qtq3LixFi1apPDwcOXPn1+dO3dO1GG1JK1Zs0ahoaGSpJYtW2ZUEQEAAAAAANxWhgWJJKlixYqqWLFiqunatGmjNm3aZECJAAAAAAAAIGVQczMAAAAAAAA82AgSAQAAAAAAwLnNzU6dOuXM7ExFihRxSb4AAAAAAAC4y6lBomLFijkzO0mSxWJRXFyc0/MFAAAAAADA/zg1SGQYhjOzAwAAAAAAQAZxapBo5syZzswOAAAAAAAAGcSpQaIePXo4MzsAAAAAAABkEEY3AwAAAAAAAEEiAAAAAAAAECQCAAAAAACAnNwnkSMMw9Du3bv1999/KyIiQtHR0amOijZ69OgMKh0AAAAAAIB7ytAg0ezZs/XOO+/o5MmTaVqOIBEAAAAAAIBrZViQaOTIkRo/fnyqtYYkyWKxOJQOAAAAAAAAzpEhfRJt3bpV48aNkyQ9/fTT2r17t/766y9JdwNC8fHxunTpklasWKHWrVvLMAzVqVNH58+fl9VqzYgiAgAAAAAAuLUMCRJ99dVXkqSQkBAtX75cjz/+uLy9vc35FotFOXPmVNOmTbV06VJNnjxZGzZsULNmzRQTE5MRRQQAAAAAAHBrGRIk2rRpkywWi/7zn//Iyyv1Fm4vv/yynn32Wf3zzz/68ssvM6CEAAAAAAAA7i1DgkTnz5+XJJUvX/5/K/b436pjY2MTLdOtWzcZhqEFCxa4voAAAAAAAABuLkOCRAlBoDx58pjvBQQEmNOXLl1KtEyhQoUkSUeOHHFx6QAAAAAAAJAhQaLcuXNLkm7cuGG+lzdvXnl6ekqS9u/fn2iZhNpHkZGRLinTxYsXtWzZMo0ePVrNmzdXrly5ZLFYZLFY1LNnT4fyiIqK0uLFi/Xyyy8rNDRUwcHB8vb2Vs6cOVWrVi29/fbbCg8PTzWfBg0amOtO7c8Re/fuVf/+/VWiRAn5+fkpd+7cqlu3rqZMmaK4uDiH8gAAAAAAAO4l9Q6CnKB8+fI6d+6cDhw4oLp160qSfHx8VL58ee3Zs0cLFizQU089ZbfMd999J0kqUKCAS8qUN2/e+1r+n3/+Ue3atXXz5s1E865cuaItW7Zoy5Yt+uyzzzR16lR16tTpvtbnqGnTpmnQoEF2HX7fvn1bGzZs0IYNGzRz5kwtX75cuXLlypDyAAAAAACAh0OGBInq1q2rVatWKSwsTH379jXf79Spk/755x998803yp8/vzp27Khbt25p1qxZ+uGHH2SxWNS8eXOXl69IkSIqU6aMVq1a5fAyN27cMANEtWvXVsuWLVWtWjXlzJlTly5d0uLFizVt2jTduHFDXbt2VVBQUKrbUq1aNc2cOTPd2/Hrr7/qpZdektVqVd68eTVy5EjVqFFDV65c0bRp07R48WJt27ZN7dq105o1a8yaXAAAAAAAABkSJGrbtq3efPNNLVu2TDdu3FBQUJAkaciQIZo2bZpOnDihsWPHauzYsXbLBQcH64033nBJmUaPHq3Q0FCFhoYqb968OnHihIoVK+bw8h4eHurYsaPeeustlStXLtH8Jk2aqHnz5mrXrp3i4+M1ePBgHT58OMUmY1mzZlWFChXStT2xsbEaPHiwrFargoKCtHHjRpUoUcKc36xZMw0cOFBffvmlNmzYoO+++87hZnUAAAAAAODRlyF9EpUvX15hYWFasmSJXZ84/v7+CgsLU+3atWUYht1fhQoV9Mcff5gdWDvbO++8o5YtW6a72dmTTz6pBQsWJBkgStCmTRu1b99eknT06FHt2rUrXetyxJIlS3Ts2DFJ0htvvGEXIErw0UcfKTg42JwGAAAAAABIkCFBIkmqX7++nnrqKeXIkcPu/ZCQEK1fv1779+/XokWLNH/+fO3cuVP//POPKlWqlFHFc5mGDRua00ePHnXZepYuXWpOJ1dDyN/fXx07dpQk7du3T4cOHXJZeQAAAAAAwMMlQ5qbOaJ06dIqXbp0ZhfD6e7cuWNOu7IPoA0bNki6+znmy5cv2XT169fX119/LUnauHGjSpUq5bIyAQAAAACAh0eG1SRyV2vXrjWny5Ytm2LaAwcOqEaNGsqePbt8fX1VqFAhtWnTRt9++61iY2OTXe7mzZs6ffq0JKlMmTIprsN2/v79+x3ZBAAAAAAA4AYemJpEj6K///5by5cvlyRVrFgx1SDRhQsXdOHCBfP12bNndfbsWf3888/64IMPtGjRoiTzOHPmjDmdWh9OhQsXNqcTAkuOsl1PUs6fP29OW61WWa3WNOWPh5TBfnYLhvV/+5p97jY4jwOPMM7l7oHrt1vi+u0eXLWfnRok+vbbb83p7t27J/l+etjm9bC4c+eO+vTpo/j4eEnSe++9l2xaDw8PPfXUU2rRooUqVaqknDlzKjIyUn/99Ze+/vpr7d+/X/v27VPDhg21bds2FSlSxG75yMhIczogICDFcmXNmtWcvnnzZpq2yTbAlJrIyEjduHEjTfnj4eQbG5XZRUBGMKzyibv9v9cWKqK6A87jwKOL67eb4Prtlrh+uwfbOIAzOTVI1LNnT1ksFlksFrvATsL76XFvXg+LQYMGaceOHZKkHj16qFWrVsmmXbx4sbJnz57o/bp162rAgAHq27evZs+erQsXLuiVV17R4sWL7dLdvv2/E7+Pj0+K5cqSJYs5HR0d7cimAAAAAAAAN+D05maGYaTp/UfRuHHjNH36dElSaGioJk+enGL6pAJECby9vTV9+nRt2bJFBw8e1JIlS3T27FkVLFjQTOPr62tOx8TEpLgu2460/fz8Ukx7r9Sap50/f17Vq1eXJAUGBiooKChN+ePhdNs75e8cHhE2VdRve/vzJNJNcB4HHl1cv90E12+3xPXbPbiqxphTg0THjx9P0/uPoq+//lr//e9/Jd3tJPrXX3+1a+KVHl5eXurdu7eGDRsm6W5n2F26dDHnBwYGmtOpNSG7deuWOZ1a07R7pdbfkS0PDw95eHARcgvcbLiPhH1t8WC/uwnO48AjjPO4++D67Xa4frsHV+1npwaJQkJC0vT+o2bevHkaMGCApLvbvHr1auXKlcspeZcrV86cPnv2rN0821pFqXUubVsbKC19DAEAAAAAgEdbhoQYT506pVOnTunKlSsZsbpM8fPPP6t79+6yWq3Knz+//vjjjzTVvElNSn06BQYGmgGfAwcOpJiP7fzURlsDAAAAAADuI0OCREWLFlWxYsU0f/78jFhdhvvjjz/UsWNHxcXFKWfOnFq9erVKlCjh1HXs27fPnC5QoECi+XXq1JEkHTx4UOHh4cnms3btWnO6du3aTiwhAAAAAAB4mGVIkCihg+TQ0NCMWF2G2rRpk9q0aaM7d+4oW7ZsWrlypcqXL+/UdcTFxembb74xX9erVy9RmrZt25rTs2bNSjKfqKgo/fDDD5LuNl8rVaqUU8sJAAAAAAAeXhkSJEroMyc+Pj4jVpdhdu/erWeeeUa3bt1S1qxZtXz5clWtWjVNeYSFhenatWvJzo+NjVWfPn20f/9+SVKrVq2S7EuoXbt2Kl68uKS7o6sdPXo0UZqhQ4fq6tWr5jQAAAAAAEACp3ZcnZwmTZroq6++0oYNG1SzZs2MWGWqNmzYoCNHjpivIyIizOkjR44kqo3Ts2dPu9dHjx5V06ZNzQDP2LFjlS1bNu3duzfZdebJk0d58uSxe2/27Nlq3bq1WrdurQYNGqh06dIKCgrSzZs3tXPnTk2dOtVsapYnTx5NnDgxyby9vb31xRdfqFWrVrpx44Zq166tUaNGqXr16rp69aqmTZumH3/8UdLdpmndunVL8fMBAAAAAADuxWIYhuHqlRw+fFiVK1dWQECAdu7caTcaV2bp2bOnZs+e7XD6ez+mWbNmqVevXmla51tvvaW33347XeWoWLGi5s+fbzfKWVKmTZumQYMGKSYmJsn51atX1/Lly5026pqtM2fOmLWcTp8+7dSOu/HgGr8rIvVEePgZVvnGRkmSbnv7M4SumxhR2fnXCgAPBq7fboLrt1vi+u0eXPX7O0POEo899pjmzp2rqKgo1axZU3Pnzk02iOFuhg8frs8++0wdO3ZUhQoVlDdvXnl7eysgIEAlSpRQp06dtHDhQu3atSvVAJEk9e3bVzt37lTfvn1VvHhx+fr6KmfOnKpTp46++uorbdy40SUBIgAAAAAA8HDLkJpEjRo1kiSdPHlSx48fl8VikY+Pjx577DEFBwfL09Mz+QJaLPrjjz9cXUQ4ATWJ3BNPIt0ETyLdEk8igUcX1283wfXbLXH9dg+u+v3t9D6JPDw85OHhoX/++ces+bJmzRpZLBYzjWEYunPnTor991gsFhmGYbccAAAAAAAAXMMlHVffWzmpXr16BHsAAAAAAAAeYBkyutmaNWsyYjUAAAAAAABIJxqlAgAAAAAAgCARAAAAAAAACBIBAAAAAABABIkAAAAAAAAgF3Zc3atXL2XNmvW+87FYLPrjjz+cUCIAAAAAAAAkx2VBoh07dtx3HoZhyGKxOKE0AAAAAAAASInLgkSGYbgqawAAAAAAADiZy/ok2rt3r6xW633/xcfHu6qIAAAAAAAA+P/ouBoAAAAAAAAEiQAAAAAAAECQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQJKXszM8fvy4JKlgwYLOzhoAAAAAAAAu4vQgUUhIiLOzBAAAAAAAgIvR3AwAAAAAAAAEiQAAAAAAAECQCAAAAAAAACJIBAAAAAAAABEkAgAAAAAAgAgSAQAAAAAAQE4OErVv317PPvuszpw548xsAQAAAAAA4GJODRItXbpUS5cu1Y0bN+xX4uEhLy8v7du3z5mrAwAAAAAAgJO4pLmZYRgOvQcAAAAAAIAHg1ODRIGBgZKkCxcuODNbAAAAAAAAuJhTg0RlypSRJE2cOFE3b95MNN9isThzdQAAAAAAAHASL2dm1qVLF23fvl3Lli1Tjhw5lDdvXnl7e5vzmzRpYvfaERaLRUePHnVmMQEAAAAAAHAPpwaJBg8erI0bN2rRokWKi4vT2bNnzXmGYdi9dhS1jwAAAAAAAFzPqUEiDw8P/fDDD9q8ebN+//13nT17Vnfu3NHs2bNlsVjUunVrZc+e3ZmrBAAAAAAAgBM4NUiUoFatWqpVq5b5evbs2ZKk9957T+XKlXPFKgEAAAAAAHAfnNpxNQAAAAAAAB5OLqlJdC+r1ZoRqwEAAAAAAEA6UZMIAAAAAAAAGVOTyFZ8fLyWLl2q33//XXv37tWVK1ckSTly5FCFChXUuHFjtW3bVp6enhldNAAAAAAAALeVoUGi3377Tf369dPZs2fN9wzDkHR3qPtNmzZp6tSpKlSokKZOnaqmTZtmZPEAAAAAAADcVoY1N/vuu+/UsmVLnT17VoZhyDAMhYSEqGbNmqpZs6ZCQkIk3Q0anT59Ws8884zmzJmTUcUDAAAAAABwaxkSJDp58qT69esnq9Uqf39/jR07VuHh4Tp27Jg2bdqkTZs26dixYwoPD9d7772ngIAAWa1W9e3bV6dOncqIIgIAAAAAALi1DAkSTZw4UXfu3FFAQIDWr1+v//73v8qTJ0+idLlz59Ybb7yh9evXKyAgQHfu3NHEiRMzoogAAAAAAABuLUOCRKtWrZLFYtHQoUP1xBNPpJq+UqVKev3112UYhlauXOn6AgIAAAAAALi5DAkSJTQZa9y4scPLPP3003bLAgAAAAAAwHUyJEgUHx8vSWka1t7L6+7Aa1ar1SVlAgAAAAAAwP9kSJCoYMGCkqRNmzY5vExC2gIFCrikTAAAAAAAAPifDAkSNWzYUIZhaPz48Tp37lyq6c+dO6fx48fLYrGoUaNGGVBCAAAAAAAA95YhQaLBgwfLw8NDly5dUo0aNbRo0SKzCZotq9WqRYsWqVatWrpw4YI8PDw0aNCgjCgiAAAAAACAW/PKiJVUqFBBY8aM0ciRI3Xu3Dl16tRJ2bNnV5UqVZQnTx5ZLBZduHBBf/31l65duybDMCRJY8aMUYUKFTKiiAAAAAAAAG4tQ4JEkvTGG28oW7ZsGjZsmKKionT16lX9+eefdmkSgkP+/v766KOP9PLLL2dU8QAAAAAAANxahgWJJGnAgAHq2LGjZs6cqd9//1179+7VlStXJEk5cuRQhQoV1LhxY/Xq1Uu5cuXKyKIBAAAAAAC4tQwNEklSrly5NHToUA0dOjSjVw0AAAAAAIBkZEjH1QAAAAAAAHiwESQCAAAAAAAAQSIAAAAAAAAQJAIAAAAAAIAIEgEAAAAAAEAEiQAAAAAAACCCRAAAAAAAABBBIgAAAAAAAIggEQAAAAAAACR5ZcRK3n33XUlSjRo11LRp04xYJQAAAAAAANIgQ4JEb7/9tiwWi5YsWZIRqwMAAAAAAEAaZUhzs5w5c0qSihQpkhGrAwAAAAAAQBplSJCoZMmSkqTw8PCMWB0AAAAAAADSKEOCRJ06dZJhGPrhhx8yYnUAAAAAAABIowwJEg0YMECVKlXSt99+q1mzZmXEKlN18eJFLVu2TKNHj1bz5s2VK1cuWSwWWSwW9ezZM835rVixQu3atVOhQoWUJUsWFSpUSO3atdOKFSscziMuLk5TpkxR3bp1lTt3bvn5+alEiRLq37+//v33X4fziYiI0OjRo/X4448rKChIQUFBevzxxzV69Ghdvnw5zdsGAAAAAAAefRnScXV4eLimT5+u3r17q3fv3po7d666dOmixx9/XMHBwfL09ExxeVf0ZZQ3b16n5GO1WtWvXz/NmDHD7v2zZ8/q7NmzWrp0qfr06aOvv/5aHh7Jx+QiIiLUokULbd++3e79Y8eOaerUqZo9e7YmTZqkPn36pFierVu3qm3btoma9u3Zs0d79uzR9OnTtXTpUlWvXj2NWwoAAAAAAB5lGRIkKlq0qCwWiyTJMAz98ccf+uOPPxxa1mKxKC4uzpXFU5EiRVSmTBmtWrUqzcuOHDnSDBBVrlxZw4YNU4kSJXT06FF9+OGH2rVrl6ZPn67cuXPr/fffTzKP+Ph4tWvXzgwQtW/fXn379lWOHDm0detWjR07VhcvXlT//v1VsGBBNW/ePMl8Tp8+rVatWunSpUvy8vLS//3f/6lly5aSpGXLlunTTz/V+fPn1apVK+3cuVOFChVK8/YCAAAAAIBHU4YEiaS7waGkpjPL6NGjFRoaqtDQUOXNm1cnTpxQsWLF0pTHoUOH9PHHH0uSqlWrpnXr1snPz0+SFBoaqtatW6t+/frasWOHPvroI7344otmJ962Zs+erQ0bNki62zRv8uTJ5rzq1aurefPmqlq1qm7cuKH//Oc/2r9/v7y8Eu+6kSNH6tKlS5KkuXPn6rnnnjPn1a1bV1WrVlWnTp108eJFjRo16oFp+gcAAADg/7V333FZ1f//x58XIMhyb8GRI1FLzZ2ammVFjtS2JpY7c5Rpn5ajoaaZ5qjcI7WhZeVKG7hJRbHMjevrwBItUREFOb8/+F2nC7kGClwo1+N+u3HzwHmf93ldg3O8nrzP+wBA7nNLSDRnzhx37OaGjBw5Mst9TJw40RzlNHnyZDMgsgoICNDkyZPVuHFjpaSkaMKECekCICtr0FSkSBGNGzcuw/rKlSvr9ddf1+uvv67Y2FgtXbo0XQAkpV3St3DhQknSQw89lGG9JD355JOaPXu2Vq9erc8//1xjxoxRqVKlbu7BAwAAAACAPMUtIVFERIQ7duNWhmHo+++/lyRVq1ZNjRo1stuuUaNGuvPOO7V//359//33mjJlinnpnZQ2Gmnv3r2S0kKcgIAAu/1069ZNr7/+uiTZDYl++OEHpaamSpKef/55h3V369ZNq1evVmpqqn744Qf16tUrk48YAAAAAADkZW65u1ledOTIEZ06dUqS1Lx5c6dtretPnjypo0ePpltnvczMVT+lSpVS1apVJUmbNm3KsD6z/dius9cPAAAAAADwTIREN2nPnj3mcrVq1Zy2tV1vHTWUlX6OHz+uS5cu2e2nYMGCTi8hK126tAoUKGC3FgAAAAAA4LncNnG1VWpqqiIjIxUVFaXTp08rMTFR77//vkqXLm22uXr1qlJSUuTt7S0/Pz93l5gpJ06cMJdd3SUsNDTUXD5+/HiW+zEMQydOnNCdd96ZoZ/M3LEsNDRUu3fvzlCLK7a12hMXF2cup6ammpe/IY8zeJ09gpH632vNa+4xOI4DeRjHcs/A+dsjcf72DDn1Ors1JFq+fLkGDBigY8eOpfv5q6++mi4kmjlzpvr376+goCCdOnVKgYGB7iwzUy5cuGAuBwUFOW1rW//FixdztB9Xfdj2c30frtiGXa5cuHBBCQkJN9Q/bk/5kxNzuwS4g5Eq35Sk/763MBDVE3AcB/Iuzt8egvO3R+L87Rlss4Ts5LajxIwZM9S+fXsdPXpUhmGoaNGiMgzDbtsePXqoYMGCunjxopYuXequEm9IUtJ/B1tfX1+nbW1HQ12+fDlH+3HVh20/1/cBAAAAAAA8l1tGEh08eFD9+vWTJN1///2aMmWKqlWrJi8v+xmVr6+vOnXqpFmzZmnNmjXq0qWLO8q8Ifnz5zeXr1696rTtlStXzGV/f3+n/dh+f6P9JCYmuqzFtp/r+3DF1eVpcXFxatCggSQpODjYnPsIeVtSPtfvOeQBNkPUk/IF8JdID8FxHMi7OH97CM7fHonzt2fIqRFjbgmJJkyYoJSUFNWsWVMrV67M1GiXZs2aadasWYqJiXFDhTcuODjYXHZ12ZbtJNPXXw52fT/OQiJX/SQmJmbqEjJrP5m5NM1WZuY7svLy8nIYAiKP4T8bnsP6Wlu8eN09BMdxIA/jOO45OH97HM7fniGnXme3vHt+/fVXWSwWDRo0KFMBkSRVrlxZkuvRK7nFNjBxNaGz7WO4fl6fm+nHYrFkCGys37vqw7afG5ljCAAAAAAA5G1uCYmswUWtWrUyvY11cuXExFtzUr3q1auby/v27XPa1nZ9WFhYlvsJDQ3NMJm3tZ/z58/r9OnTDvuIi4szh6VdXwsAAAAAAPBcbgmJLBaLpBsLfM6ePStJKliwYI7UlFUVK1ZUmTJlJEnr1q1z2nb9+vWSpLJly6pChQrp1jVt2tRcdtbP6dOndeDAAUlSkyZNMqzPbD+26+z1AwAAAAAAPJNbQqKyZctKkg4fPpzpbTZu3ChJuuOOO3KkpqyyWCxq3769pLQRPr/99pvddr/99ps5Aqh9+/ZmYGZVtWpVc0TP119/7TBImzt3rrncoUOHDOvbtWtnXpM4Z84ch3Vb+/Hy8lK7du0ctgMAAAAAAJ7FLSFRixYtZBiG5s2bl6n258+f12effSaLxaL7778/h6u7eYMGDZK3t7ckqX///hluKX/58mX1799fkuTj46NBgwbZ7efVV1+VJJ07d05Dhw7NsP7QoUMaPXq0pLS5muyFRKVKlVLnzp0lSatXr9aSJUsytFm8eLFWr14tSXruuedUqlSpzDxMAAAAAADgAdxyd7PevXtrxowZWrdunebOnatu3bo5bHv27Fk9/vjjOn36tPLly6c+ffrkSE0bN25UbGys+X18fLy5HBsbm27kjiS7NVetWlVDhgzRmDFjFB0drSZNmui1115TpUqVdOjQIX3wwQfm3dmGDBmiKlWq2K0lIiJCs2fP1qZNmzR16lSdPn1aPXv2VOHChbV161a9++67SkhIkJeXlyZNmiQfH/sv2/vvv68ff/xRZ86c0TPPPKPo6Gi1adNGkrR8+XKNHz9eklS8eHG99957mX6uAAAAAABA3mcxDMNwx45eeeUVTZw4URaLRY8//rg6deqkp59+WhaLRdOmTVNAQIA2bdqkRYsWmRMrjxw5Um+99VaO1NOtW7dMj2ySJEdPU2pqqnr27KnZs2c73LZ79+6aPn2601vUxcfHKzw8XNu2bbO73s/PT1OmTFGPHj2c1rllyxY99thjDievLlWqlL777js1bNjQaT8348SJE+Yd044fP57hDmzIm8bExLtuhNufkar8yWmXwyblC+AWuh7if3WK5XYJAHII528PwfnbI3H+9gw59fnbLSOJJGn8+PG6cuWKPv30Uy1ZskRLliwx5+fp3bu32c4axgwaNCjHAqLs5OXlpVmzZqlTp06aPn26tm3bpvj4eBUrVkz169dX79699cgjj7jsp1ixYtq8ebNmzJihRYsWae/evbp06ZLKlCmjVq1aaeDAgapRo4bLfho2bKhdu3bp448/1nfffaejR49KSptou3379ho0aJCKFi2a1YcNAAAAAADyGLeNJLL66aefNGbMGK1bt06pqanpi7FY1KhRI7311luZClZwa2EkkWfiL5Eegr9EeiT+EgnkXZy/PQTnb4/E+dsz3PYjiawefPBBPfjgg7pw4YJiYmL0999/69q1aypatKhq166tYsV4QwMAAAAAALib20Miq+DgYN133325tXsAAAAAAADYYLwhAAAAAAAAcmck0d9//621a9dq165dOnfunCSpSJEiqlmzplq0aKGSJUvmRlkAAAAAAAAey60h0cmTJzV48GAtXbpUKSkpdtt4e3urQ4cOGjdunMqVK+fO8gAAAAAAADyW2y4327hxo2rWrKnFixcrOTlZhmHY/UpJSdGSJUt09913a+PGje4qDwAAAAAAwKO5JSQ6deqU2rZtq/Pnz8swDD3yyCNavHixjh07pqSkJCUlJenYsWNasmSJwsPDZRiGEhIS1LZtW506dcodJQIAAAAAAHg0t4REo0eP1vnz5+Xt7a358+drxYoV6tSpk0JDQ+Xr6ytfX1+FhoaqY8eOWr58uRYsWCAvLy8lJCRozJgx7igRAAAAAADAo7klJFq5cqUsFot69uypLl26uGz/7LPPqlevXjIMQytWrHBDhQAAAAAAAJ7NbZebSdITTzyR6W2sbbncDAAAAAAAIOe5JSQqXLiwJKlgwYKZ3sba1rotAAAAAAAAco5bQqJ69epJknbt2pXpbaxtrdsCAAAAAAAg57glJBowYIAMw9DYsWOVmJjosn1iYqI++OADWSwW9e/f3w0VAgAAAAAAeDa3hEQPPPCAhg8frr1796pFixbauXOnw7a///67WrZsqf3792v48OF68MEH3VEiAAAAAACAR/PJzs7eeecdh+ssFovq1aun6Oho1a1bV3fddZfq16+vEiVKyGKx6K+//tK2bdsyXGb2zjvvaNiwYdlZJgAAAAAAAK6TrSHRiBEjZLFYnLaxWCwyDEO7du2yO0eRYRiyWCyKjo5WdHS0JBESAQAAAAAA5LBsDYmktJAnq+0y2wcAAAAAAACyR7aGRKmpqdnZHQAAAAAAANzELRNXAwAAAAAA4NZGSAQAAAAAAABCIgAAAAAAAOTAxNWZlZCQoAsXLujatWsu25YrV84NFQEAAAAAAHgut4ZEa9as0aeffqoNGzbon3/+ydQ2FotFKSkpOVwZAAAAAACAZ3NbSNSnTx/NmDFDEre4BwAAAAAAuNW4JSSaNm2apk+fLkkKDg5Whw4dVKtWLRUqVEheXkyLBAAAAAAAkNvcEhJZA6KwsDD9+uuvKlmypDt2CwAAAAAAgExyyzCeffv2yWKxaMSIEQREAAAAAAAAtyC3hERBQUGSpCpVqrhjdwAAAAAAALhBbgmJwsLCJElxcXHu2B0AAAAAAABukFtCol69eskwDH3xxRfu2B0AAAAAAABukFtComeffVadOnXSwoULNWXKFHfsEgAAAAAAADfALXc3k6SFCxfq1Vdf1aBBg/Tll1/qySefVNWqVRUQEOBy2/vuu88NFQIAAAAAAHgut4VE+fLlU61atVS4cGFFRUUpKioqU9tZLBalpKTkcHUAAAAAAACezS0hUUpKip555hl9++23kiTDMNyxWwAAAAAAAGSSW0Kizz77TN98840kqXz58oqIiFCtWrVUqFAheXm5ZVokAAAAAAAAOOGWkGjmzJmSpEaNGumXX36Rv7+/O3YLAAAAAACATHLLMJ7Y2FhZLBa9/vrrBEQAAAAAAAC3ILeERIGBgZKk0NBQd+wOAAAAAAAAN8gtIVGtWrUkSceOHXPH7gAAAAAAAHCD3BIS9enTR4ZhaNasWe7YHQAAAAAAAG6QW0Kijh07qk+fPlq+fLleffVVXbt2zR27BQAAAAAAQCa55e5m8+fPV6NGjRQTE6MJEyZoyZIl6tixo6pWraqAgACX23ft2tUNVQIAAAAAAHgut4RE3bp1k8ViMb8/fvy4Pv7440xta7FYCIkAAAAAAABymFtCIkkyDMNduwIAAAAAAMANcktIdOTIEXfsBgAAAAAAADfJLSFR+fLl3bEbAAAAAAAA3CS33N0MAAAAAAAAtzZCIgAAAAAAABASAQAAAAAAwE1zEt1xxx03va3FYtGhQ4eysRoAAAAAAABczy0h0dGjRzPd1mKxyDCMdN8DAAAAAAAgZ7klJIqIiHDZ5tKlSzpw4ID++OMPWSwW1alTR3fddZcbqgMAAAAAAIBbQqI5c+Zkuu3u3bvVvXt37dq1S2+88YY6duyYg5UBAAAAAABAugUnrq5Ro4Z+/vlnlSlTRl27dtW+fftyuyQAAAAAAIA875YLiSQpKChIr7zyihITEzVu3LjcLgcAAAAAACDPuyVDIkmqV6+eJOmXX37J5UoAAAAAAADyvls2JLLe4eyvv/7K5UoAAAAAAADyvls2JFq9erUkqWDBgrlcCQAAAAAAQN53S4ZEX375pUaPHi2LxaKmTZvmdjkAAAAAAAB5no87dvLCCy+4bJOamqp//vlHO3bs0KlTp2QYhnx8fPS///3PDRUCAAAAAAB4NreERHPnzpXFYslUW+tcRAUKFNDMmTPNCawBAAAAAACQc9wSEpUrV85lSOTl5aXg4GBVrFhRzZs3V5cuXVSsWDF3lAcAAAAAAODx3BISHT161B27AQAAAAAAwE26JSeuBgAAAAAAgHsREgEAAAAAAICQCAAAAAAAAIREWdKiRQtZLJYb+lq7dm26Pqx3fsvM19y5c13WlJiYqLFjx6p+/foqUqSIAgMDVa1aNQ0ePFjHjh3LmScCAAAAAADc9rJ94mpvb+9s7c9isSglJSVb+8wtXl5eqlKlSo71Hxsbq/DwcB08eDDdz/fv36/9+/dr5syZWrhwodq0aZNjNQAAAAAAgNtTtodEhmFkd5e3rDlz5ujSpUtO2+zZs0dPPfWUJKlVq1YqW7asw7arV69WmTJlHK4PCQlxuO7ChQt69NFHzYCoZ8+eevrpp+Xv76/IyEiNHj1aCQkJeuqpp7Rp0ybVrl3bad0AAAAAAMCzZHtIFBERkaXtDcPQypUrdfbs2Vs+cKpYsaLLNp9//rm53LVrV6dtq1atqgoVKtxULePGjdOBAwckSWPHjtWQIUPMdY0bN1aLFi3UvHlzJSYmatCgQRkuewMAAAAAAJ4t20OiOXPm3PS23333nYYPH66zZ8+aPwsNDc2OsnJFamqqFi5cKEkKCgpSx44dc2Q/ycnJmjRpkiQpLCxMgwcPztDm3nvvVffu3TVt2jStW7dO27ZtU/369XOkHgAAAAAAcPu5JSauXrlyperXr69OnTrpzz//lGEYKlWqlCZPnmyOjrkd/fLLLzp58qQk6fHHH1dAQECO7CcyMlLnz5+XlDaSy8vL/svarVs3c3np0qU5UgsAAAAAALg9ZftIohvx008/afjw4dqyZYuktEvNSpQooddee019+/ZV/vz5c7O8LJs/f7657OpSs6zYuHGjudy8eXOH7erVq6eAgAAlJiZq06ZNOVYPAAAAAAC4/eTKSKJ169bpvvvu08MPP6wtW7bIMAwVKVJEY8aM0eHDh/Xyyy/f9gHRxYsXzdE65cuXV4sWLVxu8/zzz6tMmTLy9fVVsWLF1KhRI7311lvmaCRH9uzZYy5Xq1bNYTsfHx9VrlxZkrR3795MPAoAAAAAAOAp3DqSaPPmzRo2bJgiIyMlpY0cKlSokF555RUNGjRIQUFB7iwnR33zzTfmnc+6dOkii8XichvbyaTPnj2rs2fPasuWLRo/frwmTpyo3r17293uxIkTkqTAwEAVKlTI6T5CQ0P1xx9/6MyZM7py5Yr8/Pwy94Bs9uNIXFycuZyamqrU1NRM943bmMHr7BGM1P9ea15zj8FxHMjDOJZ7Bs7fHonzt2fIqdfZLSFRdHS03n77ba1Zs0ZSWjgUHBysQYMG6ZVXXlHBggXdUYZb3cilZnfccYc6duyoxo0bmxN1Hz58WN98842WLFmipKQk9enTRxaLRb169cqw/YULFyQpUyFbYGCguXzx4sUbColuZBLxCxcuKCEhIdPtcfvKn5yY2yXAHYxU+aYk/fe95ZaY0g45jOM4kHdx/vYQnL89Eudvz2DNAbJbjoZEv//+u4YNG6bly5dLSguHAgMD9dJLL2nIkCEqUqRITu4+15w4ccIcFdSoUSNVrVrVYdsOHTooIiIiw0ij+vXr66mnntLy5cvVsWNHJScn6+WXX1a7du1UqlSpdG2TktIO/L6+vi5rsw2FLl++nNmHBAAAAAAA8rgcCYl2796t4cOHm3PyGIYhf39/9e3bV6+99pqKFy+eE7u9ZSxYsMAc+hUREeG0ratRVG3atNGwYcP09ttvKzExUbNmzdKbb76Zro11/qarV6+6rO3KlSvmsr+/v8v2to4fP+50fVxcnBo0aCBJCg4OVoECBW6of9yekvK5ft8hD7AZop6UL4C/RHoIjuNA3sX520Nw/vZInL89Q06NGMv2kOiZZ57R4sWLZRiGDMOQn5+fevfurf/9738ZRsDkVZ9//rmktFE7Tz31VJb769Wrl4YNGybDMLRu3boMIVFwcLCktMvHXLHOkyRl7vI0WyEhIZlu6+XlJS8vTkIegf9seA7ra23x4nX3EBzHgTyM47jn4PztcTh/e4acep2zPST66quvzOXixYtrwIABCg0NNecjuhk5efv47BYdHW3ebaxNmzYqXLhwlvssUaKEihYtqvj4eLt3OgsJCdGWLVt06dIl/fvvv04nr7aOBipevPgNzUcEAAAAAADythy53Mw6v058fLyGDRuW5b5up5DIdsJqV5ea3Qhnd0erXr26vvnmG0nSvn371KhRI7vtUlJSdOjQIUlSWFhYttUGAAAAAABufzkyPsl6qVl2fd0ukpOT9eWXX0pKG6nzyCOPZEu/Z86cUXx8vCSpTJkyGdY3bdrUXF63bp3DfqKjo83LzZo0aZIttQEAAAAAgLwh20cSRUZGZneXt41Vq1bpzJkzkqRnn31WPj7Z8/ROnz7dDMuaN2+eYX2LFi1UsGBBnT9/XvPmzdPQoUPtjjyaO3euudyhQ4dsqQ0AAAAAAOQN2R4S2QsxPIXtpWaZuUTu6NGj+ueff1SnTh2HbZYvX6533nlHUtrdyJ5//vkMbXx9fTVgwAC9++672rt3rz788EMNGTIkXZuoqCjNmjVLUtprVL9+/Uw9JgAAAAAA4BlyZE4iT/TPP/9o+fLlkqSaNWvqnnvucbnN0aNH1bJlSzVu3Fht27ZVrVq1VKJECUnS4cOHtWTJEi1ZssQcRfThhx+qbNmydvsaMmSIvvrqKx04cEBDhw5VbGysnn76afn7+ysyMlKjRo1SSkqK/P39NXHixOx50AAAAAAAIM8gJMomX331la5cuSLpxu/GFhUVpaioKIfrAwICNGHCBPXq1cthm+DgYK1YsULh4eE6ePCgpk+frunTp6drU6BAAS1cuFC1a9e+ofoAAAAAAEDeR0iUTT7//HNJkre3tzp37pypberWrasFCxYoKipK0dHRiouLU3x8vFJSUlS4cGHVqFFDrVq1Uo8ePcwRRs5UrlxZMTExmjp1qhYvXqzY2FhdvXpVoaGhCg8P18CBA1W+fPksPU4AAAAAAJA3ERJlk02bNt3wNsHBwercuXOmQ6XMCAwM1NChQzV06NBs6xMAAAAAAOR9XrldAAAAAAAAAHIfIREAAAAAAAAIiQAAAAAAAEBIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAECERAAAAAAAAREgEAAAAAAAAERIBAAAAAABAhEQAAAAAAAAQIREAAAAAAABESAQAAAAAAAAREgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAECERAAAAAAAAREgEAAAAAAAAERIBAAAAAABAhEQAAAAAAAAQIREAAAAAAABESAQAAAAAAAAREgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAECERAAAAAAAAREgEAAAAAAAAERIBAAAAAABAhEQAAAAAAAAQIREAAAAAAABESAQAAAAAAAAREgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAECERAAAAAAAAREgEAAAAAAAAERIBAAAAAABAhEQAAAAAAAAQIREAAAAAAABESAQAAAAAAAAREgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAECERAAAAAAAAREgEAAAAAAAAERIBAAAAAABAhEQAAAAAAAAQIREAAAAAAABESAQAAAAAAAAREgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAECFRllkslkx9tWjRwmVfq1atUocOHRQSEiI/Pz+FhISoQ4cOWrVqVabrSUlJ0WeffaZmzZqpePHi8vf3V6VKldS7d2/t3r07C48UAAAAAADkZT65XQCk1NRU9erVS7NmzUr385MnT+rkyZP67rvv1KNHD02bNk1eXo5zvfj4eIWHh2vbtm3pfn748GFNnz5d8+bN05QpU9SjR48ceRwAAAAAAOD2RUiUTfr27asXX3zR4frAwECH6958800zIKpTp46GDh2qSpUq6dChQxo7dqxiYmI0c+ZMFS9eXKNGjbLbx7Vr19ShQwczIOrYsaN69uypIkWKaMuWLXrvvff0999/q3fv3ipbtqweeeSRLDxaAAAAAACQ1xASZZMSJUqoZs2aN7zdgQMH9OGHH0qS6tWrp/Xr18vf31+SVL9+fbVr107NmzdXdHS0xo0bpxdeeEGVK1fO0M+8efO0ceNGSdKLL76oqVOnmusaNGigRx55RHXr1lVCQoIGDBigvXv3yseHlx8AAAAAAKRhTqJcNnHiRKWkpEiSJk+ebAZEVgEBAZo8ebKktPmGJkyYYLcfa9BUpEgRjRs3LsP6ypUr6/XXX5ckxcbGaunSpdn2GAAAAAAAwO2PkCgXGYah77//XpJUrVo1NWrUyG67Ro0a6c4775Qkff/99zIMI936AwcOaO/evZKkJ598UgEBAXb76datm7lMSAQAAAAAAGwREuWiI0eO6NSpU5Kk5s2bO21rXX/y5EkdPXo03TrrZWau+ilVqpSqVq0qSdq0adPNlAwAAAAAAPIoQqJssnjxYlWvXl0BAQEKDg5WlSpVFBERocjISIfb7Nmzx1yuVq2a0/5t11tHDWWln+PHj+vSpUtO2wIAAAAAAM/BzMXZxDaokdLm/YmNjdX8+fP12GOPae7cuSpYsGC6NidOnDCXQ0JCnPYfGhpqLh8/fjzL/RiGoRMnTpiXsWWG7X7siYuLM5dTU1OVmpqa6b5xGzN4nT2Ckfrfa81r7jE4jgN5GMdyz8D52yNx/vYMOfU6ExJlUUBAgNq1a6dWrVqpWrVqCgoK0pkzZ7Ru3Tp99tlnOnv2rL777ju1b99eP/30k/Lly2due+HCBXM5KCjI6X4CAwPN5YsXL6Zbl139uGIbVLly4cIFJSQk3FD/uD3lT07M7RLgDkaqfFOS/vvewkBUT8BxHMi7OH97CM7fHonzt2ewzQGyEyFRFp08eVKFChXK8PMHH3xQ/fv31yOPPKKYmBitW7dOn376qQYMGGC2SUr674Dt6+vrdD9+fn7m8uXLl9Oty65+AAAAAACA5yIkyiJ7AZFVyZIltWTJElWrVk3JycmaPHlyupAof/785vLVq1ed7ufKlSvmsr+/f7p11/dj+/2N9OPK9Ze5XS8uLk4NGjSQJAUHB6tAgQI31D9uT0n5nL93kUfYDFFPyhfAXyI9BMdxIO/i/O0hOH97JM7fniGnRowREuWwO+64Qw8++KBWrlyp2NhYnTp1SmXKlJGUFqRYubr0y3aS6esvKbu+H2chkbN+XHE135EtLy8veXlxEvII/GfDc1hfa4sXr7uH4DgO5GEcxz0H52+Pw/nbM+TU68y7xw2qV69uLp88edJctg1dXE0KbTuK5/q5gW6mH4vFckOhDwAAAAAAyNsIidzAYrHY/blteLRv3z6nfdiuDwsLy3I/oaGh6SaxBgAAAAAAno2QyA327NljLlsvNZOkihUrmt+vW7fOaR/r16+XJJUtW1YVKlRIt65p06bmsrN+Tp8+rQMHDkiSmjRpkrniAQAAAACARyAkymFHjhzRTz/9JEmqVKmSypYta66zWCxq3769pLQRPr/99pvdPn777TdzBFD79u0zjEyqWrWqObro66+/VmKi/Vuazp0711zu0KHDzT0gAAAAAACQJxESZcGyZcuUkpLicP1ff/2lTp06mXcue/HFFzO0GTRokLy9vSVJ/fv3z3Bb+suXL6t///6SJB8fHw0aNMjuvl599VVJ0rlz5zR06NAM6w8dOqTRo0dLkipXrkxIBAAAAAAA0uHuZlnQv39/JScnq1OnTmrcuLEqVKggf39/xcfHa+3atZo2bZri4+MlpV0S1q9fvwx9VK1aVUOGDNGYMWMUHR2tJk2a6LXXXlOlSpV06NAhffDBB4qJiZEkDRkyRFWqVLFbS0REhGbPnq1NmzZp6tSpOn36tHr27KnChQtr69atevfdd5WQkCAvLy9NmjRJPj689AAAAAAA4D8WwzCM3C7idlWhQgUdO3bMZbtOnTpp5syZKlSokN31qamp6tmzp2bPnu2wj+7du2v69OlOb3MXHx+v8PBwbdu2ze56Pz8/TZkyRT169HBZ8804ceKEeee148ePc/c0DzEmJj63S4A7GKnKn5x2KWtSvgBuoesh/lenWG6XACCHcP72EJy/PRLnb8+QU5+/GU6SBfPmzdO6desUFRWlw4cPKz4+XgkJCQoKClJoaKjuvfdeRUREqHHjxk778fLy0qxZs9SpUydNnz5d27ZtU3x8vIoVK6b69eurd+/eeuSRR1zWU6xYMW3evFkzZszQokWLtHfvXl26dEllypRRq1atNHDgQNWoUSO7Hj4AAAAAAMhDCImyoHnz5mrevHm29RceHq7w8PAs9eHj46O+ffuqb9++2VQVAAAAAADwBIw3BAAAAAAAACERAAAAAAAACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIibIsOjpa77zzjlq3bq2QkBD5+fkpKChIVatW1fPPP6+NGze67GPu3LmyWCyZ+po7d67L/hITEzV27FjVr19fRYoUUWBgoKpVq6bBgwfr2LFj2fCoAQAAAABAXuOT2wXczu677z5t2LAhw8+vXr2qgwcP6uDBg5o7d666du2qGTNmyNfXN8drio2NVXh4uA4ePJju5/v379f+/fs1c+ZMLVy4UG3atMnxWgAAAAAAwO2DkCgLTp06JUkqU6aMnnjiCTVr1kzlypXTtWvXFBUVpfHjx+vkyZOaP3++kpOTtWjRIpd9rl69WmXKlHG4PiQkxOG6Cxcu6NFHHzUDop49e+rpp5+Wv7+/IiMjNXr0aCUkJOipp57Spk2bVLt27Rt7wAAAAAAAIM8iJMqCatWqadSoUerUqZO8vb3TrWvUqJGee+45NWnSRAcOHNAXX3yhPn366L777nPaZ9WqVVWhQoWbqmfcuHE6cOCAJGns2LEaMmSIua5x48Zq0aKFmjdvrsTERA0aNEhr1669qf0AAAAAAIC8hzmJsmD58uV68sknMwREVsWKFdP48ePN75csWZJjtSQnJ2vSpEmSpLCwMA0ePDhDm3vvvVfdu3eXJK1bt07btm3LsXoAAAAAAMDthZAoh7Vs2dJcPnToUI7tJzIyUufPn5ckRUREyMvL/kvbrVs3c3np0qU5Vg8AAAAAALi9EBLlsCtXrpjLjkYcZQfbu6g1b97cYbt69eopICBAkrRp06YcqwcAAAAAANxeCIly2Lp168zlsLAwl+2ff/55lSlTRr6+vipWrJgaNWqkt956SydPnnS63Z49e8zlatWqOWzn4+OjypUrS5L27t3rsh4AAAAAAOAZmLg6B6WmpmrMmDHm908++aTLbWwnkz579qzOnj2rLVu2aPz48Zo4caJ69+5td7sTJ05IkgIDA1WoUCGn+wgNDdUff/yhM2fO6MqVK/Lz83P9YGz24UhcXJy5nJqaqtTU1Ez1i9ucwevsEYzU/15rXnOPwXEcyMM4lnsGzt8eifO3Z8ip15mQKAdNmDBBW7dulSR17NhRdevWddj2jjvuUMeOHdW4cWOFhoZKkg4fPqxvvvlGS5YsUVJSkvr06SOLxaJevXpl2P7ChQuSpKCgIJd1BQYGmssXL17MdEhkrSszLly4oISEhEy3x+0rf3JibpcAdzBS5ZuS9N/3FgaiegKO40DexfnbQ3D+9kicvz2DNQPIboREOWTdunX63//+J0kqUaKEPv30U4dtO3TooIiICFkslnQ/r1+/vp566iktX75cHTt2VHJysl5++WW1a9dOpUqVStc2KSnt4O/r6+uyNttQ6PLly5l+TAAAAAAAIO8iJMoBu3fvVocOHZSSkqL8+fNr8eLFKlGihMP2BQsWdNpfmzZtNGzYML399ttKTEzUrFmz9Oabb6Zrkz9/fknS1atXXdZnO5m2v7+/y/ZWx48fd7o+Li5ODRo0kCQFBwerQIECme4bt6+kfK7fc8gDbIaoJ+UL4C+RHoLjOJB3cf72EJy/PRLnb8+QUyPGCImy2ZEjR9S6dWv9888/8vb21pdffqn77rsvy/326tVLw4YNk2EYWrduXYaQKDg4WFLa5WOuXLp0yVzOzOVpViEhIZlu6+XlJS8vTkIegf9seA7ra23x4nX3EBzHgTyM47jn4PztcTh/e4acep1592SjU6dO6YEHHtCpU6dksVg0e/ZstW/fPlv6LlGihIoWLSpJdu90Zg1wLl26pH///ddpX9YRQcWLF8/0fEQAAAAAACBvIyTKJvHx8XrwwQd1+PBhSdLkyZPVtWvXbN3H9XMW2apevbq5vG/fPoftUlJSdOjQIUlSWFhY9hUHAAAAAABua4RE2eD8+fN66KGHtGfPHknSmDFj1K9fv2zdx5kzZxQfHy9JKlOmTIb1TZs2NZfXrVvnsJ/o6GjzcrMmTZpka40AAAAAAOD2RUiURYmJiXr00Ue1Y8cOSdKbb76p1157Ldv3M336dBmGIUlq3rx5hvUtWrQwJ8CeN2+e2fZ6c+fONZc7dOiQ7XUCAAAAAIDbEyFRFly9elUdOnTQpk2bJEkDBw7Ue++9d0N9HD16VDExMU7bLF++XO+8846ktLuRPf/88xna+Pr6asCAAZKkvXv36sMPP8zQJioqSrNmzZKUFjTVr1//hmoFAAAAAAB5F3c3y4JnnnlGa9askSTdf//96t69u/7880+H7X19fVW1atV0Pzt69Khatmypxo0bq23btqpVq5ZKlCghSTp8+LCWLFmiJUuWmCODPvzwQ5UtW9Zu/0OGDNFXX32lAwcOaOjQoYqNjdXTTz8tf39/RUZGatSoUUpJSZG/v78mTpyYDc8AAAAAAADIKwiJsuDbb781l3/99VfdfffdTtuXL19eR48etbsuKipKUVFRDrcNCAjQhAkT1KtXL4dtgoODtWLFCoWHh+vgwYOaPn26pk+fnq5NgQIFtHDhQtWuXdtprQAAAAAAwLMQEuWyunXrasGCBYqKilJ0dLTi4uIUHx+vlJQUFS5cWDVq1FCrVq3Uo0cPc4SRM5UrV1ZMTIymTp2qxYsXKzY2VlevXlVoaKjCw8M1cOBAlS9f3g2PDAAAAAAA3E4IibLA0eTQNyI4OFidO3dW586ds6GiNIGBgRo6dKiGDh2abX0CAAAAAIC8jYmrAQAAAAAAQEgEAAAAAAAAQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCojzr2LFjGjx4sKpVq6bAwEAVKVJE9evX17hx45SYmJjb5QEAAAAAgFuMT24XgOy3bNkydenSRQkJCebPEhMTFR0drejoaM2cOVMrVqxQ5cqVc7FKAAAAAABwK2EkUR4TExOjp556SgkJCQoKCtL777+vzZs365dfflHPnj0lSQcOHNCjjz6qCxcu5HK1AAAAAADgVsFIojxm4MCBunz5snx8fLRmzRo1btzYXHf//ferSpUqGjp0qA4cOKDx48drxIgRuVcsAAAAAAC4ZTCSKA/ZunWrNmzYIEnq3r17uoDIavDgwQoLC5Mkffzxx0pOTnZrjQAAAAAA4NZESJSHfPfdd+by888/b7eNl5eXunbtKkn6999/FRkZ6Y7SAAAAAADALY6QKA/ZuHGjJCkwMFB169Z12K558+bm8qZNm3K8LgAAAAAAcOtjTqI8ZO/evZKkypUry8fH8UtbrVq1DNtkxokTJ5yuP378uLl88uRJpaamZrpv3L7Onz6X2yXAHYxUJaVcliRd8fGXLPyNwRP83/8l5nYJAHII528PwfnbI3H+9gxxcXHmckpKSrb1S0iURyQlJSk+Pl6SFBIS4rRt4cKFFRgYqEuXLqULdlwJDQ3NdNtGjRplui0A4NY0JrcLAAAAN4zzt+c5c+aMKlSokC19ESXnEba3sw8KCnLZPjAwUJJ08eLFHKsJAAAAAADcPhhJlEckJSWZy76+vi7b+/n5SZIuX76c6X24GnWUlJSkffv2qWTJkipevLjTS94A3F7i4uLUoEEDSWl3UixdunQuVwQAAFzh/A3kXSkpKTpz5owk6a677sq2fvkUn0fkz5/fXL569arL9leuXJEk+fv7Z3ofri5jk9LmQwKQt5UuXTpTxwMAAHDr4PwN5D3ZdYmZLS43yyOCg4PN5cxcQnbp0iVJmbs0DQAAAAAA5H2ERHlE/vz5VbRoUUmu70L2zz//mCHRjUxGDQAAAAAA8i5CojykevXqkqTY2Fint8Dbt2+fuRwWFpbjdQEAAAAAgFsfIVEe0rRpU0lpl5Jt377dYbt169aZy02aNMnxugAAAAAAwK2PkCgPeeyxx8zlOXPm2G2Tmpqq+fPnS5IKFSqkli1buqM0AAAAAABwiyMkykMaNGigZs2aSZJmzZqlqKioDG3Gjx+vvXv3SpIGDhyofPnyubVGAAAAAABwa/LJ7QKQvT7++GM1adJEly9fVuvWrfXGG2+oZcuWunz5sr788ktNnz5dklS1alUNHjw4l6sFAAAAAAC3CothGEZuF4HstWzZMnXp0kUJCQl211etWlUrVqxQ5cqV3VwZAAAAAAC4VRES5VHHjh3Txx9/rBUrVujEiRPy9fVV5cqV9cQTT+ill15SQEBAbpcIAAAAAABuIYREAAAAAAAAYOJqAAAAAAAAEBIBAAAAAABAhEQAAAAAAAAQIREAAAAAAABESAQAAAAAAAAREgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAeZe3atbJYLObXU0895XKbbt26me0BAEDOevTRR2WxWOTl5aWNGzdmapuNGzfKy8tLFotFbdq0yeEKAeRlhEQA4MEWL16sXbt25XYZAADg/5s2bZoKFCggwzDUo0cPJSUlOW1/5coV9ejRQ4ZhqECBAvrss8/cVCmAvIiQCAA8mGEYGj58eG6XAQAA/r+QkBB98MEHkqT9+/dr5MiRTtu/88472r9/vyRp7NixCgkJyfEaAeRdhEQA4KGKFSsmSVq6dKliYmJyuRoAAGDVu3dvNW/eXJL04YcfOjxP//777xo7dqwkqUWLFurVq5fbagSQNxESAYCHGjBggPz8/CRJw4YNy+VqAACAlcVi0cyZM+Xv76+UlBR1795dKSkp6dpcu3bN/Lm/v79mzpzJ/IEAsoyQCAA8VGhoqPkXx+XLl2vr1q033deZM2f01ltvqU6dOipUqJDy58+vChUq6Lnnnsv0pJsAAOA/lStX1jvvvCNJiomJ0bhx49Kt/+ijj7R9+3ZJ0rvvvqtKlSqZ606fPq0333xT9erVU5EiReTn56fQ0FA9+eST+vnnn53u99q1a5o7d64eeughlSpVSr6+vipYsKCqVKmiVq1aadSoUdqzZ082P1oAtwqLYRhGbhcBAHCPtWvXqmXLlpKkOXPm6KGHHlKlSpV0+fJltW7dWqtXr86wTbdu3TRv3jxJaXMYXW/NmjV64oknlJCQ4HC//fr106RJk+Tlxd8mAADIrGvXrqlx48batm2b/Pz89Pvvv+vOO+/UoUOHdNddd+ny5cuqX7++oqKi5O3tLUlauHChevfurUuXLjnst3v37vrss8/k4+OT7ucXL15UeHi4NmzY4LSuTp06acmSJVl/gABuOfxvHQA8WOnSpdW3b19JaWHPjY762blzp9q2bauEhATly5dPL7/8siIjI7V161ZNmzZNFStWlCRNnTpVr7/+erbXDwBAXubt7a1Zs2YpX7585l3MUlNT1bNnT12+fFn58uXT7NmzzYDo66+/1nPPPadLly7pjjvu0EcffaQff/xR27dv1zfffKPw8HBJ0qxZszR06NAM+xsxYoQZELVp00ZffPGFNm3apO3bt2vVqlUaNWqU7r33Xi5rA/IwRhIBgAe5fiRRt27d9Pfff+uOO+7QpUuX1LJlS/3666/ptnE2kqhBgwbatm2bvL29tXLlSrVu3Trd+n/++UdNmzbVnj175OXlpT/++EM1atTIwUcIAEDeM3z4cPPSs1atWumXX34xfz5ixAhJUnx8vCpXrqzz58/rhRde0LRp0zKMFJKkN998U6NGjZKXl5f27NmjO++801xXrlw5HT9+XI8//rgWL17ssJ5z586pSJEi2fgIAdwqGEkEAB6uRIkSeumllyRJkZGRioyMzNR2W7du1bZt2yRJPXv2zBAQSVLhwoU1ffp0SVJqaqo++eSTbKoaAADP8eabb5p/ZLEGRDVr1tQbb7xhtvn00091/vx5lS1bVp988ondgEiSRo4cqbJlyyo1NVXz589Pt+706dOSpGbNmjmth4AIyLsIiQAAGjJkiIKDgyVJb7/9dqa2sZ34snv37g7bNWnSRGFhYRm2AQAAmePr65vusjLrZWi+vr5mmx9++EFS2mVi1ruX2uPj46PGjRtLkqKiotKtK126tCTpq6++UmJiYrY+BgC3B0IiAICKFi2qQYMGSZI2bdpkdwLr6/3555+S0v7jWrt2badtGzZsKEk6ePCgrl69mqVaAQDwRA0aNFBISIgkKSQkRA0aNDDXXbt2TTt37pQkTZs2TRaLxemXddJp68ghq4iICEnS5s2bVbFiRb300ktaunSpzpw544ZHCOBWQEgEAJAkvfLKKypUqJCktDkOXDl37pyktCHnjoa0W5UqVUpS2pxG//zzT9YKBQAA6Zw7d04pKSk3vN31o4XefvttvfDCC7JYLPr77781depUdezYUSVKlFDNmjU1fPhw/fXXX9lVNoBbkPP/1QMAPEahQoX0yiuvaNiwYdqyZYuWL1+uNm3auNyOO5wAAJC7rl27Zi736NFDAwcOzNR2tperSVK+fPk0a9YsDR48WF988YV+/fVXRUdH6+rVq9q9e7d2796tjz76SAsWLFD79u2z9TEAuDUQEgEATIMGDdLHH3+ss2fPavjw4U5DIuuklWfPnlVKSorT0UTW4ewWi0WFCxfO3qIBAPBwthNJG4ahmjVrZqm/6tWr691339W7776rpKQkbdy4UYsWLdL8+fN18eJFPfPMMzp06JA5hxGAvIPLzQAApuDgYA0ZMkSStGPHDi1dutRhW+t/QK9evWrOg+DI1q1bJUlVqlTJ8FdLAACQNb6+vubdzzZt2pStfefPn18PPPCAZs+erXHjxkmSLl++rOXLl2frfgDcGgiJAADpvPTSSypRooSktLmJDMOw2+6BBx4wl2fPnu2wv6ioKO3ZsyfDNgAAIPu0a9dOkrRv375M3YDiZrRq1cpcjo+Pz5F9AMhdhEQAgHQCAwP12muvSZJ27dqllStX2m3XoEED1atXT5I0Y8YM/fLLLxnanD9/Xr1795YkeXl5qW/fvjlUNQAAnm3gwIEKCgqSJD3//PPavXu30/YrVqzQH3/8YX5/7tw5LVu2zOEfhyRpzZo15nLFihWzWDGAWxFzEgEAMujbt68+/PBDxcXFOf1L4YwZM9SwYUNdvXpV4eHh6t+/v9q2bavAwEDFxMRozJgxOnz4sCTp1VdfzfIcCQAAwL6SJUtq3rx5evzxxxUXF6d69eqpW7dueuSRRxQSEqLk5GSdOHFCW7du1ZIlS3T48GEtW7ZMd999tyQpISFB7dq1U4UKFdSxY0c1bNhQ5cuXl4+Pj+Li4rRs2TLNnDlTklS2bNlM3dwCwO3HYjiLigEAecratWvVsmVLSdKcOXPUrVs3h22nTJmi/v37p/uZvVPGmjVr9MQTTyghIcFhX/369dOkSZPk5cUAVgAAblaFChV07NgxlS9fXkePHrXbZtmyZerWrZvOnTvntC8vLy/9/PPP5v8Ljh49mqnRQaVLl9ayZctUt27dG64fwK2PkUQAALt69uypsWPH6vjx407btW7dWrGxsZo4caJWrlypw4cP68qVKypZsqSaNWumPn36qGnTpm6qGgAAz9a2bVsdOXJEM2bM0MqVK7V7926dO3dOPj4+KlWqlGrUqKH7779fjz/+uEJDQ83typcvr61bt2rlypXavHmzjh07pr/++ksXL15UoUKFVL16dbVt21a9evVSgQIFcvERAshJjCQCAAAAAAAAE1cDAAAAAACAkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAAAAAIiQCAAAAAAAACIkAgAAAAAAgAiJAAAAAAAAIEIiAAAAAAAAiJAIAAAAAAAAIiQCAAAAAACACIkAAAAAAAAgQiIAAAAAAACIkAgAAAAAAAAiJAIAAAAAAIAIiQAAAAAAACBCIgAAAOQxI0aMkMVikcViye1SdPToUbOWuXPn5mot2f28DBs2TBaLRW3atMmW/nDz+vXrJ4vFooiIiNwuBcBtjpAIAHBT1q5da37YuP4rICBA5cuX12OPPaZFixYpJSUlt8tFDtu2bZv5+r/yyitO2/7+++/p3i+HDx922v7555832+7duzc7y4YdtqFGZr8ee+yx3C4bbvZ///d/GjdunCRp+PDh5s+tYYXFYtHChQsz1VdsbKwCAgJksVhUp06dW+accfLkSfOxxMTEmD+vUKGC+fPg4GDFx8c77cf2fJlTQeFrr70mX19fff7559q+fXuO7AOAZyAkAgBku8uXL+v//u//9P3336tz58669957dfr06dwuC3bMnTvX/PBy9OjRm+6nTp06CgoKkiRt2LDBadvr12e2ffHixRUWFnbTNQLIPu+9956SkpL08MMPq379+ubPx4wZo3LlykmSBg0apDNnzjjtxzAM9ezZU5cvX5aPj49mz54tHx+fHK09s5YvXy5JCgkJUZ06dey2uXjxoj744AN3lmVXuXLlFBERIcMw9Pbbb+d2OQBuY4REAIAs69u3r3bt2mV+RUVFafLkyapQoYKktFEm7du3l2EYuVsocoyPj48aN24sSYqJidHFixcdtrWGPt7e3um+tycuLk6HDh2SJDVr1iy7ykUmtW/fPt3vtqOvSZMm5XapcKOTJ0+aI2IGDx6cbl1wcLCmTZsmSYqPj9eAAQOc9jVz5kytXbtWkvTqq686DGNyw7JlyyTJ5eV0U6dOvSX+EGJ9LVatWsVoIgA3jZAIAJBlJUqUUM2aNc2vRo0a6aWXXtKOHTtUuXJlSdLWrVvNv8oib7rvvvskSdeuXdPmzZsdtrOGQk888YQkaf369S7b2vYP9ylUqFC6321HX9aRI/AMn3zyiZKTk1WmTBndf//9GdY//PDD6tq1qyTpyy+/dHjsP3XqlIYMGSJJuvPOO9NdtpbbEhMT9csvv0iS2rZta7dNsWLFJKWNnh09erTbanPkzjvv1D333CNJmjx5ci5XA+B2RUgEAMgxhQsX1uuvv25+/+OPP+ZiNchptiN9HI0Oio2NVVxcnKS0OTQk6eDBg/rrr7/stickAm4tqamp5iiip59+Wl5e9j9OTJgwQSVLlpQk9enTRwkJCRnavPjiizp//rwsFotmzpyp/Pnz51jdN+rnn39WUlKSAgIC7AZhklSjRg2Fh4dLkqZPn66TJ0+6s0S7OnfuLElavHixLly4kMvVALgdERIBAHJUgwYNzOVjx46Zy7YTea5du1apqamaPXu2WrZsqZIlS8rLy0vdunXL0N+OHTvUp08f3XnnnQoKClJgYKDuvPNO9e3bVwcOHHBZT2Jiot59913dfffdCgwMVNGiRdW0aVPNnj1bhmFkqOt6LVq0kMViUYsWLSSlXXbxyiuvqHLlyvL391fRokX10EMPadWqVU7r+OeffzRnzhx16dJF1atXV1BQkHx9fVWqVCk99NBDmj59uq5evepwe3t3TPrpp5/Utm1blSpVSn5+fqpYsaL69u2rEydOZNje+jiff/5582cVK1bMMCGxvefAkYYNG8rPz0+S45DI+vOwsDDVrl1b5cuXz1T7ggULqlatWhnWHz16VC+//LJq1Kih4OBgBQQEqEqVKurdu7d27drltF7rYxwxYoQkKTIyUo899pjKlCkjf39/hYWF6d1339WlS5fSbbdy5UqFh4eb7apXr67Ro0c7fb2skpKSNGXKFLVq1UqlSpWSr6+vSpQooQceeECzZs1yOmGvdbJc6+/F/v371bNnT1WoUEF+fn4qWbKkOnTooN9++81lHTmtV69e5vO7ePFih+1++OEHs52juzJduXJF06dP16OPPqqyZcvKz89PgYGBqlGjhnr06KHVq1ff8KWs17/2jlz/+27PtWvX9Mknn6hhw4YqUKCAChYsqHvuuUcffvihrly5ckN1fffdd3riiSdUrlw55c+fX4UKFVK9evU0cuRI/fPPPy63P3HihPr166c77rhD+fPnV5kyZdSuXTv9/PPPN1SHMxs3btSpU6ckSZ06dXLYrkiRIpoyZYqktOOkdcSQ1eLFi/X9999LSpvsumnTpunWnz9/XqNHj1aTJk1UvHhx+fr6qnTp0mrbtq2WLFni8jVfunSpHnvsMYWEhMjPz0/BwcG644471KxZM7399tvaunWr0+2to58eeOABp+HVO++8Iyntd/v999932qcrqampWrBggcLDw83jQ/HixdWyZUt98sknmTrGWF+TxMRE8/kFgBtiAABwEyIjIw1JhiRj+PDhDtvt27fPbPfwww/b3X7VqlXGAw88YH5v/YqIiDDbX7t2zXj55ZcNi8WSoZ31y8fHx5g2bZrDWo4fP25UqVLF4fZt2rQx1qxZY34fGRmZoY/mzZsbkozmzZsbGzduNIoVK+awv3HjxjmspXz58g63s37VqVPHiIuLs7v9kSNHzHZz5swx/ve//znsp3jx4saePXvSbW/7/Dv7svccONO0aVNDkpE/f37jypUrGdZ369bNkGT07NnTMAzD6Ny5syHJ6N+/f4a2//77r+Hl5WVIMsLDwzOsnzdvnuHn5+ewdm9vb2PUqFEOa7V9/44ePdrhe+vee+81Ll68aKSmphoDBgxwuL+HH37YSElJcbi/nTt3unzd69evb5w+fdru9tZtIyIijG+//dYICAhw+Li//PJLh3W4Yvvesv0dvBEXL140f9cKFy5sHD9+PEObuLg4o3jx4oYko0KFCsb58+cztImJiTEqVqzo8n165MiRdNsNHz7cXGdPZo5dhpH+992eCxcuGM2aNXNY1z333GPs2LEj3e+qPefOnTPuv/9+p4+xRIkSRlRUlMNa169fbxQoUMDh9iNGjHD5vGTGiBEjDElGvnz5jKSkJJftO3ToYEgyLBaLeTw5d+6cUbJkSUOSUb58eePChQvptvn555+NokWLOn0+wsPDM2xnGIaRkpJiPPHEEy7fM3Xr1nVYc2pqqlG6dGlDkjFjxowM662/i9b3Rfv27Q1Jhq+vr3H06NEM7W2Pt47eA2fPnjWaNGnitOawsDC7/V+vVKlShiTj2WefddkWAK5HSAQAuCmZDYkWL15stnvhhRfsbn/33Xcbkox27doZ3377rbF9+3Zj5cqV6T7ovvjii2b7++67z5g9e7axdu1aY+vWrcaMGTOMGjVqmOu///77DHVcvXrV3I8k49FHHzW+++47Izo62vjuu++M8PBwQ5LRsGFDpwGJ9UNj1apVjWLFihklSpQwxowZY2zcuNHYunWr8dFHHxmFChUypLTQ6s8//7T7vISEhBgNGzY03n33XWP58uXGtm3bjE2bNhkLFiwwHn74YbMGRx9ObT/I33vvvWbbRYsWGdHR0cbPP/9sdO3a1WzTqFGjdNtfvHjR2LVrl/Hee++ZbVavXm3s2rUr3dfFixcdvrb2vPHGG2Z/GzduzLC+UqVKhiRj3rx5hmEYxqeffmpIMmrXrp2h7YoVK8y+xowZk27d8uXLzVAnKCjIGD58uLFhwwYjKirKGD9+fLrw7pNPPrFbq3V9gwYNDElG48aNzefvxx9/NB555BGzzZtvvmmMHz/ekGQ88sgjxjfffGNs377d+P77741GjRqZ7T799FO7+zp48KBRsGBBQ5JRoEAB4/XXXzeWLl1qREdHG6tXrzb69etn+Pj4mO/Bq1evZujD+sH0nnvuMfLnz29UrFjRmDJlivHbb78ZUVFRxogRI4z8+fOb+/j7779dvl72ZEdIZBiGsXXrVvMx3X///UZqamq69db3ube3t933yp49e4ygoCCzlg4dOhhfffWVsW3bNuO3334z5s+fb3Tp0sUIDAzMtZDIGg5Y30dffPGFER0dbaxYscIMKurXr+80IEhKSjLuuece87l47rnnjC+++ML47bffjA0bNhjvv/++GZgULlzYbkhw7NgxMyDy8vIy+vTpY/z888/Gtm3bjFmzZpmBXb169bIcErVq1cp8H2ZGXFycUbhwYUOSUalSJSMxMdGIiIgw6/jxxx/Ttd+4caORL18+Q5JRsmRJ47333jOWLVtmbN++3Vi2bJnRpUsXc9uOHTtm2N/kyZPN9U2bNjXmzp1rbNiwwdixY4fx008/GePHjzcefPBBo0GDBg5r3rZtmxlsnTp1KsP660OinTt3msej7t27Z2jvKiRKSUkxGjdunO64v3jxYiM6Otr44YcfjMcee8xcV6lSJbvhmK127doZkoyyZcs6bQcA9hASAQBuSmZCouTk5HQfoOfPn293e0nGW2+95XBftqN7Zs6cabfN5cuXzb/Ely9f3khOTk63fuLEiWYfgwYNstvHSy+9lK4mZyGRdT8nTpzI0GbDhg3mB4YBAwbY3deBAwccPl7DMIzZs2eb+/n5558zrLf9IC+ljcy5/kO4YRhGjx49zDY7duzIsH7OnDnm+us/aN+MVatWmf2NHj063bpTp06Z6w4fPmwYhmHs2rXL/GD777//pmtvOzpq8+bN5s+vXr1qlClTxgyIYmJiMtRx9OhRcyRAQECAcebMmQxtbJ+/Tp06ZRgFlJKSYr5/g4ODjfz589t971y6dMn80Hj33XfbfV6sQV6dOnXs1mJ97qwjp6ZPn55hve0opLp169odebNgwQKzzUcffWR3P67Yvrfat2+fITi09+UoTLQNIW1H1k2aNCldAGePNTjx8vIyvvjiC4f1xsfHG4mJiel+5o6QaPny5WY/4eHhGY45hmEYI0eOTPc+sxcQWIPVQoUKGdHR0XbrsH0/2xsd8vjjj5v7WLRoUYb1CQkJRq1atdLVcjNSU1ONwMBAh2GII7bHM2vIZC+EvHr1qlGhQgVDShuZd+nSJbv9TZ8+3exjzZo16dZZR3Y1bNjQ7mtidfbsWYfrhg0bZoZq9lwfEhmGYYaCPj4+RmxsbLr2rkKiKVOmmOu7du1q91huG8APHTrUYe2Gkf5952hkIgA4QkgEALgpzkKiixcvGmvXrjVatGiRLlCxvTTBdvuqVas6vUzHGv506tTJaU179uxx+MGhWrVqhiQjJCTE4SUSiYmJZviQmZDohx9+cFiLNVyoU6eO05qdqV27tiHJeOmllzKss/0gX7p0aYePyfZyv48//jjD+uwOiRISEgxvb2/zg7Otr776KsNft1NTU81RBitXrkzX3nrpRUBAQLqRNdZ+pIwjjGzZBiZjx47NsN66LiAgwOEHRtsPt6GhoXZH+BjGfx8qJWUIu9avX2+u++OPPxzWaxiG8eSTTxpS2uiw69mGRL///rvd7VNTU833cIcOHZzuy5HrA8jMfDm6LDElJcW8BNHX19fYuXOnsXv3bnPEU/369e1+kF+9erXZt6NQ1xl3hETW0Yd+fn7GyZMn7W5/7do1o2bNmg4DggsXLpgjzCZPnuy0lk8++cSQ0i7zsg3l4uLizN+5Nm3aONx+y5YtWQ6Jzp49a27/+uuv39C2Dz74YLr9lypVyjh37ly6NvPnzzektMtVXY2Es44AvD40s46aevnll2+oPlvWgHLkyJF219sLiXbv3m2GvF27dk3X3lVIFBYWZkhplwYnJCTY3WdycrJ5HitcuLDTS/2sIzSl9AE7AGQGE1cDALJs5MiR6SY7DgoKUosWLcxJj0uUKKHvvvvOnNT4ek899ZS8vb3trktISDD7efzxx53WERYWZt6SOCoqyvz5yZMntW/fPklpt113VIe/v795W3ZXChUqpEcffdTh+rp160qSDh8+7LIvwzB0+vRpHThwQH/++af5VbZsWUnS77//7nT7xx9/3OFjsk7wndlasio4OFi1a9eWJG3atEmpqanmOuut7ps0aWL+zGKx6N577023XkqbBHbbtm2SpEaNGilfvnzmOuskvBaLRS+88ILDWp544gkVLFgw3Tb2PPjggypSpIjddbaTZXfs2DFdHY7aHTlyJN26H374QVLaa3HXXXc5rEP67w5u27ZtcziJ9V133aW7777b7jqLxaI6depIcs/r7Yq3t7c+//xzFShQQFevXtWzzz6rZ5991rxr1IIFC+Tj45NhO9tbpg8aNMiNFWfOtWvXzONS69atVaZMGbvtvLy8HE7ILUnr1q3T+fPnJbk+vlnfG8nJydq+fbv588jISF27dk2S0k1Ef70GDRqoRo0aTvfhypkzZ8zlwoUL39C2M2bMMI9FkjRlypQMfVh/V5o3b67ixYs77c/6fNge6yWpdOnSkqRly5YpPj7+hmqU0s4XO3bskCS1bds209tVr15dTz/9tCRp4cKF2r9/f6a2O3XqlPbu3StJevLJJxUcHGy3nY+Pj/n6/vPPP2aN9tgez06fPp2pOgDAipAIAJBjKlasqCFDhmjXrl1mcGCPow+8khQTE2MGDc8880yGu29d/2X9UGD7H+M///zTXLaGN47Uq1cvMw9NVapUcXjrZ+m//6Q7uwXxihUr1KZNGxUsWFClS5c2QwTr14oVKyTJ5QedatWqOV1v/SDmrtshN2vWTFLa3Yn++OMP8+fWO5VZ11/f3vYOZ1u3bjXv5HN9e+vrWbFiRacfJH19fc3AxPY9cL2qVas6XFeoUKEbbnf98xwdHS0p7W5krt6/L730kqS0IODcuXN29+Xq9c7Mey+zIiIiZKSNPHf65ezuXxUqVNDUqVMlSXv27DFDzwkTJjh8TmNiYiRJ5cqVM++Adys5dOiQEhMTJUn169d32tb2Do/Xs743pLRww9l7o2bNmmZb2+Ob7V38slJLZti+J280JCpfvny646+9O6NZn4/Vq1e7/F358MMPJWUMQayhXGxsrCpXrqwXXnhBX3zxhd27PNpjDShDQkLM40dmDR8+XN7e3rp27ZrLO+dZ2R6bGjZs6LSt7XpnxzTb1+b6uzMCgCuERACALOvbt6927dqlXbt26c8//1RsbKz+/fdfHT58WGPHjlWJEiWcbu/sw8bff/99UzVZP8BJSnfraFd/nXa13iogIMDpemuAZDuSxsowDPXo0UNt2rTRihUrXH6Yv3z5crbUYh1tkNOsf+GX/gt+/v33X/NDzfW3urZ+v23bNiUlJaXb7vr+pP8+qLp6X0lSqVKl0m1jj7PnzzYIzGy765/n7HgP27rVXu/M6NKli5o3b25+/+CDD6pXr14O21uDUeuokFuN7fvJ1fuwZMmSDtdlx3sju2rJDNtbwbs6Lt2Mm3k+rq/jhRde0BtvvCEfHx+dP39ec+bM0bPPPqvQ0FBVrlxZgwcPdjrKbtmyZZLkdKSoI1WrVtVzzz0nSfr666+1e/dul9vcyOtnPZ5dv931bJ8TR6MfAcCRjON7AQC4QSVKlEj3V+4b5ehSMyn9B91p06aZlya5cqN/5Xan2bNna9asWZKk2rVra9CgQWrYsKHKli2rgIAA8/no2rWrPv/8cxmGkZvl3rBmzZrJYrHIMAytX79e/fv318aNG5WamqoCBQpkGDlWr149+fn56cqVK9qyZYuaN29uhkT58uVT48aN7e7HYrHk+GPJDtb3cK1atbRgwYJMb2e93DAv2L59uzZv3mx+//vvv+vvv//OVNB3q8vK+9D2+LZjx45Mf6APCQnJ9loywzZEdxZS3Czr8/HII49o7NixN93P+++/r169emnhwoX65Zdf9NtvvykxMVGHDh3SRx99pMmTJ2vSpEnq06dPuu0uX76sX3/9VdKNXWpm6+2339aCBQuUkpKi4cOHa8mSJZneNrteP9vXxnaUIwBkBiERAOCWVrRoUXM5ICDgpsIo28DIdk4Ne1ytzw4zZsyQJFWuXFmbN2+Wv7+/3XY58SHMHYoVK6awsDDt2bPHDHus/957770ZLtPz8/NT/fr1tXHjRm3YsEFNmzY1A4V69epleH6sl1P99ddfLmuxXoriaM4hd7C+hy9evJilMPV2dfnyZXXp0kXJyckKCgrSpUuX9Pfff6t79+7mqI3rWecWi4uLy5GarCGmvZF+thxdqmN7THH1PnS23vb4Vrx4cYfhjzPX1xIaGnpTtWSGbUhkO0IzuxQtWlSnTp3S1atXs/y7Ur58eb3xxht64403lJycrG3btunrr7/WtGnTlJSUpBdffFENGzZMd0nZzz//rMuXLysgIECtWrW6qf3ecccdev755zVjxgx9++232rlzp9P2tscmV6+P7aV1zo5ptq9NuXLlXFQMAOlxuRkA4JZWu3Zt86+rmzZtuqk+bCdrtZ3w1R7bOUJyivUShHbt2jkMiAzDcDoxaXbJqZEH1nmE/vrrLx08eNAMia6/1MzK+vMNGzZo586d5iV4119qJsn88HjkyBGnoV5ycrI5t01uhjO2E0l74iSygwcPNieO/+yzz/TKK69ISpv75bPPPrO7zT333CNJ+r//+z8dO3Ys22uyTg7sLOgwDEOxsbF211WqVMn83bVOsO6Is/W2AcXNHt9sJ0PPSi2Z4efnpypVqkiSDhw4kKW+7LE+H9HR0eacZNkhX758uvfeezVx4kQtWrRIUtrre/0oH2to+cADD6S7tO5GvfXWW/L19ZVhGBo+fLjTtrbHpi1btjhtu3XrVrvbXc/62vj5+aly5cqZKRkATIREAIBbWvHixdWoUSNJ0qJFi25qpE9ISIg5Qe7ixYt15coVu+2SkpK0ePHimy82k6x3rXI2oej333+fY6MobNl+EHL0vNwM23Bn9erVZvjmKiTavHmzIiMj7fZj9cADD0hK+5A3Z84chzUsWbLEvHOUdZvc0K5dO0lp9X788ce5VkduWLlypT799FNJaRPPd+7cWaNGjTLvBjd48GC7YYPtpT4TJkzI9roqVqwoyXkovGrVKv3777921/n4+JiTda9Zs8bh72pqaqrmzZvncB8PPPCAOcfUpEmTburS0pYtW5qXqDrb17Zt25xOdpxZ1gA4q4GTPdbfFetcQjnBdoSQ7U0BDMMwJ62+2UvNrMqVK6eePXtKSrtjm7PnqkyZMgoLC5OUNo/RxYsX7ba7du2a5s6dKylt9Jg1SLXHur86deowJxGAG0ZIBAC45b311luSpISEBD3++OMOP7hJaUHH1KlTzQmQrXr37i1JOnHihP73v//Z3XbIkCE6depU9hTthPUv8cuWLbN7SdmhQ4fUr1+/HK9DSj8x8KFDh7KtX9twZ8KECUpOTpavr6/Du/c0adJEFotFFy9eNEMFLy8vu6HSY489Zt5y/P333093dyer48eP69VXX5WUdpmis1uD57TWrVubd5UaN26cvv76a6ftd+3a5fAyrNvJmTNn9MILL0iSQkND9cknn0hKu+vcwoULlT9/fiUmJqpLly5mcGr1wAMPmHfCmjx5sr788kuH+zl79uwNT6JsnUR7y5YtdkfwnD59Wv3793faR9++fSWlHXN69+5td6Lw0aNH231/WhUqVMi8o93mzZv18ssvO70E7q+//tLMmTPT/ax06dJq3769pLRAwt776+LFi+YxMKusIVF8fLyOHDmSLX1aRUREmJfLvfrqq1q/fr3T9hs3btS6devS/cw6H5Aja9asMZetYaGUNso0Li5OFovlpiatvt4bb7xhhvCu5leyHu/PnDmjAQMG2G0zcuRI7dmzR5LUs2dP+fn52W135coV866SrVu3vqnaAXg2QiIAwC0vPDxcAwcOlCStX79eYWFhGjlypH755Rft3LlTmzZt0rx589SjRw+VLl1aL730UoYPCS+99JI5PH/ixIlq27atfvjhB+3YsUM//PCD2rRpoylTpqS7RXROXYrVtWtXSdKpU6fUuHFjzZ49W1u3btX69es1YsQI1a1bV+fOnXP6l+LsUqdOHfODzNtvv62ffvpJBw4cUGxsrGJjY2/6DkYhISGqUKGCJJl3Eqpbt67DSzgKFSpkXhZobV+rVi0VKFAgQ1tfX19Nnz5dFotFCQkJatKkid59911t3rxZW7Zs0YQJE1SvXj0z8Pvwww/NOW5yy6JFi1SkSBFdu3ZNTz31lNq1a6eFCxdq69at2r59u1atWqVRo0apcePGuvvuuzN88M0t1rvSufrau3dvhm179Oihv/76S15eXpo/f366CXRr1KihMWPGSEob9fDOO+9k2P7zzz9XUFCQUlNT9cwzz6hTp05avHixtm/frq1bt2rRokXq1q2bypcvf8Nz7fTq1Us+Pj4yDENt27bVxIkTFR0drc2bN2vcuHGqU6eOzp8/bwa69rRt29YccbJs2TI1adJEX331lXbs2KEff/xRTz/9tN566y3Vq1fPaS3vvPOOGZ5+/PHHuueeezR16lRt2rRJO3fuVGRkpKZMmaLHHntM5cqVs3uJ3vjx481L6J599ln169dPkZGR2r59u+bMmaO6desqJibGZS2ZER4ebo5O+eWXX7Lcny0/Pz99/fXX8vPz08WLF3X//ferS5cuWrJkibZv365t27bphx9+0PDhw3X33XerWbNmGUK45557TiEhIXrxxRe1YMECRUVFKSYmRj/++KMGDx5sHn+DgoLUuXNnczvrKKK6detmy131ypQpY06MbTtiyZ4+ffqYE/TPmTNHrVq10jfffKMdO3ZoxYoV6tSpk959911JaZc6vv322w77Wr9+vZKTkyVJHTp0yPLjAOCBDAAAbkJkZKQhyZBkDB8+PEvbR0ZGumyfmppqjBw50vDx8TG3c/QVGBhoJCYmZujj2LFjRqVKlRxu17p1a2PVqlXm97/99luGPpo3b25IMpo3b+603uHDh5v9XO/q1atG69atHdbh7+9vfP3110ZERIQhyShfvnyGPo4cOWK2nzNnjtNaypcvb0gyIiIi7K4fOnSow1oy89o40rVr13R9DRkyxGn7Pn36pGs/cOBAp+3nzp1r+Pn5Oazd29vbGDVqlMPtM/P+zezznJn38/79+42aNWu6fP9KMkaOHJlhe1evo5Wz901m2D7mzH4VLFgwXR/Tpk1z+bqnpqaavwfe3t7G5s2bM7SJjo42QkNDXe7/yJEj6bZz9vtn9dFHHznsr0iRIsb69etd/r4nJCQYTZo0cdhPnTp1jO3bt7t8DyUkJBgdO3bM1HPdsmVLu31ERkYawcHBDrcbNmxYpp6XzOjUqZPTWhyxPp+u9h8VFZWp112SMW/evHTbZvb9umrVqnTb3XPPPQ5/965n/V10dR44ffq0ERAQkG7fjt4DZ8+edfpekmSEhYUZR48edbrPbt26GZKMGjVquHwcAGAPI4kAALcFi8WiYcOG6cCBAxo6dKjq1aunIkWKyNvbW8HBwapevbo6d+6sefPmKS4uzu6E0OXKldPvv/+ukSNHqmbNmvL391ehQoXUqFEjffLJJ1q1alW6y9QKFiyYI48lX758WrFihSZNmqR69eopICBA/v7+qly5svr06aMdO3boiSeeyJF92zNmzBjNmDFDzZo1M5/T7HD9fEKO5iOysl7G4mj760VERGjfvn0aOHCgwsLCFBgYKH9/f1WqVEk9e/ZUTEyMXn/99ZsrPgdUrVpVO3fu1KJFi9SpUyeVK1dO/v7+8vX1VenSpdWiRQu99dZb2r59u4YNG5bb5d60gwcPmpNT165dW++9957ddhaLRXPmzFHRokV17do1denSJcN8LHXr1tX+/fs1adIk3X///SpRooR8fHwUFBSku+66S7169dIvv/xijlq7ES+//LJ+/PFHPfTQQypcuLD8/PxUsWJF9evXTzExMRnej/YEBwdr7dq1mjx5surXr6+goCAFBwerdu3aGj16tDZv3pypO+sFBwfrm2++0YYNG9SjRw/deeedCg4Olo+Pj4oUKaL69eurX79+WrlypX766Se7fbRo0UK7d+9W3759Vb58efn6+qpkyZJ69NFH9eOPP2rkyJE3/Bw50qtXL0nSunXrcuQS3UaNGungwYP67LPP9Oijj6pMmTLy9fVV/vz5FRoaqtatW+v999/Xvn37zJFBVn/++ac++OADtW3bVtWrV1fRokXl7e1tHuuHDx+u/fv36+GHHza3OXnypHmjgKzOR2SrZMmS5uWErhQpUkTr16/X/Pnz9fDDD6tkyZLKly+fihYtqhYtWmjKlCnauXOnypcv77CPpKQkffvtt5KkF198MVseAwDPYzGMm5ghDwCAPOq9997T22+/LR8fH124cCFLd7gBgLzIMAzddddd2r17t9577z29+eabuV1SlkybNk19+vRR2bJldeLEidwu56YtWLBAzz33nIoWLaqjR48qKCgot0sCcBtiJBEAAP+fYRj66quvJKWNgCAgAoCMLBaLRo8eLSltjjdnd2q8HVjnI2rTpk0uV3LzUlNTNWrUKElpN2EgIAJwswiJAAAe4+jRo07vejNs2DDzFtERERHuKgsAbjtt27ZVs2bNFB8fr6lTp+Z2OVnSrFkzDR8+3Lxj3e1o8eLF2rt3r8qVK+fwDmkAkBlcbgYA8BgjRozQnDlz9Oyzz6pJkyYqU6aMkpOTtXfvXs2bN09r166VJFWvXl07duxweIthAIC0a9cuffPNNypRogRz4OSyRYsW6cCBA7r//vtdzucGAM4QEgEAPMaIESNcTt5arVo1rVq16qYmwgUAAABuZz65XQAAAO7SvXt3FSxYUGvWrFFsbKzOnDmjxMREFSlSRLVq1VKHDh30wgsvyNfXN7dLBQAAANyOkUQAAAAAAABg4moAAAAAAAAQEgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAECERAAAAAAAAREgEAAAAAAAAERIBAAAAAABAhEQAAAAAAAAQIREAAAAAAABESAQAAAAAAAAREgEAAAAAAECERAAAAAAAABAhEQAAAAAAAERIBAAAAAAAABESAQAAAAAAQIREAAAAAAAAkPT/AGDa0aTY5LtZAAAAAElFTkSuQmCC","text/plain":["<Figure size 640x480 with 1 Axes>"]},"metadata":{"image/png":{"height":454,"width":580}},"output_type":"display_data"}],"source":["# Calculate percentages for pregnancy exclusion\n","pregnancy_exclusion_percentages = (\n","    df['Spacy Pregnant Women Excluded'].value_counts(normalize=True) * 100\n",")\n","\n","# Bar chart with percentages displayed\n","plt.figure()\n","pregnancy_exclusion_counts.plot(kind='bar', color='skyblue')\n","for index, value in enumerate(pregnancy_exclusion_counts):\n","    plt.text(index, value + 5, f\"{pregnancy_exclusion_percentages[index]:.1f}%\", ha='center')\n","\n","plt.title(\"SpaCy Analysis: Pregnancy Exclusion in Clinical Trials\")\n","plt.xlabel(\"Pregnant Women Excluded (Yes/No)\")\n","plt.ylabel(\"Number of Trials\")\n","plt.xticks(rotation=0)\n","plt.grid(alpha=0.2)\n","plt.show()"]}],"metadata":{"colab":{"provenance":[],"toc_visible":true},"kaggle":{"accelerator":"gpu","dataSources":[{"datasetId":6105728,"sourceId":9932556,"sourceType":"datasetVersion"}],"dockerImageVersionId":30787,"isGpuEnabled":true,"isInternetEnabled":true,"language":"python","sourceType":"notebook"},"kernelspec":{"display_name":"Python 3 (ipykernel)","language":"python","name":"python3"},"language_info":{"codemirror_mode":{"name":"ipython","version":3},"file_extension":".py","mimetype":"text/x-python","name":"python","nbconvert_exporter":"python","pygments_lexer":"ipython3","version":"3.13.0"}},"nbformat":4,"nbformat_minor":5}